2021 esc guideline diagnosis acute chronic heart failure developed task force diagnosis acute chronic heart failure european society cardiology esc special contribution heart failure association hfa esc authorstask force member theresa mcdonagh chairperson united kingdom marco metra chairperson italy marianna adamo task force coordinator italy roy gardner task force coordinator united kingdom andreas baumbach united kingdom michael bo¨hm germany haran burri switzerland javed butler united state america jelena celutkiene lithuania ovidiu chioncel romania john gf cleland united kingdom andrew j coat united kingdom maria g crespoleiro spain dimitrios farmakis greece martine gilard france stephane heymans corresponding author two chairperson contributed equally document theresa mcdonagh cardiology department king’s college hospital denmark hill london se5 9rs united kingdom tel þ44 203 299 325 email theresamcdonaghkclacuk marco metra institute cardiology asst spedali civili di brescia department medical surgical specialty radiological science public health university brescia brescia italy tel þ39 303 07221 email metramarcoliberoit authortask force member afﬁliations listed author information esc clinical practice guideline committee cpg listed appendix esc subspecialty community participated development document association association acute cardiovascular care acvc association cardiovascular nursing allied profession acnap european association cardiovascular imaging eacvi european association preventive cardiology eapc european association percutaneous cardiovascular intervention eapci european heart rhythm association ehra heart failure association hfa council council cardiooncology council basic cardiovascular science council valvular heart disease working group adult congenital heart disease cardiovascular pharmacotherapy cardiovascular regenerative reparative medicine cardiovascular surgery ecardiology myocardial pericardial disease myocardial function patient forum content european society cardiology esc guideline ha published personal educational use commercial use authorized part esc guideline may translated reproduced form without written permission esc permission obtained upon submission written request oxford university press publisher european heart journal party authorized handle permission behalf esc journalspermissionsoupcom disclaimer esc guideline represent view esc produced careful consideration scientiﬁc medical knowledge evidence available time publication esc responsible event contradiction discrepancy andor ambiguity esc guideline ofﬁcial recommen dations guideline issued relevant public health authority particular relation good use healthcare therapeutic strategy health professional encouraged take esc guideline fully account exercising clinical judgment well determination implementation preventive diagnostic therapeutic medical strategy however esc guideline override way whatsoever individual responsibility health professional make appropriate accurate deci sion consideration patient’s health condition consultation patient appropriate andor necessary patient’s caregiver esc guideline exempt health professional taking full careful consideration relevant ofﬁcial updated recommendation guideline issued competent public health authority order manage patient’s case light scientiﬁcally accepted data pursuant respective ethical professional obligation also health professional’s responsibility verify applicable rule regulation relating drug medical device time prescription article ha copublished permission european heart journal european journal heart failure v c european society cardiology 2021 right reserved article identical except minor stylistic spelling difference keeping journal’s style either citation used citing article permission please email journalspermissionsoupcom european heart journal 2021 42 35993726 doi10.1093eurheartjehab368 downloaded guest 24 november 2024 netherlands arno w hoe netherlands tiny jaarsma sweden ewa jankowska poland mitja lainscak slovenia carolyn sp lam singapore alexander r lyon united kingdom john jv mcmurray united kingdom alexandre mebazaa france richard mindham united kingdom claudio muneretto italy massimo francesco piepoli italy susanna price united kingdom giuseppe mc rosano united kingdom frank ruschitzka switzerland anne kathrine skibelund denmark esc scientific document group document reviewer rudolf de boer cpg review coordinator netherlands p christian schulze cpg review coordinator germany magdy abdelhamid egypt victor aboyans france stamatis adamopoulos greece stefan anker germany elena arbelo spain riccardo asteggiano italy johann bauersachs germany antoni bayesgenis spain michael borger germany werner budts belgium maja cikes croatia kevin damman netherlands victoria delgado netherlands paul dendale belgium polychronis dilaveris greece heinz drexel austria justin ezekowitz canada volkmar falk germany laurent fauchier france gerasimos filippatos greece alan fraser united kingdom norbert frey germany chris p gale united kingdom finn gustafsson denmark julie harris united kingdom bernard iung france stefan janssens belgium mariell jessup united state america aleksandra konradi russia dipak kotecha united kingdom ekaterini lambrinou cyprus patrizio lancellotti belgium ulf landmesser germany christophe leclercq france basil lewis israel francisco leyva united kingdom ales linhart czech republic majalisa løchen norway lars h lund sweden donna mancini united state america josep masip spain davor milicic croatia christian mueller switzerland holger nef germany jenscosedis nielsen denmark li neubeck united kingdom michel noutsias germany steffen e petersen united kingdom anna sonia petronio italy piotr ponikowski poland eva prescott denmark amina rakisheva kazakhstan dimitrios j richter greece evgeny schlyakhto russia petar seferovic serbia michele senni italy marta sitges spain miguel sousauva portugal carlo g tocchetti italy rhian touyz united kingdom carsten tschoepe germany johannes waltenberger germanyswitzerland expert involved development guideline submitted declaration interest compiled report published supplementary document simultaneously guideline report also available esc website supplementary data include background information detailed discussion data provided basis guideline see european heart journal online online publishaheadofprint 27 august 2021 keywords guideline • heart failure • natriuretic peptide • ejection fraction • diagnosis • pharmacotherapy • neurohormonal antagonist • cardiac resynchronization • mechanical circulatory support • transplantation • arrhythmia • comorbidities • hospitalization • multidisciplinary management • advanced heart failure • acute heart failure content 1 preamble                                                      2 introduction                                                   2.1 new                                              3 definition epidemiology prognosis                         3.1 definition heart failure                                  3.2 terminology                                              3.21 heart failure preserved mildly reduced reduced ejection fraction                                            3.22 right ventricular dysfunction                           3.23 common terminology used heart failure       3.24 terminology related symptomatic severity heart failure                                                3.3 epidemiology natural history heart failure            3.31 incidence prevalence                               3.32 aetiology heart failure                              3.33 natural history prognosis                          4 chronic heart failure                                           4.1 key step diagnosis chronic heart failure           downloaded guest 24 november 2024 4.2 natriuretic peptide                                       4.21 use nonacute setting                           4.3 investigation determine underlying aetiology chronic heart failure                                           5 heart failure reduced ejection fraction                     5.1 diagnosis heart failure reduced ejection fraction 5.2 pharmacological patient heart failure reduced ejection fraction                          5.21 Goals pharmacotherapy patient heart failure reduced ejection fraction                        5.22 General principle pharmacotherapy heart failure reduced ejection fraction                        5.3 drug recommended patient heart failure reduced ejection fraction                                      5.31 angiotensinconverting enzyme inhibitor              5.32 betablockers                                         5.33 mineralocorticoid receptor antagonist                5.34 angiotensin receptorneprilysin inhibitor               5.35 sodiumglucose cotransporter 2 inhibitor            5.4 drug recommended considered selected patient heart failure reduced ejection fraction                                              5.41 diuretic                                              5.42 angiotensin ii type 1 receptor blocker                 5.43 ifchannel inhibitor                                    5.44 combination hydralazine isosorbide dinitrate    5.45 digoxin                                               5.46 recently reported advance heart failure reduced ejection fraction                        5.5 strategic phenotypic overview management heart failure reduced ejection fraction                     6 cardiac rhythm management heart failure reduced ejection fraction                                                 6.1 implantable cardioverterdefibrillator                       6.11 secondary prevention sudden cardiac death         6.12 primary prevention sudden cardiac death            6.13 patient selection implantable cardioverter defibrillator                                        6.14 implantable cardioverterdefibrillator programming     6.15 subcutaneous wearable implantable cardioverterdefibrillators                                  6.2 cardiac resynchronization                         6.3 device evaluation                                  7 heart failure mildly reduced ejection fraction              7.1 diagnosis heart failure mildly reduced ejection fraction                                                       7.2 clinical characteristic patient heart failure mildly reduced ejection fraction                           7.3 patient heart failure mildly reduced ejection fraction                                      7.31 angiotensinconverting enzyme inhibitor              7.32 angiotensin receptor ii type 1 receptor blocker       7.33 betablockers                                         7.34 mineralocorticoid receptor antagonist                7.35 angiotensin receptorneprilysin inhibitor               7.36 drug                                          7.37 device                                               8 heart failure preserved ejection fraction                   8.1 background heart failure preserved ejection fraction                                                       8.2 clinical characteristic patient heart failure preserved ejection fraction                                    8.3 diagnosis heart failure preserved ejection fraction                                                       8.4 heart failure preserved ejection fraction  9 multidisciplinary team management prevention chronic heart failure                                9.1 prevention heart failure                                 9.2 multidisciplinary management chronic heart failure       9.21 model care                                        9.22 characteristic component heart failure management programme                                   9.3 patient education selfcare lifestyle advice              9.4 exercise rehabilitation                                     9.5 followup chronic heart failure                          9.51 General followup                                     9.52 monitoring biomarkers                           9.6 telemonitoring                                            10 advanced heart failure                                        10.1 epidemiology diagnosis prognosis                    10.2 management                                             10.21 pharmacological renal replacement       10.22 mechanical circulatory support                       10.23 heart transplantation                                10.24 symptom control endoflife care                 11 acute heart failure                                            11.1 epidemiology diagnosis prognosis                    11.2 clinical presentation                                     11.21 acute decompensated heart failure                   11.22 acute pulmonary oedema                            11.23 isolated right ventricular failure                       11.24 cardiogenic shock                                   11.3 management                                             11.31 General aspect                                      11.32 oxygen andor ventilatory support           11.33 diuretic                                            11.34 vasodilator                                         11.35 inotropes                                            11.36 vasopressor                                        11.37 opiate                                              11.38 digoxin                                              11.39 thromboembolism prophylaxis                      11.310 shortterm mechanical circulatory support          11.311 predischarge assessment postdischarge management planning                                       12 cardiovascular comorbidities                                 12.1 arrhythmia conduction disturbance                 12.11 atrial fibrillation                                      12.12 ventricular arrhythmia                              12.13 symptomatic bradycardia pause atrioventricular block                                                      12.2 chronic coronary syndrome                             12.21 medical                                      12.22 myocardial revascularization                          downloaded guest 24 november 2024 12.3 valvular heart disease                                    12.31 aortic stenosis                                       12.32 aortic regurgitation                                  12.33 mitral regurgitation                                   12.34 tricuspid regurgitation                               12.4 hypertension                                            12.5 stroke                                                   13 noncardiovascular comorbidities                            13.1 diabetes                                                 13.2 thyroid disorder                                        13.3 obesity                                                  13.4 frailty cachexia sarcopenia                               13.5 iron deficiency anaemia                               13.6 kidney dysfunction                                       13.7 electrolyte disorder hypokalaemia hyperkalaemia hyponatraemia hypochloraemia                               13.8 lung disease sleepdisordered breathing                  13.9 hyperlipidaemia lipidmodifying               13.10 Gout arthritis                                       13.11 erectile dysfunction                                     13.12 depression                                             13.13 cancer                                                 13.14 infection                                                14 special condition                                            14.1 pregnancy                                               14.11 pregnancy preexisting heart failure                 14.12 new heart failure presenting pregnancy        14.2 cardiomyopathy                                       14.21 epidemiology diagnosis                           14.22                                           14.3 left ventricular noncompaction                          14.4 atrial disease                                             14.41 definition                                            14.42 diagnosis                                            14.43 management                                         14.5 myocarditis                                              14.51 epidemiology diagnosis                           14.52                                           14.6 amyloidosis                                              14.61 epidemiology diagnosis                           14.62 amyloidosis heart failure              14.7 iron overload cardiomyopathy                            14.8 adult congenital heart disease                            15 key message                                                16 Gaps evidence                                             17 ‘what do’ ‘what do’ message guideline 18 quality indicator                                            19 supplementary data                                          20 author information                                           21 appendix                                                    22                                                   list recommendation recommended diagnostic test patient suspected chronic heart failure                                   recommendation specialized diagnostic test selected patient chronic heart failure detect reversibletreatable cause heart failure                                            pharmacological indicated patient nyha class IIiv heart failure reduced ejection fraction lvef 40                                                    pharmacological indicated selected patient nyha class IIiv heart failure reduced ejection fraction lvef 40                                            recommendation implantable cardioverterdefibrillator patient heart failure                                      recommendation cardiac resynchronization implantation patient heart failure                         pharmacological considered patient nyha class IIiv heart failure mildly reduced ejection fraction                                                         recommendation patient heart failure preserved ejection fraction                                  recommendation primary prevention heart failure patient risk factor development                     multidisciplinary intervention recommended management chronic heart failure                                           recommendation exercise rehabilitation patient chronic heart failure                                             recommendation telemonitoring                            recommendation patient advanced heart failure                                                     recommendation initial acute heart failure   recommendation use shortterm mechanical circulatory support patient cardiogenic shock                        recommendation predischarge early postdischarge followup patient hospitalized acute heart failure           recommendation atrial fibrillation patient heart failure                                        recommendation myocardial revascularization patient heart failure reduced ejection fraction                  recommendation management valvular heart disease patient heart failure                              recommendation diabetes heart failure   recommendation management anaemia iron deficiency patient heart failure                                      recommendation management patient cancer heart failure                                                 recommendation transthyretin amyloidosiscardiac amyloidosis                                  list 1 class recommendation                             2 level evidence                                       3 definition heart failure reduced ejection fraction mildly reduced ejection fraction preserved ejection fraction   4 new york heart association functional classification based severity symptom physical activity               5 cause heart failure common mode presentation specific investigation                                        6 symptom sign typical heart failure                downloaded guest 24 november 2024 7 cause elevated concentration natriuretic peptide                                                        8 evidencebased dos diseasemodifying drug key randomized patient heart failure reduced ejection fraction                                                 9 objective evidence cardiac structural functional serological abnormality consistent presence left ventricular diastolic dysfunctionraised left ventricular filling pressure                                                       10 risk factor development heart failure potential corrective action                                      11 important characteristic component heart failure management programme                                 12 patient education selfcare                          13 criterion definition advanced heart failure           14 interagency registry mechanically assisted circulatory support profile description patient advanced heart failure                                                     15 term describing various indication mechanical circulatory support                                              16 patient potentially eligible implantation left ventricular assist device                                          17 heart transplantation indication contraindication                                                18 patient heart failure endoflife care considered                                            19 key component palliative care service patient advanced heart failure                              20 diagnostic test patient acute heart failure       21 clinical presentation acute heart failure              22 inotropes andor vasopressor used treat acute heart failure                                                           23 cancer drug causing heart failure                       24 infection patient heart failure                   25 possible cause disease modifier frequent cardiomyopathy                                               26 initial diagnostic assessment patient suspected cardiomyopathy                                                 27 dilated cardiomyopathy hypokinetic nondilated cardiomyopathy specific aspect diagnosis       28 hypertrophic cardiomyopathy specific aspect diagnosis                                         29 arrhythmogenic cardiomyopathy specific aspect diagnosis                                         30 aetiology considered triggering acute myocarditis                                                     31 diagnostic workup suspected acute myocarditis       32 endomyocardial biopsy patient suspected myocarditis                                                     33 cardiac magnetic resonance patient suspected myocarditis                                                     34 followup acute myocarditis           35 “red flags” common form cardiac amyloidosis                                                     36 adult congenital heart disease heart failure specialized centre                                      37 main european society cardiology quality indicator evaluation care outcome patient heart failure list 1 diagnostic algorithm heart failure                 2 therapeutic algorithm Class indication patient heart failure reduced ejection fraction           3 central illustration strategic phenotypic overview management heart failure reduced ejection fraction        4 algorithm patient advanced heart failure                                                     5 triage patient advanced heart failure appropriate timing referral                                    6 diagnostic workup new onset acute heart failure       7 management acute decompensated heart failure       8 management pulmonary oedema                      9 management right ventricular failure                   10 management cardiogenic shock                      11 stage management patient acute heart failure                                                     12 initial management acute heart failure                13 diuretic furosemide acute heart failure      14 management atrial fibrillation patient heart failure reduced ejection fraction                             15 algorithm medical chronic coronary syndrome patient heart failure reduced ejection fraction                                                 16 management patient severe lowflow lowgradient aortic stenosis heart failure                     17 management secondary mitral regurgitation patient heart failure reduced ejection fraction                  18 management patient cancer heart failure    19 management patient heart failure pregnancy                                                20 management patient heart failure acute myocarditis                                                     21 diagnosis cardiac amyloidosis heart failure patient                                             abbreviation acronym 6mwt 6minute walk test 99mtcpyp technetiumlabelled pyrophosphate aatac ablation v amiodarone atrial fibrillation patient congestive heart failure implanted icdcrtd ac arrhythmogenic cardiomyopathy ace angiotensinconverting enzyme acei angiotensinconverting enzyme inhibitor achd adult congenital heart disease ac acute coronary syndrome adhf acutely decompensated heart failure af atrial ﬁbrillation afchf atrial ﬁbrillation  congestive heart failure downloaded guest 24 november 2024 affirm atrial fibrillation followup investigation rhythm management affirmahf randomized doubleblind placebo controlled comparing effect intravenous ferric carboxymaltose hospitalization mortality iron deﬁcient subject admitted acute heart failure ahf acute heart failure al light chain immunoglobulin alca light chain immunoglobulin cardiac amyloidosis amica atrial fibrillation management congestive heart failure ablation anca antineutrophil cytoplasmic antibody arb angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor arvc arrhythmogenic right ventricular cardiomyopathy attr transthyretin amyloidosis av atrioventricular bid bi die twice bag3 bcl2associated athanogene 3 bivad biventricular assist device bmi body mass index bnp btype natriuretic peptide bp blood pressure bpm beat per minute btb bridge bridge btc bridge candidacy btd bridge decision btr bridge recovery btt bridge transplantation ca cardiac amyloidosis amyloid cardiomyopathy cabana catheter ablation v antiarrhythmic drug atrial ﬁbrillation cabg coronary artery bypass graft cad coronary artery disease canvasr canagliﬂozin cardiovascular assessment renal carehf cardiac resynchronization heart failure castleaf catheter ablation standard conventional patient left ventricular atrial fibrillation ccb calcium channel blocker cc chronic coronary syndrome cha2ds2vasc congestive heart failure left ventricular dysfunction hypertension age 75 doubled diabetes stroke doubled vascular disease age 6574 sex category female score champit acute coronary syndromehypertension emergencyarrhythmiaacute mechanical causepulmonary embolisminfections tamponade charm candesartan heart failure assessment mortality morbidity chf chronic heart failure ci conﬁdence interval ckd chronic kidney disease cmp cardiomyopathy cmr cardiac magnetic resonance cmv cytomegalovirus coapt cardiovascular outcome assessment mitraclip percutaneous hf patient functional mitral regurgitation coc cardiooncology council part european society cardiology commanderhf assess effectiveness safety rivaroxaban reducing risk death myocardial infarction stroke participant heart failure coronary artery disease following episode decompensated heart failure compass rivaroxaban prevention major cardiovascular event coronary peripheral artery disease copd chronic obstructive pulmonary disease corona controlled rosuvastatin multinational covid19 coronavirus disease 2019 cr controlled release credence canagliﬂozin renal endpoint diabetes established nephropathy clinical evaluation crt cardiac resynchronization crtd cardiac resynchronization deﬁbrillator crtp cardiac resynchronization pacemaker csa central sleep apnoea ct computed tomography ctca computed tomography coronary angiography cv cardiovascular dapahf dapagliﬂozin prevention adverse outcome heart failure dcm dilated cardiomyopathy declare timi 58 dapagliﬂozin effect cardiovascular event thrombolysis myocardial infarction diamond patiromer management hyperkalemia subject receiving raasi medication heart failure dig digitalis investigation group dna deoxyribonucleic acid doac directacting oral anticoagulant dpd 33diphosphono12propanodicarboxylic acid downloaded guest 24 november 2024 dpp4 dipeptidyl peptidase4 dsc2 desmocollin 2 dsg2 desmoglein 2 dsp desmoplakin dt destination ee0 ratio ee0 ratio early ﬁlling velocity transmitral dopplerearly relaxation velocity tissue doppler eacvi european association cardiovascular imaging part european society cardiology eastafnet 4 early atrial fibrillation stroke prevention 4 ecg electrocardiogram echocrt echocardiography guided cardiac resynchronization ecls extracorporeal life support ecmo extracorporeal membrane oxygenation ef ejection fraction egfr estimated glomerular ﬁltration rate ehra european heart rhythm association ema european medicine agency emb endomyocardial biopsy empareg outcome empagliﬂozin cardiovascular outcome event type 2 diabetes mellitus patient emperor reducedType 2gliﬂozin outcome patient chronic heart failure reduced ejection fraction eroa effective regurgitant oriﬁce area esc european society cardiology eu european union euroscore ii european system cardiac operative risk evaluation ii score fda food drug administration fdg fluorodeoxyglucose fio2 fraction inspired oxygen fln filamin flnc filamin c ggt gammaglutamyl transferase gissihf gruppo italiano per lo studio della streptochinasi nell’infarto miocardico  heart failure glp1 glucagonlike peptide1 guidehf hemodynamicguided mana1 Gnt heart failure 1 Gal h hourhours h2fpef heavy bmi 30 kgm2 hypertensive use 2 antihypertensive medicat30 kg atrial fibrillation paroxysmal persistent pulmonary hypertension doppler echocardiographic estimated pulmonary artery systolic pressure 35 elderly age 60 year filling pressure doppler35 mmHgardiographic ee0 9 score hba1c glycated haemoglobin hcm hypertrophic cardiomyopathy heart heart failure revascularisation her2 human epidermal growth factor receptor 2 hf heart failure hfa heart failure association hfapeff heart failure association esc diagnostic algorithm p  initial workup step 1 pretest assessment e diagnostic workup step 2 echocardiographic natriuretic peptide score f1  advanced workup step 3 functional testing case uncertainty f2  aetiological workup step 4 final aetiology hfmp heart failure management programme hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejection fraction hhv human herpes virus hiv human immunodeﬁciency virus hladr human leukocyte antigendr isotype hmdp hydroxylmethylenediphosphonate hr hazard ratio ht heart transplantation htm home telemonitoring iv intravenous iabp intraaortic balloon pump iccu intensive coronary care unit icd implantable cardioverterdeﬁbrillator icu intensive care unit ihd ischaemic heart disease inr international normalized ratio intermacs interagency registry mechanically assisted circulatory support intrepid investigation nontransplanteligible patient inotrope dependent iocm iron overload cardiomyopathy ipd individual patient data ipreserve irbesartan patient heart failure preserved ejection fraction kcnh2 potassium voltagegated channel subfamily h member 2 kcnq1 potassium voltagegated channel subfamily q member 1 la left atriumatrial lae left atrial enlargement lbbb left bundle branch block ldb3 lim domain binding 3 lft liver function test lge late gadolinium enhancement lmna lamin ac lmwh lowmolecularweight heparin lu lung ultrasound lv left ventricularventricle lvad left ventricular assist device downloaded guest 24 november 2024 lvedp left ventricular enddiastolic pressure lvef left ventricular ejection fraction lvesd left ventricular endsystolic diameter lvh left ventricular hypertrophy lvnc left ventricular noncompaction lvot left ventricular outﬂow tract lvoto left ventricular outﬂow tract obstruction maditcrt multicenter automatic deﬁbrillator implantation cardiac resynchronization maditii multicenter automatic deﬁbrillator implantation ii maditrit multicenter automatic deﬁbrillator implantation  reduce inappropriate maggic metaanalysis global group chronic heart failure mc mechanical circulatory support mek mitogenactivated protein kinase mi myocardial infarction mitrafr percutaneous repair mitraclip device severe functionalsecondary mitral regurgitation mmr mismatch repair mr mitral regurgitation mra mineralocorticoid receptor antagonist mri magnetic resonance imaging mrna messenger ribonucleic acid mrproanp midregional proatrial natriuretic peptide mt medical mv mitral valve mwho modiﬁed world health organization mypc myosinbinding protein c nicm nonischaemic cardiomyopathy nkx25 nk2 transcription factor related locus 5 np natriuretic peptide nsaid nonsteroidal antiinﬂammatory drug nsvt nonsustained ventricular tachycardia ntprobnp nterminal probtype natriuretic peptide nyha new york heart association od omne die omt optimal medical osa obstructive sleep apnoea pa pulmonary artery pao2 partial pressure oxygen paradigmhf prospective comparison arni acei determine impact global mortality morbidity heart failure pco2 partial pressure carbon dioxide pci percutaneous coronary intervention pcr polymerase chain reaction pcwp pulmonary capillary wedge pressure pepchf perindopril elderly people chronic heart failure pet positron emission tomography pkp2 plakophilin 2 pln phospholamban ppcm peripartum cardiomyopathy prevend prevention renal vascular endstage disease pv pulmonary vein pvc premature ventricular contraction pvi pulmonary vein isolation pvo2 peak exercise oxygen consumption qi quality indicator qol quality life qrs q r wave ecg raas reninangiotensinaldosterone system race ii rate control efﬁcacy permanent atrial fibrillation comparison lenient strict rate control ii raft resynchronizationdeﬁbrillation ambulatory heart failure rasi reninangiotensin system inhibitor rateaf rate control evaluation permanent atrial fibrillation rbm20 ribonucleic acid binding motif 20 rct randomized controlled rematch randomized evaluation mechanical assistance congestive heart failure reverse resynchronization revers remodeling systolic left ventricular dysfunction revived revascularization ischaemic ventricular dysfunction rna ribonucleic acid rrt renal replacement rv right ventricularventricle rvad right ventricular assist device rvedp right ventricular enddiastolic pressure sarscov2 severe acute respiratory syndrome coronavirus 2 savr surgical aortic valve replacement sbp systolic blood pressure scn5a sodium channel alpha subunit 5 scored effect sotagliﬂozin cardiovascular renal event patient type 2 diabetes moderate renal impairment caType 2scular risk senior effect nebivolol intervention outcome rehospitalizations senior heart failure servehf sleepdisordered breathing predominant central sleep apnea adaptive servo ventilation patient heart failure sglt2 sodiumglucose cotransporter 2 sicd subcutaneous implantable cardioverter deﬁbrillator smr secondary mitral regurgitation spect singlephoton emission computed tomography downloaded guest 24 november 2024 spo2 transcutaneous oxygen saturation sr sinus rhythm stemi stelevation myocardial infarction stich surgical ischemic heart failure stiches extended followup patient stich stsprom society thoracic surgeon predicted risk mortality szc sodium zirconium cyclosilicate t2dm type 2 diabetes mellitus tavi transcatheter aortic valve implantation tft thyroid function test tidType 2 ter die three time day tki tyrosine kinase inhibitor tmem43 transmembrane protein 43 tnnt troponint tr tricuspid regurgitation trpm4 transient receptor potential cation channel subfamily member 4 tsat transferrin saturation tsh thyroidstimulating hormone ttn titin ttr transthyretin uk united kingdom u united state vad ventricular assist device valheft valsartan heart failure vegf vascular endothelial growth factor vertiscv cardiovascular outcome following ertugliﬂozin Type 2 diabetes mellitus participant vascular disease vest vest prevention early sudden death vka vitamin k antagonist vo2 oxygen consumption vpb ventricular premature beat v vv interval interventricular delay interval warcef warfarin aspirin reduced cardiac ejection fraction wtttrca wildtype transthyretin cardiac amyloidosis xl extended release 1 preamble guideline summarize evaluate available evidence aim assisting health professional proposing best management strat egies individual patient given condition guideline recommendation facilitate decision making health pro fessionals practice however final decision concerning individual patient must made responsible health professio nals consultation patient caregiver appropriate great number guideline issued recent year european society cardiology esc well society organization impact clinical prac tice quality criterion development guideline established order make decision transparent user recommendation formulating issuing esc guideline found esc website guideline esc guideline represent official position esc given topic regularly updated addition publication clinical practice guideline esc carry eurobservational research programme international registry cardiovascular cv disease intervention essential assess diagnostictherapeutic process use resource adherence guideline registry aim providing better understanding medical practice europe around world based highquality data collected routine clinical practice furthermore esc ha developed embedded document set quality indicator qi tool evaluate level implementation guideline may used esc hospital healthcare provider professional measure clinical practice well used educational programme alongside key message guideline improve quality care clinical outcome member task force selected esc includ ing representation relevant esc subspecialty group order represent professional involved medical care patient pathology selected expert field undertook comprehensive review published evidence management given condition according esc clinical practice guideline cpg committee policy critical evaluation diagnostic ther apeutic procedure wa performed including assessment riskbenefit ratio level evidence strength rec ommendation particular management option weighed graded according predefined scale outlined expert writing reviewing panel provided declara tion interest form relationship might perceived real potential source conflict interest declaration interest reviewed according esc declaration interest rule found esc website guideline compiled report published supplementary document simultaneously guideline process ensures transparency prevents potential bias development review process change declaration interest arise writing period notified esc updated task force received entire financial support esc without involvement healthcare industry esc cpg supervises coordinate preparation new guideline committee also responsible endorsement process guideline esc guideline undergo extensive review cpg external expert appropriate revision guideline signedoff expert involved task force finalized document signedoff cpg publica tion european heart journal guideline developed careful consideration scientific medical knowledge evidence available time dating task developing esc guideline also includes creation educational tool implementation programme recommen dations including condensed pocket guideline version summary slide summary card nonspecialists electronic version digital application smartphones etc version abridged thus downloaded guest 24 november 2024 detailed information user always access full text version guideline freely available via esc web site hosted european heart journal website national cardiac society esc encouraged endorse adopt trans late implement esc guideline implementation programme needed ha shown outcome disease may favourably influenced thorough application clinical recommendation health professional encouraged take esc guideline fully account exercising clinical judgment well determination implementation preventive diagnostic therapeutic medical strategy however esc guideline override way whatso ever individual responsibility health professional make appropriate accurate decision consideration patient’s health condition consultation patient patient’s caregiver appropriate andor necessary also health professional’s responsibility verify rule regulation applicable country drug device time prescription 2 level evidence ©esc 2021 level evidence data derived multiple randomized clinical metaanalyses level evidence b data derived single randomized clinical large nonrandomized level evidence c consensus opinion expert andor small retrospective registry 1 class recommendation ©esc 2021 class recommendation Class evidence andor general agreement given procedure beneficial useful effective conflicting evidence andor divergence opinion usefulness efficacy given procedure recommended indicated wording use definition Class III evidence general agreement given procedure usefuleffective case may harmful recommended Class IIb usefulnessefficacy less well established evidenceopinion may considered Class IIa weight evidenceopinion favour usefulnessefficacy considered Class II downloaded guest 24 november 2024 2 introduction aim esc guideline help health professional manage people heart failure hf according best available evi dence fortunately wealth clinical help u select best management improve outcome people hf many preventable treatable guideline provides practical evidencebased recommendation revised format previous 2016 esc hf guidelines1 make phenotype heart failure standalone term diagnosis management recommendation men tion effect supported class level evidence presented heart failure reduced ejection fraction hfref tabular recommendation focus mortality mor bidity outcome symptomatic benefit highlighted text andor web appendix detailed sum mary underpinning recommendation available web appendix diagnostic indication suggested investigation patient heart failure receive investiga tions targeted specific circumstance diagnostic test rarely subject randomized controlled rcts evidence would regarded level c however doe mean ha appropriate rigorous evaluation diagnostic test guideline decided focus diagnosis hf prevention management cardiovascular risk many cardiovascular disease especially systemic hypertension diabetes melli tus coronary artery disease myocardial infarction mi atrial fibrilla tion af asymptomatic left ventricular lv systolic dysfunction reduce risk developing hf addressed many esc guideline section 9.1 current guideline27 guideline result collaboration task force including two patient representative reviewer esc cpg committee consensusmajority opinion expert consulted development 2.1 new addition recommendation listed following list new concept compared 2016 version new concept change term ‘heart failure midrange ejection fraction’ ‘heart failure mildly reduced ejection fraction’ hfmref new simpliﬁed algorithm hfref addition algorithm hfref according phenotype modiﬁed classiﬁcation acute hf updated noncardiovascular comorbidities including diabetes hyperkalaemia iron deﬁciency cancer update cardiomyopathy including role genetic testing new addition key quality indicator heart failure heart failure new recommendation recommendation class recommendation diagnosis hf right heart catheterization considered patient heart failure thought due constrictive pericarditis restrictive cardiomyopathy congenital heart disease high output state iia right heart catheterization may considered selected patient hfpef conﬁrm diagnosis iib recommendation chronic hf hfref dapagliﬂozin empagliﬂozin recommended patient hfref reduce risk heart failure hospitalization death vericiguat may considered patient nyha class IIiv worsening heart failure despite acei arni betablocker mra reduce risk cardiovascular mortality heart failure hospitalization iib hfmref acei may considered patient hfmref reduce risk heart failure hospitalization death iib angiotensin receptor blocker may considered patient hfmref reduce risk heart failure hospitalization death iib betablocker may considered patient hfmref reduce risk heart failure hospitalization death iib mra may considered patient hfmref reduce risk heart failure hospitalization death iib sacubitrilvalsartan may considered patient hfmref reduce risk heart failure hospitalization death iib hfpef screening aetiology cardiovascular non cardiovascular comorbidities recommended patient hfpef see relevant section document prevention monitoring selfmanagement strategy recommended reduce risk heart failure hospitalization mortality either homebased andor clinicbased programme improve outcome recommended reduce risk hf hospitalization mortality inﬂuenza pneumococcal vaccination consid ered order prevent heart failure hospitalization iia supervised exercisebased cardiac rehabilitation pro gramme considered patient severe disease frailty comorbidities iia noninvasive htm may considered patient heart failure order reduce risk recurrent cardiovascular heart failure hospitaliza tions cardiovascular death iib recommendation management patient advanced hf patient considered longterm mc must good compliance appropriate capacity device handling psy chosocial support continued esc 2021 downloaded guest 24 november 2024 heart transplantation recommended patient advanced hf refractory medicaldevice absolute contraindication continuous inotropes andor vasopressor may considered patient low cardiac output evidence organ hypo perfusion bridge mc heart transplantation iib recommendation management patient hf hospitalization recommended patient hospitalized heart failure care fully evaluated exclude persistent sign congestion discharge optimize oral recommended evidencebased oral medical treat ment administered discharge early followup visit recommended 12 week discharge assess sign congestion drug tolerance start andor uptitrate evidencebased recommendation management patient heart failure atrial ﬁbrillation longterm oral anticoagulant considered stroke prevention atrial fibrillation patient cha2ds2vasc score 1 men 2 woman iia recommendation management patient heart failure cc cabg considered ﬁrstchoice revasculariza tion strategy patient suitable surgery especially diabetes multivessel disease iia lvad candidate needing coronary revascularization cabg avoided possible iia coronary revascularization may considered improve come patient hfref cc coronary anatomy suit able revascularization careful evaluation individual risk beneﬁt ratio including coronary anatomy ie proximal stenosis 90 large vessel stenosis left main proximal lad comorbidities life expectancy patient’s perspective iib pci may considered alternative cabg based heart team evaluation considering coronary anatomy comorbidities surgical risk iib recommendation management patient heart failure valvular heart disease aortic valve intervention tavi savr recommended patient heart failure severe highgradient aortic stenosis reduce mortality improve symptom recommended choice tavi savr made heart team according individual patient preference feature including age surgical risk clinical anatomical procedural aspect weighing risk beneﬁts approach percutaneous edgetoedge mitral valve repair consid ered carefully selected patient secondary mitral regurgi tation eligible surgery needing coronary revascularization symptomatic despite omt fulﬁl criterion achieve reduction heart failure hospitalization iia percutaneous edgetoedge mitral valve repair may con sidered improve symptom carefully selected patient secondary mitral regurgitation eligible surgery needing coronary revascularization highly symptomatic despite omt fulﬁl criterion reducing heart failure hospitalization iib continued recommendation management patient heart failure diabetes sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂozin ertugliﬂozin sotagliﬂozin recommended patient t2dm risk cardiovascular event reduce hospitalization hf major cardiovascular event endstage renal dysfunction cardiovascular death sglt2 inhibitor dapagliﬂozin empagliﬂozin sotagliﬂo zin recommended patient t2dm hfref reduce hospitalization heart failure cardiovascular death dpp4 inhibitor saxagliptin recommended patient hf iii recommendation management patient heart failure iron deﬁciency recommended patient heart failure periodically screened anaemia iron deﬁciency full blood count serum ferritin concentration tsat intravenous iron supplementation ferric carboxymaltose considered symptomatic heart failure patient recently hospi talized heart failure left ventricular ejection fraction 50 iron deﬁciency deﬁned serum ferritin 100 ngml serum ferritin 100299 ngml tsat 20 reduce risk heart failure hospitalization iia anaemia heart failure erythropoietin stimulating agent recommended absence indica tions iii recommendation management patient heart failure cancer recommended cancer patient increased risk cardi otoxicity deﬁned history risk factor cardiovascular disease pre vious cardiotoxicity exposure cardiotoxic agent undergo cardiovascular evaluation scheduled anticancer preferably cardiologist experienceinterest cardiooncology acei betablocker preferably carvedi lol considered cancer patient developing lv systolic dysfunction deﬁned 10 decrease left ventricular ejection fraction value lower 50 anthracycline chemotherapy iia baseline cardiovascular risk assessment considered cancer patient scheduled receive cancer potential cause hf iia recommendation patient heart failure amyloidosis tafamidis recommended patient genetic testing pro ven httrca nyha class ii symptom reduce symptom cardiovascular hospitalization mortality tafamidis recommended patient wtttrca nyha class ii symptom reduce symptom cardiovascular hospi talization mortality acei angiotensinconverting enzyme inhibitor angiotensin receptor blocker angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor cabg coronary artery bypass graft cc chronic coronary syndrome cha2ds2vasc con gestive heart failure left ventricular dysfunction hypertension age 75 doubled diabetes stroke doubledvascular disease age 6574 sex cate gory female score cmp cardiomyopathy cardiovascular cardiovascular dpp4 dipeptidyl peptidase4 heart failure heart failure hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejection fraction htm home telemonitor ing httr hereditary transthyretin lad left anterior descending artery lv left ventricular lvad left ventricular assist device left ventricular ejection fraction left ventricular ejec tion fraction mc mechanical circulatory support mra mineralocorticoid receptor antagonist nyha new york heart association omt optimal medical pci percutaneous coronary intervention savr surgical aortic valve replacement sglt2 sodiumglucose cotransporter 2 t2dm type 2 diabetes mellitus tavi transcatheter aortic valve implantation tsat transferrin saturation wtttrca wildtype transthyretin cardiac amyloidosis esc 2021 downloaded guest 24 november 2024 change recommendation class class recommendation diagnosis hf invasive coronary angiography may considered patient hfref intermediate high pretest probability cad presence ischaemia non invasive stress test iib invasive coronary angiography considered patient heart failure intermediate high pretest proba bility cad presence ischaemia noninva sive stress test considered suitable potential coronary revascularization order establish diag nosis cad severity iia ctca considered patient low intermediate pretest probability cad equivocal noninvasive stress test order rule coronary artery stenosis iia cardiac ct may considered patient heart failure low intermediate pretest probability cad equivocal noninvasive stress test order rule coronary artery stenosis iib recommendation device hfref icd considered reduce risk sud den death allcause mortality patient sympto matic heart failure nyha class IIiii nonischaemic aetiology left ventricular ejection fraction 335nths omt provided expected survive substantially longer 1 year good functional status iia primary prevention icd recommended reduce risk sudden death allcause mortality patient symptomatic heart failure nyha class IIiii left ventricular ejection fraction 335onths omt provided expected survive substantially longer 1 year good functional sta tus dcm crt considered symptomatic patient heart failure sinus rhythm qrs duration 130149 lbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbid ity mortality iia crt recommended symptomatic patient hf sinus rhythm qrs duration 130149 lbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbid ity mortality patient left ventricular ejection fraction 35 received conven tional pacemaker icd subsequently develop worsening heart failure despite omt signiﬁcant proportion rv pacing considered ‘upgrade’ crt iia patient hfref received conventional pacemaker icd subsequently develop worsening heart failure despite omt high proportion rv pacing may considered upgrade crt doe apply patient stable hf iib recommendation management patient acute hf combination loop diuretic thiazidetype diuretic considered patient resistant oedema respond increase loop diuretic dos iia combination loop diuretic either thiazidetype diu retic spironolactone may considered patient resistant oedema insufﬁcient symptomatic response iib patient ahf sbp 110 iv vasodila tor may considered initial improve symptom reduce congestion iib patient hypertensive ahf iv vasodilator considered initial improve symptom reduce congestion iia routine use opiate recommended unless selected patient severeintractable pain anxiety iii opiate may considered cautious use relieve dyspnoea anxiety patient severe dyspnoea nausea hypopnea may occur iib shortterm mc considered patient cardiogenic shock btr btd btb indica tions include cause cardiogenic shock longterm mc transplantation iia shortterm mc may considered refractory cardio genic shock depending patient age comorbidities neurological function iib continued downloaded guest 24 november 2024 3 definition epidemiology prognosis 3.1 definition heart failure heart failure single pathological diagnosis clinical syn drome consisting cardinal symptom eg breathlessness ankle swelling fatigue may accompanied sign eg elevated jugular venous pressure pulmonary crackle peripheral oedema due structural andor functional abnormality heart result elevated intracardiac pressure andor inad equate cardiac output rest andor exercise identification aetiology underlying cardiac dysfunction mandatory diagnosis heart failure specific pathology determine subsequent commonly heart failure due myocardial dysfunction either systolic diastolic however pathology valve pericardium endocardium abnor malities heart rhythm conduction also cause contribute hf 3.2 terminology 3.21 heart failure preserved mildly reduced reduced ejection fraction traditionally heart failure ha divided distinct phenotype based measurement left ventricular ejection fraction lvef 3 rationale behind relates original heart failure demonstrated substantially improved outcome patient left ventricular ejection fraction 40 however heart failure span entire range left ventricular ejection fraction normally distributed variable measurement echocar diography subject substantial variability decided following classification heart failure 3 • reduced left ventricular ejection fraction defined 40 ie significant reduction lv systolic function designated hfref • patient left ventricular ejection fraction 41 49 mildly reduced lv systolic function ie hfmref retrospective analysis rcts hfref heart failure preserved ejection fraction hfpef included patient ejection fraction 4050 range suggest may benefit similar recommendation management patient heart failure af doacs recommended preference vkas patient hf except moderate severe mitral stenosis mechanical prosthetic heart valve patient heart failure nonvalvular atrial fibrillation eligible anti coagulation based cha2ds2vasc score noacs rather warfarin considered anticoagula tion noacs associated lower risk stroke intracranial haemorrhage mortality outweigh increased risk gastrointestinal haemorrhage iia betablockers considered short long term rate control patient heart failure af iia patient nyha class Iiii betablocker usually given orally safe therefore recommended ﬁrst line control ventricular rate provided patient euvolaemic case clear association paroxysmal persistent atrial fibrillation worsening heart failure symptom persist despite medical catheter ablation considered prevention af iia av node catheter ablation may considered control heart rate relieve symptom patient unresponsive intolerant intensive pharmacological rate rhythm control accepting patient become pacemakerdependent iib recommendation management patient heart failure cc coronary revascularization considered relieve persistent symptom angina angina equivalent patient hfref cc coronary anatomy suitable revascularization despite omt including antianginal drug iia myocardial revascularization recommended angina persists despite antianginal drug recommendation management patient heart failure diabetes sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂo zin ertugliﬂozin sotagliﬂozin recommended patient t2dm risk cardiovascular event reduce hospi talizations hf major cardiovascular event endstage renal dy function cardiovascular death empagliﬂozin considered patient t2dm order prevent delay onset heart failure prolong life iia atrial fibrillation atrial ﬁbrillation ahf acute heart failure av atrioventricular btb bridge bridge btd bridge decision btr bridge cardiac recovery cad coronary artery disease cc chronic coronary syndrome cha2ds2vasc congestive heart failure left ventricular dysfunction hypertension age 75 doubled diabetes stroke doubledvascular disease age 6574 sex category female score crt cardiac resynchronization ct computed tomography ctca computed tomography coronary angiography cardiovascular cardiovascular dcm dilated cardiomyopathy doac direct oral anticoagulant heart failure heart failure hfref heart failure reduced ejection fraction icd implantable cardioverterdeﬁbrillator lbbb left bundle branch block left ventricular ejection fraction left ventricular ejection fraction mc mechanical circulatory support noac nonvitamin k antagonist oral anticoagulant nyha new york heart association omt optimal medical qrs q r wave ecg rv right ventricularventricle sbp systolic blood pressure sglt2 sodiumglucose cotransporter 2 t2dm type 2 diabetes mellitus vka vitamin k antagonist esc 2021 downloaded guest 24 november 2024 left ventricular ejection fraction 50 hfpef4050 diagnosis hfref hfmref hfpef covered detail respective section section 5 7 8 respectively definition consistent recent report universal definition heart failure15 patient noncv disease eg anaemia pulmonary renal thy roid hepatic disease may symptom sign similar hf absence cardiac dysfunction fulfil criterion hf however pathology coexist heart failure exacerbate heart failure syndrome 3.22 right ventricular dysfunction heart failure also result right ventricular rv dysfunc tion rv mechanic function altered setting either pressure volume overload16 although main aetiology chronic rv failure lv dysfunctioninduced pulmonary hyperten sion number cause rv dysfunction eg mi arrhythmogenic right ventricular cardiomyopathy arvc valve disease17 diagnosis determined quantitative assessment global rv function commonly echocar diography using least one following measurement frac tional area change fac tricuspid annular plane systolic excursion tapse doppler tissue imagingderived systolic s0 velocity tricuspid annulus diagnosis management rv dysfunction covered comprehensively recent heart failure association hfa position paper18 3.23 common terminology used heart failure heart failure usually divided two presentation chronic heart failure chf acute heart failure ahf chf describes established diagnosis heart failure gradual onset symptom chf deteriorates either suddenly slowly episode may described ‘decompensated’ hf result hospital admission intravenous iv diuretic outpatient setting addition heart failure present acutely considered section ahf section 11 individual heart failure may recover completely eg due alcoholinduced cardiomyopathy cmp viral myocarditis takotsubo syndrome peripartum cardiomyopathy ppcm tachycardiomyopathy patient lv systolic dysfunction may show substantial even complete recovery lv systolic function receiving drug device 3.24 terminology related symptomatic severity heart failure simplest terminology used describe severity heart failure new york heart association nyha functional classification 4 however relies solely symptom many better prognostic indicator hf19 importantly patient mild symptom may still high risk hospitaliza tion death20 predicting outcome particularly important advanced heart failure guide selection cardiac transplantation device covered detail section advanced heart failure section 10 3.3 epidemiology natural history heart failure 3.31 incidence prevalence developed country ageadjusted incidence heart failure may fall ing presumably reflecting better management cardiovascular disease due ageing overall incidence increasing2124 currently inci dence heart failure europe 31000 personyears agegroups 51000 personyears adults2526 prevalence hf appears 12 adults212731 usually include recognizeddiagnosed heart failure case true prevalence likely higher32 prevalence increase age around 1 aged 10 a10 70 year over3336 3 deﬁnition heart failure reduced ejection fraction mildly reduced ejection fraction preserved ejection fraction type hf hfref hfmref hfpef criterion symptom ± signsa symptom ± signsa symptom ± signsa left ventricular ejection fraction 50   obje40ve evidenc49f cardiac 50uctural andor functional abnormality consistent presence lv diastolic dysfunctionraised lv ﬁlling pressure including raised natriuretic peptidesc heart failure heart failure hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejec tion fraction lv left ventricle left ventricular ejection fraction left ventricular ejection fraction asigns may present early stage heart failure especially hfpef optimally treated patient bfor diagnosis hfmref presence evidence structural heart disease eg increased left atrial size lv hypertrophy echocardiographic measure impaired lv ﬁlling make diagnosis likely cfor diagnosis hfpef greater number abnormality present higher likelihood hfpef esc 2021 downloaded guest 24 november 2024 generally believed hf 50 hfref 50 hfpefhfmref mainly based st50es hospitalize50patients32353738 esc longterm registry outpatient set ting report 60 hfref 24 hfmref 16 hfpef39 somew60 5024f heart failure patient 16ale214041 3.32 aetiology he50 failure common cause well key investigation heart failure shown 5 aetiology heart failure varies according geography westerntype developed country coronary artery disease cad hypertension predomi nant factors27 regard ischaemic aetiology hfmref resembles hfref higher frequency underlying cad compared hfpef384243 3.33 natural history prognosis prognosis patient heart failure ha improved considerably since publication first decade ago however remains poor quality life qol also markedly reduced improvement prognosis ha confined hfref mortality rate higher observational clinical trials44 olmsted county cohort 1year 5year mortality rate diagnosis type heart failure patient 20 53 respectively 2000 2010.45 combining framingham heart fhs cardiovascular health chs cohort reported 67 mortality rate within 5 year following diagnosis46 despite receiving less evidencebased woman better survival men47 overall prognosis better hfmref compared hfref39 note transition ejection fraction time common patient progress hfmref hfref worse prognosis remain stable transition higher ejection fraction category4852 hfpef generally considered confer better survival hfref observational show difference negligible4546 contrast large maggic metaanalysis con cluded adjusted mortality risk patient hfpef wa considerably lower patient hfref53 several country shown 1980 2000 survival heart failure patient ha improved markedly415457 however positive trend may levelled since then45 initial diagnosis heart failure patient hospitalized every year average54 2000 2010 mean rate hospitaliza tion olmsted county cohort wa 1.3 per personyear interestingly majority 63 hospitalization related noncv causes45 several european country united state u shown heart failure hospitalization rate peaked 1990s declined54555860 however recent incident heart failure conducted 1998 2017 united kingdom uk ageadjusted rate first hospitalization increased 28 allcause heart failure admission 42 noncv admissions61 increase higher woman perhaps related higher comorbidity rate risk heart failure hospital ization 1.5 time higher patient diabetes compared con trols af higher body mass index bmi higher glycated haemoglobin hba1c well low estimated glomerular filtra tion rate egfr strong predictor heart failure hospitalizations29 due population growth ageing increasing prevalence comorbidities absolute number hospital admission hf expected increase considerably future perhaps much 50 next 25 years2462 4 chronic heart failure 4.1 key step diagnosis chronic heart failure diagnosis chf requires presence symptom andor sign heart failure objective evidence cardiac dysfunction 1 typical symptom include breathlessness fatigue ankle swelling 6 symptom sign lack sufficient accuracy used alone make diagnosis hf6366 diagnosis chf made likely patient history mi arterial hypertension cad diabetes mellitus alcohol misuse chronic kidney disease ckd cardiotoxic chemotherapy family history cmp sudden death following diagnostic test recommended assess ment patient suspected chronic hf 1 electrocardiogram ecg normal ecg make diagnosis heart failure unlikely63 ecg may reveal abnormality af q wave lv hypertrophy lvh widened qrs complex 7 increase likelihood diagnosis heart failure also may guide 4 new york heart association functional classiﬁcation based severity symptom physical activity Class limitation physical activity ordinary physical activity doe cause undue breathlessness fatigue palpitation Class II slight limitation physical activity comfortable rest ordinary physical activity result undue breathless ness fatigue palpitation Class III marked limitation physical activity comfortable rest less ordinary activity result undue breathless ness fatigue palpitation Class IV unable carry physical activity without discom fort symptom rest present physical activ ity undertaken discomfort increased esc 2021 downloaded guest 24 november 2024 suspected heart failure echocardiography ntprobnp ≥ 125 pgml bnp ≥ 35 pgml n diagnostic algorithm heart failure risk factor symptom andor sign abnormal ecg heart failure strongly suspected ntprobnpbnp unavailable abnormal finding heart failure confirmed define heart failure phenotype based left ventricular ejection fraction measurement ≤40 hfref 41–49 hfmref ≥50 hfpef determine aeti40gy commen49treatment he50 failure unlikely consider diagnosis n 1 diagnostic algorithm heart failure bnp btype natriuretic peptide ecg electrocardiogram hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejection fraction lvef left ventricu lar ejection fraction ntprobnp nterminal prob type natriuretic peptide abnormal echocardiographic finding described detail respective section hfref section 5 hfmref section 7 hfpef section 8 downloaded guest 24 november 2024 5 cause heart failure common mode presentation speciﬁc investigation cause example presentation specific investigation cad myocardial infarction angina “anginaequivalent” arrhythmia invasive coronary angiography ct coronary angiography imaging stress test echo nuclear cmr hypertension heart failure preserved systolic function malignant hypertensionacute pulmonary oedema 24 h ambulatory bp plasma metanephrines renal artery imaging renin aldosterone valve disease primary valve disease eg aortic stenosis secondary valve disease eg functional regurgitation congenital valve disease echo  transoesophagealstress arrhythmia atrial tachyarrhythmias ventricular arrhythmia ambulatory ecg recording electrophysiology indicated cmps dilated hypertrophic restrictive arvc peripartum takotsubo syndrome toxin alcohol cocaine iron copper cmr genetic testing right left heart catheterization cmr angiography trace element toxicology lfts ggt congenital heart disease congenitally correctedrepaired transposition great artery shunt lesion repaired tetralogy fallot ebstein’s anomaly cmr infective viral myocarditis chaga disease hiv lyme disease cmr emb serology druginduced anthracyclines trastuzumab vegf inhibitor immune checkpoint inhibitor proteasome inhibitor rafþmek inhibitor inﬁltrative amyloid sarcoidosis neoplastic serum electrophoresis serum free light chain bence jones protein bone scintigraphy cmr ctpet emb serum ace cmr fdgpet chest ct emb cmr emb storage disorder haemochromatosis fabry disease glycogen storage disease iron genetics cmr t2 imaging emb agalactosidase genetics cmr t1 mapping endomyocardial disease radiotherapy endomyocardial ﬁbrosiseosinophilia carcinoid cmr emb 24 h urine 5hiaa pericardial disease calciﬁcation inﬁltrative chest ct cmr right left heart catheterization metabolic endocrine disease nutritional disease thiamine vitamin b1 selenium deﬁciencies autoimmune disease tfts plasma metanephrines renin aldosterone cortisol speciﬁc plasma nutrient ana anca rheumatology review neuromuscular disease friedreich’s ataxia muscular dystrophy nerve conduction electromyogram genetics ck electromyogram genetics 5hiaa 5hydroxyindoleacetic acid angiotensin converting enzyme angiotensinconverting enzyme ana antinuclear antibody anca antinuclear cytoplasmic antibody arvc arrhythmogenic right ventricular cardiomyopathy bp blood pressure cad coronary artery disease cmp cardiomyopathy cmr cardiac magnetic resonance ck creatinine kinase ct computed tomography ecg electrocardiogram echo echocardiography emb endomyocardial biopsy fdg ﬂuorodeoxyglucose ggt gammaglutamyl transferase hiv human immunodeﬁciency virus h hour lft liver function test lge late gadolinium enhancement mek mitogenactivated protein kinase pet positron emission tomography tft thyroid function test vegf vascular endothelial growth factor esc 2021 downloaded guest 24 november 2024 2 measurement np recommended available plasma concentration btype natriuretic peptide bnp 35 pgml nterminal probtype natriuretic peptide ntprobnp 125 pg midregional proatrial natriuretic peptide mrproanp 40 pmoll68 make diagnosis heart failure unlikely dis cussed detail section 4.26970 3 basic investigation serum urea electrolyte creatinine full blood count liver thyroid function test recommended differentiate heart failure condition provide prognostic information guide potential 4 echocardiography recommended key investigation assessment cardiac function well determination lvef echocardiography also provides information param eters chamber size eccentric concentric lvh regional wall motion abnormality may suggest underlying cad takotsubo syndrome myocarditis rv function pulmonary hypertension valvular function marker diastolic function1671 5 chest xray recommended investigate potential cause breathlessness eg pulmonary disease may also provide sup portive evidence hf eg pulmonary congestion cardiomegaly 4.2 natriuretic peptide plasma concentration np recommended initial diagnostic test patient symptom suggestive heart failure rule diag nosis elevated concentration support diagnosis hf useful prognostication72 may guide cardiac investigation73 however noted many cause ele vated np—both cardiovascular noncv—that might reduce diagnostic accuracy 7 cause include af increasing age acute chronic kidney disease74 conversely np concentration may disproportionately low obese patients75 4.21 use nonacute setting diagnostic value np addition sign symptom diagnostic test ecg ha assessed several primary care setting687680 aim wa either exclude establish diagnosis hf task force considered adequate quality included np cutoff point diagnostic algorithm probability hf wa extremely low upper limit normal nonacute setting 35 pgml bnp 125 pgml ntprobnp stud negative predictive value np concentration threshold range 0.94 0.987678 fewer data available mrproanp chf ahf concentration 40 pmoll used rule hf68 4.3 investigation determine underlying aetiology chronic heart failure recommended test determine underlying aetiology chf summarized 5 recommended diagnostic test patient suspected chronic heart failure recommendation classa levelb bnpntprobnpc b 12lead ecg c transthoracic echocardiography c chest radiography xray c routine blood test comorbidities including full blood count urea electrolyte thyroid function fasting glucose hba1c lipid iron status tsat ferritin c bnp btype natriuretic peptide ecg electrocardiogram hba1c glycated haemoglobin ntprobnp nterminal probtype natriuretic peptide tsat transferrin saturation aclass recommendation blevel evidence creferences listed section 4.2 item 6 symptom sign typical heart failure symptom sign typical speciﬁc breathlessness orthopnoea paroxysmal nocturnal dyspnoea reduced exercise tolerance fatigue tiredness increased time recover exercise ankle swelling elevated jugular venous pressure hepatojugular reﬂux third heart sound gallop rhythm laterally displaced apical impulse less typical less speciﬁc nocturnal cough wheezing bloated feeling loss appetite confusion especially elderly depression palpitation dizziness syncope bendopneaa weight gain 2 kgweek weight loss advanced hf tissue wasting cachexia cardiac murmur peripheral oedema ankle sacral scrotal pulmonary crepitation pleural effusion tachycardia irregular pulse tachypnoea cheynestokes respiration hepatomegaly ascites cold extremity oliguria narrow pulse pressure heart failure heart failure athis symptom advanced heart failure corresponds shortness breath leaning forward67 esc 2021 esc 2021 downloaded guest 24 november 2024 exercise pharmacological stress echocardiography may used assessment inducible ischaemia consid ered suitable coronary revascularization81 patient hfpef valve disease unexplained dyspnoea stress echocardiogra phy might help clarify diagnosis82 cardiac magnetic resonance cmr imaging late gadoli nium enhancement lge t1 mapping extracellular volume identify myocardial fibrosisscar typically subendo cardial patient ischaemic heart disease ihd contrast midwall scar typical dilated cardiomyopathy dcm addition cmr allows myocardial characterization eg myocar ditis amyloidosis sarcoidosis chaga disease fabry disease lv noncompaction cmp haemochromatosis arrhythmogenic cardiomyopathy ac8384 computed tomography coronary angiography ctca may considered patient low intermediate pretest probability cad equivocal noninvasive stress test order exclude diagnosis cad5 singlephoton emission ct spect also used assess myocardial ischaemia viability myocardial inflammation infil tration scintigraphy technetium tclabelled bisphosphonate ha shown high sensitivity specificity imaging cardiac trans thyretin amyloid85 esc 2021 recommendation specialized diagnostic test selected patient chronic heart failure detect reversibletreatable cause heart failure recommendation classa levelb cmr cmr recommended assessment myocardial structure function poor echocardiogram acoustic window c cmr recommended characterization myocardial tissue suspected inﬁltrative dis ease fabry disease inﬂammatory disease myo carditis lv noncompaction amyloid sarcoidosis iron overloadhaemochromatosis c cmr lge considered dcm distinguish ischaemic nonischae mic myocardial damage iia c invasive coronary angiography considered eligible potential coronary revascularization invasive coronary angiography recommended patient angina despite pharmacological ther apy symptomatic ventricular arrhythmias5 b invasive coronary angiography may considered patient hfref intermediate high pretest probability cad presence ischaemia noninvasive stress tests89 iib b noninvasive testing ctca considered patient low intermediate pretest probability cad equivocal noninvasive stress test order rule coronary artery stenosis iia c noninvasive stress imaging cmr stress echocar diography spect pet may considered assessment myocardial ischaemia viability patient cad considered suitable coronary revascularization9093 iib b exercise testing may considered detect reversible myocardial ischaemia investigate cause dyspnoea9496 iib c cardiopulmonary exercise testing cardiopulmonary exercise testing recom mended part evaluation heart transplantation andor mcs9496 c cardiopulmonary exercise testing considered optimize prescription exercise training9496 iia c cardiopulmonary exercise testing considered identify cause unexplained dyspnoea andor exercise intolerance9496 iia c right heart catheterization right heart catheterization recommended patient severe heart failure evaluated heart transplantation mc c continued 7 cause elevated concentration natriuretic peptides8688 cardiac heart failure ac pulmonary embolism myocarditis left ventricular hypertrophy hypertrophic restrictive cardiomyopathy valvular heart disease congenital heart disease atrial ventricular tachyarrhythmias heart contusion cardioversion icd shock surgical procedure involving heart pulmonary hypertension noncardiac advanced age ischaemic stroke subarachnoid haemorrhage renal dysfunction liver dysfunction mainly liver cirrhosis ascites paraneoplastic syndrome copd severe infection including pneumonia sepsis severe burn anaemia severe metabolic hormone abnormality eg thyrotoxicosis diabetic ketosis ac acute coronary syndrome copd chronic obstructive pulmonary dis ease icd implantable cardioverterdeﬁbrillator downloaded guest 24 november 2024 coronary angiography recommended patient hf angina pectoris ‘angina equivalent’ despite pharmacological order establish diagnosis cad severity coronary angiography may also considered patient hfref intermediate high pretest probability cad considered potentially suitable coronary revascularization5 5 heart failure reduced ejection fraction 5.1 diagnosis heart failure reduced ejection fraction diagnosis hfref requires presence symptom andor sign heart failure reduced ejection fraction lvef 40 usually obtained echocardiography detail quality standard adhered determining presence reduced lv systolic function echocardiography found european association cardiovascular imaging eacvi position paper99 assessment ef possi ble echocardiography cmr rarely nuclear technique employed algorithm diagnosis hfref depicted 1 investigation underlying aetiology please refer 5 5.2 pharmacological patient heart failure reduced ejection fraction 5.21 Goals pharmacotherapy patient heart failure reduced ejection fraction pharmacotherapy cornerstone hfref implemented considering device alongside nonpharmacological intervention three major goal patient hfref reduction mortality ii prevention recurrent hospitalization due worsening hf iii improvement clinical status func tional capacity qol100102 key evidence supporting recommendation section patient symptomatic hfref given supplementary 1 2 depicts algorithm strategy including drug device patient hfref Class indication reduction mortality either allcause cv recommen dations summarized 5.22 General principle pharmacotherapy heart failure reduced ejection fraction modulation reninangiotensinaldosterone raas sympa thetic nervous system angiotensinconverting enzyme inhibi tor acei angiotensin receptorneprilysin inhibitor arni betablockers mineralocorticoid receptor antagonist mra ha shown improve survival reduce risk heart failure hospital izations reduce symptom patient hfref drug serve foundation pharmacotherapy patient hfref triad aceiarni betablocker mra recommended cornerstone patient unless drug contraindicated tolerated103105 uptitrated dos used clinical maximally tolerated dos possible guideline still recom mend use arni replacement acei suitable patient remain symptomatic acei betablocker mra however arni may considered firstline ther apy instead acei106107 recommended dos drug given 8 angiotensinreceptor blocker arb still role intolerant acei arni sodiumglucose cotransporter 2 sglt2 inhibitor dapagli flozin empagliflozin added aceiarnibeta blockermra reduced risk cardiovascular death worsening heart failure patient hfref108109 unless contraindicated tolerated dapagliflozin empagliflozin recommended patient hfref already treated aceiarni betablocker mra regardless whether diabetes drug may used selected patient hfref discussed section 5.4 right heart catheterization considered patient heart failure thought due constrictive pericarditis restrictive cardiomyop athy congenital heart disease high output state iia c right heart catheterization considered patient probable pulmonary hyperten sion assessed echo order conﬁrm diagnosis assess reversibility correction valvestructural heart disease iia c right heart catheterization may considered selected patient hfpef conﬁrm diagnosis iib c emb emb considered patient rap idly progressive heart failure despite standard probability speciﬁc diagnosis conﬁrmed myocardial samples9798 iia c cad coronary artery disease cmr cardiac magnetic resonance ctca computed tomography coronary angiography dcm dilated cardiomyopathy emb endomyocardial biopsy heart failure heart failure hfpef heart failure pre served ejection fraction hfref heart failure reduced ejection fraction lge late gadolinium enhancement lv left ventricular mc mechanical cir culatory support pet positron emission tomography spect singlephoton emission computed tomography aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 management patient hfref left ventricular ejection fraction ≤35 qrs 35 device indicated inappro35ate aceiarnia betablocker mra dapaglClass Iempagliflozin l35 diuretic fluid retention ischaemic class nonischaemiClass IIs iia icd qrs ≥150 ms35class qrs 130–149 class iia crtdbp 2 therapeutic algorithm class indication patient heart failure reduced ejeClass IractionClass IIaClass IClass IIaClass acei angiotensincon verting enzyme inhibitor arni angiotensin receptorneprilysin inhibitor crtdcardiac resynchronization defibrillator crtp cardiac resynchronization pacemaker icd implantable cardioverterdefibrillator hfref heart failure reduced ejection fraction mra mineralo corticoid receptor antagonist qrs q r wave ecg sr sinus rhythm aa replacement acei bwhere appropriate Class green Class IIa yellow pharmacological indicated patient nyha class II–iv heart failure reduced ejection fraction lvef 40 recommendation classa levelb acei recommended patient hfref reduce risk hf hospitalization death110113 betablocker recommended patient stable hfref reduce risk heart failure hospitalization death114120 mra recommended patient hfref reduce risk heart failure hospitalization death121122 dapagliﬂozin empagliﬂozin recommended patient hfref reduce risk heart failure hospitalization death108109 sacubitrilvalsartan recommended replacement acei patient hfref reduce risk hf hospitalization death105 b acei angiotensinconverting enzyme inhibitor heart failure heart failure hfref heart failure reduced ejection fraction left ventricular ejection fraction left ventricular ejection fraction mra miner alocorticoid receptor antagonist nyha new york heart association aclass recommendation blevel evidence esc 2021 5.3 drug recommended patient heart failure reduced ejection fraction downloaded guest 24 november 2024 5.31 angiotensinconverting enzyme inhibitor aceis first class drug shown reduce mortality morbidity patient hfref110113 also shown improve symptoms111 recommended patient unless contraindicated tolerated uptitrated maximum tolerated recommended dos practical guidance use aceis given supplementary 2 5.32 betablockers betablockers shown reduce mortality morbidity patient hfref addition acei diu retic114120 also improve symptoms123 consensus acei betablockers commenced together soon diagnosis symptomatic hfref established evi dence favouring initiation betablocker acei vice versa124 betablockers initiated clinically stable euvolaemic patient low gradually uptitrated maximum tolerated patient admitted ahf beta blocker cautiously initiated hospital patient haemodynamically stabilized individual patient data ipd metaanalysis major beta blocker hfref ha shown benefit hospital admission mortality subgroup patient hfref af125 however since retrospective subgroup analysis betablockers increase risk guideline committee decided make separate recommendation according heart rhythm practical guidance use betablockers given supplementary 3 5.33 mineralocorticoid receptor antagonist mras spironolactone eplerenone recommended addition acei betablocker patient hfref reduce mortality risk heart failure hospitalization121122 also improve symptoms121 mras block receptor bind aldosterone different degree affinity steroid hormone eg corticoste roid androgen receptor eplerenone specific aldos terone blockade therefore cause less gynaecomastia caution exercised mras used patient impaired renal function serum potassium concen trations 5.0 mmoll practical guidance use mras given supplementary 4 5.34 angiotensin receptorneprilysin inhibitor paradigmhf sacubitrilvalsartan arni wa shown superior enalapril reducing hospitalization worsening hf cardiovascular mortality allcause mortality patient ambulatory hfref left ventricular ejection fraction 40 changed 35 patient elevated plasma np concentration egfr 30 min1.73 m2 able tolerate enalapril sacubitril valsartan runin period105 additional benefit sacubitril valsartan included improvement symptom qol105 reduction incidence diabetes requiring insulin treatment126 reduction decline egfr127 well reduced rate hyperkalaemia128 additionally use sacubitrilvalsartan may allow reduction loop diuretic requirement129 symptomatic hypotension wa reported commonly patient treated sacubitrilvalsartan compared enalapril despite developing hypotension patient also gained clinical benefit sacubi trilvalsartan therapy128130 8 evidencebased dos diseasemodifying drug key randomized patient heart failure reduced ejection fraction starting target acei captoprila 6.25 tid 50 tid enalapril 2.5 bid 1020 bid lisinoprilb 2.55 od 2035 od ramipril 2.5 bid 5 bid trandolaprila 0.5 od 4 od arni sacubitrilvalsartan 4951 bidc 97103 bid betablockers bisoprolol 1.25 od 10 od carvedilol 3.125 bid 25 bide metoprolol succinate crxl 12.525 od 200 od nebivolold 1.25 od 10 od mra eplerenone 25 od 50 od spironolactone 25 odf 50 od sglt2 inhibitor dapagliﬂozin 10 od 10 od empagliﬂozin 10 od 10 od agent candesartan 4 od 32 od losartan 50 od 150 od valsartan 40 bid 160 bid ivabradine 5 bid 7.5 bid vericiguat 2.5 od 10 od digoxin 62.5 od 250 od hydralazine isosorbide dinitrate 37.5 tid20 tid 75 tid40 tid acei angiotensinconverting enzyme inhibitor arni angiotensin receptor neprilysin inhibitor bid bi die twice cr controlled release cardiovascular cardiovascular mra mineralocorticoid receptor antagonist od omne die sglt2 sodiumglucose cotransporter 2 tid ter die three time day xl extended release aindicates acei dosing target derived postmyocardial infarction bindicates drug higher ha shown reduce morbiditymor tality compared lower drug substantive randomized placebocontrolled optimum uncertain csacubitrilvalsartan may optional lower starting 2426 bid history symptomatic hypotension dindicates shown reduce cardiovascular allcause mortality patient heart failure shown noninferior doe ea maximum 50 twice administered patient weighing 85 kg fspironolactone ha optional starting 12.5 patient renal status hyperkalaemia warrant caution esc 2021 downloaded guest 24 november 2024 therefore recommended acei angiotensin receptor blocker replaced sacubitrilvalsartan ambulatory patient hfref remain symptomatic despite optimal outlined two examined use arni hospitalized patient previously treated acei initiation setting appears safe reduces subsequent cardiovascular death heart failure hospi talizations 42 compared enalapril106107131 initiation sacubitrilvalsartan acei naive ie de novo patient hfref may considered class recommendation iib level evidence b patient commenced sacubitrilvalsartan adequate blood pressure bp egfr 30 mLmin1.73 m2 washout period least 36 h acei required order minimize risk angioedema practical guidance use arni given supplementary 5 5.35 sodiumglucose cotransporter 2 inhibitor dapahf investigated longterm effect dapagliflozin sglt2 inhibitor compared placebo addition optimal medi cal omt morbidity mortality patient ambu latory hfref108 patient participated nyha class IIiv left ventricular ejection fraction 40 despite omt patient also required elevated plasma ntprobnp egfr 30 mLmin1.73 m2.108 dapagliflozin resulted 26 reduction pri mary endpoint composite worsening heart failure hospitalization urgent visit resulting iv hf cardiovascular death component significantly reduced moreover dapagliflozin reduced allcause mortality108 alleviated heart failure symptom improved physical function qol patient symptomatic hfref132 benefit seen early initiation dapagliflozin absolute risk reduction wa large survival benefit seen extent patient hfref without diabetes across whole spectrum hba1c values108 subsequently emperorreduced found empagliflo zin reduced combined primary endpoint cardiovascular death heart failure ho pitalization 25 patient nyha class IIiv symptom left ventricular ejection fraction 2040min1.73 m2 wa also reduction decline i20 mLr individual receiving empagliflozin wa also asso ciated improvement qol133 although wa significant reduction cardiovascular mortality emperorreduced recent metaanalysis dapahf emperorreduced tri al found heterogeneity cardiovascular mortality134 therefore dapagliflozin empagliflozin recommended addition omt aceiarni betablocker mra patient hfref regardless diabetes status diuretic natriuretic property sglt2 inhibitor may offer additional bene fit reducing congestion may allow reduction loop diuretic requirement135 combined sglt1 2 inhibitor sotagliflozin ha also studied patient diabetes hospitalized hf drug reduced cardiovascular death hospitalization hf136 discussed ahf comorbidity section sglt2 inhibitor may increase risk recurrent genital fungal infection small reduction egfr following initiation expected reversible lead premature dis continuation drug practical guidance use sglt2 inhibitor dapagliflo zin empagliflozin given supplementary 6 5.4 drug recommended considered selected patient heart failure reduced ejection fraction pharmacological indicated selected patient nyha class II–iv heart failure reduced ejection fraction lvef 40 recommendation classa levelb loop diuretic diuretic recommended patient hfref sign andor symptom congestion alleviate heart failure symptom improve exercise capacity reduce heart failure hospitalizations137 c arb arbc recommended reduce risk heart failure hospitalization cardiovascular death symptomatic patient unable tolerate acei arni patient also receive betablocker mra138 b ifchannel inhibitor ivabradine considered symptomatic patient left ventricular ejection fraction 735pm despite evidencebased betablocker maxi mum tolerated aceior arni mra reduce risk hf hospitalization cardiovascular death139 iia b ivabradine considered symptomatic patient left ventricular ejection fraction 735pm unable tolerate contraindication betablocker reduce risk heart failure hospitalization cv death patient also receive acei arni mra140 iia c soluble guanylate cyclase stimulator vericiguat may considered patient nyha class IIiv worsening hf despite acei arni betablocker mra reduce risk cardiovascular mortality heart failure hospitalization141 iib b hydralazine isosorbide dinitrate hydralazine isosorbide dinitrate considered selfidentiﬁed black patient left ventricular ejection fraction 35 left ventricular ejection fraction 45 combined dilated left ventricle nyha class IIIiv despite acei arni betablocker mra reduce risk heart failure hospitalization death142 iia b continued downloaded guest 24 november 2024 5.41 diuretic loop diuretic recommended reduce sign andor symp tom congestion patient hfref quality evi dence regarding diuretic poor effect morbidity mortality studied rcts however also remembered major diseasemodifying hfref conducted high background use loop diuretic one metaanalysis ha shown patient hfref loop thiazide diuretic appear reduce risk death worsening heart failure compared placebo compared active control diuretic improve exercise capacity137 loop diuretic produce intense shorter diuresis thiazide although act synergistically sequential nephron block ade combination may used treat diuretic resistance however adverse effect likely combination used care note arni mras sglt2 inhibitor may also possess diuretic properties129145 aim diuretic achieve maintain euvolaemia lowest diuretic euvolaemichypovolaemic patient use diuretic drug might reduced discontin ued146 patient trained selfadjust diuretic based monitoring symptomssigns congestion weight measurement practical guidance use diuretic given supplementary 7 5.42 angiotensin ii type 1 receptor blocker place arb management hfref ha changed last year recommended patient tolerate acei arni serious side effect candesartan charmalternative reduced cardiovascular death heart failure hospitalization patient receiving acei due previous intolerance138 valsartan addition usual including acei reduced heart failure hospitalization valheft trial147 however angiotensin receptor blocker ha reduced allcause mortality 5.43 channel inhibitor ivabradine slows heart rate inhibition channel sinus node therefore effective patient sr ivabradine reduced combined endpoint cardiovascular mortality heart failure hospitaliza tion patient symptomatic hfref left ventricular ejection fraction 735pm evidencebased including acei arb betablocker mra139140 recom mendation based heart rate 70 bpm used shift however european medicine agency ema approved ivabradine use europe patient hfref left ventricular ejection fraction 735pm group ivabradine conferred survival benefit148 based retrospective subgroup analysis every effort made commence uptitrate betablocker guideline recommendedmaximally tolerated dos prior considering ivabradine practical guidance use ivabradine given supplementary 8 5.44 combination hydralazine isosorbide dinitrate clear evidence suggest use fixeddose com bination patient hfref small rct conducted selfidentified black patient showed addition combina tion hydralazine isosorbide dinitrate conventional acei betablocker mra reduced mortality hf hospitalization patient hfref nyha class iiiiv142 result difficult translate patient racial ethnic origin additionally combination hydralazine isosorbide dinitrate may considered symptomatic patient hfref cannot tolerate acei arni angiotensin receptor blocker contraindi cated reduce mortality however recommendation based result relatively small veteran administration cooperative included male patient sympto matic hfref treated digoxin diuretics143 5.45 digoxin digoxin may considered patient hfref sr reduce risk hospitalization144 although effect routinely treated betablockers ha tested dig overall effect mortality digoxin wa neutral effect digoxin patient hfref atrial fibrillation studied rcts suggested potentially higher risk event patient atrial fibrillation receiving digoxin149150 whereas another metaanalysis concluded basis nonrcts digoxin ha deleterious effect mortality patient atrial fibrillation hf hfref151 therefore patient sympto matic heart failure af digoxin may useful patient hfref atrial fibrillation rapid ventricular rate therapeu tic option cannot pursued150152155 digoxin ha narrow therapeutic window level checked aiming serum digoxin concentration 1.2 ngml156157 caution also exercised using female elderly frail hypokalaemic malnourished subject patient reduced renal function digitoxin could considered digitoxin use heart failure sr currently investigated158 hydralazine isosorbide dinitrate may con sidered patient symptomatic hfref cannot tolerate acei arb arni contraindicated reduce risk death143 iib b digoxin digoxin may considered patient symptomatic hfref sinus rhythm despite acei arni beta blocker mra reduce risk hospi talization allcause hf hospitalizations144 iib b acei angiotensinconverting enzyme inhibitor angiotensin receptor blocker angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor bpm beat per minute cardiovascular cardiovascular heart failure heart failure hfref heart failure reduced ejection fraction left ventricular ejection fraction left ventricular ejection fraction mra minera locorticoid receptor antagonist nyha new york heart association sr sinus rhythm aclass recommendation blevel evidence cthe arb evidence hfref candesartan losartan valsartan esc 2021 downloaded guest 24 november 2024 diuretic sr lbbb ≥ 150 reduce mortality patient reduce heart failure hospitalizationmortality selected patient volume overload aceiarni bb mra sglt2i exercise rehabilitation reduce heart failure hospitalization improve qol patient selected advanced heart failure patient crtpd atrial fibrillation anticoagulation mc bttbtc aortic stenosis savrtavi mitral regurgitation tee mv repair heart rate sr70 bpm ivabradine black race hydralazineisdn aceiarni intolerance arb atrial fibrillation digoxin coronary artery disease cabg iron deficiency ferric carboxymaltose icd ischaemic aetiology heart transplantation longterm mc dt multiprofessional disease management nonischaemic aetiology sr lbbb 130–149 non lbbb ≥ 150 crtpd management hfref icd pvi 3 central illustration strategic phenotypic overview management heart failure reduced ejection fraction aceiangiotensinconvert ing enzyme inhibitor arbangiotensin receptor blocker arniangiotensin receptorneprilysin inhibitor bbbetablocker bpmbeats per minute btc bridge candidacy bttbridge transplantation cabgcoronary artery bypass graft crtd cardiac resynchronization defibrillator crtpcardiac resynchronization pacemaker dtdestination hfheart failure hfrefheart failure reduced ejection fraction icd implantable cardioverterdefibrillator isdnisosorbide dinitrate lbbbleft bundle branch block mcsmechanical circulatory support mramineralocor ticoid receptor antagonist mvmitral valve pvipulmonary vein isolation qolquality life savrsurgical aortic valve replacement sglt2isodium glucose cotransporter 2 inhibitor srsinus rhythm tavitranscatheter aortic valve replacement teetranscatheter edge edge colour code class recommendation green class recommendation yellow class recommendation iia see 1 detail class recommenda tion show management option Class iia recommendation see specific Class IIb recommendation downloaded guest 24 november 2024 5.46 recently reported advance heart failure reduced ejection fraction soluble guanylate cyclase stimulator victoria assessed efficacy safety oral soluble guanylate cyclase stimulator vericiguat patient reduced ef recently decompensated chf incidence primary endpoint death cardiovascular cause hospitalization heart failure wa lower among received vericiguat among received placebo141 wa reduction either allcause cardiovascular mortality thus vericiguat may consid ered addition standard hfref reduce risk cardiovascular mortality hospitalization hf cardiac myosin activator galactichf assessed efficacy safety car diac myosin activator omecamtiv mecarbil hfref patient enroll ing patient inpatient outpatient setting primary endpoint first heart failure event cardiovascular death wa reduced 8 wa significant reduction cardiovascular mortality currently drug licensed use hf however future may able considered addition standard hfref reduce risk cardiovascular mortality hospitalization hf159 5.5 strategic phenotypic overview management heart failure reduced ejection fraction addition general considered section 5 appropriate consider selected patient covered detail later section main one ie Class iia mortalityhospitalization indication depicted 3 effect intervention symptomsqol outlined supplementary 9 6 cardiac rhythm management heart failure reduced ejection fraction section provides recommendation use implantable cardioverterdefibrillators icd cardiac resynchronization ther apy crt implantable device discussed end section 6.1 implantable cardioverter defibrillator high proportion death among patient hf especially milder symptom occur suddenly unexpectedly many may due electrical disturbance including ven tricular arrhythmia bradycardia asystole although due acute vascular event improve delay progression cardiovascular disease shown reduce annual rate sudden death105160 treat arrhythmic event occur icds effective correcting potentially lethal ventricular arrhythmia case transvenous system also prevent bradycardia antiarrhythmic drug might reduce rate tachyarrhythmias sudden death reduce overall mortality161 may increase recommendation implantable cardioverter deﬁbrillator patient heart failure recommendation classa levelb secondary prevention icd recommended reduce risk sudden death allcause mortality patient recovered ventricular arrhyth mia causing haemodynamic instability expected survive 1 year good functional status absence reversible cause unless ventricular arrhythmia ha occurred 3 month omt provided expected survive substantially longer 1 year good functional status161165 icd considered reduce tclass II sudden death allcause mortality patient symptomatic heart failure nyha class iiiii nonischa35c aetiology lvef 3 month omt provided expected survive substantially longer 1 year good functional status161166167 iia patient carefully evaluated experienced cardiologist generator replacement management goal patient’s need clinical sta35 may changed168172 iia b wearable icd may considered patient heart failure risk sudden cardiac death limited period bridge implanted device173176 iib b icd implantation recommended within 40 day myocardial infarction implantation time doe improve prognosis177178 iii icd recommended patient nyha class iv severe symptom refractory pharmacological unless didates crt vad cardiac transplantation179183 iii c crt cardiac resynchronization heart failure heart failure icd implantable cardioverterdeﬁbrillator left ventricular ejection fraction left ventricular ejection fraction myocardial infarction myoclass IVal infarction nyha new york heart association omt optimal medical vad ventricular assist device aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 6.11 secondary prevention sudden cardiac death compared amiodarone icds reduce mortality survivor cardiac arrest patient experienced sus tained symptomatic ventricular arrhythmia icd recom mended patient intent increase survival decision implant take account patient’s view qol left ventricular ejection fraction survival benefit uncertain left ventricular ejection fraction 35 absence disease likely cause death within fol lowing year162164184 6.12 primary prevention sudden cardiac death analysis 40 000 patient 12 pivotal heart failure rate sudden cardiac death decreased 44 20year period mid1990s 2015160 almost certainly due advance heart failure many key guidelinerecommended including betablockers mras sacubitrilvalsartan crt pacemaker crtp reduce risk sudden death aforementioned heart failure shown reduce mor tality patient hfref amiodarone ha not161 however used caution due significant sideeffect profile conversely dronedarone185 class antiarrhythmic agent disopyramide encainide flecainide186 used prevention arrhythmia due increase mortality seen clinical although icd reduces rate sudden arrhythmic death patient hfref187 would expected wellmanaged patient additional benefit afforded icd would lower danish rate sudden death low patient non ischaemic cardiomyopathy nicm 70 patient 1116 fol lowed 5 year sudden death166 whilst wa modest absolute reduction sudden death defibrillatorcontaining device significantly improve overall risk mortality however subgroup analysis suggested wa benefit 70 years188 recent metaanalysis examined effect icds nicm survival benefit wa still seen although effect wa significantly weakened inclusion danish trial167 average patient ihd greater risk sudden death patient nicm therefore although relative benefit similar absolute benefit greater patient ihd187 two rcts showed benefit patient icd implanted within 40 day mi177178 although sudden arrhythmic death reduced wa balanced increase nonarrhythmic death accordingly icd primary prevention contraindicated time period furthermore icd implantation recommended minimum 3 month omt ha failed increase left ventricular ejection fraction 35 omt ideally includes use Class recommended drug hfref however icd cite predate use arni sglt2 inhibitor whether implantation icds reduces mortality left ventricular ejection fraction 35 unknown ongoing icd patient presence scar cmr imaging189 6.13 patient selection implantable cardioverter defibrillator patient hfref qrs duration 130 considered crt defibrillator crtd rather icd see sec tion crt detail section 6.2 patient moderate severe hf reduction sudden death may partially wholly offset increase death due worsening hf161 icd recommended patient nyha class IV severe symptom refractory phar macological candidate ventricular assist device vad cardiac transplantation patient limited life expectancy likely die pump failure similarly patient serious comorbidities unlikely sur vive substantially 1 year good qol unlikely obtain substantial benefit icd179183 although danish show significant benefit icd patient nicm remembered nicm heterogeneous condition certain subgroup eg lami nopathies sarcoidosis higher risk sudden death fore merit careful consideration icd implantation tool help risk stratification eg scar burden magnetic resonance imaging helpful regard190192 patient counselled purpose icd involved decisionmaking process also aware potential complication related implantation additional impli cation driving risk inappropriate shock furthermore patient informed circumstance defib rillator defibrillator component crtd might deactivated eg terminal disease explanted eg infection recovery lv function193 subsequent timely conversation regarding defibrillator deactivation held patient caregiver icd generator reach end life requires explan tation replaced automatically rather shared deci sion making undertaken168172 patient carefully evaluated experienced cardiologist goal may changed since implantation risk fatal arrhythmia may lower risk nonarrhythmic death may higher matter controversy whether patient whose left ventricular ejection fraction ha greatly improved required device ther apy lifetime icd another device implanted168172 6.14 implantable cardioverterdefibrillator programming routine defibrillation threshold testing longer performed fol lowing implantation icd crtd doe improve shock efficacy reduce arrhythmic death194 conservative program ming long delays195 detection icd delivering dramatically reduces risk inappropriate appropriate unnecessary shocks194196197 Generally primary prevention defibrillator programmed minimize pacing eg ventricular demand pacing vvi 40min tachycardia zone 200min194198 ultimately—and particularly secondary prevention—programming adapted according patient’s specific need 6.15 subcutaneous wearable implantable cardioverterdefibrillators subcutaneous icds sicds appear effective conven tional transvenous icds similar complication rate although risk inappropriate shock appeared higher initially downloaded guest 24 november 2024 improved patient selection ha shown sicds noninferior transvenous icds regard199202 may preferred option patient difficult venous access require icd explantation due infection patient must carefully selected sicds cannot treat bradyarrhythmia except postshock pacing cannot deliver either antitachycardia pacing crt substantial rcts device longterm data safety efficacy awaited wearable cardioverterdefibrillator able recognize treat ventricular arrhythmia may considered limited period time selected patient heart failure high risk sudden death otherwise suitable icd implantation162175176203 however large vest failed show wearable cardioverterdefibrillator reduced arrhyth mic death patient left ventricular ejection fraction 35 following recent acute mi204 detailed recommendation useindications icd refer reader esceuropean heart rhythm association ehra guideline ventricular tachyarrhythmias sudden cardiac death201 6.2 cardiac resynchronization appropriately selected individual crt reduces morbidity mortality211 furthermore crt improves cardiac function enhances qol209225 whilst carehf206208 companion210 compared effect crt medical mt majority crt compared crtd icd compared crtp backup pacing prevention fatal bradycardia might important mechanism benefit shared pacing device carehf baseline 25 patient resting heart rate 60 bpm206208209 prevention bradycardia important effect crt appear greater device con trol group however maditii 35 died icd suddenly even though protected brady tachyarrhythmia226 crt specified left ventricular ejection fraction 35 raft212 maditcrt213214 specified left ventricular ejection fraction 30 reverse207215227 specified 40 blockhf216 50 relatively patient left ventricular ejection fraction 3540 random ized ipd metaanalysis suggests diminution effect crt group211 assessing ‘response’ crt challenging indeed many appear ‘respond’ favourably term symptom lv function may well experienced mortality benefit several characteristic predict improvement morbidity mortality extent reverse remodelling one important mecha nisms action crt patient hfref ischaemic aetiology less improvement lv function due myocardial scar tissue less likely undergo favourable remodelling228 conversely woman may likely respond men possibly due smaller body heart size220224229 qrs width predicts crt response wa inclusion criterion randomized trials211 qrs morphology ha also related beneficial response crt several shown patient left bundle branch block lbbb morphology likely respond favour ably crt whereas less certainty patient non lbbb morphology230 latter group also underrepresented large crt trials206210213 however patient lbbb recommendation cardiac resynchronization implantation patient heart failure recommendation classa levelb crt recommended symptomatic patient heart failure sr qrs duration 150 lbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbidity mortality205215 crt rather rv pacing recommended patient hfref regardless nyha class qrs width indication ventricu lar pacing high degree av block order reduce morbidity includes patient af216219 crt considered symptomatic patient heart failure sr qrs duration 150 nonlbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbidity mortality205215 iia b crt considered symptomatic patient heart failure sr qrs duration 130149 lbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbidity mortality211220 iia b patient left ventricular ejection fraction 35 received conventional pacemaker icd subse quently develop worsening heart failure despite omt signiﬁcant proportion rv pacing considered ‘upgrade’ crt221 iia b continued crt may considered symptomatic patient heart failure sr qrs duration 130149 nonlbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbidity mortality208213 iib b crt recommended patient qrs duration 130 indi cation pacing due high degree av block222224 iii atrial fibrillation atrial ﬁbrillation av atrioventricular crt cardiac resynchronization heart failure heart failure hfref heart failure reduced ejection fraction icd implantable cardioverterdeﬁbrillator lbbb left bundle branch block left ventricular ejection fraction left ventricular ejection fraction nyha new york heart association omt optimal medical class recommended medical least 3 month qrs q r wave ecg rv right ventricular sr sinus rhythm aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 morphology often wider qrs duration current debate whether qrs duration qrs morphology main predictor beneficial response crt evidence two ipd metaanalyses indicates accounting qrs duration little evidence suggest qrs morphology aetiology disease influence effect crt morbidity mortal ity211220 addition none landmark selected patient inclusion according qrs morphology sex ischaemic aetiology powered subgroup analysis echocrt trial222223 ipd metaanalysis213 suggest po sible harm crt qrs duration 130 thus implanta tion crt recommended qrs duration 130 patient scheduled receive icd sr lbbb crtd considered qrs 130 149 recommended qrs 150 however clinical practice varies widely among country primary reason implanting crt relief symptom clinician choose crtp crtd whichever con sider appropriate randomized compare crtp crtd210 demonstrate difference morbidity mortality technology although wa powered show difference furthermore danish patient nicm 58 patient received crt wa suggestion subgroup analysis crtp wa inferior crtd166167 left ventricular ejection fraction reduced rv pacing may exacerbate cardiac dyssyn chrony prevented crt might improve patient outcomes216218231 however difference outcome wa observed crt rv pacing subgroup analysis raft212 balance crt rather rv pacing recommended patient hfref regardless nyha class indi cation ventricular pacing order reduce morbidity although clear effect mortality wa observed patient hfref received conventional pacemaker icd subsequently develop worsening heart failure high proportion rv pacing despite omt considered ‘upgrading’ crt two small compared pharmacological alone v crt patient af conflicting result several indicated crt superior rv pacing patient undergoing atrioventricular av node ablation217218231 however atrial fibrillation indication carry av node ablation patient crt except case ventricular rate remains persistently high despite attempt pharmacological rate control subgroup analysis patient atrial fibrillation raft found benefit crtd compared icd although less half patient 90 biventricular capture219 view paucity evidence efficacy crt patient af may option selected patients—particularly qrs 150 ms—ensuring proportion biventricular pac ing high possible observational report biventricular capture 98 prognosis patient crt declines218232 whether association reflects loss resynchronization might remedied device programming poor placement lv lead greater difficulty pacing severely diseased myocardium uncer tain observation ha confirmed randomized early suggested imaging test dyssynchrony value selecting patient crt233 however recent ha suggested two novel marker dyssynchrony apical rock ing septal flash associated response crt tested selection criterion prespecified sub group randomized trial234 patient extensive myocardial scar less improvement lv function crt true hfref doe reliably predict less clinical benefit pacing threshold higher scarred myocardium possible lead placement avoid regions235236 although patient extensive scarring intrinsically worse prognosis little evidence obtain less prognostic benefit crt211 value trying optimize av interval interventricular delay interval vv interval implantation using echo elec trocardiographic criterion bp response uncertain may con sidered patient disappointing response crt237238 option consider optimize response crt covered recently published practical article239 following crt implantation review diuretic advised reduction discontinuation may required addi tion crt implantation may afford opportunity optimize mt hfref240 reader directed guideline pacing crt recom mendations device implantation procedures240a 6.3 device evaluation cardiac contractility modulation ccm ha evaluated patient nyha class IIIiv hf left ventricular ejection fraction 25 45 qrs duration 130 wa associated small improve ment exercise tolerance qol241242 technology involve modification activity auto nomic nervous system eg baroreflex activation therapy243244 also shown offer modest improvement effort capacity qol however currently evidence considered insufficient support specific guideline recommendation reduction mortality hospitalization variety implant able electrical therapeutic technology see also gap evidence section 16 7 heart failure mildly reduced ejection fraction 7.1 diagnosis heart failure mildly reduced ejection fraction diagnosis hfmref requires presence symptom andor sign hf mildly reduced ef 4149 presence ele vated np bnp 35 pgml ntprobnp 125 pgml evidence structural heart disease eg increased left atrial la size lvh echocardiographic measure lv filling make diagnosis likely mandatory diagnosis certainty regarding measurement lvef algorithm diagnosis hfmref depicted 1 investigation underlying aetiology please refer 5 refers investigation regardless lvef downloaded guest 24 november 2024 7.2 clinical characteristic patient heart failure mildly reduced ejection fraction substantial overlap clinical characteristic risk factor pattern cardiac remodelling outcome among left ventricular ejection fraction cate gories hf patient hfmref average feature similar hfref hfpef com monly men younger likely cad 5060384243 less likely atrial fibrillation noncardiac comor bidities supplementary 10 however ambulatory patient hfmref lower mortality hfref akin hfpef patient hfmref may include patient whose left ventricular ejection fraction ha improved 54050 7.3 f50patients heart failure mildly reduced ejection fraction form hf diuretic used control conge tion substantial prospective rct ha performed exclusively patient hfmref supplementary 11 data gleaned subgroup analysis hfpef none met primary endpoint although strong recommendation cannot made specific point time included recommendation help guide management patient category 7.31 angiotensinconverting enzyme inhibitor specific acei patient hfmref although pepchf wa conducted patient hfpef included patient left ventricular ejection fraction 40 report outcome according lvef11 however patient hfmref many also cad hypertension postmi lv systolic dysfunction therefore already treated acei therefore acei use may considered patient hfmref 7.32 angiotensin receptor ii type 1 receptor blocker specific arb hfmref charm preserved missed primary endpoint cardiovascular death heart failure hospi talizations245 however retrospective analysis showed cande sartan reduced number patient hospitalized heart failure among hfmref similar trend cardiovascular allcause mortal ity8 moreover recurrentevent analysis suggested reduction hospitalization heart failure among entire charmpreserved cohort including hfmref248 acei many hfmref already angiotensin receptor blocker cardiovascular indication therefore arb may con sidered patient hfmref 7.33 betablockers specific betablockade hfmref ipd meta analysis landmark betablockers suggested similar reduc tions cardiovascular allcause mortality 50 patient sr hfref hfmref12 ipd metaanalysis included senior nebivolol reduced composite primary endpoint cause mortality cardiovascular hospital admission overall population interaction left ventricular ejection fraction 35 patient left ventricular ejection fraction 3550 effect nebivolol primary outcome wa observed119249 many patient hfmref may another cv indication atrial fibrillation angina betablocker therefore treat ment betablockers may considered patient hfmref 7.34 mineralocorticoid receptor antagonist specific mras hfmref retrospective analy si topcat patient left ventricular ejection fraction 459 spironolac tone reduced hospitalization heart failure left ventricular ejection fraction 55 wa similar trend cardiovascular allcause mortality mra may considered patient hfmref 7.35 angiotensin receptorneprilysin inhibitor specific arni hfmref paragonhf included patient ef 45 although missed primary endpoint overall significant efbytreatment interaction wa observed sacubitrilvalsartan compared valsartan reduced likelihood primary composite outcome cardiovascular death total heart failure hospitalization 22 ef equal median 5713 data available combined analysis paradigmhf paragonhf showing sacubitrilvalsartan compared form raas blockade ha beneficial effect especially hospitalization heart failure hfmref247 pharmacological considered patient nyha class II–iv heart failure mildly reduced ejection fraction recommendation classa levelb diuretic recommended patient congestion hfmref order alleviate symptom signs137 c acei may considered patient hfmref reduce risk heart failure hospitalization death11 iib c angiotensin receptor blocker may considered patient hfmref reduce risk heart failure hospitalization death245 iib c betablocker may considered patient hfmref reduce risk heart failure hospital ization death12119 iib c mra may considered patient hfmref reduce risk heart failure hospitalization death246 iib c sacubitrilvalsartan may considered patient hfmref reduce risk hf hospitalization death13247 iib c acei angiotensinconverting enzyme inhibitor angiotensin receptor blocker angiotensinreceptor blocker heart failure heart failure hfmref heart failure mildly reduced ejection fraction mra mineralocorticoid receptor antagonist nyha new york heart association aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 arni may considered patient hfmref 7.36 drug dig trial10 hfmref sr wa trend fewer hospitalization heart failure assigned digoxin reduction mortality trend excess cardiovascular death therefore insufficient data recommend use also insufficient data ivabradine hfmref draw conclusion 7.37 device post hoc analysis landmark crt suggest crt may benefit patient left ventricular ejection fraction 35 crt hfmref abandoned due poor recruitment250 substantial tri al icds primary prevention ventricular arrhythmia hfmref conducted 20 year ago suggested bene fit icd implantation secondary prevention ventricular arrhythmia hfmref therefore insufficient evidence advise crt icd patient hfmref heart failure patient left ventricular ejection fraction 40 implantation intera shunt device wa found safe device subject investigation larger recommendation use hfpef hfmref given251 8 heart failure preserved ejection fraction 8.1 background heart failure preserved ejection fraction guideline acknowledges historical change nomenclature lack consensus optimal left ventricular ejection fraction cutoff define group patient heart failure without overtly reduced ef term ‘pre served’ wa originally proposed candesartan heart failure assessment reduction mortality morbidity charm programme refer patient ef 40 wa clearly ‘reduced’ completely ‘normal’252 current guide line designated patient left ventricular ejection fraction 4149 hfmref recognize debate constitutes ‘mildly reduced’ ef ef cutoff whether different men women14253 eacvi defines sys tolic dysfunction 52 male 54 females16 whether patient higher efs heart failure named hf ‘normal’ ef ha also considered14254 however given known variability echocardiographic measurement lvef difficulty interpreting left ventricular ejection fraction measured using different imaging modality remaining controversy regarding precise lvef cutoff define ‘normal’ may vary sex also factor age ethnicity255 guideline ha kept nomenclature hfpef using ef cutoff 50 importantly clinician aware left ventricular ejection fraction continuous variable normal distribution general population ef cutoff used definition therefore arbitrary moreover lvef cutoff define ‘normal’ likely higher 50 presence high ef eg 6570 also prompt search pathology cardiac amyloidosis ca hypertrophic car diomyopathy hcm ‘supranormal’ ef may result shrinkage lv enddiastolic volume denominator ef256257 8.2 clinical characteristic patient heart failure preserved ejection fraction hfpef differs hfref hfmref hfpef patient older often female af ckd noncv comorbidities common patient hfpef hfref258 numerous potential cause hfpef 5 pathophysiology various hfpef syndrome differs thus require distinct red flag potential presence ca include low normal bp patient history hypertension intolerance betablockers acei history bilateral carpal tun nel syndrome low voltage ecg echocardiographic feature thickening septum posterior wall rv wall enlarged atrium small pericardial effusion valve thickening detail see section cmp section 14.2 furthermore important exclude condition might mimic hfpef syndrome eg lung disease anaemia obesity deconditioning comprehensive overview hfpef see eschfa position statement259 8.3 diagnosis heart failure preserved ejection fraction diagnosis hfpef remains challenging several diagnostic criterion proposed society clinical trials260 criterion vary widely sensitivity specificity diagnosing hfpef recently two scorebased algorithm h2fpef hfapeff proposed aid diagnosis259261 generaliz ability score ha tested various observational cohort diagnostic performance ha varied262269 score assign substantial proportion suspected hfpef patient intermediate likelihood wherein additional diagnostics proposed thus depending score used different patient referred additional testing allocated hfpef furthermore physician may access specialized test recommended specific diagnostic algorithm limit broad clinical applicability score demonstrates ongoing diagnostic uncertainty hfpef267 facilitate broad clinical application guideline recom mend simplified pragmatic approach distils common major element prior diagnostic criterion emphasizes frequently used variable widely available clinician variable particular la size la volume index 32 mLm2 mitral e velocity 90 cm septal e0 velocity 9 shown pivot point beyond risk cardiovascular mortality increased underscoring value270 recommendation therefore consistent consensus document hfa doe represent new algorithm diagnostic score rather simplified approach physician access expertise may refer full diagnostic approach recommended hfa259 downloaded guest 24 november 2024 simplified diagnostic approach start assessment pre test probability see clinical characteristic diagnosis include following 1 symptom sign hf 2 left ventricular ejection fraction 50 3 objective evidence cardiac structural andor functional abnor malities consistent presence lv diastolic dysfunction raised lv filling pressure including raised np 9 note patient history overtly reduced left ventricular ejection fraction 540 considered rec50red hfref ‘hf improved lvef’ rather hfpef continued hfref recommended patients271 known whether starting heart failure patient recov ered left ventricular ejection fraction beneficial patient hfpef tend stable tra jectory left ventricular ejection fraction time272 however develop clinical indication repeat echo followup around one third decline lvef273 presence af threshold la volume index 40 mLm2 exercise stress threshold include ee0 ratio peak stress 15 tricuspid regurgitation tr velocity peak stress 3.4 ms275 lv global longitudinal strain 16 ha sensitivity 62 specificity 56 diagnosis hfpef invasive testing261 approach diagnosis involve additional confirma tory test case diagnostic uncertainty cardiopulmonary exercise testing confirm reduction exercise capacity help differentiate cause dyspnoea exercise stress testing invasive haemodynamic testing259 resting echocardiographic laboratory marker equivocal diastolic stress test recommended259274 confirmatory test diagnosis hfpef invasive haemodynamic exercise testing invasively measured pulmonary capillary wedge pressure pcwp 15 rest 25 exercise lv enddiastolic pressure 16 rest generally considered diagnostic266 however instead exercise pcwp cutoff used index pcwp cardiac output invasive diag nosis hfpef260276 recognizing invasive haemodynamic exer cise testing available many centre worldwide associated risk main use limited research setting absence diseasemodifying current guide line mandate gold standard testing every patient make diagnosis emphasize greater number objective noninvasive marker raised lv filling pressure 9 higher probability diagnosis hfpef 8.4 heart failure preserved ejection fraction date ha shown convincingly reduce mortality morbidity patient hfpef although improve ments seen specific phenotype patient within overall hfpef umbrella however none large rcts conducted hfpef achieved primary endpoint include pepchf perindopril277 charmpreserved desartan245 ipreserve irbesartan278 topcat spironolac tone246 digpreserved digoxin279 paragonhf sacubitrilvalsartan13 see supplementary 12 detail additional hospitalization heart failure reduced candesartan spironolactone wa trend towards reduction sacubitrilvalsartan although neutral primary endpoint hypothesis generating finding although nebivolol significantly reduced combined primary endpoint allcause mortality cardiovascular hospi tal admission senior included 15 left ventricular ejection fraction 50119249 targeting nitric oxidecyclic guano sine monophosphate pathway also failed improve exercise 9 objective evidence cardiac structural functional serological abnormality consistent presence left ventricular diastolic dysfunctionraised left ventricular ﬁlling pressures259261 parametera threshold comment lv mass index relative wall thickness 95 gm2 female 115 gm2 male 0.42 although presence concentric lv remodelling hypertrophy supportive absence lv hypertrophy doe exclude diagno si hfpef la volume indexa 34 mLm2 sr absence atrial fibrillation valve disease la enlargement reﬂects chronically elevated lv ﬁlling pressure presence af threshold 40 mLm2 ee’ ratio resta 9 sensitivity 78 speciﬁcity 59 presence hfpef invasive exercise testing although reported accuracy ha varied higher cutoff 13 lower sensitivity 46 higher speciﬁcity 8671259274 ntprobnp bnp 125 sr 365 af pgml 35 sr 105 af pgml 20 patient invasively proven hfpef np diagnostic threshold particularly presence obesity pa systolic pressure tr velocity resta 35 2.8 sensitivity 54 speciﬁcity 85 presence hfpef invasive exercise testing259261 atrial fibrillation atrial ﬁbrillation bnp btype natriuretic peptide ee’ratio early ﬁlling velocity transmitral dopplerearly relaxation velocity tissue doppler hfpef heart failure preserved ejection fraction la left atrial lv left ventricular np natriuretic peptide ntprobnp nterminal probtype natriuretic peptide pa pulmonary artery sr sinus rhythm tr tricuspid regurgitation note greater number abnormality present higher likelihood hfpef aonly commonly used index listed less commonly used index refer consensus document eschfa259 esc 2021 downloaded guest 24 november 2024 capacity qol hfpef eg neathfpef280 indiehfpef281 vitalityhfpef282 capacityhfpef praliciguat283 despite lack evidence specific diseasemodifying thera pie hfpef vast majority hfpef patient underlying hypertension andor cad many already treated acei arb betablockers mras paragonhf base line 86 patient aceiarbs 80 betablockers 24 mras13 task force acknowledge option hfpef revised guideline published note food drug administration fda ha endorsed use sacubitrilvalsartan spironolactone left ventricular ejection fraction ‘less normal’ statement relate patient within hfmref hfpef category sacubitrilvalsartan decision wa based subgroup analysis paragonhf showed reduction heart failure hospitalization left ventricular ejection fraction 57 metaanalysis paradigmhf paragonhf showing reduction cardiovascular death hf hospitalization left ventricular ejection fraction normal range247 regarding spironolactone subgroup individual topcat recruited america significant reduc tion primary endpoint cardiovascular death heart failure hospitalization subsequent post hoc analysis ef showed significant reduction outcome left ventricular ejection fraction 559247 also ongoing sglt2 inhibitor development may well accelerate redefinition hfpef future thera peutic implication absence recommendation regarding diseasemodifying aimed reducing symptom con gestion diuretic loop diuretic preferred although thiazide diuretic may useful managing hypertension reducing body weight obese patient increasing exercise may improve symptom exercise capacity therefore considered appropriate patients284285 important identify treat underlying risk factor aeti ology coexisting comorbidities hfpef eg hypertension section 12.4 cad section 12.2 amyloidosis section 14.6 atrial fibrillation section 12.11 valvular heart disease section 12.3 undoubtably underlying phenotype hfpef syndrome lead improved outcome recommendation patient heart failure preserved ejection fraction recommendation classa levelb screening aetiology cardiovascular noncardiovascular comor bidities recommended patient hfpef see relevant section document c diuretic recommended congested patient hfpef order alleviate symp tom signs137 c hfpef heart failure preserved ejection fraction aclass recommendation blevel evidence esc 2021 esc 2021 10 risk factor development heart failure potential corrective action risk factor heart failure preventive strategy sedentary habit regular physical activity cigarette smoking cigarette smoking cessation obesity physical activity healthy diet excessive alcohol intake286 General population nolight alcohol intake beneﬁcial patient alcoholinduced cmp abstain alcohol inﬂuenza inﬂuenza vaccination microbe eg trypanosoma cruzi streptococci early diagnosis speciﬁc antimicrobial either prevention andor cardiotoxic drug eg anthracyclines cardiac function side effect moni toring adaptation change chemotherapy chest radiation cardiac function side effect moni toring adaptation hypertension lifestyle change antihypertensive dyslipidaemia healthy diet statin diabetes mellitus physical activity healthy diet sglt2 inhibitor cad lifestyle change statin cad coronary artery disease cmp cardiomyopathy sglt2 sodiumglu cose cotransporter 2 esc 2021 recommendation primary prevention heart failure patient risk factor development recommendation classa levelb hypertension recommended prevent delay onset hf prevent heart failure hospitalizations287290 statin recommended patient high risk cardiovascular disease cv disease order prevent delay onset hf prevent heart failure hospitalizations291292 sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂozin ertugliﬂozin sotagliﬂozin rec ommended patient diabetes high risk cardiovascular disease cardiovascular disease order prevent heart failure hospitalizations293297 counselling sedentary habit obesity ciga rette smoking alcohol abuse recom mended prevent delay onset hf298302 c cvcardiovascular hf heart failure sglt2 sodiumglucose cotransporter 2 aclass recommendation blevel evidence downloaded guest 24 november 2024 9 multidisciplinary team management prevention chronic heart failure 9.1 prevention heart failure general advice risk factor development heart failure see supplementary 1 strategy prevent heart failure early cv continuum summarized 10 widely recognized addition optimizing medical device hf attention also given hf care delivered hfa esc ha issued several position paper cover nonpharmacological management discharge plan ning standard delivering heart failure care303305 ha also scored need specialist heart failure cardiologist specialist hf nurse help provide care detailed curriculum aid training available adapted national implementation306307 section focus area recommendation evi dence level given multidisciplinary team management lifestyle advice exercise training followup monitoring 9.2 multidisciplinary management chronic heart failure 9.21 model care order reduce hospitalization mortality earlier guidelines1 recommended use multidisciplinary hf management programme hfmps enable patient correct investigation accurate diagnosis appropriate evidencebased education suitable followup optimal implementa tion hfmp requires multidisciplinary team active along whole heart failure trajectory onset critical event period apparent stability terminal stages303 since 2016 guide line new published underscore need hfmps reveal insight care delivered network metaanalysis including 53 randomized published 2017 concluded diseasemanagement clinic home visit nurse reduced allcause mortality compared usual care home visit effective308 ipd metaanalysis 20 stud including 5624 patient concluded selfmanagement interven tions heart failure patient improve outcome despite heterogeneity intensity content personnel deliver interventions309 hfmps vary component apply different service model clinicbased approach primary secondary tertiary care homebased programme case management hybrid component used service vary eg hfmps use telemonitoring may applied local regional national level service model ha shown consis tently superior others310 home visit heart failure clinic reduce allcause admission mortality educational programme used alone not308309 hfmps patientcentred take holistic approach patient rather focussing solely hf management comorbid condition arrhythmia hyperten sion diabetes renal dysfunction depression improve patient wellbeing selfmanagement leading better outcomes309311 organization hfmp adapted healthcare system available resource infrastructure facility staff finan ce administrative policy tailored patient’s need many patient heart failure would derive benefit early integra tion palliative supportive approach within care provided member heart failure multidisciplinary team312313 palliative supportive care thought patient hf regardless stage illness patient advanced stage considered mechanical circulatory support mc heart transplantation receive palliative care consultation intervention matter protocol see section 10.24 9.22 characteristic component heart failure management programme clinical included complex bundled intervention making difficult determine efficiency effectiveness spe cific component 11 present overview characteristic component important consider hfmp 9.3 patient education selfcare lifestyle advice adequate patient selfcare essential effective management heart failure allows patient understand beneficial agree selfmonitoring management plans319 heart failure patient report effective selfcare better qol lower readmission rate reduced mortality309 misunderstanding misconception lack knowledge con tribute insufficient selfcare therefore patient education vital improving patients’ knowledge condition fundamental development selfcare skills304 education improve selfcare tailored individual patient based available scientific evidence expert opinion little evidence specific lifestyle advice improves multidisciplinary intervention recommended management chronic heart failure recommendation classa levelb recommended heart failure patient enrolled multidisciplinary heart failure management pro gramme reduce risk heart failure hospitalization mortality309314315316 selfmanagement strategy recommended reduce risk heart failure hospitalization mortality309 either homebased andor clinicbased pro gramme improve outcome recom mended reduce risk heart failure hospitalization mortality310317 inﬂuenza pneumococcal vaccination considered order prevent hf hospitalizations315316 iia b heart failure heart failure aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 11 important characteristic component heart failure management programme characteristic 1 patientpersoncentred318 2 multidisciplinary 3 focus programme ﬂexible include • prevention disease progression • symptom control • maintaining patient preferred place care endstage heart failure 4 competent professionally educated staff 5 encourage patientcarer engagement understanding management condition component 1 optimized management lifestyle choice pharmacological device 2 patient education special emphasis selfcare symptom management 3 provision psychosocial support patient family caregiver 4 followup discharge clinic home visit telephone support telemonitoring 5 easy access healthcare especially prevent manage decompensation 6 assessment appropriate intervention response unexplained change weight nutritional functional status quality life sleep problem psychosocial problem ﬁndings eg laboratory value 7 access advanced option supportive palliative care 12 patient education selfcare education topic goal patient caregiver professional behaviour educational tool explanation hf understand cause hf symptom treat ment choice provide tailored information heart failure trajectory understand prognosis different possible phase heart failure trajectory make joint decision recognise patient’s position heart failure trajectory sensitively communicate information prognosis time diag nosis decision making option change clinical condition whenever patient request medical medication able make joint decision medication understand indication beneﬁts need long term adherence certain drug dosing side effect medication able recognize common side effect medi cation know action take provide written oral information indication beneﬁts ing effect side effect discus practical issue optimal timeschedule case missed etc discus possible barrier medication taking advise support aid dosette box electronic reminder etc appropriate320 implanted device able make joint decision device implantation understand indication importance expectation checkup routine implanted device exception management able recognize common complication including risk inappropriate deﬁbrillator shock know action take provide written oral information importance expectation implanted device possible way follow remote monitoring discus expectation possible impact driving clearly identify situation device might deactivated explanted involve patient caregiver decision making selfcare aspect activity exercise undertake regular exercise physically active able adapt physical activity symptom status personal circumstance advise exercise recognizes physical functional limita tions frailty comorbidities refer exercise programme activity mode discus possible barrier sideeffects opportunity sleep breathing recognize importance sleep rest cv health able recognize problem sleeping optimize sleep review sleep history advise discus importance good sleep provide advice ‘sleep health’ including timing diuretic continued esc 2021 downloaded guest 24 november 2024 12 continued education topic goal patient caregiver professional behaviour educational tool consider carefully discus beneﬁts deleterious effect sleep medication fluid avoid large volume ﬂuid intake ﬂuid restriction 1.52 lday may considered patient severe hfhyponatraemia relieve symptom congestion avoid dehydration ﬂuids restricted increase intake period high heathumidity andor nau seavomiting provide information discus advantage disadvantage ﬂuid restriction advise adapt ﬂuid intake weight time high heat humidity nauseavomiting adjust advice period acute decompensation con sider altering advice towards endoflife healthy diet able prevent malnutrition know eat healthily avoiding excessive salt intake 5 gday maintaining healthy body weight discus current food intake role salt role micronutrient discus need supplementing case nutrient deﬁcien cies clear role routine micronutrient supplementation321 discus maintaining healthy body weight alcohol able abstain avoid excessive alcohol intake especially alcoholinduced cmp restrict alcohol according cardiovascular prevention guideline tailor alcohol advice aetiology hf eg abstinence alco holic cmp inform discus alcohol intake according cardiovascular prevention guideline 2 unit per day men 1 unit per day womena immunization aware need immunization inﬂuenza pneumococcal disease discus beneﬁts possible barrier advise local immunization practice smoking recrea tional drug aware consequence health smoking use recreational drug stop smoking including ecigarettes taking recrea tional drug inform discus help decision making refer specialist advice smoking cessation drug drawal replacement consider referral cognitive behavioural theory psychological support patient wish stop smoking taking drug travel leisure driving able prepare travel leisure activity accord ing physical capacity able take informed decision driving inform discus practical issue related long haul travel stay ing abroad exposure sun amiodarone effect high humidity heat dehydration high altitude oxygenation provide practical advice related travel medicationdevices keep medicine hand luggage list medication device namecard treating centre inform localnationalinternational regulation related driving sexual activity able resume adapt sexual activity according physical capacity recognize possible problem sexual activity relationship heart failure inform discus sexual activity safe stable hf patient provide advice eliminating factor predisposing sexual problem discus provide available pharmacological sex ual problem refer specialist sexual counselling necessary symptom monitoring symptom self management monitor recognize change sign symptom able react adequately change sign symptom know contact healthcare professional provide individualized information support selfmanagement case increasing dyspnoea oedema sudden unex pected weight gain 2 kg 3 day patient may increase diuretic andor alert healthcare team living hf psychological issue able live good life hf able seek help case psychological problem depressive symptom anxiety low mood may occur course heart failure trajectory regularly communicate information disease option selfcare regularly discus need support treat referral specialist psychological support necessary continued downloaded guest 24 november 2024 qol prognosis however providing information ha become key component education selfcare general educational approach include • providing information variety format take account educational grade health literacy consider approach active role patient caregiver ‘asktellask’ ‘teach back’ motivational interviewing reinforce message regular time interval • recognizing barrier communication language social skill cognition anxietydepression hearing visual challenge • recommending ‘hfmattersorg’ offer help guidance use offer discussion question arising • inviting patient accompanied family member friend key topic include recommended 12 9.4 exercise rehabilitation consistent evidence physical conditioning exercise training improves exercise tolerance healthrelated qol patient hf clinical metaanalyses people hfref show exercise rehabilitation improves exercise capacity qol several metaanalyses also show reduces allcause heart failure hospitalization although uncertainty persists effect mortality322328 effect hospitalization seen highly adherent exercise programme329 high intensity interval training patient able willing may improve peak oxygen consumption vo2330331 supervised exercisebased rehabilitation considered frail severe disease comorbidities95 physical conditioning also improves exercise capacity qol332335 data hfmref available benefit observed group heart failure also apply group 9.5 followup chronic heart failure 9.51 General followup relatively understudied area patient hf even symp tom well controlled stable require followup ensure con tinued optimization detect asymptomatic progression heart failure comorbidities discus new advance care guideline recommend followup interval longer 6 month check symptom heart rate rhythm bp full blood count elec trolytes renal function patient recently discharged ho pital undergoing uptitration medication followup interval frequent whether stable patient need followedup cardiologist uncertain suggest followup primary care may appropriate303339 however uptake evidencebased intervention poor many settings340104 several suggest care followup provided hf specialist use quality improvement registry lead higher rate optimal improved outcomes341343 ecg done annually detect qrs prolongation344 patient may become candidate crt furthermore may identify conduction disturbance af serial echocardiography generally necessary although echocardiogram repeated ha deterioration clinical status echocardiogram also advised 36 month optimization standard hfref determine need addition newer pharmacological agent implanted device 9.52 monitoring biomarkers investigating use biomarkers particularly bnp andor ntprobnp guide pharmacotherapy hfref produced conflicting results345352 undoubtedly good prognostic markers72353354 conceptually clear biomarker supported strategy might offer addition assiduous application guidelinerecommended current evidence therefore doe support routine measurement bnp ntprobnp guide titration 9.6 telemonitoring telemonitoring enables patient provide remotely digital health information support optimize care data 12 continued education topic goal patient caregiver professional behaviour educational tool recognise carer family member may greatly affected need seek help family informal caregiver able ask support discus preference caregiverfamily involvement involve patient caregiver respectful way cmp cardiomyopathy cardiovascular cardiovascular heart failure heart failure a1 unit 10 pure alcohol eg 1 glass wine 12 pint beer 1 measure spirit recommendation exercise rehabilitation patient chronic heart failure recommendation classa levelb exercise recommended patient able order improve exercise capacity qol reduce heart failure hospitalizationc 324328335337 supervised exercisebased cardiac rehabilita tion programme considered patient severe disease frailty comorbidities95324327338 iia c heart failure heart failure qol quality life aclass recommendation blevel evidence cin able adhere exercise programme esc 2021 esc 2021 downloaded guest 24 november 2024 symptom weight heart rate bp collected frequently stored electronic health record used guide patient directly healthcare professional adjust seek advice home telemonitoring htm help main tain quality care facilitate rapid access care needed reduce patient travel cost minimize frequency clinic vi its355 enforced cessation facetoface consultation many coun try recent covid19 pandemic highlighted potential advantage htm356 htm diverse patient usually required make measurement many aspect heart failure management adherence may incomplete htm may provided local regional national service system focus optimizing management rather detecting managing medical emer gencies need staffed standard working hour system designed also offer support time requested patient comparative effectiveness cost effectiveness strategy uncertain system focus continuous optimization care health maintenance approach rather trying anticipate manage episode worsening strategy plagued large number falsepositive alert appear successful357 htm efficient method providing patient education motivation aiding delivery care adapted work synergy existing healthcare provision358 cochrane systematic review conducted 2017 identified 39 relevant htm largely based assessment symptom weight heart rate rhythm bp found htm wa asso ciated reduction allcause mortality 20 heart failure hospital ization 37359 since several neutral least one positive published357360364 unlikely change positive result systematic review importantly social distancing ‘green’ agenda important htm need show inferior contemporary method delivering care appropriate mean supporting care356 whether wearable technology monitoring heart rate rhythm lung congestion bioimpedance lung radar offer addi tional benefit conventional htm described uncertain365367 many implanted therapeutic device provide wirelessly remotely information either device generator lead function arrhythmia patient physiology heart rate activity heart sound bioimpedance strong evidence moni toring detect device malfunction earlier conventional monitoring may useful detecting arrhythmia af however little evidence device monitoring reduces admission heart failure mortality368370371 device provide monitoring function also available implantable looprecorders injected subcutaneously used monitor heart rate rhythm activity bioimpedance monitoring device also placed pulmonary artery monitor pressure wirelessly although external reader required detect device signal rather bulky requires patient co operation rise diastolic pulmonary artery pressure may one earliest sign congestion preliminary fairly substantial showed reduction risk recurrent heart failure hospitalization372 much larger ha completed recruitment guidehf373 thus noninvasive htm may considered patient hf order reduce risk recurrent cardiovascular heart failure hospitalization cardiovascular death evidence management guided implanted system awaited374 10 advanced heart failure 10.1 epidemiology diagnosis prognosis many patient heart failure progress phase advanced hf charac terized persistent symptom despite maximal therapy375377 prevalence advanced heart failure increasing due growing number patient hf ageing population better survival hf prognosis remains poor 1year mortality ranging 25 75378380 updated hfaesc 2018 criterion definition advanced heart failure reported 13.376 severely reduced left ventricular ejection fraction common required diagnosis advanced heart failure may develop patient hfpef well addition reported criterion extracardiac organ dysfunction due heart failure eg cardiac cachexia liver kidney dysfunction type ii pulmonary hypertension may present required definition advanced hf376 interagency registry mechanically assisted circulatory support intermacs profile developed classify patient potential indication durable mc device describes clinical parameter characteristic consistent need advanced 14381 classification ha also shown useful estimating prognosis patient going urgent heart transplantation382 lv assist device lvad implantation383 risk assessment ambulatory advanced heart failure patients384 prognostic stratification important identify ideal time referral appropriate centre ie one capable providing advanced heart failure properly convey expectation patient family plan followup strategy recommendation telemonitoring recommendation classa levelb noninvasive htm may considered patient heart failure order reduce risk recurrent cardiovascular heart failure hospitalization cv death374 iib b monitoring pulmonary artery pressure using wireless haemodynamic monitoring system may considered symptomatic patient hf order improve clinical outcomes372 iib b cardiovascular cardiovascular heart failure heart failure htm home telemonitoring left ventricular ejection fraction left ventricular ejection fraction aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 13 criterion deﬁnition advanced heart failure following criterion must present despite optimal medical 1 severe persistent symptom heart failure nyha class III advanced iv 2 severe cardiac dysfunction deﬁned least one following • left ventricular ejection fraction 30 • isolated rv failure eg arvc • nonoperable severe valve abnormality • nonoperable severe congenital abnormality • persistently high increasing bnp ntprobnp value severe lv diastolic dysfunction structural abnormality according deﬁnitions hfpef 3 episode pulmonary systemic congestion requiring highdose iv diuretic diuretic combination episode low output requiring inotropes vasoactive drug malignant arrhythmia causing 1 unplanned visit hospitalization last 12 month 4 severe impairment exercise capacity inability exercise low 6mwt distance 300 pvo2 12 mLkgmin 50 predicted value estimated cardiac origin 6mwt 6minute walk test arvc arrhythmogenic right ventricular cardiomyopathy bnp btype natriuretic peptide hfpef heart failure preserved ejection fraction iv intravenous lv left ventricular left ventricular ejection fraction left ventricular ejection fraction ntprobnp nterminal probtype natriuretic peptide nyha new york heart association pvo2 peak oxygen consumption rv right ventricular modiﬁed 376 esc 2021 14 interagency registry mechanically assisted circulatory support proﬁle description patient advanced heart failure profile time frame intervention proﬁle 1 critical cardiogenic shock patient lifethreatening hypotension despite rapidly escalating inotropic support critical organ hypoperfusion often conﬁrmed worsening acidosis andor lactate lev el “crash burn” deﬁnitive intervention needed within hour proﬁle 2 progressive decline patient declining function despite iv inotropic support may manifest wor sening renal function nutritional depletion inability restore volume balance “sliding inotropes” also describes declining status patient unable tolerate inotropic deﬁnitive intervention needed within day proﬁle 3 stable inotrope inotropedependent patient stable blood pressure organ function nutrition symptom continu ous iv inotropic support temporary circulatory support device dem onstrating repeated failure wean support due recurrent symptomatic hypotension renal dysfunction “dependent stability” deﬁnitive intervention elective period week month proﬁle 4 frequent flyer patient stabilized close normal volume status experience symptom congestion rest activity living dos diuretic generally ﬂuc tuate high level intensive management surveillance strategy considered may case reveal poor compliance would compro mise outcome patient may shuttle 4 5 deﬁnitive intervention elective period week month proﬁle 5 housebound comfortable rest activity living unable engage activity living predominantly within house patient comfortable rest without congestive symptom may underlying refractory elevated volume status often renal dysfunction underlying nutritional status organ function marginal patient may risk intermacs 4 require deﬁnitive intervention variable urgency depends upon maintenance nutrition organ function activity proﬁle 6 exertion limited patient without evidence ﬂuid overload comfortable rest activity living minor activity outside home fatigue ﬁrst minute meaningful activity attribution cardiac limitation requires careful measure ment peak oxygen consumption case haemodynamic monitoring conﬁrm severity cardiac impairment “walking wounded” variable depends upon maintenance nutrition organ function activity level continued downloaded guest 24 november 2024 4376 patient contraindication mc heart trans plantation considered palliative care see section 10.24 despite many prognostic parameter supplementary 13 predicting outcome remains difficult patient often referred advanced heart failure centre late identifying warning sign patient nonadvanced symptom may allow early referral mc heart transplantation may offered development endorgan failure 5 supplementary 14376386 organi zational model centre different level care com plexity based ‘hub spoke’ network key good patient management376 10.2 management patient advanced hf pharmacological short term mc may needed implantation longterm mc heart transplantation becomes available 10.21 pharmacological renal replacement inotropes may improve haemodynamic parameter reducing con gestion augmenting cardiac output aiding peripheral perfusion although proven may help prevent worsening endorgan function conversely traditional inotropes may favor myocardial ischaemia andor tachyarrhythmias worsen clinical course387388 used palliative relief symptom patient without option intermittent longterm use inotropes may considered outpatient improve functional class qol389390 kidney dysfunction loop diuretic resistance often characterize clinical course patient advanced hf doubling loop diuretic proposed first instance followed con comitant administration thiazide metolazone see section 11.33145 patient fail respond diureticbased strategy renal replacement considered ultrafiltration one common approach may considered diuretic resistance even data effect outcome unsettled391392 10.22 mechanical circulatory support mc improve survival symptom patient advanced hf376393 use mc considered different sce narios listed 15 indication short longterm mc based intermacs profile 14 4 shortterm mechanical circulatory support shortterm mc device indicated reverse critical end organ hypoperfusion hypoxia setting cardiogenic shock used short limited period time day several week aim support central nervous system organ perfusion reverse acidosis multiorgan failure patient’s outcome becomes clearer cardiac recovery transition durable mc heart transplantation case towards palliative approach care patient shortterm mc complex requires dedicated expertise including specific plan stopping support neither cardiac brain injury recovers shortterm mc used patient intermacs profile 1 2 bridge decision btd bridge recovery btr bridge bridge btb either longterm mc urgent heart transplantation 4394 detail short term mc reported supplementary text 11.4 longterm mechanical circulatory support longterm mc indicated selected patient mt insuffi cient shortterm mc ha led cardiac recovery clinical improvement prolong life improve qol keep patient alive transplantation bridge transplantation btt reverse contraindication heart transplantation bridge candidacy btc destination dt 15 longterm mc considered patient intermacs profile 2 4 also patient intermacs 14 continued profile time frame intervention proﬁle 7 advanced nyha class III symptom patient without current recent episode unstable ﬂuid balance living comfortably meaningful activity limited mild physical exertion heart transplantation mc may currently indicated modiﬁers proﬁles possible proﬁles modiﬁed temporary mc modify proﬁle hospitalized patient include iabp ecmo tandemheart lvad impella 1 2 3 arrhythmia modify proﬁle include recurrent ventricular tachyarrhythmias recently contributed substantially clinical compromise frequent icd shock requirement external deﬁbrillation usually twice weekly 17 frequent episode heart failure decompensation characterize patient requiring frequent emergency visit hospitalization diuretic ultraﬁltration temporary iv vaso active frequent episode may considered least two emergency visit admission past 3 month three past 6 month 3 home 4 5 6 rarely proﬁle 7 ecmo extracorporeal membrane oxygenation heart failure heart failure iabp intraaortic balloon pump icd implantable cardioverterdeﬁbrillator intermacs interagency registry mechanically assisted circulatory support iv intravenous lvad left ventricular assist device mc mechanical circulatory support nyha new york heart association modiﬁed 381 esc 2021 downloaded guest 24 november 2024 management patient advanced heart failurea weaning mc support lvaddt class iia list ht delisting close follClass IIa case meaningful improvement class withdrawal mc support advanced hf therapiesClass Iad deferred close followup contraindication ht n cardiac neurological endorgan recovered neurological endorgan recovered cardiac recovery persistence severe brain damage severe irreversible endorgan damage potentially reversible high riskb contraindication reversed lvadbtc Class IIa shortterm mc btdbtrbtbbtt Class IIa intermacs 4 “stable ambulatory” intermacs 3–4 intermacs intermacs n n n 4 algorithm patient advanced heart failure btb bridge bridge btc bridge candidacy btd bridge decision btr bridge recovery btt bridge transplantation ca cardiac amyloidosis dt destination esc european society cardiology hcmhypertrophic cardiomyopathy hf heart failure hfa heart failure association ht heart transplantation intermacs interagency registry mechanically assisted circulatory support lvad left ventricular assist device lvadbtc left ventricular assist device  bridge candidacy lvaddt left ventricular assist device  destination mc mechanical circulatory support athis algorithm applied patient advanced heart failure defined according eschfa criteria376 exception hcm ca arrhythmic storm adult congenital heart dis ease refractory angina brecurrent hospitalization progressive endorgan failure refractory congestion inability perform cardiopulmonary exercise test peak oxygen consumption 12 mLminkg 50 expected value385 colour code class recommendation green class recommen dation yellow class recommendation iia see 1 detail class recommendation downloaded guest 24 november 2024 characteristic limited life expectancy andor poor qol condition may impair followup andor worsened prognosis advanced heart failure htltmcsa n triage patient advanced heart failure appropriate timing referral 1 admission unplanned visit heart failure clinic within last 12 month prior inotropic use intolerant betablocker rasiarni left ventricular ejection fraction 20 worsening rv function worsening renal function worseni20liver function ventricular arrhythmiasicd shock need escalating diuretic dos persistent congestion sbp 90 andor sign peripheral hypoperfusion n nyha90 despite optimal medical including icdcrt indicated nyha class ii manage local heart failure service refer discus witclass IIced heart failure centre reevaluation every 3–6 month palliative care 5 triage patient advanced heart failure appropriate timing referral376 arni angiotensin receptorneprilysin inhibitor crt cardiac resynchronization hf heart failure ht heart transplantation icd implantable cardioverterdefibrillator ltmcs longterm mechanical circulatory support lvef left ventricular ejection fraction nyha new york heart association rasi reninangiotensin system inhibitor rv right ventricular sbp systolic blood pressure qol quality life alimited life expectancy may due major comorbidities cancer dementia endstage organ dysfunction condition may impair followup worsen posttreatment prognosis include frailty irreversible cogni tive dysfunction psychiatric disorder psychosocial issue downloaded guest 24 november 2024 profile 56 highrisk characteristic patient irreversible endorgan failure cardiac recovering intermacs level 1 shortterm mc may also qualify longterm mc 4376378383395402 characteristic patient potentially eligible implantation lvad reported 16 detail device longterm mc sum marized supplementary 15 current 2year survival rate patient receiving latest continuousflow lvads comparable heart transplantation although adverse event negatively affect qol among patient continuous flow lvads actuarial survival wa reported 80 1 year 70 2 years403404 twoyear sur vival wa 84.5 survival free disabling stroke need reop eration lvad malfunction wa 76.9 centrifugalflow lvad momentum 3.405 fully magnetically levitated centrifugalflow lvad ha significantly reduced pump thrombosis momentum 3 need reoperation replace malfunction ing device wa 2.3 per 24 month 0.6 per 24 month risk pump replacement pump thrombosis stroke namely disabling stroke major bleeding gastrointestinal hae morrhage also lower centrifugalflow pump group axialflow pump group however incidence bleeding event thromboembolism driveline infection remained similar older devices402 data fully magnetically centrifugalflow lvad use realworld 2year outcome elevate registry showed overall survival 74.5 gastrointestinal bleeding 9.7 stroke 10.2 pump thrombosis 1.5 patients406 according imacs registry new composite endpoint includ ing qol adverse event beyond survival wa proposed help guiding decision making sense ‘living well one year’ defined freedom death stroke bleeding requiring operation rv assist device pump replacement devicerelated infection within first year wa 56.8 isolated centrifugal flow lvad383 although outdated rematch wa rct comparing lvad dt omt patient advanced hf nyha class IV contraindication transplantation rematch showed lower allcause mortality lvad com pared medical primary endpoint however high mortality rate 2 year arms378 randomized intrepid roadmap396407408 com pared different device advance endurance momentum 3399402409 two strategy early lvad implantation v medi cal lvad implantation serious deteriora tion patient’s condition currently compared 15 term describing various indication mechanical circulatory support bridge decision btd bridge bridge btb use shortterm mc ecmo impella patient cardiogenic shock haemodynamics endorgan perfusion stabilized contraindication longterm mc excluded brain damage resuscitation additional therapeutic option including longterm vad heart transplant evaluated bridge candidacy btc use mc usually lvad improve endorgan function andor make ineligible patient eligible heart transplantation bridge transplantation btt use mc lvad bivad tah keep patient alive otherwise high risk death trans plantation donor organ becomes available bridge recovery btr use mc shortterm longterm keep patient alive cardiac function recovers sufﬁciently remove mc destination dt longterm use mc lvad alternative transplantation patient endstage heart failure ineligible transplantation bivad biventricular assist device ecmo extracorporeal membrane oxygenation heart failure heart failure lvad left ventricular assist device mc mechanical circulatory support tah total artiﬁcial heart vad ventricular assist device esc 2021 16 patient potentially eligible implantation left ventricular assist device patient persistence severe symptom despite optimal medical device without severe right ventricular dysfunction andor severe tr stable psychosocial background absence major contraindication least one following  left ventricular ejection fraction 25 unable exercise heart failure able perform cardi opulmonary exercise testing peak vo2 12 mLkgmin andor 50 predicted value  3 heart failure hospitalization previous 12 month without obvious pre cipitating cause  dependence iv inotropic temporary mc  progressive endorgan dysfunction worsening renal andor hepatic function type ii pulmonary hypertension cardiac cachexia due reduced perfusion inadequately low ventricular ﬁlling pressure pcwp 20 sbp 90 cardiac index 2 lminm2 heart failure heart failure iv intravenous lvad left ventricular assist device left ventricular ejection fraction left ventricular ejection fraction mc mechanical circulatory support pcwp pulmonary capillary wedge pressure sbp systolic blood pressure tr tricuspid regurgitation vo2 oxygen consumption stable psychosocial background includes demonstrated understanding technology patient living household caregiver help patient ie living alone poor psychosocial background lvad con traindication major contraindication include contraindication longterm oral anticoagulation infection severe renal dysfunction ventricular arrhythmia esc 2021 downloaded guest 24 november 2024 prospective earlyvad clinicaltrialsgov identifier nct02387112 also swedish evaluation lvad swevad comparing survival patient advanced heart failure ineligible heart transplantation prospectively randomized lvad dt v mt clinicaltrialsgov identifier nct02592499410 10.23 heart transplantation heart transplantation remains gold standard advanced heart failure absence contraindication posttransplant 1 year survival around 90 median survival 12.5 years385411412 transplantation significantly improves qol func tional status although unclear reason percentage patient returning work lower expected412 apart primary graft dysfunction main challenge heart transplantation relate either efficacy side effect immunosuppression eg rejection infection cardiac allograft vasculopathy late graft dy function malignancy renal failure hypertension diabetes mellitus organ donor shortage remains main limitation heart trans plantation thus donor heart criterion extended allow increased upper limit donor age particularly europe moreover careful recipient selection needed based pretransplant posttransplant life expectancy influ enced preoperative status comorbidities main indication contraindication heart transplanta tion listed 17.376385 active infection relative contraindication transplant case infected lvads may actually indication elderly age absolute contraindication although patient aged 65 year might appropriate candidate due overall life expectancy programme accept patient 70 year age biological age well chronological age must taken account surgical complexity previous sternotomies mediastinal radiation adult congenital heart disease achd also considered decision pathway transplantation lvad never straightforward unique patient eligibility option may change according particular condition patient may also change time factor related patient time heart transplant waiting list 17 heart transplantation indication contraindication indication advanced hf376 therapeutic option except lvad btt contraindication active infectiona severe peripheral arterial cerebrovascular disease pharmacologic irreversible pulmonary hypertension lvad considered reverse elevated pulmonary vascular resistance subse quent reevaluation establish candidacy malignancy poor prognosis collaboration oncology specialist occur stratify patient regard risk tumour pro gression recurrence increase use immunosuppression irreversible liver dysfunction cirrhosis irreversible renal dysfunction eg creatinine clearance 30 mLmin1.73 m2 combined heartliver heartkidney transplant may considered systemic disease multiorgan involvement serious comorbidity poor prognosis pretransplant bmi 35 kgm2 weight loss recommended achieve bmi 35 kgm2 current alcohol drug abuse psychological instability jeopardizes proper followup intensive therapeutic regime heart transplantation insufﬁcient social support achieve compliant care outpatient setting bmi body mass index btt bridge transplantation heart failure heart failure lvad left ventricular assist device aactive infection relative contraindication transplant although case infected lvads may actually indication adapted crespoleiro et al376 recommendation patient advanced heart failure recommendation classa levelb patient considered longterm mc must good compliance appropriate capacity device handling psychosocial support414416 c heart transplantation recommended patient advanced hf refractory medi caldevice absolute contraindication c longterm mc considered patient advanced hfref despite optimal medical device eligible heart transplantation surgical option without severe right ventricular dysfunction reduce risk death improve symptoms378396397401402404417 iia longterm mc considered patient advanced hfref refractory optimal med ical device bridge cardiac transplantation order improve symptom reduce risk heart failure hospitalization risk premature death398400402404 iia b renal replacement considered patient refractory volume overload endstage kidney failure iia c continuous inotropes andor vasopressor may considered patient low cardiac put evidence organ hypoperfusion bridge mc heart transplantation389390 iib c ultraﬁltration may considered refractory volume overload unresponsive diuretic treatment391392 iib c heart failure heart failure hfref heart failure reduced ejection fraction mc mechanical circulatory support aclass recommendation blevel evidence esc 2021 esc 2021 downloaded guest 24 november 2024 centre’s surgical experience resource also influence deci sion making413 10.24 symptom control endoflife care disease trajectory patient heart failure unique generalizable pattern gradual decline punctuated episode acute deterioration leading either sudden death death due progressive hf communication disease trajectory anticipatory planning start patient diagnosed advanced hf indication key component palliative care service reported 18 19.312418 teambased approach palliative endoflife care patient heart failure ha proposed419 specific model palliative care patient advanced heart failure also reported reduce hospitalization without clear effect survival effect qol symptom burden420421 symptom assessment performed regular basis addition clinical assessment symptom assessed using numeric rating scale edmonton symptom assessment scale esas esashf integrated palliative care outcome scale symptom need considered might include additional intervention top omt • breathlessness repeat dos opioids may considered relief dyspnoea however effectiveness demon strated422423 using opioids patient guided opioid side effect constipation nausea urinary retention mental status change benzodiazepine may considered second thirdline opioids nonpharmacological measure failed control breath lessness increasing inspired oxygen concentration may pro vide relief dyspnoea • pain nonpharmacologic management helpful addition opioid oxycodone hydromorphone fentanyl generally viewed safe option provided orally intravenously transdermally especially hospital patient palliative care hospice setting424 • anxiety depression adequate conventional offered proactive decision advanced planning regard palliative endoflife care discussion documented regularly reviewed routinely communicated involved patient’s care healthcare provider make sure patients’ carer preference followed wherever possible also take account patient may choose may position express preference eg due symptom depression cognitive impairment 11 acute heart failure 11.1 epidemiology diagnosis prognosis ahf refers rapid gradual onset symptom andor sign hf severe enough patient seek urgent medical atten tion leading unplanned hospital admission emergency department visit patient ahf require urgent evaluation subsequent initiation intensification includ ing iv procedure ahf leading cause hospital izations subject aged 65 year associated high mortality rehospitalization rate inhospital mortality range 4 10425428 postdischarge 1year mortality 2530 45 death readmission rates104426427429430 ahf may first manifestation heart failure new onset frequently due acute decompensation chronic hf compared patient acutely decompensated chf new onset heart failure may higher inhospital mortality425 lower postdischarge mortality rehospitalization rates425428431432 specific extrinsic factor may precipitate cause ahf patient preexisting cardiac dysfunction supplementary 16 clinical severity inhospital trajec tory determined complex interplay precipi tants underlying cardiac substrate patient’s comorbidities 18 patient heart failure endoflife care considered progressive functional decline physical mental dependence activity living severe heart failure symptom poor qol despite optimal pharma cological nonpharmacological frequent admission hospital serious episode decompen sation despite optimal heart transplantation mc ruled cardiac cachexia clinically judged close end life mc mechanical circulatory support qol quality life 19 key component palliative care service patient advanced heart failure focus improving maintaining qol patient hisher fam ily well possible heshe dy frequent assessment symptom including dyspnoea pain result ing advanced heart failure comorbidities focus symptom relief access patient hisher family psychological support spi ritual care according need advanced care planning taking account preference place death resuscitation may include deactivating device icd longterm mc may require multidisciplinary team decision icd implantable cardioverterdeﬁbrillator mc mechanical circulatory sup port qol quality life esc 2021 esc 2021 downloaded guest 24 november 2024 diagnostic workup ahf start time first medi cal contact continued throughout initial patient pathway aiming identify clinical presentation diagnose manage potentially reversible causesprecipitantscoexisting lifethreatening condition timely manner 6 diagnostic test outlined 20 addition clinical sign symp tom diagnostic workup includes ecg echocardiography po sible additional investigation ie chest xray lung ultrasound may used confirm ahf diagnosis especially np testing available plasma np level bnp ntprobnp mr proanp measured diagnosis uncertain pointofcare assay available normal concentration np make diagnosis ahf unlikely cutoff acute heart failure bnp 100 pgml ntprobnp 300 pgml mrproanp 120 pg ml74433435 however elevated np value associated wide range cardiac noncardiac condition 6 low con centrations detected patient advanced decom pensated endstage hf obesity flash pulmonary oedema right sided ahf higher level found patient concomi tant atrial fibrillation andor reduced renal function74 among laboratory test troponin useful detection acute coronary syndrome ac although elevated level detected vast majority patient ahf436438 blood urea nitrogen urea serum creatinine electrolyte sodium potassium chloride antigen carbohydrate 125 may help tailor treat ment439440 detection abnormal liver function identifies patient diagnostic workup new onset acute heart failure electrocardiogram pulse oximetry echocardiography initial laboratory investigationsa chest xray lung ultrasound specific evaluationsb patient history sign andor symptom suspected acute hf natriuretic peptide testing bnp 100 pgml ntprobnp 300 pgml mrproanp 120 pgml bnp ≥ 100 pgml ntprobnp ≥300 pgmlc mrproanp ≥120 pgml acute heart failure ruled acute heart failure confirmed comprehensive echocardiography 6 diagnostic workup new onset acute heart failure ac acute coronary syndrome bnp btype natriuretic peptide ct computed tomography hf heart failure mrproanp midregional proatrial natriuretic peptide ntprobnp nterminal probtype natriuretic peptide tsh thyroidstimulating hormone ainitial laboratory exam include troponin serum creatinine electrolyte blood urea nitrogen urea tsh liver function test well ddimer procalcitonin pulmonary embolism infection suspected arterial blood gas analysis case respiratory distress lactate case hypoperfusion bspecific evaluation includes coronary angiography case suspected ac ct case suspected pulmonary embolism crulein value diagnosis acute hf 450 pgml aged 900 pgml aged 55 75 year 1800 pgml aged 75 years433434 downloaded guest 24 november 2024 poor prognosis441 since hypothyroidism hyperthyr oidism may precipitate ahf thyroidstimulating hormone tsh assessed newly diagnosed ahf arterial blood gas analysis performed precise measurement o2 co2 partial pressure needed ie patient respira tory distress lactate ph level measured patient cardiogenic shock ddimer measured acute pulmonary embolism suspected procalcitonin may used diagnosis pneumonia antibiotic may indication plasma level 0.2 lgl however impact strategy based routine procalcitonin measurement outcome wa shown prospective controlled trial442 pulse oximetry measured routinely time first presentation patient ahf continuous monitoring may needed first hour days443444 11.2 clinical presentation four major clinical presentation described possible overlap 211425445 clinical presentation mainly based presence sign congestion andor periph eral hypoperfusion require different 211425427432446447 11.21 acute decompensated heart failure acute decompensated heart failure adhf common form ahf accounting 5070 presentations426427432 20 diagnostic test patient acute heart failure exam time measurement possible finding diagnostic value ahf indication ecg admission hospitali zationab predischarge arrhythmia myocardial ischaemia exclusion ac arrhythmia recommended chestx ray admission hospitalizationa congestion lung infection conﬁrmatory may considered lu admission hospitali zationa predischarge congestion conﬁrmatory may considered echocardiography admission hospitali zationa predischarge congestion cardiac dy function mechanical cause major recommended natriuretic peptide bnp ntprobnp mrproanp admission predischarge congestion high negative predictive value recommended serum troponin admission myocardial injury exclusion ac recommended serum creatinine admission hospitali zationa predischarge renal dysfunction none recommended prognos tic assessment serum electrolyte sodium potassium chloride admission hospitali zationa predischarge electrolyte disorder none recommended prognos tic assessment iron status transferrin ferritin predischarge iron depletion none recommended prognos tic assessment tsh admission hypo hyperthyroidism none recommended hypo hyperthyroidism suspected ddimer admission pulmonary embolism useful exclude pulmo nary embolism recommended pul monary embolism suspected procalcitonin admission pneumonia useful diagnosis pneumonia may done pneu monia suspected lactate admission hospitalizationa lactic acidosis useful assess perfusion status recommended peripheral hypoperfusion suspected pulse oximetry arterial blood gas analysis admission hospitalizationa respiratory failure useful assess respiratory function recommended respi ratory failure suspected ac acute coronary syndrome ahf acute heart failure bnp btype natriuretic peptide ecg electrocardiogram lu lung ultrasound mrproanp midregional proatrial natriuretic peptide ntprobnp nterminal probtype natriuretic peptide tsh thyroidstimulating hormone abased clinical condition bcontinuous ecg monitoring considered based clinical condition esc 2021 downloaded guest 24 november 2024 usually occurs patient history heart failure previous cardiac dysfunction across spectrum left ventricular ejection fraction may include rv dy function distinct acute pulmonary oedema phenotype ha gradual onset main alteration progressive fluid retention responsible systemic congestion sometimes congestion associated hypoperfusion426 objective identification precipitant decongestion rare instance correction hypoperfusion 7 11.22 acute pulmonary oedema acute pulmonary oedema related lung congestion clinical crite ria acute pulmonary oedema diagnosis include dyspnoea orthopnoea respiratory failure hypoxaemiahypercapnia tachyp noea 25 breathsmin increased work breathing448 three commenced indicated first oxygen given continuous positive airway pressure noninvasive positive pressureventilation andor highflow nasal cannula started second iv diuretic administered third iv vasodilator may given systolic bp sbp high reduce lv afterload 8 case advanced hf acute pulmonary oedema may associated low cardiac output case inotropes vasopressor andor mc indicated restore organ perfusion 11.23 isolated right ventricular failure rv failure associated increased rv atrial pressure systemic congestion rv failure may also impair lv filling ultimately reduce systemic cardiac output ventricular interdependence449 diuretic often first option venous conge tion noradrenaline andor inotropes indicated low cardiac output haemodynamic instability inotropes reducing cardiac fill ing pressure may preferred ie levosimendan phosphodiester ase type iii inhibitor since inotropic agent may aggravate arterial hypotension may combined norepinephrine needed 9449 11.24 cardiogenic shock cardiogenic shock syndrome due primary cardiac dysfunction resulting inadequate cardiac output comprising life threatening state tissue hypoperfusion result multi organ failure death450452 cardiac insult causing severe impair ment cardiac performance may acute result acute loss myocardial tissue acute mi myocarditis may progres sive seen patient chronic decompensated heart failure may experience decline disease stability result natural pro gression advanced heart failure andor specific precipitants426 diagnosis cardiogenic shock mandate presence clini cal sign hypoperfusion cold sweated extremity oli guria mental confusion dizziness narrow pulse pressure addition biochemical manifestation hypoperfusion elevated serum creatinine metabolic acidosis elevated serum lactate present reflect tissue hypoxia alteration cellular 21 clinical presentation acute heart failure acute decompensated heart failure acute pulmonary oedema isolated right ventricular failure cardiogenic shock main mechanism lv dysfunction sodium water renal retention increased afterload andor predominant lv diastolic dysfunction valvular heart disease rv dysfunction andor precapillary pulmonary hypertension severe cardiac dysfunction main cause symptom fluid accumulation increased intraventricular pressure fluid redistribution lung acute respira tory failure increased central venous pressure often sys temic hypoperfusion systemic hypoperfusion onset gradual day rapid hour gradual rapid gradual rapid main haemodynamic abnormality increased lvedp pcwpa low normal cardiac output normal low sbp increased lvedp pcwpa normal cardiac output normal high sbp increased rvedp low cardiac output low sbp increased lvedp pcwpa low cardiac output low sbp main clinical presentations1446 wet warm dry cold wet warmb dry cold wet cold wet cold main diuretic inotropic agentsvasopressors peripheral hypoperfu sionhypotension shortterm mc rrt needed diuretic vasodilatorsb diuretic peripheral congestion inotropic agentsvasopres sors peripheral hypo perfusionhypotension shortterm mc rrt needed inotropic agent vasopressor shortterm mc rrt lv left ventricular lvedp left ventricular enddiastolic pressure mc mechanical circulatory support pcwp pulmonary capillary wedge pressure rv right ventricular rvedp right ventricular enddiastolic pressure rrt renal replacement sbp systolic blood pressure amay normal low cardiac output bwet cold proﬁle need inotropes andor vasopressor may rarely occur esc 2021 downloaded guest 24 november 2024 metabolism leading organ dysfunction437453 note hypoper fusion always accompanied hypotension bp may preserved compensatory vasoconstriction withwithout pressor agent albeit cost impaired tissue perfusion oxygenation426427450454 management cardiogenic shock start early po sible early identification underlying cause concomitant haemodynamic stabilization management organ dysfunction key component management 10 supplementary text 11.1 supplementary 2 n management patient acute decompensated heart failure congestionfluid overload hypoperfusion medical optimization Class loop diureticsa Class loop diureticsa Class consider inotropes Class IIb congestion relief hypoperfusion congestion relief n increase diuretic dos Class andor combine diuretic Class IIa consider vasopressor Class IIb ie norepinephrine diuretic resistance endstage renal failure persistent hypoperfusion organ damage n n renal replacement Class IIa consider palliative care mc Class IIa andor renal replacement Class IIa consider palliative care n n 7 management acute decompensated heart failure mc mechanical circulatory support aadequate diuretic dos relieve congestion close monitoring diuresis recommended see figure13 regardless perfusion status downloaded guest 24 november 2024 11.3 management 11.31 general aspect management subdivided three sta1 Gprehospital inhos pital predischarge different goal requiring different approach 11 prehospital phase prehospital setting ahf patient benefit non invasive monitoring including pulse oximetry bp heart rate respira tory rate continuous ecg instituted within minute patient contact ambulance possible305 oxygen may given based clinical judgment unless oxygen saturation 90 case administered patient respiratory dis tress respiratory rate 25 breathsmin oxygen saturation 90 noninvasive ventilation initiated444448 although therapeu tic tool may available prehospital setting whether effective prehospital care would alter clinical outcome remains proven randomized clinical trials455 furthermore pre hospital management delay rapid transfer ahf patient appropriate medical setting455456 inhospital management diagnostic workup appropriate pharmacological non pharmacological must started promptly parallel 12 ahf patient triaged appropriate level care according degree haemodynamic instability severity critical illness disposition decision important component initial phase management see supplementary text 11.2 supplementary 1719 type intensity inhospital monitoring depends clinical severity setting care inhospital course see supplementary text 11.3 ahf heterogeneous condition management may differ according main clinical presentation management start search specific cause ahf1305430 include management patient pulmonary oedema sbp ≥110 loop diuretic Class andor vasodilator Class IIb n n sign hypoperfusion loop diuretic Class inotropesvasopressors Class IIb loop diuretic Class congestion relief n medical optimization Class consider rrt mc device Class IIa consider palliative care oxygen Class ventilatory support Class IIa 8 management pulmonary oedema mc mechanical circulatory support rrt renal replacement sbp systolic blood pressure downloaded guest 24 november 2024 management patient isolated right ventricular failure specific ac rv involvement acute pulmonary embolism n loop diuretic class consider careful fluid administration marked congClass rvad andor renal replacement consider palliative care n optimize fluid status n peripheral hypoperfusion persistent hypotension n vasopressor andor inotropesa class iib relief sign symptom followup figurClass IIbement right ventricular failure ac acute coronary syndrome rv right ventricular rvad right ventricular assist device ainotropes alone case hypoperfusion without hypotension downloaded guest 24 november 2024 ac hypertensive emergency rapid arrhythmia severe brady cardiaconduction disturbance acute mechanical cause acute valve regurgitation acute pulmonary embolism infection including myocarditis tamponade champit 12 exclusion condition need treatedcorrected urgently management ahf differs according clinical presentation 710 predischarge phase detail phase shown section 11.311 11.32 oxygen andor ventilatory support ahf oxygen used routinely nonhypoxaemic patient cause vasoconstriction reduction cardiac put457 oxygen recommended patient ahf mc Class IIa andor renal replacement Class IIa consider palliative care management patient cardiogenic shock identify treat specific causesb ac andor mechanical complication n emergency pci surgical treatmenta consider oxygen Class ventilatory support Class IIa consider inotropes vasopressor Class IIb consider shortterm mc Class IIa improvement hypoperfusion organ dysfunction n weaning inotropesvasopressors andor mc continue aetiological needed medical optimization Class 10 management cardiogenic shock ac acute coronary syndrome btt bridge transplantation mc mechanical circulatory support pci percutaneous coronary intervention apci ac pericardiocentesis tamponade mitral valve surgery papillary muscle rupture case inter ventricular septum rupture mc btt considered bother cause include acute valve regurgitation pulmonary embolism infection acute myocarditis arrhythmia see 12 downloaded guest 24 november 2024 spo2 90 pao2 60 correct hypoxaemia9060 chronic obstructive pulmonary disease copd hyperoxygenation may increase ventilationperfusion mismatch suppress ventilation lead hypercapnia oxygen acidbase balance spo2 monitored noninvasive positive pressure ventilation either continuous posi tive airway pressure pressure support improves respiratory fail ure increase oxygenation ph decrease partial pressure carbon dioxide pco2 work breathing although large randomized neutral result metaanalyses suggest may improve dyspnoea reduce need intubation mortality compared traditional oxygen therapy1458459 non invasive positive pressure ventilation started soon possible patient respiratory distress respiratory rate 25 breathsmin spo2 90 improve gas exchange reduce rate endotracheal intubation448459 fraction inspired oxygen fio2 increased 100 necessary according oxygen saturation level blood pressure monitored regularly noninvasive positive pressure ventilation increase intrathoracic pressure noninvasive positive pressure ventilation decrease venous return right left ventricular preload may also decrease car diac output bp therefore used caution patient reduced preload reserve hypotension increase pulmonary vascular resistance rv afterload may also detri mental rv dysfunction448 intubation recommended progressive respiratory failure spite oxygen administration noninvasive ventilation supplementary 20448 11.33 diuretic intravenous diuretic cornerstone ahf increase renal excretion salt water indicated fluid overload congestion vast majority ahf patient determine aetiology alleviate symptom improve congestion organ perfusion restore oxygenation limit organ damage cardiac renal hepatic gut prevent thromboembolism close monitoring vital sign grading severity symptomssigns disposition decision icuiccu ward initial support circulatory respiratory function vasodilator vasopressor inotropes diuretic supplemental o2 identify aetiology relevant comorbidities start targeted titrate control symptom relieve congestion manage hypoperfusion optimize blood pressure initiate uptitrate disease modifying pharmacological consider device appropriate patient goal procedure phase determine aetiology improve sign symptom limit organ damage prevent thromboembolism improve symptom quality life achieve full congestion relief prevent early readmission improve survival initiate uptitrate disease modifying pharmacological device develop care plan identification caregiver schedule uptitration monitoring pharmacological review device enrolment disease management programme immediate predischarge longterm intermediate phase 11 stage management patient acute heart failure iccu intensive coronary care unit icu intensive care unit downloaded guest 24 november 2024 loop diuretic commonly used due rapid onset action efficacy data defining optimal dosing timing method administration limited difference primary efficacy outcome patients’ symptom global assessment wa shown highdose regimen compared lowdose regi men however wa greater relief dysp noea change weight net fluid loss prognostic role increase serum creatinine higherdose regimen460462 high diuretic dos may cause greater neurohormonal activation electrolyte abnormality often associated poorer come although cause effect relation cannot proven retrospective analyses463466 based observation may appropriate starting iv diuretic use low dos assess diuretic response increase insufficient diuretic started initial iv furosemide equivalent bumetanide torasemide corresponding 12 time oral taken patient admission patient wa oral diuretic starting 2040 furosemide bolus 1020 iv torase mide used145467 furosemide given 23 bolus continuous infusion single bolus administration discouraged possibility postdosing sodium retention145461 continuous infusion loading may used achieve steady state earlier diuretic response evaluated shortly start diuretic may assessed performing spot urine sodium content measurement 2 6 h andor measuring hourly urine output satisfactory diu retic response defined urine sodium content 5070 meql 2 h andor urine output 100150 mLh dur ing first 6 h145468 insufficient diuretic response loop diuretic iv doubled assessment diuretic response145 diuretic response remains inadequate eg 100 hourly diuresis despite doubling loop diuretic identification acute aetiology cardiogenic shock andor respiratory failure n management patient suspected acute heart failure pharmacological support ventilatory support mc acute coronary syndrome hypertension emergency arrhythmia mechanical causea pulmonary embolism infection tamponade c h p immediate initiation specific treatmentb n urgent phase first medical contact immediate phase initial 60–120 min 12 initial management acute heart failure mc mechanical circulatory support aacute mechanical cause myocardial rupture complicating acute coronary syndrome free wall rupture ventricular septal defect acute mitral regurgitation chest trauma cardiac intervention acute native prosthetic valve incompetence secondary endocarditis aortic dissection thrombosis bsee 710 specific according different clinical presentation downloaded guest 24 november 2024 concomitant administration diuretic acting different site namely thiazide metolazone acetazolamide may consid ered however combination requires careful monitoring serum electrolyte renal function 13145469470 strat egy based early frequent assessment diuretic response allows starting relatively low dos loop diuretic frequent adjustment may less likely cause dehy dration increase serum creatinine loop diuretic progressively decreased significant negative fluid balance ha obtained however pointed algorithm entirely based expert opinion date145461 transition oral commenced patient’s clinical condition stable recommended achievement congestion relief oral loop diuretic continued lowest possible avoid congestion463471 care must also taken avoid patient discharged hospital persis tent congestion major predictor increased death rehospitalizations462472 hence care taken achieve adequate decongestion establish appropriate longterm diu retic discharge427473 11.34 vasodilator intravenous vasodilator namely nitrate nitroprusside supple mentary 21 dilate venous arterial vessel leading reduction venous return heart less congestion lower load increased stroke volume consequent relief symptom nitrate act mainly peripheral vein whereas nitroprusside balanced arterial venous dilator474475 mechanism action iv vasodilator may effective diuretic patient whose acute pulmonary oedema caused increased afterload fluid redistribution lung absence minimal fluid accumulation427476478 however two recent randomized comparing usual care early inten sive sustained vasodilation failed show beneficial effect iv vasodilator v highdose diuretics479480 recommendation favouring regimen based vasodilator v usual care thus given date intravenous vasodilator may considered relieve ahf symp tom sbp 110 may started low dos uptitrated achieve clinical improvement bp control nitrate generally administered initial bolus followed management diuretic patient acute heart failure oral loop diuretic 1–2 time oral iv ≥20–40 iv furosemide urinary spot sodium 2 h ≥50–70 meql urine output 6 h ≥100–150 mLh double iv maximum iv dosea repeat similar iv every 12 h check serum creatinine electrolyte least every 24 h continue complete decongestion combination diuretic therapiesb n n ≥ urinary spot sodium 50–70 meql 2–6 h ≥ urine output 100–150 mLh n 13 diuretic furosemide acute heart failure iv intravenous athe maximal iv loop diuretic generally considered furosemide 400600 though 1000 may considered patient severely impaired kidney function bcombination addi tion loop diuretic diuretic different site action eg thiazide metolazone acetazolamide modified 145 downloaded guest 24 november 2024 continuous infusion however may also given repeated bolus nitroglycerine given 12 bolus severely hypertensive patient acute pulmonary oedema477 care taken avoid hypotension due excessive decrease preload afterload reason used extreme caution patient lvh andor severe aortic stenosis however favorable effect described patient lv sys tolic dysfunction aortic stenosis vasodilator given careful monitoring haemodynamic parameters481 11.35 inotropes inotropes still needed patient low cardiac output hypotension 22 reserved patient lv systolic dysfunction low cardiac output low sbp eg 90 resulting poor vital organ perfusion however must used caution starting low dos uptitrating close monitoring387388 inotropes especially adrenergic mechanism cause sinus tachycardia increase ventricular rate patient af may induce myocardial ischaemia arrhythmia increase mor tality387388430478 levosimendan type3phosphodiesterase inhibitor may preferred dobutamine patient betablockers act independent mechanisms482483 excessive peripheral vasodilation hypotension major limi tations type3phosphodiestaerase inhibitor levosimendan especially administered high dos andor commenced bolus dose482484 11.36 vasopressor vasopressor used ahf reported 22 among drug prominent peripheral arterial vasoconstrictor action norepinephrine may preferred patient severe hypotension aim increase perfusion vital organ however expense increase lv afterload therefore combination norepinephrine inotropic agent may considered especially patient advanced heart failure car diogenic shock though limitation support use norepi nephrine first choice compared dopamine epinephrine dopamine wa compared norepinephrine firstline vaso pressor patient shock wa associated arrhythmic event greater mortality patient car diogenic shock hypovolaemic septic shock although included 1679 patient significance wa seen subgroup analysis 280 patient cardiogenic shock 10 patient mi data regarding revas cularization limit generalizability results485 another prospective randomized epinephrine wa compared nore pinephrine patient cardiogenic shock due acute mi486 wa stopped prematurely due higher incidence refractory shock epinephrine epinephrine wa also associated higher heart rate lactic acidosis despite limitation related rela tively small sample size short time followup lack data regarding maximum reached suggests superior efficacy safety norepinephrine data consistent metaanalysis including 2583 patient cardiogenic shock showing threefold increase risk death epinephrine compared norepinephrine patient cardiogenic shock487 however lack information duration aetiology make result partially explorative 11.37 opiate opiate relieve dyspnoea anxiety may used sedative agent noninvasive positive pressure ventilation improve patient adaptation dosedependent side effect include nausea hypotension bradycardia respiratory depression retrospective 22 inotropes andor vasopressor used treat acute heart failure drug infusion rate dobutamine 220 lgkgmin betaþ dopamine 35 lgkgmin inotropic betaþ 5 lgkgmin inotropic betaþ vasopressor alphaþ milrinone 0.3750.75 lgkgmin enoximone 520 lgkgmin levosimendan 0.1 lgkgmin decreased 0.05 increased 0.2 lgkgmin norepinephrine 0.21.0 lgkgmin epinephrine 0.050.5 lgkgmin esc 2021 recommendation initial acute heart failure recommendation classa levelb oxygen ventilatory support oxygen recommended patient spo2 90 pao2 60 correct hypoxaemia c intubation recommended progressive piratory failure persisting spite oxygen administration noninvasive ventilation448 c noninvasive positive pressure ventilation considered patient respiratory distress respiratory rate 25 breathsmin spo2 190mmhg iv110 vasodilator may considered initial improve symptom reduce congestion475477479480 iib b continued downloaded guest 24 november 2024 analysis suggest morphine administration associated greater frequency mechanical ventilation prolonged hospitalization intensive care unit admission increased mortality488491 thus routine use opiate ahf recommended although may considered selected patient particularly case severeintractable pain anxiety setting palliation 11.38 digoxin digoxin considered patient atrial fibrillation rapid ven tricular rate 110 bpm despite betablockers see also section 12.11151492493 given bolus 0.250.5 iv used previously however patient comorbidities ie ckd factor affecting digoxin metabolism including drug andor elderly maintenance may difficult estimate theoretically measurement serum digoxin concentration performed digitoxin potential alternative digoxin currently evaluated randomized placebocontrolled clinicaltrialsgov identifier nct03783429158 11.39 thromboembolism prophylaxis thromboembolism prophylaxis heparin eg lowmolecular weight heparin another anticoagulant recommended unless contraindicated unnecessary existing oral anticoagulants494495 11.310 shortterm mechanical circulatory support patient presenting cardiogenic shock shortterm mc may necessary augment cardiac output support endorgan per fusion shortterm mc used btr btd btb450452 initial improvement cardiac output bp arterial lactate may counterbalanced significant complication highquality evidence regarding outcome remains scarce hence unselected use mc patient cardiogenic shock supported require specialist multidisciplinary expertise implantation management similar outlined advanced heart failure centre supplementary text 11.4 supplementary 22 see also section 10.22376496 recent show ‘standardized teambased approach’ using predefined algorithm early mc implant coupled close monitoring invasive haemodynamics lactate marker endorgan damage may potentially translate improved survival497499 intraaortic balloon pump cardiogenic shock ii iabp shockii showed difference 30day well long term mortality intraaortic balloon pump iabp omt patient cardiogenic shock following acute myocardial infarction underwent early revascularization500502 according result iabp routinely recommended cardiogenic shock postmi however may still considered cardiogenic shock especially due ac refractory drug btd btr btb shortterm mc compared iabp small randomized propensitymatched analysis inconclusive results503507 similarly rcts comparing extracorporeal membrane oxygenation ecmo iabp mt lacking metaanalysis including observational showed favourable outcome patient cardiogenic shock cardiac arrest treated veno arterial vaecmo compared controls508 vaecmo may also considered fulminant myocarditis condition causing severe cardiogenic shock509 depending severity myocar dial dysfunction andor concomitant mitral aortic regurgitation vaecmo may increase lv afterload increase lv end inotropic agent inotropic agent may considered patient sbp 90 evidence hypoperfu sion respond standard including ﬂuid challenge improve peripheral perfusion maintain endorgan function387 iib c inotropic agent recommended rou tinely due safety concern unless patient ha symptomatic hypotension evidence hypoperfusion387467478 iii c vasopressor vasopressor preferably norepinephrine may considered patient cardiogenic shock increase blood pressure vital organ perfusion485487 iib b drug thromboembolism prophylaxis eg lmwh recommended patient already anticoagulated contraindication anticoagulation reduce risk deep venous thrombosis pulmonary embolism494495 routine use opiate recommended unless selected patient severeintract able pain anxiety488489 iii c ahf acute heart failure iv intravenous lmwh lowmolecularweight hep arin pao2 partial pressure oxygen sbp systolic blood pressure spo2 transcutaneous oxygen saturation aclass recommendation blevel evidence esc 2021 recommendation use shortterm mechanical circulatory support patient cardiogenic shock recommendation classa levelb shortterm mc considered patient cardiogenic shock btr btd btb indication include cause cardiogenic shock longterm mc transplantation iia c iabp may considered patient cardio genic shock btr btd btb including treat ment cause cardiogenic shock ie mechanical complication acute mi long term mc transplantation450 iib c iabp routinely recommended postmi cardiogenic shock500502 iii b btb bridge bridge btd bridge decision btr bridge recovery iabp intraaortic balloon pump mc mechanical circulatory support myocardial infarction myocardial infarction aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 diastolic pressure pulmonary congestion case lv unloading mandatory achieved mean transeptal ventricular apex vent adding unloading device impella device510511 11.311 predischarge assessment postdischarge management planning significant proportion patient ahf discharged minimal weight loss importantly persistent conge tion427472 persistent congestion discharge associated higher risk readmission mortality426472 including diuretic therefore optimized order keep patient free congestion admitted adhf oral omt continued except possible reduction withdrawal haemo dynamic instability symptomatic hypotension severely impaired renal function hyperkalaemia haemodynamic stabilization achieved iv optimized dis charge467 optimization ha three major aim first relieve congestion second treat comorbidities iron defi ciency impact postdischarge outcome512 third initiate restart oral omt beneficial effect outcome dos may uptitrated discharge andor early post discharge phase shown optimization medical associated lower risk 30day readmission although prospec tive randomized performed date103467513 retrospective analysis show discontinuation reduction betablocker ahf hospitalization associated worse outcomes514 initiation arni recently hospitalized stable patient hfref including aceiarb naı¨ve safe may considered setting106107 safety better outcome also recently shown prospective randomized sotagliflozin diabetic patient hospitalized hf irrespective lvef136 recommended one followup visit within 1 2 week discharge515516 component followup visit include monitoring sign symptom hf assessment vol ume status bp heart rate laboratory measurement including renal function electrolyte possibly np iron status hepatic function also assessed done discharge based clinical evaluation laboratory exam optimiza tion andor initiation diseasemodifying hfref occur retrospective show approach associated lower 30day readmission rate although prospective randomized performed date513516518 12 cardiovascular comorbidities 12.1 arrhythmia conduction disturbance 12.11 atrial fibrillation atrial fibrillation heart failure frequently coexist519520 cause exacerbate mechanism structural cardiac remodel ling activation neurohormonal system raterelated lv impairment519523 proportion patient heart failure develop atrial fibrillation increase age heart failure severity atrial fibrillation cause heart failure clini cal course seems favourable cause heart failure called tachycardiomyopathy524 contrast development atrial fibrillation patient chronic heart failure associated worse prognosis includ ing stroke increased mortality525526 management patient concomitant heart failure atrial fibrillation sum marized 14.7521 includes 1 identification possible cause trigger af 2 management hf 3 prevention embolic event 4 rate control 5 rhythm control identification trigger management heart failure potential cause precipitating factor hyperthyroidism electrolyte disorder uncontrolled hypertension mitral valve dis ease infection identified corrected worsening congestion due atrial fibrillation managed diu retics congestion relief may reduce sympathetic drive ventricu lar rate increase chance spontaneous return sr presence atrial fibrillation may reduce abolish prognostic benefit betablockers render ivabradine ineffective12125 treat ments heart failure decrease risk developing af including acei slightly crt probably7527 prevention embolic event unless contraindicated oral longterm anticoagulant recom mended patient heart failure paroxysmal persistent perma nent af directacting oral anticoagulant doacs preferred recommendation predischarge early postdis charge followup patient hospitalized acute heart failure recommendation classa levelb recommended patient hospitalized heart failure carefully evaluated exclude persistent sign congestion discharge opti mize oral treatment427472 c recommended evidencebased oral medical administered discharge103513 c early followup visit recommended 12 week discharge assess sign conge tion drug tolerance start andor uptitrate evidencebased therapy517518 c ferric carboxymaltose considered iron deﬁciency deﬁned serum ferritin 100 ngml serum ferritin 100299 ngml tsat 20 improve symptom reduce rehospitalizations512 iia b hr heart failure tsat transferrin saturation aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 management atrial fibrillation patient hfref haemodynamic instability anticoagulation preventing embolic event class trigger class optimization Class Iailure class Class Iablockers class iia digoxindigitoxin Class Iiia amiodarone ivClass IIaClass IIa Class IIa rate control symptom improvement sinus rhythm amiodarone Class IIb ecv Class IIb rhythm control pv ablation Class IIa ecv Class rhythm control amiodarone Class IIb rhythm control pv ablation Class IIa avn ablation Class IIb rate control sinus rhythm followup n n n n 14 management atrial fibrillation patient heart failure reduced ejection fraction af atrial fibrillation avn atrioventricular node ecv electrical cardioversion hf heart failure iv intravenous pv pulmonary vein colour code class recommendation green class recommendation yellow class recommendation iia orange class recommendation iib red class recommendation iii see 1 detail class recommendation downloaded guest 24 november 2024 prevention thromboembolic event patient atrial fibrillation without severe mitral stenosis andor mechanical valve prosthesis similar efficacy vitamin k antagonist vkas lower risk intracranial haemorrhage528 la appendage closure considered patient heart failure atrial fibrillation contraindication oral anticoagulation though data randomized included patient contraindica tions oral anticoagulants529530 rate control data regarding rate control conclusive patient atrial fibrillation hf strategy lenient rate control defined resting heart rate 110 bpm wa compared strategy strict rate con trol defined heart rate 80 bpm rest 110 bpm moderate exercise race ii pooled analysis race affirm152531 showed difference outcome two strategy however 10 patient race ii 17 pooled analysis history hf hospitalization nyha class IIiii respectively152531 higher heart rate associated worse outcome observational stud ies532533 thus lenient rate control acceptable initial approach however targeting lower heart rate case per sistent symptom cardiac dysfunction likely related tachycardia eg tachycardiainduced cardiomyopathy7534 betablockers used rate control patient hfref hfmref established safety patient see section 5.327534535 digoxin digitoxin considered ventricular rate remains high despite betablockers betablockers contraindicated tolerated151493536 may therefore considered also alternative betablockers patient nyha class IV andor haemodynamic instability iv amiodarone considered reduce ventricular rate537 hfpef paucity evidence demonstrate efficacy agent rateaf compared digoxin bisoprolol patient persistent atrial fibrillation nyha class IIiv symptom compared bisoprolol digoxin effect qol 6 month primary endpoint better effect ehra nyha functional class536 19 patient left ventricular ejection fraction 50 patient considered hfmref hfpef536 av node ablation considered patient poor ventric ular rate control despite medical eligible rhythm control catheter ablation patient biventricular pacing7538540 rhythm control urgent electrical cardioversion recommended setting acute worsening heart failure patient presenting rapid ventricular rate haemodynamic instability consideration thromboem bolic risk cardioversion considered also improve symp tom patient persistent symptomatic af despite optimal pharmacological management patient receive chronic oral anticoagulant atrial fibrillation onset 48 h least 3 week therapeutic anticoagulation transoeso phageal echocardiography needed cardioversion7 pharmacological cardioversion preferred amiodarone drug choice antiarrhythmic drug ie propafenone flecainide dronedarone associated worse outcome hfref186534541544 amiodarone help maintain heart failure patient sr cardioversion545546 including patient heart failure comparing rate control rhythm control strategy latter based antiarrhythmic drug failed show benefit one strategy oth er547550 recently eastafnet 4 enrolling patient early af 28.6 hf wa stopped early median followup 5.1 year lower occurrence primary outcome death stroke hospitalization worsening heart failure ac patient assigned early rhythm control v assigned usual care551 however patient assigned rhythm control strategy closer followup may influenced better outcome catheter ablation wa performed minority patient rhythm control arm 19.4551 la catheter ablation wa compared mt rate rhythm con trol strategy 363 patient persistent paroxysmal af lvef 35 implanted device icd crtd enrolled castleaf trial552 primary endpoint allcause death hf hospitalization occurred fewer patient ablation group v mt group 51 patient 28.5 v 82 44.6 hazard ratio hr 95 confidence interval ci 0.62 0.430.87 p 0.007 also endpoint allcause cardiovascular death worsening hf reduced catheter ablation552 suggests catheter ablation improve prognosis patient hfref however enrolled highly selected population 363 3013 patient wa blinded crossover two strategy number event observed wa low 24 13.4 v 46 25.0 allcause death 37 20.7 v 66 35.9 heart failure hospitalization ablation mt group respectively552 cabana wa investigatorinitiated openlabel multi centre randomized enrolling 2204 patient symptomatic af failed show benefit atrial fibrillation ablation strategy medical care primary composite endpoint death disabling stroke serious bleeding cardiac arrest overall population553 analysis 778 patient 35 nyha class symptom ii primary outcome occurred 34 patient 9.0 cathe ter ablation group v 49 12.3 drug group hr 95 ci 0.64 0.410.99554 however also number event wa small heart failure wa defined based symptom left ventricular ejection fraction available 73 patient 50 4049 79 11.7 case respectively554 castleaf cabana showed highly significant effect catheter ablation patients’ symptoms552554 two prospective enrolled patient hfref persistent af randomized catheter ablation mt one amica n 140 catheter ablation amio darone one aatac n 203555556 first failed show difference left ventricular ejection fraction increase two groups555 second showed superiority catheter ablation respect atrial fibrillation recurrence primary endpoint also reduction unplanned hospitalization mortality556 contrast amica trial555 accordance castleaf552 aatac also showed benefit catheter ablation lvef556 conclusion insufficient evidence favour strategy rhythm control antiarrhythmic drug v rate control patient heart failure af547551 result randomized downloaded guest 24 november 2024 catheter ablation v mt showed consistent improvement symp tom whereas result mortality hospitalization obtained relatively small number event permitting draw definitive conclusions152548550552554557 12.12 ventricular arrhythmia ventricular arrhythmia may complication instan ce cause hf frequent ventricular premature beat vpbs may lead reversible systolic dysfunction possible factor may include dyssynchrony abnormal calcium handling560 initial management ventricular arrhythmia heart failure include correction potential precipitant including electrolyte abnormal ities particularly hypohyperkalaemia proarrhythmic drug well optimization heart failure drug although ischaemia may triggering factor revascularization ha shown reduce risk ventricular arrhythmias561 amiodarone effective also suppression ventricular arrhythmia however doe reduce incidence sudden cardiac death overall mortality161 patient premature ventricular contraction pvcinduced cmp amiodarone administra tion may considered reduce recurrent arrhythmia improve symptom lv function although side effect taken consideration drug discussed supplementary text 12.1 radiofrequency ablation vpbs may improve lv function possibly outcome patient tachycardiomyopathy vpbs contribute lv dysfunction562 sustained reduction baseline pvc burden ha associated lower risk cardiac mortal ity cardiac transplantation hospitalization heart failure follow up563564 12.13 symptomatic bradycardia pause atrio ventricular block indication pacemaker differ patient hf cardiovascular disease ample evidence rv pacing may adverse effect lv systolic function leading long term hf565 patient hfref requiring frequent ven tricular pacing eg av block slow af systolic dysfunction implanted crt rather standard pacemaker avoid adverse outcome shown blockhf biventricular right ventricular pacing heart failure patient atrioventricular block trial216 quest physiological alternative rv pacing physiological pacing increasingly adopted566 nonrandomized comparison 304 con secutive patient bundle pacing 433 consecutive patient rv pacing former group less heart failure hospitalization trend reduced mortality567 although technique promising data needed confirm role 12.2 chronic coronary syndrome cad common cause heart failure industrialized middle income increasingly lowincome country con sidered possible cause heart failure patient presenting new onset hf diagnostic workup patient heart failure chronic coronary syndrome cc reported recent 2019 esc guideline ccs5 patient heart failure carefully evaluated assess sign andor symptom cc clinical family history physical examination ecg imaging test recommended5 documentation ischaemia using noninvasive invasive test difficult patient heart failure possible exercise intolerance effect increased enddiastolic lv pressure coronary angiography ctca performed establish recommendation atrial ﬁbrilla tion patient heart failure recommendation classa levelb anticoagulation longterm oral anticoagulant recommended patient af hf cha2ds2vasc score 2 men 3 women7 doacs recommended preference vkas patient hf except moderate severe mitral stenosis mechani cal prosthetic heart valves528558 longterm oral anticoagulant considered stroke prevention atrial fibrillation patient cha2ds2vasc score 1 men 2 women7559 iia b rate control betablockers considered short longterm rate control patient hf af535 iia b digoxin considered ventric ular rate remains high despite betablockers betablockers contraindicated tolerated536 iia c cardioversion urgent ecv recommended setting acute worsening heart failure patient presenting rapid ventricular rate haemodynamic instability c cardioversion may considered patient association atrial fibrillation worsening heart failure symptom despite optimal medical treatment7541 iib b atrial fibrillation catheter ablation case clear association paroxys mal persistent atrial fibrillation worsening heart failure symp tom persist despite mt catheter ablation considered prevention af552554557 iia b atrial fibrillation atrial ﬁbrillation cha2ds2vasc congestive heart failure left ventricu lar dysfunction hypertension age 75 doubled diabetes stroke doubled vascular disease age 6574 sex category female score doac direct acting oral anticoagulant ecv electrical cardioversion heart failure heart failure mt medical vka vitamin k antagonist aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 presence extent cad evaluate potential indication revascularization see section 4.35 12.21 medical betablockers mainstay patient hfref cad prognostic benefit116120568 ivabradine considered alternative betablockers contraindi cated additional antianginal patient sr whose heart rate 70 bpm139569 antianginal drug eg amlodipine felodipine nicorandil ranolazine oral transdermal nitrate effective treating symptom although data effect outcome neutral lacking5570574 trimetazidine seems additive effect improvement lv function exercise capacity patient hfref cc already betablock ers575577 trimetazidine antianginal drug may consid ered patient heart failure angina despite betablocker andor ivabradine shortacting nitrate used caution patient heart failure cause hypotension diltiazem verapamil increase hfrelated event patient hfref contraindicated578 algorithm use antianginal medication patient hfref reported 15 betablockers longacting nitrate calcium channel blocker ccbs ivabradine ranolazine trimetazidine nicorandil combination considered hfpef angina relief without foreseen benefit heart failure coronary end point lowdose rivaroxaban 2.5 twice bid add prognostic benefit patient hfref cc commanderhf assess effectiveness safety rivaroxaban reducing risk death myocardial infarction stroke participant heart failure cad following episode decompen sated hf579 included patient hfref recent episode worsening heart failure occurring within 21 day time enrolment patient high risk hfrelated event main cause death hospitalization rivaroxaban effect event contrast nonprespecified subgroup analysis compass low rivaroxaban top aspirin wa associated reduc tion ischaemic event patient hf mainly hfmref hfpef580 based data lowdose rivaroxaban may con sidered patient cad peripheral artery disease use antianginal medication patient cc hfref betablockers Class persistence cc symptom absence improvement trimetazidine Class IIb nicorandil Class IIb felopidine Class IIb ranolazine Class IIb nitrate Class IIb amlodipine Class IIb ivabradine Class IIa hr 70 bpm andor atrial fibrillation hr ≥70 bpm sinus rhythm diltiazem Class III verapamil Class III 15 algorithm medical chronic coronary syndrome patient heart failure reduced ejection fraction cc chronic coronary syndrome hfref heart failure reduced ejection fraction hr heart rate colour code class recommendation green class recommendation yellow class recommendation iia orange class recommendation iib red class recommendation iii see 1 detail class recommendation downloaded guest 24 november 2024 hf left ventricular ejection fraction 40 sr high risk stroke low haemo40agic risk 12.22 myocardial revascularization data benefit myocardial revascularization patient heart failure limited stich compared coronary artery bypass grafting cabg mt patient cad amenable cabg reduced lv function ef 35 median followup 56 month wa significant difference cabg group mt group rate death cause primary outcome trial89 extended followup report showed significant reduction death cabg group v control group 58.9 v 66.1 hr 0.84 95 ci 0.730.97 p 0.02 10 years581 cardiovascular death combined endpoint allcause death hospitalization cardiovascular cause also significantly reduced cabg 10 year followup581 post hoc analysis stich suggested neither myocardial viability angina ischaemia related outcome revascularization9293582 heart failure revascularisation heart wa underpowered 138 planned 800 patient enrolled failed show differ ences outcome heart failure patient receiving cabg mt583 currently reported rcts comparing percutaneous coronary intervention pci mt patient hfref however revivedbcis2 ha finished recruitment clinicaltrialsgov identifier nct01920048584 also randomized comparing pci cabg randomized excluded patient hfref one prospective registry including 4616 patient multivessel disease hfref propensityscore matched comparison showed similar survival mean followup 2.9 year pci v cabg group pcis associ ated higher risk mi particularly patient incomplete revascularization cabg associated higher risk stroke585 propensitymatched analysis showed significantly lower risk death major cardiovascular event diabetic patient lv dysfunction multivessel disease treated cabg compared pci586 cabg wa associated better outcome pci also patient moderate severe lv dysfunction left main complex coronary disease587588 two metaanalyses confirmed cabg associated better outcome including mortality mi repeated revascularization compared pci andor mt589590 12.3 valvular heart disease 12.31 aortic stenosis aortic stenosis may cause worsen heart failure increasing lv afterload causing lv hypertrophy remodelling591 heart failure symp tom occur patient severe aortic stenosis prognosis extremely poor mt aortic stenosis improve outcome heart failure medical given heart failure patient sympto matic severe aortic stenosis care must taken using vasodilator avoid hypotension importantly possible improvement symp tom mt delay intervention presence suspected symptomatic severe high gradient aortic stenosis valve area 40 cause 40 mmHgflow status must excluded corrected ie anaemia hyperthyroidism arteriovenous shunt proceeding aortic valve intervention592 aortic valve intervention recommended patient heart failure symptom severe highgradient aortic stenosis regardless lvef management patient lowflow lowgradient aortic stenosis reported 16.592 intervention recommended patient life expectancy 1 year avoiding futility transcatheter aortic valve implantation tavi ha shown noninferior surgical aortic valve replace ment savr reducing clinical event including mortality dis abling stroke patient high intermediate risk surgery593600 lowrisk patient mean age rcts comparing tavi savr wa 70 year followup wa restricted 2 year therefore savr recommended patient aged 75 year high prohibitive surgical risk stsprom score eu4score ii 88 case choice tavi savr made heart team weighing pro con proce dure according age life expectancy individual patient preference feature including clinical anatomical aspect aortic recommendation myocardial revascularization patient heart failure reduced ejection fraction recommendation classa levelb cabg considered ﬁrstchoice revascularization strategy patient suitable surgery especially diabetes multivessel disease581587588590 iia b coronary revascularization considered relieve persistent symptom angina anginaequivalent patient hfref cc coronary anatomy suitable revasculariza tion despite omt including antianginal drug iia c lvad candidate needing coronary revascula rization cabg avoided possible iia c coronary revascularization may considered improve outcome patient hfref cc coronary anatomy suitable revas cularization careful evaluation indi vidual risk beneﬁt ratio including coronary anatomy ie proximal stenosis 90 large vessel stenosis left main proximal lad comorbidities life expectancy patient’s perspective iib c pci may considered alternative cabg based heart team evaluation consid ering coronary anatomy comorbidities sur gical risk iib c cabg coronary artery bypass graft cc chronic coronary syndrome hfref heart failure reduced ejection fraction lad left anterior descending artery lvad left ventricular assist device omt optimal medical pci percutaneous coronary intervention aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 valve intervention performed centre interventional cardiology cardiac surgery service site structured collaborative heart team approach balloon aortic valvuloplasty may considered highly sympto matic patient ahf ie cardiogenic shock bridge tavi savr advanced heart failure btr dt management patient heart failure suspected severe lowflow lowgradient asa dobutamine echo left ventricular ejection fraction 50 tavi Class savr Class n flow reservec clinical echo criteriab high calcium scored ct severe lowflow lowgradient n medical optimization Class heart teamg Class heart teamg Class followup f n e f tavi Class IIa savr Class IIa n 16 management patient severe lowflow lowgradient aortic stenosis heart failure aortic stenosis ct computed tomogra phy euroscore ii european system cardiac operative risk evaluation ii lvef left ventricular ejection fraction omt optimal medical savr surgical aortic valve replacement stsprom society thoracic surgeon predicted risk mortality tavi transcatheter aortic valve implantation avalve area 1 cm2 peak velocity 4.0 mean gradient 40 stroke volume index 35 mLm2 bage 70 year typical symptom without explanation left ventricular hypertrophy reduced left ventricular longitudinal function mean gradient 3040 valve area 0.8 cm2 stroke volume index 35 mLm2 assessed technique standard doppler cflow reserve defined stroke volume index increase 20 da likely calcium score 3000 men 1600 woman likely calcium score 2000 men 1200 woman unlikely calcium score 1600 men 800 woman eincrease valve area 1.0 cm2 response flow increase flow reserve dobutamine echo fincrease mean gradient least 40 without significant change valve area response flow increase flow reserve dobutamine echo gsavr recommended patient aged 75 year highprohibitive surgical risk stsprom score 4roscore ii 88 case choice tavi savr rec ommended decided heart team weighing pro con procedure according age life expectancy individual patient prefer ence feature including clinical anatomical aspect colour code class recommendation green class recommendation yellow class recommendation iia see 1 detail class recommendation downloaded guest 24 november 2024 12.32 aortic regurgitation severe aortic regurgitation lead progressive lv dilation subsequent dysfunction hf poor prognosis mt improve heart failure symptom patient severe aortic regurgitation particular inhibitor raas useful601 betablockers cautiously used prolong diastole may worsen aortic regurgitation aortic valve surgery recommended patient severe aortic regurgitation heart failure symptom regardless lvef592602603 case high prohibitive surgical risk tavi ha used treat also aortic regurgitation604 12.33 mitral regurgitation primary organic mitral regurgitation primary mitral regurgitation mr caused abnormality valve apparatus cause hf surgery preferably repair recommended patient severe primary mr heart failure symptom surgery contraindicated management secondary mitral regurgitation patient hfref pci Class IIb cabg mitral valve surgery Class IIa heart team Class need coronary revascularization omt including crt indicated n high surgical risk persistence heart failure symptomsa significant smrb n mt optimization implant crt indicated Class n n consider surgery lowrisk Class IIb percutaneous ee mitral valve repair Class IIa consider percutaneous ee mitral valve repair improve symptom btt lvad Class IIb maintain ongoing consider palliative care andor mc ht possible heartteam Class followup echocardiographic clinical criterion outcome improvement percutaneous ee mitral valve repairc n 17 management secondary mitral regurgitation patient heart failure reduced ejection fraction btt bridge transplantation cabg coronary artery bypass graft crt cardiac resynchronization ee edgetoedge eroa effective regurgitant orifice area hf heart failure lvad left ventricular assist device lvef left ventricular ejection fraction lvesdleft ventricular endsystolic diameter mc mechanical cir culatory support mt medical nyha new york heart association omt optimal medical pci percutaneous coronary interven tion smr secondary mitral regurgitation tr tricuspid regurgitation anyha class IIiv bmoderatetosevere severe eroa 30 mm2 call following criterion must fulfilled left ventricular ejection fraction 2050 lvesd 70 mm systolic pulmonary pressure 70 absence moderate severe right ventricu lar dysfunction severe tr absence haemodynamic instability612 colour code class recommendation green class recommendation yellow class recommendation iia orange class recommendation iib see 1 detail class recommendation downloaded guest 24 november 2024 considered high risk percutaneous repair may considered592605 secondary functional mitral regurgitation secondary mitral regurgitation smr mostly disease left ventricle also caused mitral annulus enlargement due la dilation606 moderate severe smr associated extremely poor prognosis patient hf607608 assess ment mr aetiology severity performed experienced echocardiographer applying multiparametric approach ideally stable patient condition optimization medical resynchronization smr dynamic condition echocardiographic quantification exercise may helpful patient moderate smr rest symptom physical activity609 early referral patient heart failure moderate severe mr multidisciplinary heart team including heart failure spe cialists recommended assessment planning heart team ha verify first patient optimal including crt indicated 17 patient severe smr hfref requiring revascularization mitral valve surgery cabg considered isolated mitral valve surgery may considered symptomatic patient severe smr despite optimal low surgical risk592 two randomized mitrafr coapt evaluated effectiveness percutaneous edgetoedge mitral valve repair plus omt compared omt alone symptomatic patient reduced left ventricular ejection fraction 1540 mitrafr 2050 coapt moderatetosevere severe smr effective regurgitant orifice area eroa 20 mm2 mitrafr eroa 30 mm2 coapt610612 mitrafr failed show benefit intervention allcause mortality heart failure hospitalization 12 month primary endpoint hr 1.16 95 ci 0.731.84 24 months610611 contrast coapt showed significant reduction hospitalization heart failure 24 month primary endpoint hr 0.53 95 ci 0.400.70 mortality secondary endpoint hr 0.62 95 ci 0.460.82612 difference patient selection concomitant mt echocardiographic assessment procedural issue severity smr relation degree lv dilatation may responsible diverging result mitrafr coapt trials613615 thus percutaneous edgetoedge mitral valve repair con sidered outcome improvement carefully selected patient remain symptomatic nyha class IIiv despite omt moderatetosevere severe smr eroa 30 mm2 favourable anatomical condition fulfilling inclusion criterion coapt ie left ventricular ejection fraction 2050 lv endsystolic diameter 70 mm systolic pulmonary pressure 70 absence moderate severe rv dysfunction absence severe tr absence haemo dynamic instability 17615616 percutaneous edgetoto edge mitral valve repair may also considered improve symptom patient advanced hf severe smr severe symptom despite omt patient cardiac transplantation lvad implantation must also considered376617 percutaneous mitral valve repair system indirect annuloplasty available smr approach ha shorter learning curve lesser technical requirement percu taneous edgetoto edge mitral valve repair doe preclude different procedure performed shamcontrolled randomized testing transcatheter indirect mitral annuloplasty device met primary endpoint mitral regurgitant volume reduc tion reverse lv la remodelling 12 months618 confirmed favourable result la volume lv remodel ling trend towards improvement mean 6mwt distance symptom reduction heart failure hospitalization ipd metaana lysis619622 transcatheter mitral valve replacement also emerging possible alternative option randomized still lacking623 mitral valve intervention recommended patient life expectancy 1 year due extracardiac conditions592 recommendation management valvular heart disease patient heart failure recommendation classa levelb aortic stenosis aortic valve intervention tavi savr rec ommended patient heart failure severe high gradient aortic stenosis reduce mortality improve symptoms594 b recommended choice tavi savr made heart team according individual patient preference feature including age surgical risk clinical ana tomical procedural aspect weighing risk beneﬁts approach592 c secondary mitral regurgitation percutaneous edgetoedge mitral valve repair considered carefully selected patient secondary mitral regurgitation eligible surgery needing coronary revascularization symptomaticc despite omt fulﬁl criteriad achieving reduction heart failure hospitalizations612 iia b patient hf severe secondary mitral regurgitation cad need revasculariza tion cabg mitral valve surgery considered iia c percutaneous edgetoedge mitral valve repair may considered improve symptom carefully selected patient secondary mitral regurgitation eligible surgery needing coronary revascularization highly symp tomatic despite omt fulﬁl crite ria reducing heart failure hospitalization617 iib c cabg coronary artery bypass graft cad coronary artery disease left ventricular ejection fraction left ventricular ejection fraction lvesd left ventricular endsystolic diameter nyha new york heart association omt optimal medical savr surgical aortic valve replacement tavi transcatheter aortic valve implantation tr tricuspid regurgitation aclass recommendation blevel evidence cnyha class IIiv dall following criterion must fulﬁlled left ventricular ejection fraction 2050 lvesd 70 mm systolic pulmonary pressure 70 absence moderate severe right ventricular dysfunction severe tr absence haemodynamic instability612 esc 2021 downloaded guest 24 november 2024 12.34 tricuspid regurgitation tricuspid regurgitation tr caused consequence rv dysfunction hf management heart failure tr includes mt ie diuretic neurohormonal antagonist transcatheter ther apy surgery may considered selected cases592 multidisci plinary heart team including heart failure specialist considered assessment planning tricuspid valve surgery recommended patient severe tr requiring leftsided cardiac surgery also considered patient moderate tr tricuspid annulus dilatation requir ing leftsided cardiac surgery symptomatic patient iso lated severe tr592 however surgery isolated tr burdened high inhospital mortality 8.8 although advanced stage hf may influenced data624 transcatheter technique recently emerged potential option tr preliminary result show improvement tr severity symptom low complication rates625 prospective needed show prognostic impact heart failure patient 12.4 hypertension arterial hypertension leading risk factor development hf almost twothirds heart failure patient past history hyperten sion104626 clinical evaluating antihypertensive strategy bp target patient heart failure hypertension performed hfref similar hypertensive normotensive patient recommended medication including neurohormonal antagonist diuretic lower also bp lifestyle modification weight loss reduced sodium intake increased physical activity useful adjunctive measures4 uncontrolled hypertension patient hfref rare provided patient receiving omt recommended dos hf bp lowering required absence sign fluid overload amlodipine felodipine shown safe hfref may considered570571 non dihydropyridine ccbs diltiazem verapamil centrally acting agent moxonidine contraindicated associ ated worse outcomes627 alphablockers effect sur vival therefore indicated143 used concomitant prostatic hyperplasia drawn case hypotension hypertension important cause hfpef preva lence 60 8939 patient hfpef also frequently exaggerated hypertensive response exercise may present hypertensive acute pulmonary oedema628629 antihypertensive agent including acei arb betablockers ccb diuretic reduce incidence hf630631 reducing bp lead also lvh regression degree depends class drug used4 arb acei ccbs cause effective lvh regression betablockers diuretics632 poorly controlled hypertension may precipitate episode decompensation cause secondary hyper tension renal vascular parenchymal disease primary aldos teronism obstructive sleep apnoea osa ruled confirmed considered hyperten sion important issue patient hfpef optimal strategy uncertain strategy used hfref also considered hfpef4 bp target uncertain hfref hfpef however eval uation patient’s age comorbidities ie diabetes ckd cad valvular heart disease stroke helpful personalize bp target4 every effort made reach target dos evidencebased medication hfref patient despite slight hypo tension4633 conversely hfpef patient lvh limited pre load reserve hypotension avoided 12.5 stroke heart failure stroke frequently coexist overlap shared risk factor subsequent mechanisms519634 higher risk stroke present also heart failure patient sr39426635637 atrial fibrillation confers addi tional risk patient heart failure atrial fibrillation fivefold increased risk compared control population519634638 temporal trend incidence stroke higher first 30 day heart failure diagnosis episode heart failure decompensation decrease first 6 month following acute event637639 patient stroke heart failure higher mortality severe neu rological deficit longer hospital stay without hf637640 similarly patient heart failure stroke higher mortal ity patient without stroke640 commanderhf 47.5 stroke either disabling 16.5 fatal 31637 patient heart failure concomitant af including paroxysmal af cha2ds2vasc score least 1 therefore indi cation anticoagulation indication antithrombotic strategy patient heart failure sr controversial warfarin aspirin reduced cardiac ejection fraction warcef war farin reduced ischaemic stroke compared aspirin increased major haemorrhage influence primary endpoint ischaemic stroke intracerebral haemorrhage death641 metaanalyses confirm increased risk bleeding weighing ischaemic stroke prevention placebocontrolled patient hfref sr642 commanderhf rivaroxaban 2.5 bid improve composite outcome allcause mortality myocardial infarction stroke favourably influence hfrelated death heart failure hospitalizations579 data support rou tine strategy anticoagulation patient hfref sr history paroxysmal af however lowdose rivaroxaban may considered patient concomitant cc peripheral artery disease high risk stroke major haemorrhagic risk see section 12.2 patient visible intraventricular thrombus high throm botic risk history peripheral embolism patient ppcm lv noncompaction lvnc con sidered anticoagulation3643645 13 noncardiovascular comorbidities 13.1 diabetes heart failure similar patient without diabetes6646 conversely antidiabetic drug differ effect patient heart failure preference must given drug safe reduce hfrelated events6646647 downloaded guest 24 november 2024 sglt2 inhibitor canagliflozin dapagliflozin empagliflozin ertugliflozin sotagliflozin studied patient established cardiovascular disease empareg outcome vertiscv established cardiovascular disease cardiovascular risk factor canvas declaretimi 58 ckd cardiovascular risk scored respectively293297 small proportion patient history hf empagliflozin canagliflozin reduced primary composite endpoint major cardiovascular adverse event including cardiovascular death non fatal myocardial infarction nonfatal stroke heart failure hospitalization empareg outcome canvas respectively293294 empagliflozin also reduced allcause death cardiovascular death alone293 effect pri mary endpoint driven reduction hfrelated events293294 declaretimi 58 dapagliflozin reduce major cardiovascular event reduced coprimary efficacy endpoint cv death heart failure hospitalization heart failure hospitalization alone295 vertiscv neither primary major cardiovascular event endpoint key secondary outcome cardiovascular death heart failure hospitalization reduced significantly ertugliflozin although wa statistically significant reduction heart failure hospitalization repeated hospitaliza tions297648 scored sotagliflozin reduced cardiovascular death hf hospitalizations296 metaanalysis one patient ckd credence overall sglt2 inhibitor reduced heart failure cardiovascular hospitalization 22649 sglt2 inhibitor well tolerated although may cause genital fungal skin infec tions rarely diabetic ketoacidosis293295 result dapa gliflozin empagliflozin patient hfref without diabetes sglt12 inhibitor sotagliflozin patient type 2 diabetes stabilized hospitalization acute heart failure within 3 day discharge support administration agent see section 5.35 section 11.311108109136 empareg outcome canvas declaretimi 58 vertiscv also showed reduction worsening renal function endstage renal disease death renal cause sglt2 inhibitor based result sglt inhibitor canagliflozin dapagli flozin empagliflozin ertugliflozin sotagliflozin recommended prevent heart failure cardiovascular death worsening kidney function patient type 2 diabetes cardiovascular disease andor cardiovascular risk factor ckd dapagliflozin empagliflozin also indicated patient type 2 diabetes hfref see section 5.35 section 11.24 sotagliflozin wa shown reduce cardiovascular death heart failure rehospitalizations patient recently ho pitalized hf6296646647650 metformin thought safe patient hf compared insulin sulfonylurea based observational studies651652 however recommended patient egfr 30 min1.73 m2 hepatic impairment risk lactic acido si ha studied controlled outcome date6646 regarding dipeptidyl peptidase4 dpp4 inhibitor heart failure hospital izations increased 27 one saxagliptin patient diabetes653 however difference placebo heart failure event wa found alogliptin sitagliptin linagliptin654656 vidagliptin wa associated increase lv volume numerically greater number death cardiovascular event small patient diabetes hf657 overall effect mortality cv event neutral dpp4 inhibitor meta analyses658659 drug therefore recommended reduce cardiovascular event diabetic patient hf glucagonlike peptide1 glp1 receptor agonist reduce risk mi stroke cardiovascular death patient diabetes although prob ably reduce incident hf6660 liraglutide effect lvef increased heart rate increased serious cardiac event randomized placebocontrolled 241 patient hfref without diabetes661 neutral result primary endpoint found another 300 patient numerical increase death heart failure hospitalization compared placebo662 Glp1 receptor agonist therefore recommended preven tion heart failure event insulin needed patient type 1 diabetes control hyperglycaemia patient type 2 diabetes especially betacell function exhausted sodiumretaining hor mone concern ha raised may exacerbate fluid reten tion patient hf however rct included patient type 2 diabetes impaired glucose tolerance impaired fasting glucose insulin increase risk incident hf663 use insulin wa associated poorer outcome retrospective analy randomized administrative databases664665 insulin needed patient hf patient monitored evidence worsening heart failure initiation sulfonylurea associated higher risk heart failure event analyses666667 therefore preferred patient heart failure needed patient monitored evidence worsening heart failure initiation6646 thiazolidinediones glitazones cause sodium water retention increased risk worsening heart failure hospitalization668 contraindicated patient hf 13.2 thyroid disorder assessment thyroid function recommended patient hf hypo hyperthyroidism may cause precipitate hf669 subclinical hypothyroidism isolated low triiodothyronine level recommendation diabetes heart failure recommendation classa levelb sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂozin ertugliﬂozin sotagliﬂozin rec ommended patient t2dm risk cv event reduce hospitalization hf major cardiovascular event endstage renal dysfunction cv death293297 sglt2 inhibitor dapagliﬂozin empagliﬂozin sotagliﬂozin recommended patient t2dm hfref reduce hospitalization heart failure cardiovascular death108109136 cardiovascular cardiovascular heart failure heart failure hfref heart failure reduced ejec tion fraction sglt2 sodiumglucose cotransporter 2 t2dm type 2 diabetes mellitus aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 associated poorer outcome observational patient hf670671 thyroid disorder guided general endocrine guideline randomized evaluating efficacy thyroid replacement subclinical hypothyroidism general agreement correct tsh 10 miul particularly patient 70 year correction may also considered lower tsh level 710 miul672674 13.3 obesity obesity risk factor hypertension cad also associ ated increased risk hf possibly stronger associa tion hfpef258675677 obese patient hf obesity paradox ha described overweight mildlymoder ately obese patient better prognosis leaner patient par ticularly compared underweight678679 however variable may influence relationship obesity para dox observed patient diabetes680681 second bmi doe take account body composition eg relation lean skeletal muscle mass fat mass obese patient fit preserved skeletal muscle mass better progno si obese sarcopenic patients682 waist circumference waisttohip ratio measuring visceral obesity less influenced muscle mass may stronger relationship outcome bmi especially female patients683684 body fat ha major impact diagnostic prognostic value multiple parameter obese patient heart failure lower np con centrations due increased expression clearance receptor augmented peptide degradation adipose tissue74 peak oxygen consumption adjusted body weight underestimate exercise capacity obese patient adjustment lean body mass used risk stratification96 obesity may major cause hfpef obese hfpef patient display several pathophysiologic mechanism differ non obese patient hfpef258675677685 caloric restriction exercise training additive beneficial effect exercise capacity qol patient obesity hfpef randomized trial337 13.4 frailty cachexia sarcopenia frailty multidimensional dynamic state independent age make individual vulnerable effect stressors686 hf frailty two distinct yet commonly associated condition assessment frailty patient heart failure crucial associated unfavourable outcome reduced access toler ance several tool proposed frailty screening assessment different chronic condition including hf hfa esc ha developed hfspecific tool based four major domain clinical psychocognitive functional social686 frailty prevalent patient heart failure general pop ulation may occur 45 patient according recent metaanalysis687688 patient heart failure six time likely frail frail people significantly increased risk developing hf689690 frailty associated higher risk death hospitalization functional decline well longer dura tion hospital stay691693 frailty heart failure multifactorial targeted main component may include physical rehabilitation exercise training nutritional supplementa tion well individualized approach treating comorbidities686 cachexia defined ‘complex metabolic syndrome associated underlying illness characterized loss muscle without loss fat mass’694 major clinical feature 5 oedemafree body weight loss previous 12 month less694695 cachexia generalized wasting process may coexist frailty may occur 515 patient hf especially hfref advanced disease status associated reduced functional capacity decreased survival695698 associated chronic disease cancer alternative noncardiac cause cachexia always investigated699 sarcopenia defined presence low muscle mass together low muscle function strength performance698 usually identified appendicular skeletal muscle mass defined sum muscle mass four limb 2 standard deviation mean healthy group aged 1840years cutoff value 7.26 kgm2 men688700701 occurs physiologically aging however accelerated chronic disease cancer hf sarcopenia found 2050 patient hfref often associated frailty increased morbidity mortal ity major determinant outcome outweighing effect body weight bmi684698701702 far effective strategy sarcopenia resistance exercise training possibly com bined protein intake 11.5 gkgday698703 drug including anabolic compound like testosterone growth hormone ghrelin receptor agonist tested small showing favour able result mostly term exercise capacity muscle strength697703705 data showing favourable impact sarcopenia outcome however exercise training ha favourable effect patient heart failure see section 9.495323329 13.5 iron deficiency anaemia iron deficiency anaemia common patient hf independently associated reduced exercise capacity recurrent heart failure hospitalization high cardiovascular allcause mortality706707 according world health organization criterion anaemia defined haemoglobin concentration 12 gdl woman 13 gdl men patient hf iron deficiency defined either serum ferritin concentration 100 ngml 100299 ng transferrin saturation tsat 20708710 ferritin tissue expression concentration peripheral blood increased inflammation several disorder infection cancer liver dis ease heart failure hence higher cutoff value applied definition iron deficiency patient hf709711 another marker reflecting depleted intracellular iron high serum solu ble transferrin receptor derives proteolysis mem brane transferrin receptor synthesis increased case iron deficiency affected inflammation high serum soluble transferrin receptor identify patient high risk death beyond standard prognostic variables711712 however applicability iron supplementation ha demonstrated yet iron deficiency present independently anaemia present 55 chronic heart failure patient 80 ahf713716 may caused increased loss reduced intake absorption ie malnutrition gut congestion andor impaired iron metabolism caused chronic inflammatory activation hf although exact cause iron deficiency heart failure remains unknown iron deficiency may impair functional capacity precipitate circulatory downloaded guest 24 november 2024 decompensation promote skeletal muscle dysfunction associ ated frailty irrespective anaemia716718 recommended patient heart failure regularly screened anaemia iron deficiency full blood count serum ferritin concentration tsat detection anaemia andor iron defi ciency prompt appropriate investigation define cause darbepoetinalpha failed reduce allcause death heart failure hospital ization increased risk thromboembolic event largescale randomized patient hfref mild mod erate anaemia719 result erythropoietin stimulating agent indicated anaemia hf rcts shown iron supplementation iv ferric car boxymaltose safe improves symptom exercise capacity qol patient hfref iron deficiency720723 meta analysis rcts showed also reduction risk combined endpoint allcause death cardiovascular hospitalization cardiovascular death hf hospitalization cardiovascular death recurrent cardiovascular heart failure hospitaliza tions724725 favourable effect iron supplementation independent anaemia coexistence726 affirmahf patient hospitalized heart failure left ventricular ejection fraction 50 concomitant iron deficiency randomized iv ferric carboxymaltose placebo repeated 6 12week interval indicated according repeat iron studies512 administration ferric carboxymaltose signifi cantly reduce primary composite outcome total heart failure hospital izations cardiovascular death 52 week rate ratio 0.79 95 ci 0.621.01 p 0.059 however reduced composite endpoint first heart failure hospitalization cardiovascular death hr 0.80 95 ci 0.660.98 p 0.030 total heart failure hospitalization rate ratio 0.74 95 ci 0.580.94 p 0.013512 therefore iron supplementation iv ferric carboxymaltose considered improvement symptom exercise capacity qol patient heart failure lvef 45 also considered reduction heart failure rehospi talizations patient left ventricular ejection fraction 50 recently hospitalized wor sening hf ongoing expected provide evidence effect ferric carboxymaltose patient hfpef addi tion large outcome iron formulation ongoing hfref hfpef ahf727 oral iron effective iron repletion improve exercise capacity patient hfref iron deficiency728 therefore recommended iron deficiency patient hf 13.6 kidney dysfunction ckd heart failure frequently coexist471707729 share common risk factor diabetes hypertension ckd may worsen cardiovascular func tion causing hypertension vascular calcification heart failure may worsen renal function effect neurohormonal inflamma tory activation increased venous pressure hypoperfusion oxidative stress fibrosis likely play major role pathogenic mechanism heart failure ckd730731 ckd worsening renal function appear common hfpef compared hfmref hfref perhaps due shared pathophysiological mechanism appear less associated worse outcome hfpef hfmref hfref732733 ckd major independent determinant increased mortality morbidity hf471734736 however setting change serum creatinine associated worse outcome raas inhibitor arni sglt2 inhibitor started ini tial decrease glomerular filtration pressure may decrease gfr increase serum creatinine however change generally transient occur despite improvement patient outcome slower worsening renal function long term instance emperorreduced placebocorrected egfr dip induced empagliflozin week 4 wa 2.4 mLmin1.73 m2 patient ckd 2.7 mLmin1.73 m2 without ckd corresponding decrease baseline 5.2 3.8 respectively wa followed slower slope egfr decline reduced rate composite kidney outcome empagliflozin v placebo difference patient without ckd baseline109737 thus respect initiation raas inhibitor arni sglt2 inhibitor transient decrease renal function prompt interruption increase serum creatinine 250lmin1.73 m2 considered acceptable 3 section 5.3 supplementary t10e 825 also respect diuretic small transient rise serum creatinine acute heart failure associ ated poorer outcome patient free congestion108109460462471729737740 randomized shown patient heart failure concomi tant ckd higher risk event beneficial effect mt recommendation management anaemia iron deﬁciency patient heart failure recommendation classa levelb recommended patient heart failure periodically screened anaemia iron deﬁ ciency full blood count serum ferritin concentration tsat c intravenous iron supplementation ferric carboxymaltose considered symp tomatic patient left ventricular ejection fraction 45 iron deﬁ ciency deﬁned serum ferritin 100 ngml serum ferritin 100299 ngml tsat 20 alleviate heart failure symptom improve exer cise capacity qol720722724 iia intravenous iron supplementation ferric carboxymaltose considered symp tomatic heart failure patient recently hospitalized hf left ventricular ejection fraction 50 iron deﬁciency deﬁned serum ferritin 100 ngml serum ferritin 100299 ngml tsat 20 reduce risk heart failure hospitalization512 iia b heart failure heart failure left ventricular ejection fraction left ventricular ejection fraction qol quality life tsat transferrin saturation aclass recommendation blevel evidence esc 2021 downloaded guest 24 november 2024 similar greater patient normal renal func tion206471741742 betablockers reduce mortality hfref patient moderate egfr 4559 mlmin1.73 m2 moderately severe egfr 3044 mlmin59 mLm2 renal dysfunction whereas limited eviden44 available regarding patient severe renal impairment egfr 30 mlmin1.73 m2743 sacubitrilvalsartan compared e30 mLril led slower decline renal function despite slight increase urinary albumincreatinine ratio improved cardiovascular outcome similar extent patient ckd v others paradigmhf127 sglt2 inhibitor lead slower decline renal function compared placebo patient hfref ckd108109737738744 improve ment cardiac output crt lvad implantation may associated least transient improvement renal func tion471745746 benefit icds may reduced patient severe renal dysfunction competing risk non arrhythmic cause death747749 little direct evidence support recommendation heart failure patient severe ckd date rcts excluded patient advanced stage ckd ie egfr 30 min1.73 m2 supplementary 23 cutoff value inclusion lower recent 25 mLmin1.73 m2 dapackd 20 mLmin1.73 m2 emperorreduced galactichf 15 mLmin1.73 m2 victoria respectively109141737738750 despite difference baseline characteristic patient severely impaired renal function others interaction drug effect renal function wa noted subgroup analy si trials109141738750 13.7 electrolyte disorder hypokalaemia hyperkalaemia hyponatraemia hypochloraemia electrolyte disturbance frequent patient heart failure may often iatrogenic751 serum potassium level ushaped rela tion mortality lowest risk death within relatively narrow range 4 5 mmoll752758 hypokalaemia defined serum potassium 3.5 mmoll may occur 50 patient hf759 hypokalaemia often induced loop thiazide diuretic administration may cause lethal ventricular arrhythmia increase cardiovascular mortality treat ment includes use raas inhibitor potassiumsparing diu retics prescription oral potassium supplement ie potassium chloride tablet oral administration possible potassium supplementation infusion may necessary 20 40 potassium 2501000 normal saline potassiumrich solu tion infused slow rate large vein using venous catheter hyperkalaemia defined serum potassium 5 mmoll classified mild 5.0 65.5 mmoll760 associated 0 increased risk6.0 mmolspitalization death752753755756761762 hyperkalaemia associated administration raas inhibitor ckd increased absorption760 among patient hf prevalence hyperkalaemia given time among patient heart failure appears less 5757 incidence much higher 40 in5hronic heart failure 73 ckd followup duration40f approximately 1 y73753756757763765 paradigm hf sacubitrilvalsartan wa associated lower risk severe hyperkalaemia compared enalapril128 lifethreatening hyperkalaemia requires immediate combination calcium carbonate andor sodium bicarbonate insulin glucose beta adrenoceptor agonist eg salbutamol label use european union eu country agent favour potassium entry cell increase potassium excretion thus provide temporary benefit rebound hyperkalaemia occur hour loop diuretic administered facilitate potassium loss potassium binder bind potassium gastrointestinal tract reducing absorption used acute chronic potassium lowering include sodium polystyrene sulfonate cal cium polystyrene sulfonate much better tolerated patiromer sorbitex calcium sodium zirconium cyclosilicate szc sodium polystyrene sulfonate still indicated anuric severely oliguric patient used medium long term may cause severe gastrointestinal side effect including bowel necrosis760 patiromer szc increase faecal potassium excretion act mainly colon compound effective normal izing elevated potassium level maintaining normokalaemia time preventing recurrence hyperkalaemia consid ered hyperkalaemia766768 see supplementary 24 renal dysfunction hyperkalaemia major cause underuse raas inhibitor particularly mra clinical practice342753758769771 administration potassiumlowering agent patiromer szc may allow initiation uptitration larger proportion patient hypothesis wa tested double blind placebocontrolled randomized patiromer pla cebo administration patient ckd hyperkalaemia dis continuation raas inhibitor hyperkalaemia indication spironolactone heart failure andor resistant hypertension patiromer wa likely lower serum potassium decreased episode hyperkalaemia spironolactone initiation uptitration772775 ongoing rct diamond nct03888066 testing impact clinical outcome strategy based patiromer administration compared placebo patient hfref hyperkalaemic raas inhibitor history hyperkalaemia subsequent reduction discontinua tion raas inhibitor776777 see supplementary text 13.1 hyponatraemia defined serum sodium concentration lower 136 mmoll common heart failure may present 30 patient admitted hospital hf reflects neurohormo nal activation powerful independent marker poor come patient acute chronic hf778779 severe hyponatraemia may cause neurologic symptom seizure obtundation delirium due cerebral oedema may require immediate hypertonic saline serum sodium increase 12 mmoll per hour though less 8 mmoll 24 h rapid correction increase risk myelinolysis intravenous required hyponatraemia less downloaded guest 24 november 2024 severe eg 124 mmoll absence symptom pathogenesis hyponatraemia heart failure dilutional eg caused water retention induced increased vasopressin secretion treat ment based water restriction vasopressin antagonist fluid restriction less 8001000 mLday may indicated achieve negative water balance treat hyponatraemia water restriction wa associated improved qol small random ized slight increase serum sodium obser vational registry780781 tolvaptan orally active selective arginine vasopressin v2 receptor antagonist considered increase serum sodium diuresis patient persistent hyponatraemia congestion however effect outcome shown rcts782785 see supplementary text 13.1 infusion hyper tonic saline combined loop diuretic wa associated increase serum sodium level greater diuretic efficacy small observational studies786788 hypochloraemia 96 mmoll powerful independent predic tor mortality patient acute chronic hf439789792 serum chloride may direct role control renin secre tion response loop thiazide diuretics439793 car bonic anhydrase inhibitor acetazolamide increase chloride reabsorption causing greater bicarbonate sodium excretion proximal tubule nephron increase serum chloride level diuresis patient severe heart failure risk diuretic resist ance145794 currently tested multicentre randomized decompensated hf469 13.8 lung disease sleepdisordered breathing overall copd affect 20 patient heart failure ha major impact symptom outcomes795797 due overlap symptom sign differentiation heart failure copd may difficult pulmonary function testing spirometry recom mended first diagnostic tool considered patient suspected copd adequate interpretation performed stable euvolaemic patient avoid con gestion related obstructive pulmonary function pattern uncertainty reversibility airflow obstruction pneumol ogy referral sophisticated test bronchodilatatory test bronchial provocation test diffusion capacity warranted798799 heart failure generally well tolerated copd800 beta blocker worsen pulmonary function individual patient contraindicated either copd asthma stated global initiative chronic obstructive lung disease gold global initiative asthma gina respectively801802 Gina state asthma regarded absolute contraindi cation use cardioselective betablockers bisoprolol meto prolol succinate nebivolol consideration relative risk benefit clinical practice starting low dos cardioselective betablockers combined close monitoring sign airway obstruction wheezing shortness breath lengthening expiration encouraged although tested hf patient inhaled corticosteroid betaadrenergic agonist seem increase cardiovascular event including hf patient high risk803804 moreover optimal copd management improve car diac function805 sleepdisordered breathing occurs one third patient heart failure even prevalent patient ahf common type central sleep apnoea csa similar cheynestokes respiration osa mixed pattern two csa osa shown associated worse prog nosis hf osa associated increased risk incident heart failure men csa common form sleepdisordered breathing hfref hfmref common cause csa806807 patient heart failure investigated sleepdisordered breath ing history taking involve partner questionnaire instru mental identifying patient risk home monitoring usually identify distinguish type sleep apnoea however overnight polysomnography remains definitive investigation807 use adaptive servoventilation patient hfref predominantly csa recommended based result servehf wa neutral regarding composite primary endpoint death cause lifesaving cardiovascular intervention showed increase allcause mortality cardiovascular mortality adaptive servoventi lation808 transvenous phrenic nerve stimulation wa tested pro spective multicentre randomized involving 151 patient csa809 primary efficacy endpoint wa reduction apnoeahypopnoea index baseline 6 month wa achieved larger percentage patient active measurement sleep quality qol improved difference safety endpoint wa found active treat ment control809 similar result observed 96 patient hf810 patient hfref considered sleepdisordered breathing positive pressure airway mask must undergo formal sleep document predominant type sleep apnoea central v obstructive sleepdisordered breathing caused osa nocturnal hypoxaemia treated nocturnal oxygen supplementation continuous positive airway pressure bilevel positive airway pressure adaptive servo ventilation however none intervention ha shown beneficial effect outcome hf807 sleep disordered breathing caused csa positive pressure airway mask contraindicated hfref patients808 patient implantable phrenic nerve stimulation considered sympto matic relief 13.9 hyperlipidaemia lipidmodifying two large rcts including mainly patient hfref well metaanalysis 24 rcts showed benefit statin cardiovascular mortality stroke patient hfref811812 reduction heart failure hospitalization well small reduction myocardial infarction wa observed metaanalysis corona gissihf trials813815 based current evidence routine administration statin patient heart failure without indication use eg cad downloaded guest 24 november 2024 recommended evidence harm patient statin occurrence hf need sta tin discontinuation patient already treated 13.10 Gout arthritis hyperuricemia common finding patient chf prev alence 50816817 hyperuricemia may caused aggravated diuretic related symptom exercise capacity severity diastolic dysfunction longterm prognosis817818 every 1 mgdl increase serum uric acid level risk allcause mortality heart failure hospitalization increase 4 28 respec tively819 febuxostat allopurinol reduce uric acid level however allopurinol wa associated lower rate allcause death cardiovascular death compared febuxostat prospective multicentre doubleblind noninferiority enrolling 6190 patient gout cardiovascular disease 20 hf median followup 32 months820 allopurinol therefore recommended first choice uratelowering drug heart failure patient contraindication evidence uric acidlowering ha beneficial effect lv function symptom outcome patient hf821823 respect acute gout attack nonsteroidal antiinflammatory drug nsaid worsen renal function precipitate acute heart failure decompensation colchicine pre ferred associated less side effects824 however used caution patient severe renal dysfunction contraindicated patient dialysis increase ventricu lar vulnerability wa shown experimental models825 arthritis common comorbidity common cause selftaken prescribed nsaid agent relatively contra indicated may precipitate acute decompensation patient hf826 rheumatoid arthritis associated two three fold increase risk heart failure increased risk independent ischaemic heart disease suggesting direct role heart failure pathophysi ology827828 safety diseasemodifying drug used treat ment rheumatoid arthritis ha established hf high dos antitumour necrosis factor alpha agent associated worsening heart failure initial used caution adverse effect noted lower doses829831 13.11 erectile dysfunction erectile dysfunction serious problem heart failure patient due association cardiovascular risk factor comorbidities eg diabetes life style eg inactivity eg drugs832 general pop ulation prevalence erectile dysfunction estimated 50 men aged 60 erectile dysfunction present 81 cardiac patient across different culture ethnic groups833 optimal assessment include question assessing presence erectile dysfunction factor related erectile dysfunction numerous class cardiovascular drug particularly diu retics betablockers implicated causing erectile dy function however relationship many contemporary cardiovascular drug erectile dysfunction clear834 erectile dysfunction phosphodiesterase type 5 inhibitor gen erally safe effective patient compensated hf834835 shown one agent effective safer others however phosphodiesterase type 5 inhibitor used patient receiving nitrate nitrate adminis tered patient within 24 h sildenafil vardenafil administration within 48 h tadalafil administration834 13.12 depression depression affect 20 patient heart failure severe half occurrence higher woman associated worse clinical status poor prognosis836838 screening using validated questionnaire recommended clinical sus picion depression beck depression inventory cardiac depression scale tool formally validated assessment depression patient hf questionnaire eg geriatric depression scale hamilton depression scale hospital anxiety depression scale also used837838 still consensus best heart failure patient depression psychosocial intervention may improve depressive symptom ha effect prognosis depressed patient hf839 depressive symptom may improve selective serotonin reuptake inhibitor specifically designed assess effect drug patient heart failure depression failed show significant benefit placebo symptom comes840841 interestingly patient improved also placebo arm showing importance better care patient showed safety sertraline escitalopram respectively840841 tricyclic antidepressant avoided depression heart failure may cause hypotension worsening hf arrhythmias837838 13.13 cancer heart failure occurs patient cancer result interaction among anticancer cancer patients’ cardiovascular background risk factor coexisting cardiovascular disease842846 several anticancer thera pie may cause heart failure directly thorough cardiotoxic effect 23 indirectly mechanism myocarditis ischaemia systemic pulmonary hypertension arrhythmia valve disease844845847852 hf turn may affect cancer outcome depriving patient effective anticancer therapies699 epide miological experimental evidence suggests reciprocal interaction cancer heart failure though showing higher incidence rate cancer patient hf853858 prevention heart failure patient cancer undergoing potential cardiotoxic requires careful patient’s assessment man agement cancer preferably context integrated cardiooncology service 18845859860 cardiovascular baseline risk assessment patient scheduled receive potentially cardiotoxic cancer using hfaicos risk assessment advisable846 baseline cardiovascular risk assessment form developed different potentially car diotoxic cancer history heart failure cmp characterizes patient high risk high risk cancer thera pie except antiandrogen prostate cancer lvef 50 additional factor highrisk patient elevated level downloaded guest 24 november 2024 np troponin baseline additional criterion medium risk cancer treatments846 cancer potential cardiotoxic lv systolic function monitored echocardiography chemotherapy reconsidered acei betablocker preferably carvedilol started patient develop lv systolic dysfunction defined 10 absolute reduction left ventricular ejection fraction value 50844861864 Global longitudinal strain detect cardiac dysfunction earlier stage865866 12 relative reduction global longitudinal strain wa compared left ventricular ejection fraction decline prospective randomized highrisk patient undergoing potentially cardiotoxic chemother apy compared based lvef based change global longitudinal strain led decrease lvef primary endpoint fewer patient developed cardiac dysfunction end thus suggesting usefulness global longitudinal strain early detection cardiotoxicity867 promising result early detection cardiac dysfunction also obtained monitoring biomarkers np troponin868869 patient immunotherapy immune check point inhibitor increased risk myocarditis monitored related symptom sign weekly assessment cardiac troponin least first 6 week managed accordingly870 timing imaging procedure biomarkers assessment depend anticancer patient’s risk profile 18865 general patient scheduled potential cardi otoxic must undergo baseline evaluation would define level risk cardiotoxicity low medium high intensity monitoring followup cancer treatment865 cancer survivor exposed potentially cardiotoxic periodically monitored long term heart failure may develop several year cancer therapy865871 23 cancer drug causing heart failure cancer indication anthracycline chemotherapy doxorubicin epirubicin daunorubicin idarubicin breast cancer lymphoma acute leukaemia sarcoma her2targeted trastuzumab pertuzumab trastuzumab emtansine tdm1 lapatinib neratinib tucatinib her2þ breast cancer her2þ gastric cancer vegf inhibitor tkis sunitinib pazopanib sorafenib axitinib tivozanib cabozantinib regorafenib lenvatinib vandetinib antibody bevacizumab ramucirumab vegf tkis renal cancer hepatocellular cancer thyroid cancer colon cancer sarcoma gist antibody breast cancer ovarian cancer gastric cancer gastrooesopha geal cancer colon cancer multitargeted kinase inhibitor second third generation bcrabl tkis ponatinib nilotinib dasatinib bosutinib chronic myeloid leukaemia proteasome inhibitor carﬁlzomib bortezomib ixazomib immunomodulatory drug lenalidomide pomalidomide multiple myeloma combination raf mek inhibitor dabrafenibþtrametinib vemurafenibþcobimetinib encorafenibþ binimetinib raf mutant melanoma androgen deprivation gnrh agonist goserelin leuprorelin antiandrogrens abiraterone prostate cancer breast cancer immune checkpoint inhibitor antiprogrammed cell death 1 inhibitor nivolumab pembrolizumab anticytotoxic tlymphocyteassociated protein 4 inhibitor ipilimumab antiprogrammed deathligand 1 inhibitor avelumab atezolizumab durvalumab melanoma metastatic adjuvant metastatic renal cancer nonsmall cell lung cancer small cell lung cancer refractory hodgkin’s lymphoma metastatic triple negative breast cancer metastatic urothelial cancer liver cancer mmrdeﬁcient cancer gist gastrointestinal stromal tumour gnrh gonadotropinreleasing hormone her2 human epidermal growth factor receptor 2 mek mitogenactivated protein kinase mmr mismatch repair tki tyrosine kinase inhibitor vegf vascular endothelial growth factor esc 2021 downloaded guest 24 november 2024 management patient receiving potential cardiotoxic baseline risk assessment including clinical assessment ecg resting echocardiogram cardiac biomarkers np troponin preexisting heart failure highrisk cardiovascular disease medium highrisk patientb increasedc surveillance ecg cardiac biomarkers reassessment 3 month 12 month completion cancer lowrisk patientb standard surveillanced cardiotoxic cancer treatmenta cardiotoxic cancer treatmenta cardiotoxic cancer treatmenta reassessment 12 month completion cancer surveillance every 5 year following established cardiotoxicity eg highdose anthracycline chemotherapye followup heart failure cardiooncology team new heart failure left ventricular systolic dysfunction 18 management patient cancer heart failure ecg electrocardiogram her2 human epidermal growth factor receptor 2 hf heart failure hfa heart failure association icos international cardiooncology society mek mitogenactivated protein kinase npnatriuretic peptide vegf vascular endothelial growth factor aanthracycline chemotherapy trastuzumab her2 targeted vegf inhibitor proteasome inhibitor combination rafþmek inhibitor blow medium high risk may calculated using hfaicos baseline cardiovascular risk proformas846 cincreased surveillance intended 1 4 week dstandard surveillance intended every 3 month e5 yearly surveillance followup clinical review every 5 year history examination np troponin level echocardiogram865 downloaded guest 24 november 2024 13.14 infection infective disorder may worsen heart failure symptom precipitant factor ahf872873 severe sepsis pneumonia cause myo cardial injury depress cardiac function leading cardiac dysfunc tion heart failure risk greater patient history hf873875 recently coronavirus disease 2019 covid 19 pandemic ha emerged major cause morbidity mortal ity well heart failure decompensation873876878 specific guidance available879 general recommendation related infection given 879 Gble 24 influenza vaccination associated reduced risk allcause death patient heart failure observational retrospective analyses880882 influenza pneumococcal vaccination well covid19 vaccination available considered patient hf879883 14 special condition 14.1 pregnancy 14.11 pregnancy preexisting heart failure woman preexisting heart failure higher risk pregnancyrelated cardiovascular complication including heart failure decompensation moderate highrisk patient according modified world health organization mwho class IIIiv referred specialist centre multidisciplinary pregnancy heart team884 algorithm management heart failure patient preg nancy reported 19 prepregnancy management includes modification existing heart failure medication avoid foetal harm aceis arb arni mras ivabradine sglt2 inhibitor contraindicated stopped prior conception close clinical echocardio graphic monitoring betablockers continued switched beta1selective blocker bisoprolol metoprolol succinate hydralazine oral nitrate methyldopa started required therapeutic anticoagulation lowmolecularweight heparin lmwh first last trimester vkas usual tar get international normalized ratio inr lmwh second trimester recommended patient heart failure af doacs avoided884 assessment patient heart failure prepregnancy presenta tion new pregnancy include clinical assessment symptom clinical examination bp sao2 ecg resting echo cardiography modality delivery planned cardi ologists obstetrician anaesthesiologists around 35 week multidisciplinary pregnancy heart team bimonthly assessment woman mwho iiiii monthly assessment woman preexisting heart failure mwho iii must performed woman advanced heart failure lvef 30 nyha class IIIiv mwho iv pregnant referred specialist centre counselling regarding consideration termination pregnancy deci sion regarding modality delivery planned cardiologist obstetrician anaesthesiologists around 35 week multidisci plinary pregnancy heart team discussed patient884 14.12 new heart failure presenting pregnancy increased demand ventricular function due increased circulating volume cardiac output pregnancy unmask pre recommendation management patient cancer heart failure recommendation classa levelb recommended cancer patient increased risk cardiotoxicity deﬁned history risk factor cardiovascular disease previous cardiotoxicity exposure cardiotoxic agent undergo cardiovascular evaluation sched uled anticancer preferably cardi ologist experienceinterest cardio oncology c acei betablocker preferably carvedilol considered cancer patient developing lv systolic dy function deﬁned 10 decrease left ventricular ejection fraction value lower 50 anthracycline chemotherapy861862 iia b baseline cardiovascular risk assessment con sidered cancer patient scheduled receive cancer potential cause heart failure846865 iia c acei angiotensinconverting enzyme inhibitor cardiovascular cardiovascular lv left ventricular left ventricular ejection fraction left ventricular ejection fraction aclass recommendation blevel evidence 24 infection patient heart failure patient heart failure increased risk infection poorer come infected telemonitoring avoids risk infection caused close contact useful pandemic condition telemonitoring may implemented patients’ followup pandemic condition pandemic heart failure patient screened infection time hospitalization case urgent admission elective hospitalization careful assessment ﬂuid status addition clinical sign hf mandatory hospitalization patient concomitant sepsis repeated measure inferior vena cava diameter collapsibility echocardiography may used assess ﬂuid status omt including betablocker acei angiotensin receptor blocker arni mra sglt2 inhibitor continued chronic heart failure patient whenever bp haemodynamic condition permit considering drug interaction infection related side effect proﬁle acei angiotensinconverting enzyme inhibitor angiotensin receptor blocker angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor bp blood pressure heart failure heart failure mra mineralocorticoid receptor antagonist omt optimal medical sglt2 sodiumglucose cotransporter 2 esc 2021 esc 2021 downloaded guest 24 november 2024 existing previously undiagnosed cause heart failure cmps valve diseases885 symptom likely occur second trimester demand increased cardiac output highest severe emotionally stressful episode pregnancy delivery also cause takotsubo syndrome884885 ppcm present heart failure secondary lv systolic dysfunction usually shown left ventricular ejection fraction 45 occurring towards end pregnancy third trimester month following delivery without identifiable cause majority ppcm case diagnosed postpartum prevalence range 1100 nigeria 11000 management patient heart failure pregnancy bimonthly monthly review mwho ii counselling including risk assessment educationa cardiac assessment including clinical assessment ecg echocardiogram review heart failure switch nonteratogenic heart failure medication moderate highrisk heart failure patient mwho ii ii–iii iv referral specialist centre highrisk pregnancy multidisciplinary pregnancy heart team reassessment beginning second trimester ie 20 week reassessment 20 week lowrisk heart failure patient mwho discus specialist centre highrisk pregnancy reassessment beginning second trimester ie 20 week monthly review mwho iii urgent counselling consideration pregnancy termination mwho iv prepregnancy pregnancy diagnosis planning pregnancy 19 management patient heart failure pregnancy ecg electrocardiogram hf heart failure mwho modified world health organization aadvice regarding contraception heart failure medication contact heart failure specialist planning pregnancy downloaded guest 24 november 2024 south africa 11500 germany643 prospective large cohort report 6month mortality ranging 2.0 germany 12.6 206 ppcm patient cohort s2.0 africa643 ppc12.6quently present acute heart failure may also present ventricular arrhythmia andor cardiac arrest left ventricular ejection fraction 630cm rv involvement associated adverse outcomes643 cardiac recovery may occur first 36 month though may delayed 2 year recovery rate vary among region 75 less 50886888 assessment management pregnant patient presenting heart failure depends upon clinical setting severity presentation detailed cardiac assessment echocardiography np level foetal ultrasound foetal monitoring recommended case new heart failure diagnostic uncertainty noncontrast cmr may considered milder case treated oral diuretic betablockers hydralazine oral nitrate pregnant woman presenting sign acute heart failure require urgent hospital admission case ppcm pre senting severe heart failure cardiogenic shock requiring inotropic vasopressor support transfer advanced heart failure centre ecmo lvad andor cardiac transplantation performed recommended urgent delivery caesarean section irrespective gestation considered mc immediately available adrenergic agent dobutamine adrenaline may detrimental effects889 ppcm patient haemodynamically unstable levo simendan mc may considered lvad implantation btt btr considered refractory case cardiogenic shock643 bromocriptine ha proposed patient acute ppcm reduce production cleaved 16 kda prolactin frag ment may contribute pathophysiology ppcm bromocriptine wa tested randomized 63 patient com paring longterm 8 week shortterm 1week wa associated recovery lv function difference two regimen line result previous international ppcm registry890891 bromocriptine may considered ppcm untoward effect including deep venous thrombosis cessation lactation must consid ered initiated therefore accompanied prophy lactic therapeutic anticoagulation 14.2 cardiomyopathy 14.21 epidemiology diagnosis cmps either inherited geneticfamilial andor acquired also accelerated disease modifiers892894 heter ogeneous group disease major cause hf895 dcm ha estimated prevalence 1 250 1 500 general popula tion hcm range 1 500 1 5000 ac estimated present around 1 1000 1 5000 persons895896 direct cause cmps include pathogenic gene variant muta tions toxin autoimmunity storage disease infection tachyarrhythmias disease modifier condition may aggravate trigger cmp include epigenetic factor acquired modifier pregnancy cardiovascular comorbidities important consider key interaction genetic acquired cause diagnostic workup897 identification acquired cause cmp doe exclude underlying pathogenic gene variant whereas latter may require additional acquired cause andor disease modifier become manifest clinically commonest cause disease modifier shown 25 key element diagnostic workup patient hf cmp reported 26.892894895898899 specific aspect diagnosis summarized 2729 clinical history laboratory test imaging firstline investigation echocardiography central diagnosis monitoring hcm dcm ac cmr imaging provides detailed morpho logical prognostic information performed baseline prevalence gene mutation may vary according morphological phenotype underlying acquired cause gene mutation occur 40 dcm 60 hcm 15 chemotherapyinduced alcoholic peripartum cmps895898900905 prevalence genetic mutation 10 also nonfamilial dcm898906 finding pathogenic gene var iant patient cmp allows better prediction disease come progression may contribute indication device implantation inform genetic counselling family endomyocardial biopsy emb immunohistochemical quantifi cation inflammatory cell remains gold standard investigation identification cardiac inflammation may confirm diag nosis autoimmune disease patient dcm suspected giant cell myocarditis eosinophilic myocarditis vasculitis sarcoi dosis893907 may also help diagnosis storage disease including amyloid fabry disease imaging genetic testing doe provide definitive diagnosis see also section 14.6 emb might considered also hcm genetic acquired cause cannot identified risk benefit ebm evaluated procedure reserved specific situation result may affect 14.22 current pharmacological heart failure dcm hcm ac patient doe differ general heart failure management except peculiar aspect reported 2729 pilot randomized tredhf investigated possibility withdrawing medical treat ment patient nonischaemic dcm partial complete recovery left ventricular ejection fraction 40 however relapse dcm within 6 month wa observed 44 patient rapid lv remodelling early tissue functional change even amongst patient relapse wa found271908 phase 3 randomized doubleblind placebocontrolled explorerhcm mavacamten improved exercise capacity lvot obstruction nyha functional class health status patient obstructive hcm offer possibility diseasespecific inherited cmps icd implantation considered patient dcm hcm ac see section 6895910912 strength indication varies according clinical risk factor sudden cardiac death higher priority given patient significant lge downloaded guest 24 november 2024 25 possible cause disease modiﬁers frequent cardiomyopathy cause disease modifier phenotype genetic mutation lmna x dcm ttn x x dcm hcm rbm20 x dcm myh7 x dcm hcm mypc x dcm hcm tnnt x dcm hcm pln x dcm hcm ac dsp x x ac dcm myocarditis scn5a x x ac dcm tropomyosin1 x dcm haemochromatosis hfe gene c282y x hcm dcm galactosidasea fabry disease x hcm neuromuscular disorder duchenne muscular dystrophy becker muscular dystrophy myotonic dystrophy x dcm syndromic disorder mitochondrial xlinked mutation x dcm acquired disease infection virus x x myocarditis dcm immunomediated disease rheumathoid arthritis systemic lupus erythematosus dermatomyositis x x myocarditis dcm toxic alcohol amphetamine cocaine x x dcm myocarditis drug anthracyclines trastuzumab immune checkpoint inhibitor x x dcm myocarditis overload haemochromoatosis x x hcm dcm peripartum pregnancy x x dcm comorbidities possible interaction gene mutation effect phenotype outcome tachyarrhythmias x x dcm diabetes mellitus x x dcm hcm hypertension x x dcm hcm hypo hyperthyroidism x dcm hcm myocarditis ac arrhythmogenic cardiomyopathy dcm dilated cardiomyopathy dsp desmoplakin hcm hypertrophic cardiomyopathy lmna lamin ac myh7 gene myosin heavy chain 7 mypc myosinbinding protein c pln phospholamban rbm20 ribonucleic acid binding motif 20 scn5a sodium channel alpha unit 5 ttn titin tnnt troponint 26 initial diagnostic assessment patient suspected cardiomyopathy history including detailed question systemic disease toxic agent chemotherapy alcohol drug familial history cardiac neuromuscular disease sudden cardiac death family member young age 50 year laboratory exam including cardiac muscular enzyme liver renal function haemoglobin white blood cell count including differential white blood cell count detect eosinophilia natriuretic peptide thyroid function test iron status marker systemic autoimmune disease hscrp anti nuclear antibody soluble il2 receptor standard 12lead ecg echocardiography detect arrhythmia assess cardiac structure function concomitant abnormality invasive coronary angiography ctca rule signiﬁcant cad patient cardiac dysfunction cmr imaging t1 t2 sequencing lge visualize structural change storage inﬁltration inﬂammation ﬁbrosis scarring genetic counselling genetic testing performed depending age family history cardiac phenotype 24 48hour ambulatory ecg monitoring detect atrial ventricular arrhythmia cad coronary artery disease cmr cardiac magnetic resonance ctca computed tomography coronary angiography ecg electrocardiogram hscrp highsensitivity creactive protein il2 interleukin2 lge late gadolinium enhancement esc 2021 esc 2021 downloaded guest 24 november 2024 27 dilated cardiomyopathy hypokinetic nondilated cardiomyopathy speciﬁc aspect diagnosis diagnostic criterion deﬁnitions894895 dcm lv dilatation systolic dysfunction absence known abnormal loading condition signiﬁcant cad hndc lv biventricular global systolic dysfunction lvef 45 without dilatation absence known abnormal loading condition signiﬁcant cad dcm hndc considered “familial” two ﬁrst seconddegree relative dcm hndc ﬁrstdegree relative ha autopsy proven dcm sudden death 50 year age genetic counselling testing892894898916 indication patient diagnosis dcm hndc ﬁrstdegree adult relative patient deﬁnite diseasecausing mutation regardless phenotype order identify genetically affected individual preclinical phase firstdegree adult relative evaluation repeated every 5 year less aged 50 year nondiagnostic abnormality found clinical evaluation ecg echocardiography possibly cmr must performed ﬁrstdegree relative patient result identify patient dcm hndc highest risk arrhythmia andor deserving speciﬁc early identiﬁcation asymptomatic relative may lead early prevention progression heart failure proper genetic counseling minimal set genesa ttn lmna mhc tnnt troponinc mypc rbm20 pln sodium channel alpha unit bag3 actin alpha cardiac muscle nexilin tropomyosin1 vinculin use additional sequencing analysis large panel gene may considered clear familial history structural pheno type preference combined family segregation endomyocardial biopsy97907917919 indication suspected phenotype requiring speciﬁc ie giant cell myocarditis eosinophilic myocarditis sarcoidosis vasculitis sle systemic autoimmune inﬂammatory condition storage disease number sample minimum 5 possibly least 7 sample 3 pathology 2 infection dna pcr 2 rna virusesviral replication918919 aetiology search common cardiotropic virus parvovirus b19 hhv4 hhv6 enterovirus adenovirus coxsackie quantitative rtpcr viral aetiology suspected viral mrna active viral replication assessed possible assessment indicated cmv hiv borrelia burgdorferi lyme disease coxiella burnetii qfever trypanosoma cruzi chaga disease sarscov2 immunohistochemistry quantiﬁcation cd3 cd4 cd8 cd45 staining lymphocyte cd68 macrophage per mm2 antihladr histology haematoxylin eosin staining ﬁbrosis assessment masson’s trichrome picrosirius red amyloid ﬁbrils detection congo red therapeutic options895917 heart failure hfref see section 5 6 lmna rbm20 pln fln mutation higher risk sudden cardiac death early indication primary prevention icd implantation considered guided risk factor detailed920 ttn mutation higher rate lv reverse remodeling 70 higher risk atrial ventricular tachyarrhythmias lyme disease borrelia doxycycline chaga disease trypanosoma cruzi speciﬁc according current recommendations921922 autoimmuneinﬂammatory consider immunosuppressive giant cell myocarditis eosinophilic myocarditis sarcoidosis vasculitis highly selected patient increased cardiac inﬂammation unknown origin based upon multidisciplinary counselling cardiology immunology bag3 bcl2associated athanogene 3 cad coronary artery disease cmr cardiac magnetic resonance cmv cytomegalovirus dcm dilated cardiomyopathy dna deoxyribonucleic acid ecg electrocardiogram fln ﬁlamin heart failure heart failure hfref heart failure reduced ejection fraction hhv human herpes virus hiv human immunodeﬁciency virus hladr human leukocyte antigendr isotype hndc hypokinetic nondilated cardiomyopathy icd implantable cardioverterdeﬁbrilla tor lmna lamin ac lv left ventricular left ventricular ejection fraction left ventricular ejection fraction mhc myosin heavy chain mypc myosinbinding protein c mrna messenger ribo nucleic acid nsvt nonsustained ventricular tachycardia pcr polymerase chain reaction pln phospholamban rbm20 ribonucleic acid binding motif 20 rna ribonucleic acid rtpcr reverse transcriptase polymerase chain reaction sarscov2 severe acute respiratory syndrome coronavirus 2 sle systemic lupus erythemato sus tnnt troponint ttn titin athis list gene exhaustive change time increasing knowledge pathogenicity contact genetic department ask core panel gene using brisk factor patient conﬁrmed lmna mutation nsvt ambulatory ecg monitoring left ventricular ejection fraction 45 ﬁrst evaluation male sex nonmissense mutation insertion deletion truncation mutation affecting splicing esc 2021 downloaded guest 24 november 2024 28 hypertrophic cardiomyopathy speciﬁc aspect diagnosis deﬁnition895896923 wall thickness 14 mm one lv myocardial segment sufﬁciently explained solely abnormal loading condition lvoto 30 rest exercise asymmetric hypertrophy increased lge patchy midwall pattern hypertrophied segment suggest presence hcm considered familial two ﬁrst seconddegree relative hcm ﬁrstdegree relative autopsy proven hcm sudden death 50 year age detected differential diagnosis might difﬁcult physiological hypertrophy induced intense athletic training severe hypertension aortic stenosis isolated septal hypertrophy consider genetic hcm degree lv hypertrophy disproportionate respect acquired trigger consider amyloidosis cause increased thickness interatrial septum av valve andor rv free wall detected see section 14.6 genetic counselling testing indication must offered patient diagnosis hcm identify possible underlying genetic cause ﬁrstdegree adult relative patient hcm deﬁnite diseasecausing mutation regardless phenotype order identify genetically affected individual preclinical phase clinical evaluation ecg echocardiography must performed ﬁrstdegree relative deﬁnite diseasecausing mutation index patient deﬁnite genetic mutation identiﬁed index patient genetic testing performed clinical evaluation ecg echocardiography considered ﬁrstdegree adult relative repeated every 25 year less nondiagnostic abnormality present minimal set genesa sarcomeric gene mutation 60 case ttn lmna mhc tnnt troponinc mypc rmb20 pln sodium channel alpha unit bag3 actin alpha cardiac muscle nexilin tropomyosin1 vinculin898924926 use additional sequencing analysis large panel gene may considered clear familial history structural phenotype preference combined family segregation speciﬁc condition muscular weakness consider mitochondrial xlinked mutation glycogen storage disorder fhli mutation friedreich’s ataxia syndromic condition cognitive visual impairment drooping eyelid consider mitochondrial xlinked mutation noonan syndrome danon disease cafe´ au lait spot lentigo consider leopardnoonan syndrome endomyocardial biopsy indication may considered baseline clinical assessment suggests cardiac inﬂammation storage disease cannot diagnosed means896 see also section 14.6 therapeutic options895896923 lvoto avoid hypovolaemia dehydration arterial venous dilator nitrate phosphodiesterase type 5 inhibitor digoxin use nonvasodilating betablockers use verapamil betablockers nontolerated ineffective lowdose loop thiazide diuretic must used caution improve dyspnoea associated lvoto avoiding hypovolaemia invasive septal reduction alcohol ablation myomectomy experienced centre may considered patient resting maximum provoked lvot 50 andor remain symptomatic nyha class III iv syncope despite omt novel drug device may considered available909927 symptomatic without lvoto cautious use lowdose loop thiazide diuretic avoiding hypovolaemia verapamildiltiazem left ventricular ejection fraction 50 betablockers tolerated ineffective indication icd based sudden cardiac death risk models928930 consider icd implantation family history sudden cardiac death one ﬁrst degree relative 40 year age sudden cardiac death ﬁrst degree relative conﬁrmed hcm age nsvt unexplained syncope931 fabry disease enzyme replacement alphagalactosidase deﬁciency895 amyloidosis see section 14.6 21 av atrioventricular bag3 bcl2associated athanogene 3 ecg electrocardiogram hcm hypertrophic cardiomyopathy icd implantable cardioverterdeﬁbrillator lge late gadolinium enhancement lmna lamin ac lv left ventricular lvef left ventricular ejection fraction lvot left ventricular outﬂow tract lvoto left ventricular ﬂow tract obstruction mhc myosin heavy chain mypc myosinbinding protein c nsvt nonsustained ventricular tachycardia nyha new york heart association omt optimal medical pln phospholamban rmb20 ribonucleic acid binding motif 20 rv right ventricular tnnt troponint ttn titin athe list gene exhaustive change time increasing knowledge pathogenicity contact genetic department ask core panel gene using esc 2021 downloaded guest 24 november 2024 cmr younger age specific familialgenetic phenotype 2729 risk model prediction icd benefit applied patient enrolled danish may help indi cation icd implantation dcm166913 hcm ac including indication icd detailed previous documents895896899912914915 14.3 left ventricular noncompaction lvnc rare congenital cmp characterized endomyo cardial trabeculations increase number prominence case including condition caused mutation myh7 mybpc3 gene lvnc inherited autosomal dominant pattern644937938 clear overlap exists family 29 arrhythmogenic cardiomyopathy speciﬁc aspect diagnosis treatment912915932 deﬁnition inherited heart muscle disease characterized progressive ﬁbrofatty replacement rv myocardium may act substrate ventricular arrhythmia unexplained syncope andor sudden cardiac death lv involvement systolic dysfunction occurs 30 ac patient therefore phenotype may overlap dcm diagnosis933 based upon evaluation combination genetic factor case autosomal dominant desmosomal mutation documentation ventricular arrhythmia imaging criterion echocardiography mri rv dysplasia ﬁbrofatty replacement either conﬁrmed emb speciﬁc ecg abnormality present absent genetic counsellingtesting898912 indication must offered patient suspected ac ha offered ﬁrstdegree adult relative patient ac deﬁnite diseasecausing mutation regardless phenotype order identify genetically affected individual preclinical phase genetic family screening also indicated arrhythmic risk stratiﬁcation purpose clinical evaluation ecg echocardiography possibly cmr performed ﬁrstdegree relative deﬁnite diseasecausing mutation index patient deﬁnite genetic mutation identiﬁed index patient genetic testing performed clinical evaluation ecg echocardiography considered ﬁrstdegree adult relative repeated every 25 year less nondiagnostic abnormality present minimal set gene desmosomal mostly isolated rv involvement plakoglobin dsp pkp2 dsg2 dsc2a frequent lv involvementdcm dsp flnc scn5a tmem43 fln ldb3 desmin aactinin bag3 nkx25 rbm20 scn5a kcnq1 kcnh2 trpm4 pln variant particular mild lv hypertrophy consider tnnt variant cutaneous abnormality palmar plantar hyperkeratosis consider rare recessive mutation leading carvajal syndrome naxos disease plakoglobin jup cmr presentation myocarditis along ac consider dsp gene variants934935 endomyocardial biopsy reserved highly selected case noninvasive assessed fibrofatty replacement without replacement type ﬁb rosis rv septal biopsy characteristic ﬁndings emb ha low sensitivity diagnosis ac case focal distribution therapeutic option heart failure hfref see section 5 6 competitive sport avoided limit activity leisuretime activities936 patient ventricular arrhythmia betablockers must titrated maximally tolerated ﬁrstline amiodarone considered addition betablockers betablockers contraindicated tolerated icd implantation indicated history aborted sudden cardiac death sustained andor haemodynamically poorly tolerated ventricular tachycardia910912 patient ventricular arrhythmia icd considered see section 6.1 even patient lmna flnc gene mutation lvef 45912 ac arrhythmogenic cardiomyopathy bag3 bcl2associated athanogene 3 cmr cardiac magnetic resonance dcm dilated cardiomyopathy dsc2 desmocollin 2 dsg2 desmoglein 2 dsp desmoplakin ecg electrocardiogram emb endomyocardial biopsy fln ﬁlamin flnc ﬁlamin c heart failure heart failure hfref heart failure reduced ejection fraction icd implantable cardioverterdeﬁbrillator jup junction plakoglobin kcnh2 potassium voltagegated channel subfamily h member 2 kcnq1 potassium voltagegated channel subfamily q member 1 ldb3 lim domain binding 3 lmna lamin ac lv left ventricular left ventricular ejection fraction left ventricular ejection frac tion mri magnetic resonance imaging nkx25 nk2 transcription factor related locus 5 pln phospholamban pkp2 plakophilin 2 rmb20 ribonucleic acid binding motif 20 rv right ventricular scn5a sodium channel alpha subunit 5 tmem43 transmembrane protein 43 tnnt troponint trpm4 transient receptor potential cation channel subfamily member 4 esc 2021 downloaded guest 24 november 2024 dcm hcm phenotype quite commonly individual feature lvnc found family affected rela tives typical hcm dcm therefore lvnc treated separate disease entity separate rare presentation genetic susceptibility either hcm dcm939 14.4 atrial disease 14.41 definition atrial disease also termed atrial failure myopathy defined complex subclinical structural electrophysiological func tional change affect atrium potential produce clinical consequences606940941 ha suggested atrial dis ease link pathophysiology hf especially hfpef af often coexist closely interrelated share common risk factors606685942943 14.42 diagnosis atrial size function evaluated multimodality imaging including two threedimensional echocardiography myocar dial deformation computed tomography ct cmr944 cardiac biomarkers including highsensitivity cardiac troponins np may assess pathophysiological aspect atrial dis ease945947 increased level np atrial fibrillation may also indi cator underlying atrial disease942948 comprehensive characterization atrial disease combining clinical imaging bio chemical molecular feature however still lacking 14.43 management atrial disease emerging therapeutic target prevention af systemic thromboembolism perhaps hfpef949 atrial disease appears result intersection shared risk factor comorbidities predisposing atrial fibrillation hf diabetes mellitus hypertension obesity smoking physical inactivity may para mount importance development7950 effective management heart failure atrial fibrillation see section 12.11 well mitral regurgi tation see section 12.33 may also important counteract atrial disease progression 14.5 myocarditis 14.51 epidemiology diagnosis incidence acute myocarditis estimated 1.5 million case per year globally951 contribution myocarditis cause hf varies age region approximately 0.5 4.0918952 chronic emb proven inflammation found 9 30 adult patient dcm918953 frequent potential aetiology triggering acute myocarditis europe reported 30 clinical presentation acute myocarditis may vary mild symptom cardiogenic shock workup diagnosis acute myocarditis patient heart failure reported 31 20 specific criterion biopsy cmr reported 32 33 14.52 hospitalization least 48 h may useful patient acute myocarditis hf especially troponins elevated cardiac dysfunction andor arrhythmia present initial presentation despite lack evidence specific setting acute myocar ditis hfref recommended presence systolic lv dysfunction immunosuppression indicated selected case acute myocarditis 34 cardiac enzyme decrease arrhythmia absent cardiac systolic dysfunction stabilized standard heart failure continued least 6 month see also 20 immunosuppression ha considered patient chronic cardiac inflammation emb evidence active viral infection918919 wa associated improvement car diac function small better outcome retro spective observational study953963964 prospective old newer immunosuppressiveimmunomodulatory drug needed placebocontrolled testing effect immunoadsorption iv immunoglobulin lv function ongoing option tested919 14.6 amyloidosis 14.61 epidemiology diagnosis ca amyloid cardiomyopathy still underdiagnosed cause hf895965966 two prevalent form ca light chain immunoglobulin al transthyretin attr amyloidosis attr includes wildtype 90 case hereditary variant type 10 case estimated 6 16 patient 30 aetiology considered triggering acute myocarditis917 infectious viral parvovirus b19 human herpes virus6 epstein barr virus enterovirus coxsackievirus adenovirus cmv hiv sarscov2 others borrelia coxiella burnetii qfever systemic disease autoimmune others sarcoidosis giant cell myocarditis eosinophilic myocarditis sle ancapositive vasculitis rheumatoid arthritis autoimmune disease toxic medication immune check point inhibitor anthracyclines clozapine adrenergic drug 5ﬂuorouracil agent alcohol amphetamine cocaine anca antineutrophil cytoplasmic antibody cmv cytomegalovirus hiv human immunodeﬁciency virus sarscov2 severe acute respiratory syn drome coronavirus 2 sle systemic lupus erythematosus esc 2021 downloaded guest 24 november 2024 unexplained lvh hfpef hospitalization severe aortic stenosis undergoing aortic valve replacement aged 65 year may wtttrca967972 diagnosis ca recently reviewed973 age 65 year heart failure along lv wall thickness 12 mm echocar diography major criterion suspicion ca973 criterion suspicion ca confirm diagnosis reported 35 supplementary 25 21.973974 cardiac imaging emb extracardiac biopsy needed diagnosis alca patient abnormal haematological test 21 technetiumlabelled 99mtcpyp dpd hmdp scintigraphy planar spect imaging ha specificity positive predictive value ttrca 100975 contrast cmr ha sensitivity specificity 85 92 respectively966976 hereditary form excluded genetic testing emb gold standard diagnosis ttrca nearly 100 sensitivity specific ity specimen collected 4 multiple site tested amyloid deposit congo red staining966 however biopsy 31 diagnostic workup suspected acute myocarditis deﬁnition suspected acute myocarditis clinical presentation þ 1 mandatory diagnostic test positive preference cmr absence signiﬁcant coronary artery valvular congenital heart disease cause sensitivity speciﬁcity clinical presentation acutenew onset chest pain dyspnoea sign left andor right hf andor unexplained arrhythmia aborted sudden death low low mandatory diagnostic test ecg new dynamic stt abnormality including pseudoinfarct st seg ment elevation atrial ventricular arrhythmia av block qrs abnormality high low laboratory test elevated troponins dynamic change consistent myocardial necrosis standard test including white blood cell count exclude eosinophilia919954 intermediate low echocardiography new structural function abnormality regional wall motion abnormal ities global ventricular dysfunction without ventricular dilatation generally mild dilatation increased wall thickness due myocardial oedema pericardial effusion intracardiac thrombus explained condition eg cad ac valvular heart disease high low cmr oedema inﬂammation ﬁbrosis detection quantiﬁcation localiza tion t1 t2 mapping extracellular volume assessment lge see 33955956 high intermediate additional diagnostic test coronary angiography ctca excludes signiﬁcant cad ac clinically suspected myocarditis high high endomyocardial biopsy diagnosis indication speciﬁc see 32 intermediate high cardiac pet may useful patient cannot undergo cmr suspected systemic autoimmune disease cardiac sarcoidosis919957 low low additional laboratory test skeletal muscle enzyme liver renal function natriuretic peptide thyroid function test iron status marker systemic autoimmune disease low low crp elevated 8090 patients919954 intermediate low pcr testing common cardiotropic virus detect systemic infec tion doe prove cardiac infection cannot substitute viral genome analysis emb samples917 circulating igg antibody cardiotropic virus common absence viral myocarditis limited diagnostic usefulness917918 speciﬁc test sarscov2 borrelia hiv cmv clinical suspicion low low ac acute coronary syndrome av atrioventricular cad coronary artery disease cmr cardiac magnetic resonance cmv cytomegalovirus crp creactive pro tein ctca computed tomography coronary angiography ecg electrocardiogram emb endomyocardial biopsy heart failure heart failure hiv human immunodeﬁciency virus igg immunoglobulin g lge late gadolinium enhancement pcr polymerase chain reaction pet positron emission tomography qrs q r wave combination three graphical deﬂections sarscov2 severe acute respiratory syndrome coronavirus 2 st st segment electrocardiogram stt st segment wave electrocardiogram esc 2021 downloaded guest 24 november 2024 management patient heart failure suspected myocarditis clinical history sign symptom ecg laboratory echocardiography cmr imaging coronary ctcaga cad present indicated suspected autoimmunity infectious toxic heart failure clinical stabilization emb doubt diagnosis maintain heart failure consider immunosuppressive antiinfection n consider mc 20 management patient heart failure acute myocarditis ac acute coronary syndrome cad coronary artery disease cag coronary artery angiogram cmr cardiac magnetic resonance ct computed tomography ecg electrocardiogram emb endomyocardial biopsy hf heart failure mc mechanical circulatory support ato exclude cadacs 32 endomyocardial biopsy patient suspected myocarditis indication see also section 4.3 progressive persistent severe cardiac dysfunction andor lifethreatening ventricular arrhythmia andor mobitz type 2 seconddegree higher av block lack shortterm 12 week expected response usual medical aim identify aetiology indicate speciﬁc eg giant cell myocarditis eosinophilic myocarditis cardiac sarcoidosis systemic inﬂamma tory disorders9798917918958 number site sample minimum 5 possibly least 7 sample 3 pathology 2 infection dna pcr 2 rna virusesviral replication left andor right ven tricle cmr pet guided sampling may considered919 aetiology quantitative pcr viral genome analysis common cardiotropic virus parvovirus b19 hhv4 hhv6 enterovirus adenovirus coxsackievirus rtpcr viral mrna active viral replication may assessed although ha low sensitivity indication search cmv hiv borrelia coxiella burnetii qfever sarscov2 diagnosis inﬂammation immunohistochemistry staining anticd3 cd4 cd8 cd45 antibody lymphocyte anticd68 antibody macrophage anti hladr antibodies907917918959 therapeutic implication immunosuppressive may indicated based result emb giant cell myocarditis eosinophilic myocarditis possibly also sarcoidosis vasculitis selected patient increased cardiac inﬂammation unknown origin based upon multidisciplinary counselling98917919954 antibiotic borrelia lyme disease antiviral hiv cmv hhv6 pending load viral replication mrna cmr cardiac magnetic resonance cmv cytomegalovirus dna deoxyribonucleic acid emb endomyocardial biopsy hhv human herpes virus hiv human immuno deﬁciency virus hladr human leucocyte antigendr isotype mrna messenger ribonucleic acid pcr polymerase chain reaction pet positron emission tomography rna ribonucleic acid rtpcr reverse transcriptase polymerase chain reaction sarscov2 severe acute respiratory syndrome coronavirus 2 esc 2021 downloaded guest 24 november 2024 needed grade 23 positivity scintigraphy spect 21grade 2.62 amyloidosis heart failure maintenance euvolaemia central management chal lenging due markedly reduced ventricular capacitance977 heart failure symptom present loop diuretic possibly mra may given orthostatic hypotension may cause intolerance betablockers digitalis acei arb arni may well tol erated hypotension place ca unsettled withdrawal must often considered due hypotension andor bradycardia973974 ccb avoided may cause severe hypotension fatigue form com plexes amyloid966 amyloid infiltration atrial wall lead atrial myopathy electromechanical dissociation high embolic risk patient ca history atrial fibrillation receive anticoagulation evidence support anticoagulation patient sr yet7978 amiodarone preferred antiarrhythmic agent973 alca based underlying haema tological problem chemotherapy autologous stemcell transplant ttr stabilization reduction production basis ttrca liver andor cardiac transplantation considered endstage disease familial ttrca tafamidis reduced allcause mortality cardiovascular hospitalization cardiac noncardiac biopsyproven hereditary wtttrca mainly patient nyha class ii baseline functional improvement occurred within 6 month whereas decrease mortality took nearly 2 year occur979980 intravenous patisiran small rna interfering molecule subcu taneous inotersen antisense oligonucleotide ttr may considered patient combined httr polyneuropathy ca 21981982 offlabel use diflu nisal may considered wtttrca combination pro ton pump inhibitor983 14.7 iron overload cardiomyopathy iron overload result either genetically determined increased intestinal iron absorption context hereditary haemochro matosis primary iron overload multiple blood transfu sion required management haematological condition betathalassaemia secondary iron overload984 iron overload iron binding capacity transferrin saturated nontransferrinbound iron enters cardiomyocytes l type calcium channel causing oxidative myocardial damage985 33 cardiac magnetic resonance patient suspected myocarditis955956 indication indicated baseline patient clinical history þ ecg elevated troponin echocardiographic abnormality signiﬁcant cad excluded unlikely advised followup patient persistent dysfunction echocar diography arrhythmia ecg abnormalitiesa main ﬁndings baseline t1weighted inﬂammation injury t2weighted oedema sequence extracellular volume lge within 2 week symptom onset956960 follow lge evaluate degree scarring t1 t2 identify persistent inﬂammationa diagnostic signiﬁcance least one t2based criterion global regional increase myocardial t2 relaxation time increased signal intensity t2weighted image least one t1based criterion increased myocardial t1 extracellu lar volume lge acute phase one ie t2based t1based marker may still support diagnosis acute myocardial inﬂammation appropriate clinical scenario albeit less speciﬁcity acute phase negative t1t2 scan doe exclude still ongoing inﬂammatory proc es chronic phasea cad coronary artery disease cmr cardiac magnetic resonance ecg elec trocardiogram lge late gadolinium enhancement ait take least 3 month cmr sign oedema secondary inﬂamma tion acute phasebaseline disappear 6 month t1 t2 sign oedema disappeared inﬂammation would completely absent still absence t1 t2 oedema doe exclude chronic lowgrade inﬂammation 34 followup acute myocarditis heart failure started lv systolic dysfunction present pre sentation continued least 6 month upon complete functional recovery ef 50918919 immunosuppression least 612 month required acute myo carditis clinical emb evidence autoimmune disease including giant cell myocarditis vasculitis sarcoidosis98917919953954961 immunosuppression advised routine basis acute myocarditis without clinical embbased evidence autoimmune disease917 initial empirical administration iv corticosteroid may taken consid eration case high suspicion immunemediated myocarditis espe cially complicated acute hf malignant arrhythmia andor high degree av block954962 intense sporting activity avoided long symptom cardiac enzyme elevated ecgimaging abnormality present last least 6 month since complete recovery936 yearly followup least 4 year ecg echocardiography needed acute myocarditis may lead dcm 20 case av atrioventricular dcm dilated cardiomyopathy ecg electrocardio gram ef ejection fraction emb endomyocardial biopsy heart failure heart failure iv intravenous lv left ventricular esc 2021 esc 2021 downloaded guest 24 november 2024 additional ironinduced complication liver disease endocrine abnormality contribute cardiac deteriora tion986987 end result development iron overload cardiomyopathy iocm may either restrictive dilated phenotype former potentially evolving latter disease advance myocardial iron deposition accu rately estimated cmrt2 technique t2 value corre lated left right ventricular systolic function predict development ironinduced hf arrhythmias984 prevention iocm successfully accomplished iron chela tor including deferoxamine deferiprone deferasirox established iocm may completely reversed intensified combined iron chelation therapy985 14.8 adult congenital heart disease management achd ha reviewed detail recent esc guideline988 heart failure common problem affecting 2050 achd population important cause death989 pathophysiology cardiac dysfunction achd often different noncongenital acquired heart disease particular systemic right ventricle rv failing subpulmonary ventricle single ventricle988 surgeryrelated injury chronic pressurevolume overload systemic subpulmonary ventricle hypertrophy noncompaction induced gene mutation therefore extrapolation current heart failure guideline achd patient always appropriate addition available data heart failure treat ments achd patient often inconclusive derived small patient cohort consequence achd specific recommendation mostly based clinical experience position statements990 importantly achd patient heart failure referred expert centre general principle management awaiting trans fer specialist centre summarized 36 35 “red ﬂags” common form cardiac amyloidosis type red flag ttr al extracardiac polyneuropathy x x dysautonomia x x skin bruising x macroglossia x deafness x bilateral carpal tunnel syndrome x ruptured biceps tendon x lumbar spinal stenosis x vitreous deposit xa family history xa renal insufﬁciency x proteinuria x cardiac clinical hypotension normotensive previously hypertensive x x ecg pseudoinfarct ecg pattern lowdecreased qrs voltage degree lv thickness av conduction disease x x x x x x laboratory disproportionally elevated nt probnp degree hf persisting elevated troponin level x x x x echocardiography granular sparkling myocardium increased right ventricular wall thickness increased av valve thickness pericardial effusion reduced longitudinal strain apical sparing pattern x x x x x x x x x x cmr subendocardial lge elevated native t1 value increased extracellular volume abnormal gadolinium kinetics x x x x x x x x al light chain immunoglobulin av atrioventricular ca cardiac amyloido si cmr cardiac magnetic resonance ecg electrocardiogram heart failure heart fail ure lge late gadolinium enhancement lv left ventricular ntprobnp n terminal probtype natriuretic peptide qrs q r wave combination three graphical deﬂections ttr transthyretin modiﬁed from973 ahereditary ttrca recommendation transthyretin amyloidosiscardiac amyloidosis recommendation classa levelb tafamidis recommended patient genetic testing proven httrca nyha class ii symptom reduce symptom cv hospitalization mortality979 b tafamidis recommended patient wtttrca nyha class ii symptom reduce symptom cardiovascular hospitalization mortality979 b ca cardiac amyloidosis cardiovascular cardiovascular httr hereditary transthyretin nyha new york heart association wtttr wildtype transthyretin aclass recommendation blevel evidence esc 2021 esc 2021 downloaded guest 24 november 2024 diagnosis cardiac amyloidosis heart failure patient cardiac amyloidosis suspected heart failure lv wall thickness ≥12 mm age ≥65 least 1 red flaga serum free lightchain assay serum urine protein electrophoresis immunofixation 99mtcpyp dpd hmdp scintigraphy spect histological confirmation subtype usually cardiacb amyloidosis unlikely histological confirmation diagnosis cardiac extracardiacc tafamidis class amyloidosis unlikely abnormal abnormal haemClass myocardial uptake normal haematology grade 1 uptake normal haematology grade 2–3 uptake norGrade 1tr genetic counselling cardGrade 2loidosis cmr imaging positive inconclusive negative consider patisiran inotersen hereditaryattr polyneuropathy 21 diagnosis cardiac amyloidosis heart failure patient based on973 attr transthyretin amyloidosis cmr car diac magnetic resonance dpd 33diphosphono12propanodicarboxylic acid heart failure heart failure hmdp hydroxymethylene diphosphonate lv left ventricular spect singlephoton emission computed tomography 99mtcpyp technetiumlabelled 99mtcpyrophosphate ared flag listed 35 bgenerally requires endomyocardial biopsy diagnosis cardiac subtype crequires biopsy may cardiac abdominal downloaded guest 24 november 2024 15 key message 1 patient heart failure classified based lvef left ventricular ejection fraction 41 49 defined ‘mildly reduced lvef’ hfmref 2 measurement np echocardiography key role diagnosis hf 3 acei arni betablockers mra sglt2 inhibitor recommended cornerstone patient hfref 4 icds recommended selected patient hfref ischaemic aetiology considered non ischaemic aetiology 5 crtpd recommended patient hfref sinus rhythm lbbb 150 considered lbbb 130149 nonlbbb 150 6 advanced heart failure strategy heart transplantationmcs may appropriate selected patient 7 aceiarni betablockers mra may considered patient hfmref 8 diagnosis hfpef requires objective evidence cardiac structural functional abnormality well elevated plasma np concentration consistent presence lv diastolic dysfunction raised lv filling pressure diastolic stress test recommended marker equivocal 9 date ha shown reduce mortality morbidity patient hfpef 10 recommended patient heart failure enrolled multi disciplinary hfmp 11 exercise recommended patient able improve exercise capacity qol reduce heart failure hospitalization 12 patient advanced heart failure refractory medicaldevice absolute contraindication referred consideration heart transplantation mc also considered btt dt selected patient 13 four major clinical presentation acute heart failure may occur adhf acute pulmonary oedema rv failure cardiogenic shock 14 acute heart failure based diuretic congestion ino trope short term mc peripheral hypoperfusion 15 patient hospitalized heart failure carefully evaluated exclude persistent sign congestion oral optimized discharge 16 addition oral anticoagulation strategy rhythm control including catheter ablation considered patient whose symptom andor cardiac dysfunction associated af 17 savr tavi advised heart team recommended patient symptomatic severe aortic valve stenosis 18 patient isolated significant smr coapt criterion considered percutaneous edgetoedge repair whereas smr cad need revascularization considered surgery 19 recommended patient type ii diabetes treated sglt2 inhibitor 20 patient periodically screened anaemia iron defi ciency iv iron supplementation ferric carboxymaltose considered symptomatic patient left ventricular ejection fraction 45 iron deficiency patient recently hospitalized hf left ventricular ejection fraction 50 iron deficiency 36 adult congenital heart disease heart failure specialized centre achd patient chronic heart failure referred specialized centre speciﬁc guideline medical chronic heart failure achd lacking practitioner follow current guideline medical hf remains unknown whether longterm use neu rohormonal modulators affect clinical outcome prognosis achd sacubitrilvalsartan may decrease morbidity991993 however recom mendation made moment based retrospective anecdotical nature observation comorbidities heart failure diabetes mellitus af csa iron deﬁciency cachexia treated according speciﬁc recommendation reported document biventricular circulation patient impaired systemic lv treated conventional heart failure may also consid ered symptomatic patient failing systemic right ventricle diuretic recommended control symptom ﬂuid retention symptomatic patient failing single ventricle fontan circulation case persistent righttoleft shunt always carefully initiated taking labile balance ventricular pre load systemic afterload account crt may therapeutic option achd patient hf evi dence speciﬁc setting still lacking efﬁcacy crt depend underlying structural functional substrate anatomy systemic ventricle left right functionally single presence degree structural systemic av valve regurgitation primary myocardial disease scarring type electrical conduction delay988 acute heart failure achd patient expert centre proper knowledge inotropes availability extracorporeal membrane oxygenation advanced bridging techniques988994 timely evaluation transplantation achd heart failure specialist trans plant centre achd expertise recommended ventricular assist device bridge patient transplantation subgroup patient may option destination achd adult congenital heart disease atrial fibrillation atrial ﬁbrillation av atrioventricu lar crt cardiac resynchronization csa central sleep apnoea heart failure heart failure lv left ventricular esc 2021 downloaded guest 24 november 2024 16 gap evidence major advance diagnosis trea16 Gt patient hf occurred recent year strong evidence new option given recent rcts heart failure management may undergo major change next year new discovery however pose new challenge many area lack evidence still remain following short list selected common issue deserve addressed future clinical research 1 definition epidemiology research underlying characteristic patho physiology diagnosis hfmref hfpef ii consensus normal valuesranges ef iii better phenotyping hfpef iv information incidence prevalence ‘recovered lv’ systolic function 2 diagnosis definitive role biomarkers focusing additive value diagnosis hf ii randomized screening heart failure asympto matic subject may translate improved outcome iii biomarkers showing impact outcome measurement identification subject risk devel oping heart failure well guide patient hf iv validated diagnostic protocol diagnosis hfmref hfpef 3 pharmacotherapy chf pragmatic order adding diseasemodifying drug hfref ii specific hfmref hfpef likely dif ferent phenotype iii data prospective clinical hfref patient egfr 30 mLmin1.73 m2 iv evidence prospective rcts specific heart failure phenotype myocarditis cardiotoxicity inherited cmps ppcm amyloidosis v management strategy ‘recovered lv’ sys tolic function vi evidence effect fluid restriction dietary salt restriction nutrition 4 device intervention indication icds specific subgroup hfmrefhfpef optimal selection icd candidate hfref including patient ischaemic nonischaemic cardiomyopathy ii research crt efficacy af iii prospective randomized showing impact outcome atrial fibrillation ablation strategy compared omt heart failure patient iv research percutaneous valve heart disease impact patients’ outcome qol v larger rcts ccm baroreceptor stimulation hfref 5 disease management role remote monitoring strategy heart failure post covid19 era ii optimal model followup stable heart failure patient iii determine specific option palliative care 6 advanced hf better definition risk profile according intermacs classification ii rcts establish effect outcome longterm mc hospitalized patient well ambulatory outpatient instance intermacs 46 profile iii advance longterm mc including strategy reduce risk bleeding thromboembolic event infection iv advance medical many patient undergo mc heart transplantation including develop ment strategy novel inotropes myotropes patient advanced hf 7 ahf better definition classification patient phenotype facilitate improved ii evidencebased use imaging technique biomarkers impact patients’ clinical course iii development better strategy congestion relief includ ing monitoring diuretic administration andor improve organ perfusion iv identification impact postdischarge outcome v new device shortterm mc vi definition evidencebased option therapeu tic algorithm patient cardiogenic shock 8 cardiovascular comorbidities rcts showing best strategy ventricular arrhythmia ii rcts establish role coronary revascularization pro cedures different patient subset iii rcts establish impact patients’ outcome andor qol percutaneous mitral tricuspid valve disease patient hf 9 noncv comorbidities rcts addressing cachexia andor sarcopenia andor frailty showing impact qol andor outcome ii rcts medical device patient severe ckd hf iii rcts showing effect outcome medical electrolyte abnormality iv rcts showing effect outcome csa v prospective showing impact outcome andor qol early diagnosis better prevention cardiotoxicity cancer vi better infection prevention cardiac injury infection 10 special condition rcts ppcm ii better phenotyping cmps genetic testing bio marker imaging modality tailoring iii rcts different type myocarditis including immunosuppressive iv rcts new different form cardiac amyloid v better definition la myopathy downloaded guest 24 november 2024 17 ‘what do’ ‘what do’ message guideline recommendation classa levelb recommendation diagnosis chronic hf bnpntprobnpc b 12lead ecg c transthoracic echocardiography c chest radiography xray c routine blood test comorbidities including full blood count urea electrolyte thyroid function fasting glucose hba1c lipid iron tsat ferritin c cmr recommended assessment myocardial structure function poor echocardiogram acoustic window c cmr recommended characterization myocardial tissue suspected inﬁltrative disease fabry disease inﬂamma tory disease myocarditis lv noncompaction amyloid sarcoidosis iron overloadhaemochromatosis c invasive coronary angiography recommended patient angina despite pharmacological symptomatic ven tricular arrhythmia b cardiopulmonary exercise testing recommended part evaluation heart transplantation andor mc c right heart catheterization recommended patient severe heart failure evaluated heart transplantation mc c recommendation hfref acei recommended patient hfref reduce risk heart failure hospitalization death betablocker recommended patient stable hfref reduce risk heart failure hospitalization death mra recommended patient hfref reduce risk heart failure hospitalization death dapagliﬂozin empagliﬂozin recommended patient hfref reduce risk heart failure hospitalization death sacubitrilvalsartan recommended replacement acei patient hfref reduce risk heart failure hospitaliza tion death b diuretic recommended patient hfref sign andor symptom congestion alleviate heart failure symptom improve exercise capacity reduce heart failure hospitalization c arbc recommended reduce risk heart failure hospitalization cardiovascular death symptomatic patient unable tolerate acei arni patient also receive betablocker mra b addition angiotensin receptor blocker renin inhibitor combination acei mra recommended patient hf increased risk renal dysfunction hyperkalaemia iii c icd recommended reduce risk sudden death allcause mortality patient recovered ventricular arrhythmia causing haemodynamic instability expected survive 1 year good functional status absence reversible cause unless ventricular arrhythmia ha occurred 48 h mi icd recommended reduce risk sudden death allcause mortality patient symptomatic heart failure nyha class IIiii ischaemic aetiology unless myocardial infarction prior 40 days—see left ventricular ejection fraction 335nths omt provided expected survive substantially longer 1 year good functional status icd implantation recommended within 40 day myocardial infarction implantation time doe improve prognosis iii icd recommended patient nyha class IV severe symptom refractory pharmacological unless candidate crt vad cardiac transplantation iii c crt recommended symptomatic patient heart failure sr qrs duration 150 lbbb qrs morphology left ventricular ejection fraction 35 despite omt order improve symptom reduce morbidity mortality crt rather rv pacing recommended patient hfref regardless nyha class qrs width indication ventricular pacing high degree av block order reduce morbidity includes patient af crt recommended patient qrs duration 130 indication pacing due high degree av block iii recommendation hfmref hfpef diuretic recommended patient congestion hfmref order alleviate symptom sign c continued downloaded guest 24 november 2024 screening aetiology cardiovascular noncv comorbidities recommended patient hfpef see relevant section document c diuretic recommended congested patient hfpef order alleviate symptom sign c recommendation prevention chronic hf hypertension recommended prevent delay onset hf prevent heart failure hospitalization statin recommended patient high risk cardiovascular disease cardiovascular disease order prevent delay onset hf prevent heart failure hospitalization sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂozin ertugliﬂozin sotagliﬂozin recommended patient dia betes high risk cardiovascular disease cardiovascular disease order prevent heart failure hospitalization counselling sedentary habit obesity cigarette smoking alcohol abuse recommended prevent delay onset hf c recommendation management chronic hf recommended heart failure patient enrolled multidisciplinary heart failure management programme reduce risk hf hospitalization mortality selfmanagement strategy recommended reduce risk heart failure hospitalization mortality either homebased andor clinicbased programme improve outcome recommended reduce risk heart failure hospi talization mortality exercise recommended patient able order improve exercise capacity qol reduce hf hospitalizationd recommendation patient advanced hf patient considered longterm mc must good compliance appropriate capacity device handling psy chosocial support c heart transplantation recommended patient advanced hf refractory medicaldevice absolute contraindication c recommendation patient acute hf oxygen recommended patient spo2 90 pao2 60 correct hypoxaemia c intubation recommended progressive respiratory failure persisting spite oxygen administration noninvasive ventilation c intravenous loop diuretic recommended patient ahf admitted signssymptoms ﬂuid overload improve symptom c thromboembolism prophylaxis eg lmwh recommended patient already anticoagulated contra indication anticoagulation reduce risk deep venous thrombosis pulmonary embolism inotropic agent recommended routinely due safety concern unless patient ha symptomatic hypotension evidence hypoperfusion iii c routine use opiate recommended unless selected patient severeintractable pain anxiety iii c iabp routinely recommended postmi cardiogenic shock iii b recommendation management patient heart failure hospitalization recommended patient hospitalized heart failure carefully evaluated exclude persistent sign congestion discharge optimize oral c recommended evidencebased oral medical administered discharge c early followup visit recommended 12 week discharge assess sign congestion drug tolerance start andor uptitrate evidencebased c recommendation patient heart failure af longterm oral anticoagulant recommended patient af hf cha2ds2vasc score 2 men 3 woman doacs recommended preference vkas patient hf except moderate severe mitral steno si mechanical prosthetic heart valve urgent ecv recommended setting acute worsening heart failure patient presenting rapid ventricular rate haemodynamic instability c antiarrhythmic agent ﬂecainide encainide disopyramide dronedarone dsotalol recom mended due safety concern iii continued downloaded guest 24 november 2024 diltiazem verapamil recommended patient hfref increase risk heart failure worsening hf hospitalization iii c recommendation patient heart failure aortic stenosis aortic valve intervention tavi savr recommended patient heart failure severe highgradient aortic stenosis reduce mortality improve symptom b recommended choice tavi savr made heart team according individual patient pref erence feature including age surgical risk clinical anatomical procedural aspect weighing risk beneﬁts approach c recommendation patient heart failure diabetes sglt2 inhibitor canagliﬂozin dapagliﬂozin empagliﬂozin ertugliﬂozin sotagliﬂozin recommended patient t2dm risk cardiovascular event reduce hospitalization hf major cardiovascular event endstage renal dysfunction cardiovascular death sglt2 inhibitor dapagliﬂozin empagliﬂozin sotagliﬂozin recommended patient t2dm hfref reduce hospitalization heart failure cardiovascular death thiazolidinediones glitazones recommended patient hf increase risk heart failure worsening hf hospitalization iii dpp4 inhibitor saxagliptin recommended patient hf iii b recommendation patient heart failure iron deﬁciency recommended patient heart failure periodically screened anaemia iron deﬁciency full blood count serum ferritin concentration tsat c anaemia heart failure erythropoietinstimulating agent recommended absence indication iii b recommendation patient heart failure sleep apnoea adaptive servoventilation recommended patient hfref predominant csa increased cause cardiovascular mortality iii recommendation patient heart failure arthritis nsaid cox2 inhibitor recommended patient hf increase risk heart failure worsening hf hospitalization iii b recommendation patient heart failure cancer recommended cancer patient increased risk cardiotoxicity deﬁned history risk factor cardiovascular disease previous cardiotoxicity exposure cardiotoxic agent undergo cardiovascular evaluation scheduled anticancer pref erably cardiologist experienceinterest cardiooncology c recommendation patient heart failure amyloidosis tafamidis recommended patient genetic testing proven httrca nyha class ii symptom reduce symptom cardiovascular hospitalization mortality b tafamidis recommended patient wtttrca nyha class ii symptom reduce symptom cardiovascular hospitaliza tion mortality b acei angiotensinconverting enzyme inhibitor atrial fibrillation atrial ﬁbrillation ahf acute heart failure angiotensin receptor blocker angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor av atrioventricular bnp btype natriuretic peptide cha2ds2vasc congestive heart failure left ventricular dysfunction hypertension age 75 doubled diabetes stroke doubledvascular disease age 6574 sex category female score cmp cardiomyopathy cmr cardiac magnetic resonance crt cardiac resynchro nization csa central sleep apnoea cardiovascular cardiovascular doac directacting oral anticoagulant dpp4 dipeptidyl peptidase4 ecg electrocardiogram ecv electrical cardioversion hba1c glycated haemoglobin heart failure heart failure hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejection fraction httr hereditary transthyretin iabp intraaortic balloon pump icd implantable cardioverterdeﬁb rillator lbbb left bundle branch block lmwh lowmolecularweight heparin lv left ventricularventricle left ventricular ejection fraction left ventricular ejection fraction mc mechanical cir culatory support myocardial infarction myocardial infarction mra mineralocorticoid receptor antagonist nsaid nonsteroidal antiinﬂammatory drug ntprobnp nterminal prob type natriuretic peptide nyha new york heart association omt optimal medical pao2 partial pressure oxygen qol quality life qrs q r wave ecg rv right ventricular savr surgical aortic valve replacement sglt2 sodiumglucose cotransporter 2 spo2 transcutaneous oxygen saturation sr sinus rhythm t2dm type 2 diabetes mellitus tavi transcatheter aortic valve implantation tsat transferrin saturation vad ventricular assist device vka vitamin k antagonist wtttrca wildtype transthyretin cardiac amyloidosis aclass recommendation blevel evidence creferences listed section 4.2 item din able adhere exercise programme esc 2021 downloaded guest 24 november 2024 18 quality indicator qi tool may used evaluate care quality including process care clinical outcomes995 may also serve mechanism enhancing adherence guideline recommendation quality assurance endeavour bench marking care providers996 role qi driving qual ity improvement increasingly recognized attracts interest healthcare authority professional organization payer public997 esc recognizes need measuring reporting quality outcome cardiovascular care methodology esc qi developed ha published997 date suite qi initial tranche cardiovascular condition ha produced998999 facili tate quality improvement initiative diseasespecific esc qi included corresponding esc clinical practice guidelines71000 enhanced way integration esc registry eurobservational research programme eorp european unified registry heart care evaluation randomized euroheart project1001 patient hf qi may help healthcare provider simul taneously operationalize discrete guideline recommendation enable discrimination missed opportunity appro priate care furthermore qi allow capture patients’ 37 main european society cardiology quality indicator evaluation care outcome patient heart failure full list published separate article domain 1 structural qisa main 1 centre dedicated multidisciplinary team manage patient hf numerator availability dedicated multidisciplinary team manage patient hf domain 2 patient assessmentb main 1 proportion patient heart failure documentation heart failure clinical type hfref hfmref hfpef numerator number patient heart failure documentation heart failure clinical type hfref hfmref hfpef denominator number patient hf main 2 proportion patient heart failure documentation ecg ﬁndings numerator number patient heart failure documentation ecg ﬁndings denominator number patient hf main 3 proportion patient heart failure np measured numerator number patient heart failure documentation np level denominator number patient hf domain 3 initial main 1 proportion patient hfref prescribed betablocker bisoprolol carvedilol sustainedrelease metoprolol succinate nebivolol absence contraindication numerator number patient hfref prescribed betablocker bisoprolol carvedilol sustainedrelease metoprolol succinate nebivolol denominator number patient hfref without contraindication betablocker bisoprolol carvedilol sustainedrelease metoprolol succinate nebivolol main 2 proportion patient hfref prescribed angiotensin converting enzyme inhibitor angiotensin receptor blocker arni absence contraindication numerator number patient hfref prescribed angiotensin converting enzyme inhibitor angiotensin receptor blocker arni denominator number patient hfref without contraindication angiotensin converting enzyme inhibitor arb arni main 3 proportion patient heart failure prescribed diuretic evidence ﬂuid retention numerator number patient hf evidence ﬂuid retention prescribed diuretic denominator number patient heart failure evidence ﬂuid retention contraindication diuretic main 4 proportion patient hfref prescribed mra absence contraindication numerator number patient hfref prescribed mra denominator number patient hfref without contraindication mra main 5 proportion patient hfref prescribed sglt2 inhibitor absence contraindication numerator number patient hfref prescribed sglt2 inhibitor denominator number patient hfref without contraindication sglt2 inhibitor angiotensin converting enzyme angiotensinconverting enzyme angiotensin receptor blocker angiotensinreceptor blocker arni angiotensin receptorneprilysin inhibitor heart failure heart failure hfmref heart failure mildly reduced ejection fraction hfpef heart failure preserved ejection fraction hfref heart failure reduced ejection fraction icd implantable cardioverter deﬁbrillator ihd ischaemic heart disease lbbb left bundle branch block left ventricular ejection fraction left ventricular ejection fraction mra mineralocorticoid receptor antagonist np natriu retic peptide nyha new york heart association omt optimal medical qi quality indicator sglt2 sodiumglucose cotransporter 2 astructural qi binary measurement yesno thus numerator deﬁnitions bblood test include urea creatinine electrolyte full blood count glucose glycated haemoglobin thyroidstimulating hormone liver function test lipid iron proﬁle esc 2021 downloaded guest 24 november 2024 experience parallel writing guideline suite qi evaluation care outcome patient heart failure wa developed qi alongside specifica tions development process published separately short summary shown 37 19 supplementary data supplementary data additional supplementary text complementing full text available european heart journal website via esc website 20 author information authortask force member affiliation marianna adamo medical surgical specialty radiological science public asst spedali civili di brescia brescia italy andreas baumbach bart heart centre queen mary university london london united kingdom michael bo¨hm klinik fu¨r innere medizin iii saarland university homburgsaar saarland germany haran burri cardiology university hospital geneva geneva switzerland jelena celutkiene clinic cardiac vascular disease vilnius university faculty medicine vilnius lithuania ovidiu chioncel emergency institute cardiovascular disease ‘prof drcciliescu’ university medicine carol davila bucuresti romania john gf cleland robertson centre biostatistics clinical institute health wellbeing glasgow lanarkshire united kingdom andrew j coat university warwick coventry united kingdom maria g crespoleiro cardiology complexo hospitalario universitario coruna chuac cibercv universidade da coruna udc instituto de investigacion biomedica de coruna inibic la coruna spain dimitrios farmakis university cyprus medical school nicosia cyprus roy gardner scottish national advanced heart failure service golden jubilee national hospital clyderbank glasgow scotland united kingdom martine gilard cardiology brest university brest france stephane heymans department cardiology maastricht university carim school cardiovascular disease maastricht netherlands arno w hoe university medical center utrecht utrecht netherlands tiny jaarsma department health medicine caring science linko¨ping university linko¨ping sweden ewa jankowska department heart disease wroclaw medical university wroclaw poland mitja lainscak division cardiology general hospital murska sobota murska sobota slovenia carolyn sp lam national heart centre singapore dukenational university singapore singapore alexander r lyon department cardiology royal brompton hospital london united kingdom john jv mcmurray british heart foundation cardiovascular research centre university glasgow glasgow scotland united kingdom alexandre mebazaa anesthesiology critical care universite´ de paris hoˆpital lariboisiere paris france richard mindham united kingdom esc patient forum sophia antipolis france claudio muneretto cardiothoracic surgery asst spedali civili university brescia brescia italy massimo francesco piepoli cardiology guglielmo da saliceto hospital ausl piacenza piacenza italy susanna price cardiology adult intensive care unit royal brompton hospital london united kingdom giuseppe mc rosano irccs san raffaele rom italy frank ruschitzka department cardiology university hospital zurich zurich switzerland anne kathrine skibelund denmark esc patient forum sophia antipolis france 21 appendix esc scientific document group includes document reviewer esc national cardiac society document reviewer rudolf de boer cpg review coordinator netherlands p christian schulze cpg review coordinator germany magdy abdelhamid egypt victor aboyans france stamatis adamopoulos greece stefan anker germany elena arbelo spain riccardo asteggiano italy johann bauersachs germany antoni bayesgenis spain michael borger germany werner budts belgium maja cikes croatia kevin damman netherlands victoria delgado netherlands paul dendale belgium polychronis dilaveris greece heinz drexel austria justin ezekowitz canada volkmar falk germany laurent fauchier france gerasimos filippatos greece alan fraser united kingdom norbert frey germany chris p gale united kingdom finn gustafsson denmark julie harris united kingdom bernard iung france stefan janssens belgium mariell jessup united state america aleksandra konradi russia dipak kotecha united kingdom ekatirini lambrinou cyprus patrizio lancellotti belgium ulf landmesser germany christophe leclercq france basil lewis israel francisco leyva united kingdom ales linhart czech republic majalisa løchen norway lars h lund sweden donna mancini united state america josep masip spain davor milicic croatia christian mueller switzerland holger nef germany jenscosedis nielsen denmark li neubeck united kingdom michel noutsias germany steffen e petersen united kingdom anna sonia petronio italy piotr ponikowski poland eva prescott denmark amina rakisheva kazakhstan dimitrios richter greece evgeny schlyakhto russia petar seferovic serbia michele senni italy marta sitges spain miguel sousauva portugal carlo gabriele tocchetti italy rhian touyz united kingdom carsten tschoepe germany johannes waltenberger germany esc national cardiac society actively involved review process 2021 esc guideline diagnosis acute chronic heart failure algeria algerian society cardiology messaad krim armenia armenian cardiologist association hamlet hayrapetyan austria austrian society cardiology deddo moertl azerbaijan azerbaijan society cardiology isakh mustafayev belarus belorussian scientific society cardiologist alena kurlianskaya belgium belgian society cardiology michel depauw bosnia herzegovina association cardiologist bosnia herzegovina zumreta kusljugic bulgaria bulgarian society downloaded guest 24 november 2024 cardiology plamen gatzov croatia croatian cardiac society davor milicic cyprus cyprus society cardiology petros agathangelou czech republic czech society cardiology vojtech melenovsky denmark danish society cardiology brian bridal løgstrup egypt egyptian society cardiology ahmed magdy mostafa estonia estonian society cardiology tiina uuetoa finland finnish cardiac society johan lassus france french society cardiology damien logeart georgia georgian society cardiology zviad kipiani germany german cardiac society johann bauersachs greece hellenic society cardiology christina chrysohoou hungary hungarian society cardiology robert sepp iceland icelandic society cardiology inga jona ingimarsdottir ireland irish cardiac society jim o’neill israel israel heart society israel gotsman italy italian federation cardiology massimo iacoviello kazakhstan association cardiologist kazakhstan amina rakisheva kosovo republic kosovo society cardiology gani bajraktari kyrgyzstan kyrgyz society cardiology olga lunegova latvia latvian society cardiology ginta kamzola lebanon lebanese society cardiology tony abdel massih libya libyan cardiac society hisham benlamin lithuania lithuanian society cardiology dianazaliaduonyte luxembourg luxembourg society cardiology stephanie noppe malta maltese cardiac society alice moore moldova republic moldavian society cardiology eleonora vataman montenegro montenegro society cardiology aneta boskovic morocco moroccan society cardiology ahmed benni netherlands netherlands society cardiology olivier c manintveld north macedonia north macedonian society cardiology elizabeta srbinovska kostovska norway norwegian society cardiology geeta gulati poland polish cardiac society ewa straburzynskamigaj portugal portuguese society cardiology jose´ silvacardoso romania romanian society cardiology roxana cristina rimbas¸ russian federation russian society cardiology yury lopatin san marino san marino society cardiology marina foscoli serbia cardiology society serbia sinisa stojkovic slovakia slovak society cardiology eva goncalvesova slovenia slovenian society cardiology zlatko fras spain spanish society cardiology javier segovia sweden swedish society cardiology krister lindmark switzerland swiss society cardiology micha maeder syrian arab republic syrian cardiovascular association walid bsata tunisia tunisian society cardiology cardiovascular surgery leila abid turkey turkish society cardiology hakan altay ukraine ukrainian association cardiology leonid voronkov united kingdom great britain northern ireland british cardiovascular society ceri davy uzbekistan association cardiologist uzbekistan timur abdullaev esc clinical practice guideline committee cpg colin n baigent chairperson united kingdom magdy abdelhamid egypt victor aboyans france sotiris antoniou united kingdom elena arbelo spain riccardo asteggiano italy andreas baumbach united kingdom michael borger germany jelena celutkiene lithuania maja cikes croatia jeanphilippe collet france volkmar falk germany laurent fauchier france chris p gale united kingdom sigrun halvorsen norway bernard iung france tiny jaarsma sweden aleksandra konradi russia konstantinos c koskinas switzerland dipak kotecha united kingdom ulf landmesser germany basil lewis israel ale linhart czech republic majalisa løchen norway jenscosedis nielsen denmark steffen e petersen united kingdom eva prescott denmark li neubeck united kingdom amina rakisheva kazakhstan marta sitges spain rhian touyz united kingdom 22 1 ponikowski p voors aa anker sd bueno h cleland jgf coat ajs falk v gonzalezjuanatey jr harjola vp jankowska ea jessup linde c nihoyannopoulos p parissis jt pieske b riley jp rosano gmc ruilope lm ruschitzka f rutten fh van der meer p esc scientific document group esc guideline diagnosis acute chronic heart failure task force diagnosis acute chronic heart failure european society cardiology esc developed special contri bution heart failure association hfa esc eur heart j 20163721292200 2 piepoli mf hoe aw agewall albus c brotons c catapano al cooney mt corra u cosyns b deaton c graham hall hobbs fdr lochen lollgen h marquesvidal p perk j prescott e redon j richter dj sattar n smulders tiberi van der worp hb van dis verschuren wmm binno esc scientific document group 2016 european guideline cardiovascular dis ease prevention clinical practice sixth joint task force european society cardiology society cardiovascular disease prevention clinical practice constituted representative 10 society invited expertsdeveloped special contribution european association cardiovascular prevention rehabilitation eacpr eur heart j 20163723152381 3 ibanez b james agewall antunes mj bucciarelliducci c bueno h caforio alp crea f goudevenos ja halvorsen hindricks g kastrati lenzen mj prescott e roffi valgimigli varenhorst c vranckx p widimsky p esc scientific document group 2017 esc guideline management acute myocardial infarction patient presenting stsegment elevation task force management acute myocardial infarction patient presenting stsegment elevation european society cardiology esc eur heart j 201839119177 4 williams b mancia g spiering w agabiti rosei e azizi burnier clement dl coca de simone g dominiczak kahan mahfoud f redon j ruilope l zanchetti kerins kjeldsen se kreutz r laurent lip gyh mcmanus r narkiewicz k ruschitzka f schmieder shlyakhto e tsioufis c aboyans v desormais esc scientific document group 2018 escesh guideline management arterial hypertension eur heart j 20183930213104 5 knuuti j wijns w saraste capodanno barbato e funckbrentano c prescott e storey rf deaton c cuisset agewall dickstein k edvardsen escaned j gersh bj svitil p gilard hasdai hatala r mahfoud f masip j muneretto c valgimigli achenbach bax jj esc scientific document group 2019 esc guideline diagnosis management chronic coronary syn drome eur heart j 202041407477 6 cosentino f grant pj aboyans v bailey cj ceriello delgado v federici filippatos g grobbee de hansen tb huikuri hv johansson juni p lettino marx n mellbin lg ostgren cj rocca b roffi sattar n seferovic pm sousa uva valensi p wheeler dc esc scientific document group 2019 esc guideline diabetes prediabetes cardiovascular disease developed collaboration easd eur heart j 202041255323 7 hindricks g potpara dagres n arbelo e bax jj blomstromlundqvist c boriani g castella dan ga dilaveris pe fauchier l filippatos g kalman jm la meir lane da lebeau jp lettino lip gyh pinto fj thomas gn valgimigli van gelder ic van putte bp watkins cl esc scientific document group 2020 esc guideline diagnosis management atrial fibrillation developed collaboration european association cardiothoracic surgery eacts eur heart j 202142373498 8 lund lh claggett b liu j lam c jhund p rosano gm swedberg k yusuf granger cb pfeffer mcmurray jjv solomon sd heart failure mid range ejection fraction charm characteristic outcome effect cande sartan across entire ejection fraction spectrum eur j heart fail 20182012301239 downloaded guest 24 november 2024 9 solomon sd claggett b lewis ef desai anand sweitzer nk o’meara e shah sj mckinlay fleg jl sopko g pitt b pfeffer topcat investigator influence ejection fraction outcome efficacy spironolactone patient heart failure preserved ejection fraction eur heart j 201637455462 10 abdulrahim ah shen l rush cj jhund p lee kr mcmurray jjv viccta heart failure collaborator effect digoxin patient heart failure midrange borderline left ventricular ejection fraction eur j heart fail 20182011391145 11 cleland jg tendera adamus j freemantle n polonski l taylor j pepchf investigator perindopril elderly people chronic heart failure pep chf eur heart j 20062723382345 12 cleland jgf bunting kv flather md altman dg holmes j coat ajs manzano l mcmurray jjv ruschitzka f van veldhuisen dj von lueder tg bohm andersson b kjekshus j packer rigby rosano g wedel h hjalmarson wikstrand j kotecha betablockers heart failure collaborative group betablockers heart failure reduced midrange preserved ejection fraction individual patientlevel analysis double blind randomized eur heart j 2018392635 13 solomon sd mcmurray jjv anand ge j lam csp maggioni ap martinez f packer pfeffer pieske b redfield mm rouleau jl van veldhuisen dj zannad f zile mr desai claggett b jhund p boytsov sa comincolet j cleland j dungen hd goncalvesova e katova kerr saraiva jf lelonek merkely b senni shah sj zhou j rizkala ar gong j shi vc lefkowitz mp paragonhf investigator committee angiotensinneprilysin inhibition heart failure preserved ejection fraction n engl j med 201938116091620 14 lam csp voors aa piotr p mcmurray jjv solomon sd time rename middle child heart failure heart failure mildly reduced ejection fraction eur heart j 20204123532355 15 bozkurt b coat ajs tsutsui h abdelhamid cm adamopoulos albert n anker sd atherton j bohm butler j drazner mh michael felker g filippatos g fiuzat fonarow gc gomezmesa je heidenreich p imamura jankowska ea januzzi j khazanie p kinugawa k lam csp matsue metra ohtani francesco piepoli ponikowski p rosano gmc sakata seferovic p starling rc teerlink jr vardeny yamamoto k yancy c zhang j zieroth universal definition classification heart failure report heart failure society america heart failure association european society cardiology japanese heart failure society writing committee universal definition heart failure endorsed canadian heart failure society heart failure association india cardiac society australia new zealand chinese heart failure association eur j heart fail 202123352380 16 galderisi cosyns b edvardsen cardim n delgado v di salvo g donal e sade le ernande l garbi grapsa j hagendorff kamp magne j santoro c stefanidis lancellotti p popescu b habib g eacvi scientific document committee standardization adult transthoracic echocardiography reporting agreement recent chamber quantification diastolic function heart valve disease recommendation expert consensus document european association cardiovascular imaging eur heart j cardiovasc imaging 20171813011310 17 arrigo huber lc winnik mikulicic f guidetti f frank flammer aj ruschitzka f right ventricular failure pathophysiology diagnosis card fail rev 20195140146 18 gorter tm van veldhuisen dj bauersachs j borlaug ba celutkiene j coat ajs crespoleiro guazzi harjola vp heymans hill l lainscak lam csp lund lh lyon ar mebazaa mueller c paulus wj pieske b piepoli mf ruschitzka f rutten fh seferovic pm solomon sd shah sj triposkiadis f wachter r tschope c de boer ra right heart dysfunction failure heart failure preserved ejection fraction mechanism management position statement behalf heart failure association european society cardiology eur j heart fail 2018201637 19 caraballo c desai nr mulder h alhanti b wilson fp fiuzat felker gm pina il o’connor cm lindenfeld j januzzi jl cohen l ahmad clinical implication new york heart association classification j heart assoc 20198e014240 20 solomon sd claggett b packer desai zile mr swedberg k rouleau j shi v lefkowitz mcmurray jjv efficacy sacubitrilvalsartan relative prior decompensation paradigmhf jacc heart fail 20164816822 21 conrad n judge tran j mohseni h hedgecott crespillo ap allison hemingway h cleland jg mcmurray jjv rahimi k temporal trend pat tern heart failure incidence populationbased 4 million individual lancet 2018391572580 22 dunlay sm roger vl understanding epidemic heart failure past present future curr heart fail rep 201411404415 23 roth ga forouzanfar mh moran ae barber r nguyen g feigin vl naghavi mensah ga murray cj demographic epidemiologic driver global car diovascular mortality n engl j med 201537213331341 24 savarese g lund lh global public health burden heart failure card fail rev 20173711 25 meyer brouwers fp voors aa hillege hl de boer ra gansevoort rt van der harst p rienstra van gelder ic van veldhuisen dj van gilst wh van der meer p sex difference newonset heart failure clin cardiol 2015104342350 26 brouwers fp de boer ra van der harst p voors aa gansevoort rt bakker sj hillege hl van veldhuisen dj van gilst wh incidence epidemiology new onset heart failure preserved v reduced ejection fraction communitybased cohort 11year followup prevend eur heart j 20133414241431 27 gbd 2017 disease injury incidence prevalence collaborator global regional national incidence prevalence year lived disability 354 disease injury 195 country territory 19902017 system atic analysis global burden disease 2017 lancet 201839217891858 28 roger vl epidemiology heart failure circ 2013113646659 29 mosterd hoe aw clinical epidemiology heart failure heart 20079311371146 30 smeets vaes b mamouris p van den akker van pottelbergh g goderis g janssens aertgeerts b henrard burden heart failure flemish general practice registrybased intego database bmj open 20199e022972 31 virani alonso benjamin ej bittencourt callaway cw carson ap chamberlain chang ar cheng delling fn djousse l elkind msv ferguson jf fornage khan kissela bm knutson kl kwan tw lackland dt lewis tt lichtman jh longenecker ct loop lutsey pl martin matsushita k moran ae mussolino perak rosamond wd roth ga sampson uka satou gm schroeder eb shah sh shay cm spartano nl stokes tirschwell dl vanwagner lb tsao cw american heart association council epidemiology prevention statistic committee stroke statistic subcommittee heart disease stroke statistics—2020 update report american heart association circulation 2020141e139e596 32 van riet ee hoe aw limburg landman van der hoeven h rutten fh prevalence unrecognized heart failure older person shortness breath exertion eur j heart fail 201416772777 33 van riet ee hoe aw wagenaar kp limburg landman rutten fh epidemiology heart failure prevalence heart failure ventricular dy function older adult time systematic review eur j heart fail 201618242252 34 benjamin ej virani callaway cw chamberlain chang ar cheng chiuve se cushman delling fn deo r de ferranti sd ferguson jf fornage gillespie c isasi cr jimenez mc jordan lc judd se lackland lichtman jh lisabeth l liu longenecker ct lutsey pl mackey j matchar db matsushita k mussolino nasir k o’flaherty palaniappan lp pandey pandey dk reef mj ritchey md rodriguez cj roth ga rosamond wd sampson uka satou gm shah sh spartano nl tirschwell dl tsao cw voeks jh willey jz wilkins jt wu jh alger hm wong muntner p american heart association council epidemiology prevention statistic committee stroke statistic subcommittee heart disease stroke statis tics—2018 update report american heart association circulation 2018137e67e492 35 ceia f fonseca c mota morais h matias f de sousa oliveira epica investigator prevalence chronic heart failure southwestern europe epica eur j heart fail 20024531539 36 bibbinsdomingo k pletcher mj lin f vittinghoff e gardin jm arynchyn lewis ce williams od hulley sb racial difference incident heart failure among young adult n engl j med 200936011791190 37 bleumink g knetsch sturkenboom mc straus sm hofman decker jw witteman jc stricker bh quantifying heart failure epidemic preva lence incidence rate lifetime risk prognosis heart failure rotterdam eur heart j 20042516141619 38 koh tay wt teng thk vedin benson l dahlstrom u savarese g lam csp lund lh comprehensive populationbased characterization heart fail ure midrange ejection fraction eur j heart fail 20171916241634 39 chioncel lainscak seferovic pm anker sd crespoleiro harjola vp parissis j laroche c piepoli mf fonseca c mebazaa lund l ambrosio ga coat aj ferrari r ruschitzka f maggioni ap filippatos g epidemiology oneyear outcome patient chronic heart failure preserved mid range reduced ejection fraction analysis esc heart failure long term registry eur j heart fail 20171915741585 40 shah ru klein l lloydjones dm heart failure woman epidemiology biology womens health lond 20095517527 downloaded guest 24 november 2024 41 roger vl weston sa redfield mm hellermannhoman jp killian j yawn bp jacobsen sj trend heart failure incidence survival communitybased population jama 2004292344350 42 vedin lam csp koh benson l teng thk tay wt braun oo savarese g dahlstrom u lund lh significance ischemic heart disease patient heart failure preserved midrange reduced ejection fraction nation wide cohort circ heart fail 201710e003875 43 kapoor jr kapoor r ju c heidenreich pa eapen zj hernandez af butler j yancy cw fonarow gc precipitating clinical factor heart failure characteriza tion outcome patient hospitalized heart failure reduced bor derline preserved ejection fraction jacc heart fail 20164464472 44 heiat gross cp krumholz hm representation elderly woman minority heart failure clinical arch intern med 200216216821688 45 gerber weston sa redfield mm chamberlain manemann sm jiang r killian jm roger vl contemporary appraisal heart failure epidemic olmsted county minnesota 2000 2010 jama intern med 20151759961004 46 tsao cw lyass enserro larson ho je kizer jr gottdiener j psaty bm vasan r temporal trend incidence mortality associated heart failure preserved reduced ejection fraction jacc heart fail 20186678685 47 motiejunaite j akiyama e cohensolal maggioni ap mueller c choi dj kavoliuniene celutkiene j parenica j lassus j kajimoto k sato n miro peacock wf matsue voors aa lam csp ezekowitz ja ahmed fonarow gc gayat e regitzzagrosek v mebazaa association longterm come biological sex patient acute heart failure different geo graphic region eur heart j 20204113571364 48 dunlay sm roger vl weston sa jiang r redfield mm longitudinal change ejection fraction heart failure patient preserved reduced ejection fraction circ heart fail 20125720726 49 clarke cl grunwald gk allen la baron ae peterson pn brand dw magid dj masoudi fa natural history left ventricular ejection fraction patient heart failure circ cardiovasc qual outcome 20136680686 50 tsuji k sakata nochioka k miura yamauchi onose abe r oikawa kasahara sato shiroto takahashi j miyata shimokawa h chart2 investigator characterization heart failure patient midrange left ven tricular ejection fraction–a report chart2 eur j heart fail 20171912581269 51 rastogi novak e platts ae mann dl epidemiology pathophysiology clin ical outcome heart failure patient midrange ejection fraction eur j heart fail 20171915971605 52 lupon j gavidiabovadilla g ferrer e de antonio pereralluna lopez ayerbe j domingo nunez j zamora e moliner p diazruata p santesmases j bayesgenis dynamic trajectory left ventricular ejection fraction heart failure j coll cardiol 201872591601 53 pocock sj ariti ca mcmurray jj maggioni kober l squire ib swedberg k dobson j poppe kk whalley ga doughty rn metaanalysis global group chronic heart failure predicting survival heart failure risk score based 39 372 patient 30 eur heart j 20133414041413 54 barasa schaufelberger lappas g swedberg k dellborg rosengren heart failure young adult 20year trend hospitalization aetiology case fatality sweden eur heart j 2014352532 55 jhund p macintyre k simpson cr lewsey jd stewart redpath chalmers jw capewell mcmurray jj longterm trend first hospitalization heart failure subsequent survival 1986 2003 population 5.1 million people circulation 2009119515523 56 dunlay sm redfield mm weston sa therneau tm hall long k shah nd roger vl hospitalization heart failure diagnosis community perspective j coll cardiol 20095416951702 57 taylor cj ordonezmena jm roalfe ak layflurrie jones nr marshall hobbs fdr trend survival diagnosis heart failure united kingdom 20002017 population based cohort bmj 2019364l223 58 lorenzoni g azzolina lanera c brianti g gregori vanuzzo baldi time trend first hospitalization heart failure communitybased popula tion int j cardiol 2018271195199 59 mosterd reitsma jb grobbee de angiotensin converting enzyme inhibition hospitalisation rate heart failure netherlands 1980 1999 end epidemic heart 2002877576 60 chen j hsieh af dharmarajan k masoudi fa krumholz hm national trend heart failure hospitalization acute myocardial infarction medicare benefi ciaries 19982010 circulation 201312825772584 61 lawson ca zaccardi f squire ling davy mj lam csp mama khunti k kadam ut 20year trend causespecific heart failure outcome sex socioeconomic status place diagnosis populationbased lancet public health 20194e406e420 62 almohammad mant j laramee p swain chronic heart failure guideline development group diagnosis management adult chronic heart failure summary updated nice guidance bmj 2010341c4130 63 mant j doust j roalfe barton p cowie mr glasziou p mant mcmanus rj holder r deeks j fletcher k qume sohanpal sander hobbs fd systematic review individual patient data metaanalysis diagnosis heart failure modelling implication different diagnostic strategy primary care health technol assess 2009131207 iii 64 davie ap francis cm caruana l sutherland gr mcmurray jj assessing diagno si heart failure feature use qjm 199790335339 65 oudejans mosterd bloemen ja valk mj van velzen e wielders jp zuithoff np rutten fh hoe aw clinical evaluation geriatric outpatient sus pected heart failure value symptom sign additional test eur j heart fail 201113518527 66 kelder jc cramer mj van wijngaarden j van tooren r mosterd moon kg lammers jw cowie mr grobbee de hoe aw diagnostic value physi cal examination additional testing primary care patient suspected heart failure circulation 201112428652873 67 thibodeau jt turer gualano sk ayers cr velezmartinez mishkin jd patel pc mammen pp markham dw levine bd drazner mh characterization novel symptom advanced heart failure bendopnea jacc heart fail 201422431 68 gohar rutten fh den ruijter h kelder jc von haehling anker sd mockel hoe aw midregional proatrial natriuretic peptide early detection nonacute heart failure eur j heart fail 20192112191227 69 hildebrandt p collinson po aminoterminal probtype natriuretic peptide testing assist diagnostic evaluation heart failure symptomatic primary care patient j cardiol 20081012528 70 maisel mueller c adam k jr anker sd aspromonte n cleland jg cohensolal dahlstrom u demaria di somma filippatos g fonarow gc jourdain p komajda liu pp mcdonagh mcdonald k mebazaa nieminen peacock wf tubaro valle r vanderhyden yancy cw zannad f braunwald e state art using natriuretic peptide level clinical practice eur j heart fail 200810824839 71 lancellotti p galderisi edvardsen donal e goliasch g cardim n magne j laginha hagendorff haland tf aaberge l martinez c rapacciuolo santoro c ilardi f postolache dulgheru r mateescu ad beladan cc deleanu marchetta auffret v schwammenthal e habib g popescu ba echodoppler estimation left ventricular filling pressure result multi centre eacvi eurofilling eur heart j cardiovasc imaging 201718961968 72 gardner r ozalp f murday aj robb sd mcdonagh ta nterminal probrain natriuretic peptide new gold standard predicting mortality patient advanced heart failure eur heart j 20032417351743 73 robert e ludman aj dworzynski k almohammad cowie mr mcmurray jj mant j nice guideline development group acute heart failure diagnostic accuracy natriuretic peptide heart failure systematic review diagnostic metaanalysis acute care setting bmj 2015350h910 74 mueller c mcdonald k de boer ra maisel cleland jgf kozhuharov n coat ajs metra mebazaa ruschitzka f lainscak filippatos g seferovic pm meijers wc bayesgenis mueller richards januzzi jl jr heart failure association european society cardiology heart failure association european society cardiology practical guidance use natriuretic peptide concentration eur j heart fail 201921715731 75 madamanchi c alhosaini h sumida runge obesity natriuretic pepti de bnp ntprobnp mechanism diagnostic implication heart fail ure int j cardiol 2014176611617 76 cowie mr struthers ad wood da coat aj thompson sg poolewilson pa sutton gc value natriuretic peptide assessment patient po sible new heart failure primary care lancet 199735013491353 77 zaphiriou robb murraythomas mendez g fox k mcdonagh hardman sm dargie hj cowie mr diagnostic accuracy plasma bnp ntprobnp patient referred primary care suspected heart failure result uk natriuretic peptide eur j heart fail 20057537541 78 kelder jc cramer mj verweij wm grobbee de hoe aw clinical utility three btype natriuretic peptide assay initial diagnostic assessment new slowonset heart failure j card fail 201117729734 79 verdu jm comincolet j domingo lupon j gomez molina l casacuberta jm munoz mena brugueracortada j rapid pointofcare ntprobnp optimal cutoff point heart failure diagnosis primary care rev esp cardiol engl ed 201265613619 80 taylor cj roalfe ak iles r hobbs fr investigator r barton p deeks j mccahon cowie mr sutton g davis rc mant j mcdonagh tait l primary care referral echocardiogram refer heart failure diagnostic accuracy br j gen pract 201767e94e102 81 sicari r nihoyannopoulos p evangelista kasprzak j lancellotti p poldermans voigt ju zamorano jl european association echocardiography stress downloaded guest 24 november 2024 echocardiography expert consensus statement–executive summary european association echocardiography eae registered branch esc eur heart j 200930278289 82 lancellotti p pellikka pa budts w chaudhry fa donal e dulgheru r edvardsen garbi ha jw kane gc kreeger j mertens l pibarot p picano e ryan tsutsui jm varga clinical use stress echocardiography nonischaemic heart disease recommendation european association cardiovascular imaging american society echocardiography eur heart j cardiovasc imaging 20161711911229 83 gonzalez ja kramer cm role imaging technique diagnosis prognosis management heart failure patient cardiac magnetic resonance curr heart fail rep 201512276283 84 messroghli dr moon jc ferreira vm grossewortmann l kellman p mascherbauer j nezafat r salerno schelbert eb taylor aj thompson r ugander van heeswijk rb friedrich clinical recommendation cardi ovascular magnetic resonance mapping t1 t2 t2 extracellular volume consensus statement society cardiovascular magnetic resonance scmr endorsed european association cardiovascular imaging eacvi j cardiovasc magn reson 20171975 85 witteles rm bokhari damy elliott pm falk rh fine nm gospodinova obici l rapezzi c garciapavia p screening transthyretin amyloid cardiomy opathy everyday practice jacc heart fail 20197709716 86 gupta dk wang tj natriuretic peptide cardiometabolic health circ j 20157916471655 87 zois ne bartels ed hunter kousholt b olsen lh goetze jp natriuretic pepti de cardiometabolic regulation disease nat rev cardiol 201411403412 88 nishikimi kuwahara k nakao k current biochemistry molecular biology clinical relevance natriuretic peptide j cardiol 201157131140 89 velazquez ej lee kl deja jain sopko g marchenko ali pohost g gradinac abraham wt yii prabhakaran szwed h ferrazzi p petrie mc o’connor cm panchavinnin p l bonow ro rankin gr jones rh rouleau jl stich investigator coronaryartery bypass surgery patient left ventricular dysfunction n engl j med 201136416071616 90 allman kc shaw lj hachamovitch r udelson je myocardial viability testing impact revascularization prognosis patient coronary artery dis ease left ventricular dysfunction metaanalysis j coll cardiol 20023911511158 91 ling lf marwick th flores dr jaber wa brunken rc cerqueira md hachamovitch r identification therapeutic benefit revascularization patient left ventricular systolic dysfunction inducible ischemia hiber nating myocardium circ cardiovasc imaging 20136363372 92 bonow ro maurer g lee kl holly ta binkley pf desvignenickens p drozdz j farsky p feldman doenst michler berman nicolau jc pellikka pa wrobel k alotti n asch fm favaloro le l velazquez ej jones rh panza ja stich investigator myocardial viability survival ischemic left ventricular dysfunction n engl j med 201136416171625 93 panza ja elli alkhalidi hr holly ta berman oh jk pohost gm sopko g chrzanowski l mark db kukulski favaloro le maurer g farsky p tan r asch fm velazquez ej rouleau jl lee kl bonow ro myocardial viability longterm outcome ischemic cardiomyopathy n engl j med 2019381739748 94 corra u piepoli mf adamopoulos agostoni p coat aj conraads v lambrinou e pieske b piotrowicz e schmid jp seferovic pm anker sd filippatos g ponikowski pp cardiopulmonary exercise testing systolic heart failure 2014 evolving prognostic role position paper committee exercise physiology training heart failure association esc eur j heart fail 201416929941 95 piepoli mf conraads v corra u dickstein k francis dp jaarsma mcmurray j pieske b piotrowicz e schmid jp anker sd solal ac filippatos g hoe aw gielen giannuzzi p ponikowski pp exercise training heart failure theory practice consensus document heart failure association european association cardiovascular prevention rehabilitation eur j heart fail 201113347357 96 corra u agostoni pg anker sd coat ajs crespo leiro de boer ra hairola vp hill l lainscak lund lh metra ponikowski p riley j seferovic pm piepoli mf role cardiopulmonary exercise testing clinical stratification heart failure position paper committee exercise physiology training heart failure association european society cardiology eur j heart fail 201820315 97 cooper lt baughman kl feldman frustaci jessup kuhl u levine gn narula j starling rc towbin j virmani r role endomyocardial biopsy management cardiovascular disease scientific statement american heart association american college cardiology european society cardiology endorsed heart failure society america heart failure association european society cardiology eur heart j 20072830763093 98 cooper lt jr berry gj shabetai r idiopathic giantcell myocarditis–natural tory multicenter giant cell myocarditis group investigator n engl j med 199733618601866 99 lang rm badano lp moravi v afilalo j armstrong ernande l flachskampf fa foster e goldstein sa kuznetsova lancellotti p muraru picard mh rietzschel er rudski l spencer kt tsang w voigt ju recommendation cardiac chamber quantification echocardiography adult update american society echocardiography european association cardiovascular imaging eur heart j cardiovasc imaging 201516233270 100 gheorghiade shah vaduganathan butler j bonow ro rosano gm taylor kupfer misselwitz f sharma fonarow gc recognizing hospital ized heart failure entity developing new improve come academics’ clinicians’ industry’s regulators’ payers’ perspective heart fail clin 20139285290 vvi 101 ambrosy ap fonarow gc butler j chioncel greene sj vaduganathan nodari lam csp sato n shah gheorghiade global health economic burden hospitalization heart failure lesson learned hospitalized heart failure registry j coll cardiol 20146311231133 102 anker sd schroeder atar bax jj ceconi c cowie mr crisp dominjon f ford ghofrani ha gropper hindricks g hlatky holcomb r honarpour n jukema jw kim kunz lefkowitz le floch c landmesser u mcdonagh ta mcmurray jj merkely b packer prasad k revkin j rosano gm somaratne r stough wg voors aa ruschitzka f traditional new composite endpoint heart failure clinical facilitating comprehensive efficacy assessment improving effi ciency eur j heart fail 201618482489 103 gayat e arrigo littnerova sato n parenica j ishihara spinar j muller c harjola vp lassus j miro maggioni ap alhabib kf choi dj park jj zhang zhang j januzzi jl jr kajimoto k cohensolal mebazaa network g heart failure oral discharge associated better outcome acute heart failure propensityscore matched eur j heart fail 201820345354 104 crespoleiro anker sd maggioni ap coat aj filippatos g ruschitzka f ferrari r piepoli mf delgado jimenez jf metra fonseca c hradec j amir logeart dahlstrom u merkely b drozdz j goncalvesova e hassanein chioncel lainscak seferovic pm tousoulis kavoliuniene fruhwald f fazlibegovic e temizhan gatzov p erglis laroche c mebazaa heart failure association european society cardiology european society cardiology heart failure longterm registry eschf lt 1year followup outcome difference across region eur j heart fail 201618613625 105 mcmurray jj packer desai gong j lefkowitz mp rizkala ar rouleau jl shi vc solomon sd swedberg k zile mr paradigmhf investigator committee angiotensinneprilysin inhibition enalapril heart failure n engl j med 20143719931004 106 velazquez ej morrow da devore ad duffy ci ambrosy ap mccague k rocha r braunwald e pioneerhf investigator angiotensinneprilysin inhibition acute decompensated heart failure n engl j med 2019380 539548 107 wachter r senni belohlavek j straburzynskamigaj e witte kk kobalava z fonseca c goncalvesova e cavusoglu fernandez chaaban bohmer e pouleur ac mueller c tribouilloy c lonn e buraiki alj gniot j mozheiko lelonek noe schwende h bao w butylin pascualfigal transition investigator initiation sacubitrilvalsartan haemodynami cally stabilised heart failure patient hospital early discharge primary result randomised transition eur j heart fail 2019219981007 108 mcmurray jjv solomon sd inzucchi se køber l kosiborod mn martinez fa ponikowski p sabatine anand belohlavek j bo¨hm chiang ce chopra vk de boer ra desai diez drozdz j dukat ge j howlett jg katova kitakaze ljungman cea merkely b nicolau jc o’meara e petrie mc vinh pn schou tereshchenko verma held c demets dl docherty kf jhund p bengtsson sjo¨strand langkilde dapahf committee investigator dapagliflozin patient heart failure reduced ejection fraction n engl j med 201938119952008 109 packer anker sd butler j filippatos g pocock sj carson p januzzi j verma tsutsui h brueckmann jamal w kimura k schnee j zeller c cotton bocchi e bohm choi dj chopra v chuquiure e giannetti n janssens zhang j gonzalez juanatey jr kaul brunnerla rocca hp merkely b nicholls sj perrone pina ponikowski p sattar n senni seronde mf spinar j squire taddei wanner c zannad f emperor reduced investigator cardiovascular renal outcome empagli flozin heart failure n engl j med 202038314131424 110 consensus group enalapril congestive heart failure n engl j med 198731713491351 downloaded guest 24 november 2024 111 garg r yusuf overview randomized angiotensinconverting enzyme inhibitor mortality morbidity patient heart failure collaborative group angiotensin converting enzyme inhibitor jama 199527314501456 112 packer poolewilson pa armstrong pw cleland jg horowitz jd massie bm ryden l thygesen k uretsky bf comparative effect low high dos angiotensinconverting enzyme inhibitor lisinopril morbidity mortality chronic heart failure atlas group circulation 199910023122318 113 solvd investigator yusuf pitt b davis ce hood wb cohn jn effect enalapril survival patient reduced left ventricular ejection fraction congestive heart failure n engl j med 1991325293302 114 merithf group effect metoprolol crxl chronic heart failure metoprolol crxl randomised intervention congestive heart failure merithf lancet 199935320012007 115 packer bristow mr cohn jn colucci w fowler mb gilbert em shusterman nh effect carvedilol morbidity mortality patient chronic heart failure u carvedilol heart failure group n engl j med 199633413491355 116 packer coat aj fowler mb katus ha krum h mohacsi p rouleau jl tendera castaigne roecker eb schultz mk demets dl carvedilol prospective randomized cumulative survival group effect carvedilol survival severe chronic heart failure n engl j med 200134416511658 117 hjalmarson goldstein fagerberg b wedel h waagstein f kjekshus j wikstrand j el allaf vitovec j aldershvile j halinen dietz r neuhaus kl janosi thorgeirsson g dunselman ph gullestad l kuch j herlitz j rickenbacher p ball gottlieb deedwania p effect controlledrelease metoprolol total mortality hospitalization wellbeing patient heart failure metoprolol crxl randomized intervention conge tive heart failure merithf merithf group jama 200028312951302 118 packer fowler mb roecker eb coat aj katus ha krum h mohacsi p rouleau jl tendera staiger c holcslaw tl amannzalan demets dl carvedilol prospective randomized cumulative survival group effect carvedilol morbidity patient severe chronic heart failure result carvedilol prospective randomized cumulative survival copernicus circulation 200210621942199 119 flather md shibata mc coat aj van veldhuisen dj parkhomenko borbola j cohensolal dumitrascu ferrari r lechat p solersoler j tavazzi l spinarova l toman j bohm anker sd thompson sg poole wilson pa senior investigator randomized determine effect nebivolol mortality cardiovascular hospital admission elderly patient heart failure senior eur heart j 200526215225 120 cibisii investigator committee cardiac insufficiency bisoprolol ii cibisii randomised lancet 1999353913 121 pitt b zannad f remme wj cody r castaigne perez palensky j wittes j effect spironolactone morbidity mortality patient severe heart failure randomized aldactone evaluation investigator n engl j med 1999341709717 122 zannad f mcmurray jj krum h van veldhuisen dj swedberg k shi h vincent j pocock sj pitt b emphasishf group eplerenone patient systolic heart failure mild symptom n engl j med 20113641121 123 fowler mb effect beta blocker symptom functional capacity heart failure j cardiol 19978055l58l 124 willenheimer r van veldhuisen dj silke b erdmann e follath f krum h ponikowski p skene van de ven l verkenne p lechat p cibis iii investigator effect survival hospitalization initiating chronic heart failure bisoprolol followed enalapril compared opposite sequence result randomized cardiac insufficiency bisoprolol cibis iii circulation 200511224262435 125 kotecha holmes j krum h altman dg manzano l cleland jg lip gy coat aj andersson b kirchhof p von lueder tg wedel h rosano g shibata mc rigby flather md betablockers heart failure collaborative group efficacy beta blocker patient heart failure plus atrial fibrillation individualpatient data metaanalysis lancet 201438422352243 126 seferovic jp claggett b seidelmann sb seely ew packer zile mr rouleau jl swedberg k lefkowitz shi vc desai mcmurray jjv solomon sd effect sacubitrilvalsartan enalapril glycaemic control patient heart failure diabetes posthoc analysis paradigmhf lancet diabetes endocrinol 20175333340 127 damman k gori claggett b jhund p senni lefkowitz mp prescott mf shi vc rouleau jl swedberg k zile mr packer desai solomon sd mcmurray jjv renal effect associated outcome angiotensin neprilysin inhibition heart failure jacc heart fail 20186489498 128 desai vardeny claggett b mcmurray jj packer swedberg k rouleau jl zile mr lefkowitz shi v solomon sd reduced risk hyperkalemia heart failure mineralocorticoid receptor antagonist use sacubitrilvalsartan compared enalapril secondary analysis paradigmhf jama cardiol 201727985 129 vardeny claggett b kachadourian j desai packer rouleau j zile mr swedberg k lefkowitz shi v mcmurray jjv solomon sd reduced loop diuretic use patient taking sacubitrilvalsartan compared enalapril paradigmhf eur j heart fail 201921337341 130 vardeny claggett b kachadourian j pearson sm desai packer rouleau j zile mr swedberg k lefkowitz shi v mcmurray jjv solomon sd incidence predictor outcome associated hypotensive episode among heart failure patient receiving sacubitrilvalsartan enalapril paradigmhf prospective comparison angiotensin receptor neprilysin inhibitor angiotensinconverting enzyme inhibitor determine impact global mortality morbidity heart failure circ heart fail 201811e004745 131 morrow da velazquez ej devore ad desai duffy ci ambrosy ap gurmu mccague k rocha r braunwald e clinical outcome patient acute decompensated heart failure randomly assigned sacubitrilvalsar tan enalapril pioneerhf circulation 201913922852288 132 kosiborod mn jhund p docherty kf diez petrie mc verma nicolau jc merkely b kitakaze demets dl inzucchi se kober l martinez fa ponikowski p sabatine solomon sd bengtsson lindholm niklasson sjostrand langkilde mcmurray jjv effect dapagliflozin symp tom function quality life patient heart failure reduced ejec tion fraction result dapahf circulation 20201419099 133 butler j anker sd filippatos g khan ferreira jp pocock sj giannetti n januzzi jl pina il lam csp ponikowski p sattar n verma brueckmann jamal w vedin peil b zeller c zannad f packer emperorreduced committee investigator empagliflozin healthrelated quality life outcome patient heart failure reduced ejection fraction emperorreduced eur heart j 20214212031212 134 zannad f ferreira jp pocock sj anker sd butler j filippatos g brueckmann ofstad ap pfarr e jamal w packer sglt2 inhibitor patient heart failure reduced ejection fraction metaanalysis emperor reduced dapahf lancet 2020396819829 135 jackson dewan p anand belohlavek j bengtsson de boer ra bohm boulton dw chopra vk demets dl docherty kf dukat greasley pj howlett jg inzucchi se katova kober l kosiborod mn langkilde lindholm ljungman cea martinez fa o’meara e sabatine sjostrand solomon sd tereshchenko verma jhund p mcmurray jjv dapagliflozin diuretic use patient heart failure reduced ejection fraction dapahf circulation 202014210401054 136 bhatt dl szarek steg pg cannon cp leiter la mcguire dk lewis jb riddle mc voors aa metra lund lh komajda testani jm wilcox c ponikowski p lope rd verma lapuerta p pitt b soloistwhf investigator sotagliflozin patient diabetes recent worsening heart failure n engl j med 2021384117128 137 faris r flather purcell h henein poolewilson p coat current evi dence supporting role diuretic heart failure meta analysis rando mised controlled int j cardiol 200282149158 138 granger cb mcmurray jj yusuf held p michelson el olofsson b ostergren j pfeffer swedberg k charm investigator committee effect candesartan patient chronic heart failure reduced left ventricular systolic function intolerant angiotensinconvertingenzyme inhibi tor charmalternative lancet 2003362772776 139 swedberg k komajda bohm borer j ford dubostbrama lerebours g tavazzi l shift investigator ivabradine outcome chronic heart failure shift randomised placebocontrolled lancet 2010376875885 140 swedberg k komajda bohm borer j robertson tavazzi l ford shift investigator effect outcome heart rate reduction ivabradine patient congestive heart failure influence betablocker finding shift systolic heart failure inhibitor ivabradine j coll cardiol 20125919381945 141 armstrong pw pieske b anstrom kj ezekowitz j hernandez af butler j lam csp ponikowski p voors aa jia g mcnulty se patel mj roessig l koglin j o’connor cm victoria group vericiguat patient heart fail ure reduced ejection fraction n engl j med 202038218831893 142 taylor al ziesche yancy c carson p d’agostino r jr ferdinand k taylor adam k sabolinski worcel cohn jn africanamerican heart failure investigator combination isosorbide dinitrate hydralazine black heart failure n engl j med 200435120492057 143 cohn jn archibald dg ziesche franciosa ja harston tristani fe dunkman wb jacob w francis g flohr kh effect vasodilator mortality chronic congestive heart failure result veteran administration cooperative n engl j med 198631415471552 downloaded guest 24 november 2024 144 digitalis investigation group effect digoxin mortality morbidity patient heart failure n engl j med 1997336525533 145 mullens w damman k harjola vp mebazaa brunnerla rocca hp marten p testani jm tang whw orso f rossignol p metra filippatos g seferovic pm ruschitzka f coat aj use diuretic heart failure congestion – position statement heart failure association european society cardiology eur j heart fail 201921137155 146 rohde le rover mm figueiredo neto ja danzmann lc bertoldi eg simoes mv silvestre om ribeiro alp moura lz beckdasilva l prado sant’anna rt bridi lh zimerman raupp da rosa p biolo shortterm diuretic drawal stable outpatient mild heart failure fluid retention receiving optimal doubleblind multicentre randomized eur heart j 20194036053612 147 cohn jn tognoni g valsartan heart failure investigator randomized angiotensinreceptor blocker valsartan chronic heart failure n engl j med 200134516671675 148 bohm borer j ford gonzalezjuanatey jr komajda lopezsendon j reil jc swedberg k tavazzi l heart rate baseline influence effect ivabradine cardiovascular outcome chronic heart failure analysis shift clin cardiol 20131021122 149 ouyang aj lv yn zhong hl wen jh wei xh peng hw zhou j liu metaanalysis digoxin use risk mortality patient atrial fibrilla tion j cardiol 2015115901906 150 vamos erath jw hohnloser sh digoxinassociated mortality systematic review metaanalysis literature eur heart j 20153618311838 151 ziff oj lane da samra griffith kirchhof p lip gy steed rp townend j kotecha safety efficacy digoxin systematic review metaanalysis observational controlled data bmj 2015351h4451 152 van gelder ic groenveld hf crijns hj tuininga tijssen jg alings hillege hl bergsmakadijk ja cornel jh kamp tukkie r bosker ha van veldhuisen dj van den berg mp race ii investigator lenient strict rate control patient atrial fibrillation n engl j med 201036213631373 153 bavishi c khan ar ather digoxin patient atrial fibrillation heart failure metaanalysis int j cardiol 201518899101 154 freeman jv reynolds k fang udaltsova n steimle pomernacki nk borowsky lh harrison tn singer de go digoxin risk death adult atrial fibrillation atriacvrn circ arrhythm electrophysiol 201584958 155 washam jb stevens sr lokhnygina halperin jl breithardt g singer de mahaffey kw hankey gj berkowitz sd nessel cc fox ka califf rm piccini jp patel mr rocket steering committee investigator digoxin use patient atrial fibrillation atrial fibrillation adverse cardiovascular outcome retro spective analysis rivaroxaban oral direct factor xa inhibition compared vitamin k antagonism prevention stroke embolism atrial fibrillation rocket af lancet 201538523632370 156 rathore curtis jp wang bristow mr krumholz hm association serum digoxin concentration outcome patient heart failure jama 2003289871878 157 adam kf jr patterson jh gattis wa o’connor cm lee cr schwartz ta gheorghiade relationship serum digoxin concentration mortality morbidity woman digitalis investigation group retrospective analysis j coll cardiol 200546497504 158 bavendiek u berliner davila la schwab j maier l philipp sa rieth westenfeld r piorkowski c weber k hanselmann oldhafer schallhorn von der leyen h schroder c veltmann c stork bohm koch bauersachs j digithf investigator committee rationale design digithf digitoxin improve outcome patient advanced chronic heart failure randomized doubleblind placebocontrolled eur j heart fail 201921676684 159 teerlink jr diaz r felker gm mcmurray jjv metra solomon sd adam kf anand ariasmendoza bieringsorensen bohm bonderman cleland jgf corbalan r crespoleiro dahlstrom u echeverria le fang jc filippatos g fonseca c goncalvesova e goudev ar howlett jg lanfear de li j lund macdonald p mareev v momomura si o’meara e parkhomenko ponikowski p ramires fja serpytis p sliwa k spinar j suter tm tomcsanyi j vandekerckhove h vinereanu voors aa yilmaz mb zannad f sharpsten l legg jc varin c honarpour n abbasi sa malik fi kurtz ce galactichf investigator cardiac myosin activation ome camtiv mecarbil systolic heart failure n engl j med 2021384105116 160 shen l jhund p petrie mc claggett bl barlera cleland jgf dargie hj granger cb kjekshus j kuˆ¡ber l latini r maggioni ap packer pitt b solomon sd swedberg k tavazzi l wikstrand j zannad f zile mr mcmurray jjv declining risk sudden death heart failure n engl j med 20173774151 161 bardy gh lee kl mark db poole je packer dl boineau r domanski troutman c anderson j johnson g mcnulty se clappchanning n davidsonray ld fraulo e fishbein dp luceri rm ip jh sudden cardiac death heart failure scdheft investigator amiodarone implantable cardioverterdefibrillator congestive heart failure n engl j med 2005352225237 162 connolly sj hallstrom ap cappato r schron eb kuck kh zipes dp greene hl boczor domanski follmann gent robert r investigator avid cash cid metaanalysis implantable cardi overter defibrillator secondary prevention eur heart j 20002120712078 163 antiarrhythmic implantable defibrillator avid investigator com parison antiarrhythmicdrug implantable defibrillator patient resuscitated nearfatal ventricular arrhythmia n engl j med 199733715761583 164 kuck kh cappato r siebels j ruppel r randomized comparison antiar rhythmic drug implantable defibrillator patient resuscitated cardiac arrest cardiac arrest hamburg cash circulation 2000102748754 165 moss aj zareba w hall wj klein h wilber dj cannom daubert jp higgins sl brown mw andrew multicenter automatic defibrillator implantation ii investigator prophylactic implantation defibrillator patient myocardial infarction reduced ejection fraction n engl j med 2002346877883 166 kober l thune jj nielsen jc haarbo j videbaek l korup e jensen g hildebrandt p steffensen fh bruun ne eiskjaer h brandes thogersen gustafsson f egstrup k videbaek r hassager c svendsen jh hofsten de torppedersen c pehrson danish investigator defibrillator implantation patient nonischemic systolic heart failure n engl j med 201637512211230 167 beggs sa jhund p jackson ce mcmurray jjv gardner r nonischaemic cardiomyopathy sudden death implantable defibrillator review metaanalysis heart 2018104144150 168 merchant fm jones p wehrenberg lloyd saxon la incidence defib rillator shock elective generator exchange following uneventful first bat tery life j heart assoc 20143e001289 169 yap sc schaer ba bhagwandien kuhne dabiri abkenari l osswald szilitorok sticherling c theuns da evaluation need elective implantable cardioverterdefibrillator generator replacement primary preven tion patient without prior appropriate icd heart 201410011881192 170 kini v soufi mk deo r epstein ae bala r riley groeneveld pw shalaby dixit appropriateness primary prevention implantable cardioverter defibrillator time generator replacement indication still met j coll cardiol 20146323882394 171 erkapic sperzel j stiller meltendorf u mermi j wegscheider k hugl b investigator longterm benefit implantable cardioverterdefibrillator ther apy elective device replacement result incidence free survival icd replacement insure trial–a prospective multicentre eur heart j 201334130137 172 alsheikhali aa homer maddukuri pv kalsmith b estes na 3rd link timedependence appropriate implantable defibrillator patient ischemic cardiomyopathy j cardiovasc electrophysiol 200819784789 173 opreanu wan c singh v salehi n ahmad j szymkiewicz sj thakur rk wearable cardioverterdefibrillator bridge cardiac transplantation national database analysis j heart lung transplant 20153413051309 174 zishiri et williams cronin em blackstone eh elli sg roselli ee smedira ng gillinov glad ja tchou pj szymkiewicz sj chung mk early risk mortality coronary artery revascularization patient left ventricular dysfunction potential role wearable cardioverter defibrillator circ arrhythm electrophysiol 20136117128 175 kutyifa v moss aj klein h biton mcnitt mackecknie b zareba w goldenberg use wearable cardioverter defibrillator highrisk cardiac patient data prospective registry patient using wearable cardioverter defibrillator wearitii registry circulation 201513216131619 176 kutyifa v moss aj klein hu mcnitt zareba w goldenberg oneyear followup prospective registry patient using wearable defibrillator wearitii registry pacing clin electrophysiol 20184113071313 177 hohnloser sh kuck kh dorian p robert r hampton jr hatala r fain e gent connolly sj dinamit investigator prophylactic use implant able cardioverterdefibrillator acute myocardial infarction n engl j med 200435124812488 178 steinbeck g andresen seidl k brachmann j hoffmann e wojciechowski kornacewiczjach z sredniawa b lupkovics g hofgartner f lubinski rosenqvist habets wegscheider k senges j iris investigator downloaded guest 24 november 2024 defibrillator implantation early myocardial infarction n engl j med 200936114271436 179 sander gd hlatky owen dk costeffectiveness implantable cardi overterdefibrillators n engl j med 200535314711480 180 steinberg ba alkhatib sm edward r han j bardy gh bigger jt buxton ae moss aj lee kl steinman r dorian p hallstrom cappato r kadish ah kudenchuk pj mark db inoue ly sander gd outcome implantable cardioverterdefibrillator use patient comorbidities result combined analysis randomized clinical jacc heart fail 20142623629 181 raphael ce finegold ja barron aj whinnett zi mayet j linde c cleland jg levy wc francis dp effect duration followup presence com peting risk lifespangain implantable cardioverter defibrillator benefit eur heart j 20153616761688 182 miller rj howlett jg exner dv campbell pm grant ad wilton sb baseline functional class therapeutic efficacy common heart failure intervention systematic review metaanalysis j cardiol 201531792799 183 hess pl alkhatib sm han jy edward r bardy gh bigger jt buxton cappato r dorian p hallstrom kadish ah kudenchuk pj lee kl mark db moss aj steinman r inoue ly sander g survival benefit primary prevention implantable cardioverterdefibrillator among older patient doe age matter analysis pooled data 5 clinical circ cardiovasc qual outcome 20158179186 184 connolly sj gent robert r dorian p roy sheldon r mitchell lb green klein gj o’brien b canadian implantable defibrillator cid randomized implantable cardioverter defibrillator amiodar one circulation 200010112971302 185 kober l torppedersen c mcmurray jj gotzsche levy crijns h amlie j carlsen j dronedarone group increased mortality dronedarone severe heart failure n engl j med 200835826782687 186 echt liebson pr mitchell lb peter rw obiasmanno barker ah arensberg baker friedman l greene hl mortality morbidity patient receiving encainide flecainide placebo cardiac arrhythmia suppression n engl j med 1991324781788 187 theuns da smith hunink bardy gh jordaens l effectiveness pro phylactic implantation cardioverterdefibrillators without cardiac resynchro nization patient ischaemic nonischaemic heart disease systematic review metaanalysis europace 20101215641570 188 elming mb nielsen jc haarbo j videbaek l korup e signorovitch j olesen hildebrandt p steffensen fh bruun ne eiskjaer h brandes thogersen gustafsson f egstrup k videbaek r hassager c svendsen jh hofsten de torppedersen c pehrson kober l thune jj age outcome pri mary prevention implantable cardioverterdefibrillators patient noni schemic systolic heart failure circulation 201713617721780 189 selvanayagam jb hartshorne billot l grover hillis g jung w krum h prasad mcgavigan ad cardiovascular magnetic resonanceguided manage ment mild moderate left ventricular systolic dysfunction cmr guide protocol randomized controlled ann noninvasive electrocardiol 201722e12420 190 leyva f zegard acquaye e gubran c taylor r foley pwx umar f patel k panting j marshall h qiu outcome cardiac resynchronization without defibrillation patient nonischemic cardiomyopathy j coll cardiol 20177012161227 191 di marco anguera schmitt klem neilan tg white ja sramko masci pg barison mckenna p mordi haugaa kh leyva f rodriguez capitan j satoh h nabeta dallaglio pd campbell ng sabate x cequier late gadolinium enhancement risk ventricular arrhythmia sudden death dilated cardiomyopathy systematic review metaanalysis jacc heart fail 201752838 192 gulati jabbour ismail tf guha k khwaja j raza morarji k brown td ismail na dweck mr di pietro e roughton wage r daryani o’hanlon r sheppard mn alpendurada f lyon ar cook sa cowie mr assomull rg pennell dj prasad sk association fibrosis mortality sudden cardiac death patient nonischemic dilated cardiomyopathy jama 2013309896908 193 stewart gc weintraub jr pratibhu pp semigran mj camuso jm brook k tsang sw anello nguyen vt lewis ef nohria desai givertz mm stevenson lw patient expectation implantable defibrillator prevent death heart failure j card fail 201016106113 194 moss aj schuger c beck ca brown mw cannom daubert jp estes na 3rd greenberg h hall wj huang dt kautzner j klein h mcnitt olshansky b shoda wilber zareba w maditrit investigator reduction inappropriate mortality icd programming n engl j med 201236722752283 195 healey j hohnloser sh glikson neuzner j mabo p vinolas x kautzner j o’hara g vanerven l gadler f pogue j appl u gilkerson j pochet stein km merkely b chrolavicius meeks b foldesi c thibault b connolly sj shockless implant evaluation investigator cardioverter defibrillator implanta tion without induction ventricular fibrillation singleblind noninferiority randomised controlled simple lancet 2015385785791 196 gasparini proclemer klersy c kloppe lunati ferrer jb hersi gulaj wijfels mc santi e manotta l arenal effect longdetection interval v standarddetection interval implantable cardioverterdefibrillators antitachycardia pacing shock delivery advance iii randomized clinical jama 201330919031911 197 cleland jg buga l device defibrillators–a shocking cardio myopathy nat rev cardiol 201076970 198 wilkoff bl cook jr epstein ae greene hl hallstrom ap hsia h kutalek sp sharma dual chamber vvi implantable defibrillator investigator dualchamber pacing ventricular backup pacing patient implant able defibrillator dual chamber vvi implantable defibrillator david jama 200228831153123 199 boersma l barr c knops r theuns eckardt l neuzil p scholten hood kuschyk j jones p duffy e husby stein k lambiase pd group ei implant midterm outcome subcutaneous implantable cardioverter defibrillator registry effortless j coll cardiol 201770830841 200 burke mc gold mr knight bp barr c theuns boersma lva knops weiss r leon ar herre jm husby stein km lambiase pd safety effi cacy totally subcutaneous implantable defibrillator 2year result pooled analysis ide effortless registry j coll cardiol 20156516051615 201 priori sg blomstromlundqvist c mazzanti blom n borggrefe camm j elliott pm fitzsimons hatala r hindricks g kirchhof p kjeldsen k kuck kh hernandezmadrid nikolaou n norekval tm spaulding c van veldhuisen dj esc scientific document group 2015 esc guideline management patient ventricular arrhythmia prevention sud den cardiac death task force management patient ventricular arrhythmia prevention sudden cardiac death european society cardiology esc endorsed association european paediatric congenital cardiology aepc eur heart j 20153627932867 202 knops olde nordkamp lra delnoy phm boersma lva kuschyk j el chami mf bonnemeier h behr er brouwer tf kaab mittal quast abe smeding l van der stuijt w de weger de wilde kc bijsterveld nr richter brouwer de groot jr kooiman km lambiase pd neuzil p vernooy k alings betts tr bracke f burke mc de jong j wright dj tijssen jgp wilde aam praetorian investigator subcutaneous trans venous defibrillator n engl j med 2020383526536 203 duncker konig hohmann bauersachs j veltmann c avoiding untimely implantable cardioverterdefibrillator implantation intensified heart failure optimization supported wearable cardioverterdefibrillator–the prolong j heart assoc 20176e004512 204 olgin je pletcher mj vittinghoff e wranicz j malik r morin dp zweibel buxton ae elayi c chung eh rashba e borggrefe hue tf maguire c lin f simon ja hulley lee bk vest investigator wearable cardioverter defibrillator myocardial infarction n engl j med 201837912051215 205 cazeau leclercq c lavergne walker varma c linde c garrigue kappenberger l haywood ga santini bailleul c daubert jc multisite stimulation cardiomyopathy mustic investigator effect multi site biventricular pacing patient heart failure intraventricular con duction delay n engl j med 2001344873880 206 cleland jg daubert jc erdmann e freemantle n gras kappenberger l tavazzi l cardiac resynchronizationheart failure carehf investigator effect cardiac resynchronization morbidity mortal ity heart failure n engl j med 200535215391549 207 daubert c gold mr abraham wt ghio hassager c goode g szilitorok linde c reverse group prevention disease progression car diac resynchronization patient asymptomatic mildly sympto matic left ventricular dysfunction insight european cohort reverse resynchronization revers remodeling systolic left ventricular dysfunction j coll cardiol 20095418371846 208 cleland jg daubert jc erdmann e freemantle n gras kappenberger l tavazzi l longerterm effect cardiac resynchronization mortal ity heart failure cardiac resynchronizationheart failure carehf extension phase eur heart j 20062719281932 209 cleland jg freemantle n erdmann e gras kappenberger l tavazzi l daubert jc longterm mortality cardiac resynchronization cardiac resynchronizationheart failure carehf eur j heart fail 201214628634 210 bristow mr saxon la boehmer j krueger kass da de marco carson p dicarlo l demets white bg devries dw feldman comparison medical pacing defibrillation heart failure companion investigator cardiacresynchronization without implantable downloaded guest 24 november 2024 defibrillator advanced chronic heart failure n engl j med 200435021402150 211 cleland jg abraham wt linde c gold mr young jb claude daubert j sherfesee l well ga tang individual patient metaanalysis five randomized assessing effect cardiac resynchronization morbidity mortality patient symptomatic heart failure eur heart j 20133435473556 212 tang well ga talajic arnold mo sheldon r connolly hohnloser sh nichol g birnie dh sapp jl yee r healey j rouleau jl resynchronizationdefibrillation ambulatory heart failure investigator cardiacresynchronization mildtomoderate heart failure n engl j med 201036323852395 213 moss aj hall wj cannom klein h brown mw daubert jp estes na 3rd foster e greenberg h higgins sl pfeffer solomon sd wilber zareba w maditcrt investigator cardiacresynchronization prevention heartfailure event n engl j med 200936113291338 214 goldenberg kutyifa v klein hu cannom brown mw dan daubert jp estes na 3rd foster e greenberg h kautzner j klempfner r kuniss merkely b pfeffer quesada viskin mcnitt polonsky b ghanem solomon sd wilber zareba w moss aj survival cardiac resynchronization mild heart failure n engl j med 201437016941701 215 linde c abraham wt gold mr st john sutton ghio daubert c reverse resynchronization revers remodeling systolic left ventricular dysfunction group randomized cardiac resynchronization mildly symptomatic heart failure patient asymptomatic patient left ventricular dysfunction previous heart failure symptom j coll cardiol 20085218341843 216 curtis ab worley sj adamson pb chung e niazi sherfesee l shinn sutton biventricular right ventricular pacing heart failure patient atrioventricular block block af investigator biventricular pacing atrioventricular block systolic dysfunction n engl j med 201336815851593 217 brignole botto g mont l iacopino de marchi g oddone luzi tolosana jm navazio menozzi c cardiac resynchronization patient undergoing atrioventricular junction ablation permanent atrial fibril lation randomized eur heart j 20113224202429 218 stavrakis garabelli p reynolds dw cardiac resynchronization atrioventricular junction ablation symptomatic atrial fibrillation metaanal ysis europace 20121414901497 219 leclercq c walker linde c clementy j marshall aj ritter p djiane p mabo p levy gadler f bailleul c daubert jc comparative effect per manent biventricular rightuniventricular pacing heart failure patient chronic atrial fibrillation eur heart j 20022317801787 220 wood b hawkins n mealing sutton abraham wt beshai jf klein h sculpher plummer cj cowie mr individual patient data network meta analysis mortality effect implantable cardiac device heart 201510118001806 221 gage rm burn kv bank aj echocardiographic clinical response car diac resynchronization heart failure patient without pre vious right ventricular pacing eur j heart fail 20141611991205 222 ruschitzka f abraham wt singh jp bax jj borer j brugada j dickstein k ford gorcsan j 3rd gras krum h sogaard p holzmeister j echocrt group cardiacresynchronization heart failure narrow qrs complex n engl j med 201336913951405 223 steffel j robertson singh jp abraham wt bax jj borer j dickstein k ford gorcsan j 3rd gras krum h sogaard p holzmeister j brugada j ruschitzka f effect qrs duration cardiac resynchronization patient narrow qrs complex subgroup analysis echocrt eur heart j 20153619831989 224 zusterzeel r selzman ka sander canos da o’callaghan km carpenter jl pina il strauss dg cardiac resynchronization woman u food drug administration metaanalysis patientlevel data jama intern med 201417413401348 225 sohaib sm finegold ja nijjer hossain r linde c levy wc sutton r kanagaratnam p francis dp whinnett zi opportunity increase life span narrow qrs cardiac resynchronization recipient deactivating ven tricular pacing evidence randomized controlled jacc heart fail 20153327336 226 greenberg h case rb moss aj brown mw carroll er andrew maditii investigator analysis mortality event multicenter automatic defibrillator implantation maditii j coll cardiol 20044314591465 227 linde c gold mr abraham wt st john sutton ghio cerkvenik j daubert c resynchronization revers remodeling systolic left ventricular dysfunction group longterm impact cardiac resynchronization mild heart failure 5year result resynchronization revers remodeling systolic left ventricular dysfunction reverse eur heart j 20133425922599 228 cleland jg mareev linde c reflection echocrt sound guidance qrs duration morphology crt eur heart j 20153619481951 229 linde c stahlberg benson l braunschweig f edner dahlstrom u alehagen u lund lh gender underutilization cardiac resynchronization prognostic impact qrs prolongation left bundle branch block heart failure europace 201517424431 230 cunnington c kwok c satchithananda dk patwala khan zaidi ahmed fz mama cardiac resynchronisation associated reduction mortality heart failure hospitalisation patient nonleft bundle branch block qrs morphology metaanalysis randomised controlled heart 201510114561462 231 doshi rn daoud eg fellow c turk k duran hamdan mh pires la pave group left ventricularbased cardiac stimulation post av nodal ablation evaluation pave j cardiovasc electrophysiol 20051611601165 232 koplan ba kaplan aj weiner jones pw seth christman sa heart fail ure decompensation allcause mortality relation percent biventricular pacing patient heart failure goal 100 biventricular pacing neces sary j coll cardiol 200953355360 233 hawkins nm petrie mc burgess mi mcmurray jj selecting patient cardiac resynchronization fallacy echocardiographic dyssynchrony j coll cardiol 20095319441959 234 beela unlu duchenne j ciarka daraban kotrc aarones szulik winter penicka neskovic kukulski aakhus willems r fehske w faber l stankovic voigt ju assessment mechanical dyssyn chrony improve prognostic value guidelinebased patient selection cardiac resynchronization eur heart j cardiovasc imaging 2019206674 235 khan fz virdee palmer cr pugh pj o’halloran elsik read pa begley fynn sp dutka dp targeted left ventricular lead placement guide cardiac resynchronization target randomized con trolled j coll cardiol 20125915091518 236 saba marek j schwartzman jain adelstein e white p oyenuga oa onishi soman p gorcsan j 3rd echocardiographyguided left ventricular lead placement cardiac resynchronization result speckle tracking assisted resynchronization electrode region circ heart fail 20136427434 237 kosmala w marwick th metaanalysis effect optimization cardiac resynchronization left ventricular function exercise capacity quality life patient heart failure j cardiol 2014113988994 238 whinnett zi francis dp denis willson k pascale p van geldorp de guillebon ploux ellenbogen k haissaguerre ritter p bordachar p comparison different invasive hemodynamic method av delay optimiza tion patient cardiac resynchronization implication clinical design clinical practice int j cardiol 201316822282237 239 daubert c behar n martin rp mabo p leclercq c avoiding non responder cardiac resynchronization practical guide eur heart j 20173814631472 240 mullens w auricchio marten p witte k cowie mr delgado v dickstein k linde c vernooy k leyva f bauersachs j israel cw lund lh donal e boriani g jaarsma berruezo traykov v yousef z kalarus z cosedis nielsen j steffel j vardas p coat seferovic p edvardsen heidbuchel h ruschitzka f leclercq c optimized implementation cardiac resynchroniza tion call action referral optimization care joint posi tion statement heart failure association hfa european heart rhythm association ehra european association cardiovascular imaging eacvi european society cardiology eur j heart fail 20202223492369 240aglikson nielsen jc michowitz kronborg mb auricchio barbash im barrabe´s ja boriani g braunschweig f brignole burri h coat ajs deharo jc delgado v diller gp israel cw keren knops kotecha leclercq c merkely b starck c thyle´n tolosana jm esc scientific document group 2021 esc guideline cardiac pacing cardiac resynch ronization eur heart j 2021 doi 10.1093eurheartjehab364 epub ahead print 241 abraham wt kuck kh goldsmith rl lindenfeld j reddy vy carson pe mann dl saville b parise h chan r wiegn p hastings jl kaplan aj edelmann f luthje l kahwash r tomassoni gf gutterman dd stagg burkhoff hasenfuss g randomized controlled evaluate safety efficacy cardiac contractility modulation jacc heart fail 20186874883 242 nice national institute health care excellence interventional proce dures guidance cardiac contractility modulation device implantation heart failure 28 may 2021 downloaded guest 24 november 2024 243 abraham wt zile mr weaver fa butter c ducharme halbach klug lovett eg mullerehmsen j schafer je senni swarup v wachter r little wc baroreflex activation heart failure reduced ejection fraction jacc heart fail 20153487496 244 zile mr lindenfeld j weaver fa zannad f galle e rogers abraham wt baroreflex activation patient heart failure reduced ejec tion fraction j coll cardiol 202076113 245 yusuf pfeffer swedberg k granger cb held p mcmurray jj michelson el olofsson b ostergren j charm investigator committee effect candesartan patient chronic heart failure preserved leftventricular ejection fraction charmpreserved lancet 2003362777781 246 pitt b pfeffer assmann sf boineau r anand claggett b clausell n desai diaz r fleg jl gordeev harty b heitner jf kenwood ct lewis ef o’meara e probstfield jl shaburishvili shah sj solomon sd sweitzer nk yang mckinlay sm topcat investigator spironolactone heart fail ure preserved ejection fraction n engl j med 201437013831392 247 solomon sd vaduganathan claggett bl packer zile swedberg k rouleau j pfeffer desai lund lh kober l anand sweitzer n linssen g merkely b luis arango j vinereanu chen ch senni sibulo boytsov shi v rizkala lefkowitz mcmurray jjv sacubitrilvalsartan across spectrum ejection fraction heart failure circulation 2020141352361 248 rogers jk pocock sj mcmurray jj granger cb michelson el ostergren j pfeffer solomon sd swedberg k yusuf analysing recurrent hospitaliza tions heart failure review statistical methodology application charmpreserved eur j heart fail 2014163340 249 van veldhuisen dj cohensolal bohm anker sd babalis roughton coat aj poolewilson pa flather md senior investigator betablockade nebivolol elderly heart failure patient impaired preserved left ventricular ejection fraction data senior effect nebivolol intervention outcome rehospitalization senior heart failure j coll cardiol 20095321502158 250 hai oy mentz rj zannad f gasparini de ferrari gm daubert jc holzmeister j lam c pochet vincent linde c cardiac resynchroniza tion heart failure patient less severe left ventricular dysfunc tion eur j heart fail 201517135143 251 shah sj feldman ricciardi mj kahwash r lilly litwin nielsen cd van der harst p hoendermis e penicka bartunek j fail p kaye dm walton petrie mc walker n basuray yakubov hummel sl chetcuti forde mclean r herrmann hc burkhoff massaro jm cleland jgf mauri l one year safety clinical outcome transcatheter interatrial shunt device heart failure preserved ejection fraction reduce elevated left atrial pressure patient heart failure reduce laphf randomized clinical jama cardiol 20183968977 252 pfeffer swedberg k granger cb held p mcmurray jj michelson el olofsson b ostergren j yusuf pocock charm investigator committee effect candesartan mortality morbidity patient chronic heart failure charmoverall programme lancet 2003362759766 253 dewan p jackson lam csp pfeffer zannad f pitt b solomon sd mcmurray jjv interaction left ventricular ejection fraction sex effect neurohumoral modulators heart failure eur j heart fail 202022898901 254 campbell rt petrie mc mcmurray jjv redefining heart failure phenotype based ejection fraction eur j heart fail 20182016341635 255 echocardiographic normal range metaanalysis left heart collaboration ethnicspecific normative value echocardiographic la lv size lv mass systolic function echonormal jacc cardiovasc imaging 20158656665 256 wehner gj jing l haggerty cm suever jd leader jb hartzel dn kirchner hl manus jna james n ayar z gladding p good cw cleland jgf fornwalt bk routinely reported ejection fraction mortality clinical prac tice doe nadir risk lie eur heart j 20204112491257 257 stewart playford scalia gm currie p celermajer prior codde j strange g neda investigator ejection fraction mortality nationwide registerbased cohort 499 153 woman men eur j heart fail 202123406416 258 borlaug ba evaluation management heart failure preserved ejection fraction nat rev cardiol 202017559573 259 pieske b tschope c de boer ra fraser ag anker sd donal e edelmann f fu guazzi lam csp lancellotti p melenovsky v morris da nagel e pieskekraigher e ponikowski p solomon sd vasan r rutten fh voors aa ruschitzka f paulus wj seferovic p filippatos g diagnose heart failure preserved ejection fraction hfapeff diagnostic algo rithm consensus recommendation heart failure association hfa european society cardiology esc eur heart j 20194032973317 260 ho je zern ek wooster l bailey c cunningham eisman hardin km zampierollo ga jarolim p pappagianopoulos pp malhotra r nayor lewis gd differential clinical profile exercise response outcome associated existing hfpef definition circulation 2019140353365 261 reddy ynv carter obokata redfield mm borlaug ba simple evidencebased approach help guide diagnosis heart failure preserved ejection fraction circulation 2018138861870 262 segar mw patel kv berry jd grodin jl pandey generalizability impli cation h2fpef score cohort patient heart failure pre served ejection fraction circulation 201913918511853 263 myhre pl vaduganathan claggett bl lam csp desai anand sweitzer nk fang jc o’meara e shah sj shah lewis ef rouleau j pitt b solomon sd application h2 fpef score global clinical patient heart failure preserved ejection fraction topcat eur j heart fail 20192112881291 264 sepehrvand n alemayehu w dyck gjb dyck jrb anderson howlett j paterson mcalister fa ezekowitz ja external validation h2fpef model diagnosing patient heart failure preserved ejection fraction circulation 201913923772379 265 sueta yamamoto e nishihara tokitsu fujisue k oike f takae usuku h takashio arima suzuki nakamura ito kanazawa h sakamoto k kaikita k tsujita k h2fpef score prognostic value hfpef patient j hypertens 20193210821090 266 barandiaran aizpurua sandersvan wijk brunnerla rocca hp henkens heymans beussinknelson l shah sj van empel vpm validation hfapeff score diagnosis heart failure preserved ejection frac tion eur j heart fail 202022413421 267 sandersvan wijk barandiaran aizpurua brunnerla rocca hp henkens weerts j knackstedt c uszkolencer n heymans van empel v hfapeff h2 fpef score largely disagree classifying patient sus pected heart failure preserved ejection fraction eur j heart fail 202123838840 268 selvaraj myhre pl vaduganathan claggett bl matsushita k kitzman dw borlaug ba shah solomon sd application diagnostic algorithm heart failure preserved ejection fraction community jacc heart fail 20208640653 269 ouwerkerk w tromp j jin x jaufeerally f yeo psd leong ktg ong hy ling lh loh sy sim lee soon chin c richards lam csp heart failure preserved ejection fraction diagnostic score asian population eur j heart fail 20202217371739 270 playford strange g celermajer evans g scalia gm stewart prior neda investigator diastolic dysfunction mortality 436 360 men woman national echo database australia neda eur heart j cardiovasc imaging 202122505515 271 halliday bp wassall r lota khalique z gregson j newsome jackson r rahneva wage r smith g venneri l tayal u auger midwinter w whiffin n rajani r dungu jn pantazis cook sa ware j baksi aj pennell dj rosen sd cowie mr cleland jgf prasad sk withdrawal pharmacological heart failure patient recovered dilated cardiomyopathy tredhf openlabel pilot randomised lancet 20193936173 272 lupon j gavidiabovadilla g ferrer e de antonio pereralluna lopez ayerbe j domingo nunez j zamora e moliner p santiagovacas e santesmases j bayesgenis heart failure preserved ejection fraction infrequently evolves toward reduced phenotype longterm survivor circ heart fail 201912e005652 273 savarese g vedin d’amario uijl dahlstrom u rosano g lam csp lund lh prevalence prognostic implication longitudinal ejection frac tion change heart failure jacc heart fail 20197306317 274 nauta jf hummel ym van der meer p lam csp voors aa van melle jp correlation invasive left ventricular filling pressure prognostic rele vance echocardiographic diastolic parameter used 2016 esc heart failure guideline 2016 aseeacvi recommendation sys tematic review patient heart failure preserved ejection fraction eur j heart fail 20182013031311 275 sharifov schiros cg aban denney gupta h diagnostic accuracy tissue doppler index ee’ evaluating left ventricular filling pressure dia stolic dysfunctionheart failure preserved ejection fraction systematic review metaanalysis j heart assoc 20165e002078 276 eisman shah rv dhakal bp pappagianopoulos pp wooster l bailey c cunningham tf hardin km baggish al ho je malhotra r lewis gd pulmonary capillary wedge pressure pattern exercise predict exercise capacity incident heart failure circ heart fail 201811e004750 downloaded guest 24 november 2024 277 cleland jg tendera adamus j freemantle n gray c lye o’mahony polonski l taylor j perindopril elderly people chronic heart failure pepchf pep investigator eur j heart fail 19991211217 278 massie bm carson pe mcmurray jj komajda mckelvie r zile mr anderson donovan iverson e staiger c ptaszynska ipreserve investigator irbesartan patient heart failure preserved ejection fraction n engl j med 200835924562467 279 ahmed rich mw fleg jl zile mr young jb kitzman dw love te aronow w adam kf jr gheorghiade effect digoxin morbidity mortality diastolic heart failure ancillary digitalis investigation group circulation 2006114397403 280 redfield mm anstrom kj levine ja koepp ga borlaug ba chen hh lewinter mm joseph sm shah sj semigran mj felker gm cole rt reef gr tedford rj tang wh mcnulty se velazquez ej shah mr braunwald e nhlbi heart failure clinical research network isosorbide mononitrate heart failure preserved ejection fraction n engl j med 201537323142324 281 borlaug ba anstrom kj lewis gd shah sj levine ja koepp ga givertz mm felker gm lewinter mm mann dl margulies kb smith al tang whw whellan dj chen hh davilaroman vg mcnulty desvignenickens p hernandez af braunwald e redfield mm national heart lung blood institute heart failure clinical research network effect inorganic nitrite v placebo exercise capacity among patient heart failure preserved ejection fraction indiehfpef randomized clinical jama 201832017641773 282 armstrong pw lam csp anstrom kj ezekowitz j hernandez af o’connor cm pieske b ponikowski p shah sj solomon sd voors aa l vlajnic v carvalho f bamber l blaustein ro roessig l butler j vitalityhfpef group effect vericiguat v placebo quality life patient heart failure preserved ejection fraction vitalityhfpef randomized clinical jama 202032415121521 283 udelson je lewis gd shah sj zile mr redfield mm burnett j jr parker j seferovic jp wilson p mittleman r profy konstam effect pralici guat peak rate oxygen consumption patient heart failure preserved ejection fraction capacity hfpef randomized clinical jama 202032415221531 284 omar w pandey haykowsky mj berry jd lavie cj evolving role cardiorespiratory fitness exercise prevention management heart failure curr heart fail rep 2018157580 285 kitzman dw upadhya b reef g hospitalization prognosis elderly patient heart failure preserved ejection fraction time treat whole patient jacc heart fail 20153442444 286 wood kaptoge butterworth willeit p warnakula bolton paige e paul sweeting burgess bell astle w stevens koulman selmer rm verschuren wmm sato njolstad woodward salomaa v nordestgaard bg yeap bb fletcher melander kuller lh balkau b marmot koenig w casiglia e cooper c arndt v franco oh wennberg p gallacher j de la camara ag volzke h dahm cc dale ce bergmann mm crespo cj van der schouw yt kaaks r simon la lagiou p schoufour jd boer jma key tj rodriguez b morenoiribas c davidson kw taylor jo sacerdote c wallace rb quiros jr tumino r blazer dg 2nd linneberg daimon panico howard b skeie g strandberg weiderpass e nietert pj psaty bm kromhout salamancafernandez e kiechl krumholz hm grioni palli huerta jm price j sundstrom j arriola l arima h travis rc panagiotakos db karakatsani trichopoulou kuhn grobbee de barrettconnor e van schoor n boeing h overvad k kauhanen j wareham n langenberg c forouhi n wennberg despres jp cushman cooper ja rodriguez cj sakurai shaw je knuiman voortman meisinger c tjonneland brenner h palmieri l dallongeville j brunner ej assmann g trevisan gillum rf ford sattar n lazo thompson sg ferrari p leon da smith gd peto r jackson r bank e di angelantonio e danesh j emerging risk factor collaborationepiccvduk biobank alcohol group risk threshold alcohol consumption combined analysis individualparticipant data 599 912 current drinker 83 prospective stud lancet 201839115131523 287 kostis jb davis br cutler j grimm rh jr berge kg cohen jd lacy cr perry hm jr blaufox md wassertheilsmoller black hr schron e berkson dm curb jd smith wm mcdonald r applegate wb prevention heart failure antihypertensive drug older person iso lated systolic hypertension shep cooperative research group jama 1997278212216 288 group sr wright jt jr williamson jd whelton pk snyder jk sink km rocco mv reboussin dm rahman oparil lewis ce kimmel pl johnson kc goff dc jr fine lj cutler ja cushman wc cheung ak ambrosius wt randomized intensive standard bloodpressure control n engl j med 201537321032116 289 sciarretta palano f tocci g baldini r volpe antihypertensive development heart failure hypertension bayesian network meta analysis patient hypertension high cardiovascular risk arch intern med 2011171384394 290 beckett n peter r fletcher ae staessen ja liu l dumitrascu stoyanovsky v antikainen rl nikitin anderson c belhani forette f rajkumar c thijs l banya w bulpitt cj hyvet group hypertension patient 80 year age older n engl j med 200835818871898 291 scirica bm morrow da cannon cp ray kk sabatine jarolim p shui mccabe ch braunwald e prove ittimi investigator intensive statin ther apy risk hospitalization heart failure acute coronary syn drome prove ittimi 22 j coll cardiol 20064723262331 292 kjekshus j pedersen tr olsson ag faergeman pyorala k effect simvastatin incidence heart failure patient coronary heart dis ease j card fail 19973249254 293 zinman b wanner c lachin jm fitchett bluhmki e hantel mattheus devins johansen oe woerle hj broedl uc inzucchi se empareg outcome investigator empagliflozin cardiovascular outcome mortal ity type 2 diabetes n engl j med 201537321172128 294 neal b perkovic v mahaffey kw de zeeuw fulcher g erondu n shaw w law g desai matthew dr canvas program collaborative group canagliflozin cardiovascular renal event type 2 diabetes n engl j med 2017377644657 295 wiviott sd raz bonaca mp mosenzon kato et cahn silverman zelniker ta kuder jf murphy sa bhatt dl leiter la mcguire dk wilding jph ruff ct gausenilsson iam fredriksson johansson pa langkilde sabatine declaretimi 58 investigator dapagliflozin cardiovascular outcome type 2 diabetes n engl j med 2019380347357 296 bhatt dl szarek pitt b cannon cp leiter la mcguire dk lewis jb riddle mc inzucchi se kosiborod mn cherney dzi dwyer jp scirica bm bailey cj diaz r ray kk udell ja lope rd lapuerta p steg pg scored investigator sotagliflozin patient diabetes chronic kidney disease n engl j med 2020384129139 297 cannon cp pratley r dagogojack mancuso j huyck masiukiewicz u charbonnel b frederich r gallo cosentino f shih wj gantz terra sg cherney dzi mcguire dk vertis cardiovascular investigator cardiovascular outcome ertugliflozin type 2 diabetes n engl j med 202038314251435 298 suskin n sheth negassa yusuf relationship current past smok ing mortality morbidity patient left ventricular dysfunction j coll cardiol 20013716771682 299 dorans k mostofsky e levitan eb hakansson n wolk mittleman alcohol incident heart failure among middleaged elderly men cohort swedish men circ heart fail 20158422427 300 goncalves claggett b jhund p rosamond w deswal aguilar shah cheng solomon sd alcohol consumption risk heart failure atherosclerosis risk community eur heart j 201536939945 301 pandey garg khunger darden ayers c kumbhani dj mayo hg de lemos ja berry jd doseresponse relationship physical activity risk heart failure metaanalysis circulation 201513217861794 302 padwal r mcalister fa mcmurray jj cowie mr rich pocock swedberg k maggioni gamble g ariti c earle n whalley g poppe kk doughty rn bayesgenis metaanalysis global group chronic heart failure maggic obesity paradox heart failure patient preserved reduced ejection fraction metaanalysis individual patient data int j obes lond 20143811101114 303 mcdonagh ta blue l clark al dahlstrom u ekman lainscak mcdonald k ryder stromberg jaarsma european society cardiology heart failure association committee patient care european society cardiology heart failure association standard delivering heart failure care eur j heart fail 201113235241 304 lainscak blue l clark al dahlstrom u dickstein k ekman mcdonagh mcmurray jj ryder stewart stromberg jaarsma selfcare manage ment heart failure practical recommendation patient care committee heart failure association european society cardiology eur j heart fail 201113115126 305 mebazaa yilmaz mb levy p ponikowski p peacock wf laribi ristic ad lambrinou e masip j riley jp mcdonagh mueller c defilippi c harjola vp thiele h piepoli mf metra maggioni mcmurray jj dickstein k damman k seferovic pm ruschitzka f leitemoreira af bellou anker sd filippatos g recommendation prehospital early hospital management acute heart failure consensus paper heart failure association european society cardiology european society emergency medicine downloaded guest 24 november 2024 society academic emergency medicine–short version eur heart j 20153619581966 306 mcdonagh ta gardner r lainscak nielsen ow parissis j filippatos g anker sd heart failure association european society cardiology specialist heart failure curriculum eur j heart fail 201416151162 307 riley jp astin f crespoleiro deaton cm kienhorst j lambrinou e mcdonagh ta rushton ca stromberg filippatos g anker sd heart failure association european society cardiology heart failure nurse curriculum eur j heart fail 201618736743 308 van spall hgc rahman mytton ramasundarahettige c ibrahim q kabali c coppens brian haynes r connolly comparative effectiveness transitional care service patient discharged hospital heart failure systematic review network metaanalysis eur j heart fail 20171914271443 309 jonkman nh westland h groenwold rh agren anguita blue l brugginkandre de la porte pw dewalt da hebert pl heisler jaarsma kempen gi leventhal lok dj martensson j muniz j otsu h peter klimm f rich mw riegel b stromberg tsuyuki rt trappenburg jc schuurmans mj hoe aw effective program characteristic self management intervention patient heart failure individual patient data metaanalysis j card fail 201622861871 310 takeda martin n taylor r taylor sj disease management intervention heart failure cochrane database syst rev 20191cd002752 311 kalogirou f forsyth f kyriakou mantle r deaton c heart failure disease management systematic review effectiveness heart failure pre served ejection fraction esc heart fail 20207194212 312 hill l prager geller baruah r beattie jm boyne j de stoutz n di stolfo g lambrinou e skibelund ak uchmanowicz rutten fh celutkiene j piepoli mf jankowska ea chioncel ben gal seferovic pm ruschitzka f coat ajs stromberg jaarsma integration palliative approach heart fail ure care european society cardiology heart failure association position paper eur j heart fail 20202223272339 313 kyriakou middleton n ktisti philippou k lambrinou e supportive care intervention promote healthrelated quality life patient living heart failure systematic review metaanalysis heart lung circ 20202916331647 314 feltner c jones cd cene cw zheng zj sueta ca cokerschwimmer ej arvanitis lohr kn middleton jc jonas de transitional care intervention prevent readmission person heart failure systematic review metaanalysis ann intern med 2014160774784 315 blue l lang e mcmurray jj davie ap mcdonagh ta murdoch dr petrie mc connolly e norrie j round ce ford morrison ce randomised con trolled specialist nurse intervention heart failure bmj 2001323715718 316 lambrinou e kalogirou f lamnisos sourtzi p effectiveness heart failure management programme nurseled discharge planning reducing admission systematic review metaanalysis int j nurs stud 201249610624 317 stewart vandenbroek aj pearson horowitz jd prolonged beneficial effect homebased intervention unplanned readmission mortality among patient congestive heart failure arch intern med 1999159257261 318 ekman wolf olsson le taft c dudas k schaufelberger swedberg k effect personcentred care patient chronic heart failure pcc heart failure eur heart j 20123311121119 319 riegel b bennett ja davis carlson b montague j robin h glaser cognitive impairment heart failure issue measurement etiology j crit care 200211520528 320 laufs u rettigewen v bohm strategy improve drug adherence eur heart j 201132264268 321 abraityte aukrust p kou l anand young j mcmurray jjv van veldhuisen dj gullestad l ueland cell monocytemacrophage activation marker associate adverse outcome give limited prognostic value anemic patient heart failure result redhf clin cardiol 2019108133141 322 flynn ke pina il whellan dj lin l blumenthal ja elli sj fine lj howlett jg keteyian sj kitzman dw kraus miller nh schulman ka spertus ja o’connor cm weinfurt kp hfaction investigator effect exercise training health status patient chronic heart failure hfaction randomized controlled jama 200930114511459 323 o’connor cm whellan dj lee kl keteyian sj cooper l elli sj leifer e kraus kitzman dw blumenthal ja rendall miller nh fleg jl schulman ka mckelvie r zannad f pina il hfaction investigator efficacy safety exercise training patient chronic heart failure hf action randomized controlled jama 200930114391450 324 taylor r walker smart na piepoli mf warren fc ciani whellan o’connor c keteyian sj coat davos ch dalal hm dracup k evangelista l jolly k myers j nilsson bb passino c witham md yeh gy extramatch ii collaboration impact exercise rehabilitation exercise capacity qualityoflife heart failure individual participant metaanalysis j coll cardiol 20197314301443 325 taylor r walker smart na piepoli mf warren fc ciani o’connor c whellan keteyian sj coat davos ch dalal hm dracup k evangelista l jolly k myers j mckelvie r nilsson bb passino c witham md yeh gy zwisler ao extramatch ii collaboration impact exercisebased cardiac rehabilitation patient heart failure extramatch ii mortality hospitalisation individual patient data metaanalysis randomised eur j heart fail 20182017351743 326 pandey parashar kumbhani agarwal garg j kitzman levine b drazner berry j exercise training patient heart failure preserved ejection fraction metaanalysis randomized control circ heart fail 201583340 327 taylor r long l mordi ir madsen mt davy ej dalal h rees k singh sj gluud c zwisler ad exercisebased rehabilitation heart failure cochrane systematic review metaanalysis sequential analysis jacc heart fail 20197691705 328 taylor r walker ciani warren f smart na piepoli davos ch exercisebased cardiac rehabilitation chronic heart failure extramatch ii individual participant data metaanalysis health technol assess 201923198 329 cooper lb mentz rj sun jl schulte pj fleg jl cooper l pina il leifer e kraus whellan dj keteyian sj o’connor cm psychosocial factor exer cise adherence outcome heart failure patient insight heart failure controlled investigating outcome exercise training hf action circ heart fail 2015810441051 330 gomes neto duraes ar conceicao lsr saquetto mb ellingsen carvalho vo high intensity interval training moderate intensity continu ous training exercise capacity quality life patient heart failure reduced ejection fraction systematic review metaanalysis int j cardiol 2018261134141 331 ellingsen halle conraads v stoylen dalen h delagardelle c larsen ai hole mezzani van craenenbroeck em videm v beckers p christle jw winzer e mangner n woitek f hollriegel r pressler monkhansen snoer feiereisen p valborgland kjekshus j hambrecht r gielen karlsen prescott e linke smartex heart failure group high intensity interval training patient heart failure reduced ejection fraction circulation 2017135839849 332 edelmann f gelbrich g dungen hd frohling wachter r stahrenberg r binder l topper lashki dj schwarz herrmannlingen c loffler hasenfuss g halle pieske b exercise training improves exercise capacity diastolic function patient heart failure preserved ejection frac tion result exdhf exercise training diastolic heart failure pilot j coll cardiol 20115817801791 333 nolte k herrmannlingen c wachter r gelbrich g dungen hd duvinage hoischen n von oehsen k schwarz hasenfuss g halle pieske b edelmann f effect exercise training different quality life dimension heart failure preserved ejection fraction exdhfp eur j prev cardiol 201522582593 334 ismail h mcfarlane jr nojoumian ah dieberg g smart na clinical come cardiovascular response different exercise training intensity patient heart failure systematic review metaanalysis jacc heart fail 20131514522 335 kitzman dw brubaker ph herrington dm morgan tm stewart kp hundley wg abdelhamed haykowsky mj effect endurance exercise training endothelial function arterial stiffness older patient heart failure preserved ejection fraction randomized controlled singleblind j coll cardiol 201362584592 336 ismail h mcfarlane j smart na exercise training beneficial heart failure patient taking betaadrenergic blocker systematic review metaanalysis congest heart fail 2013196169 337 kitzman dw brubaker p morgan haykowsky hundley g kraus eggebeen j nicklas bj effect caloric restriction aerobic exercise training peak oxygen consumption quality life obese older patient heart failure preserved ejection fraction randomized clinical jama 20163153646 338 taylor r sagar va davy ej briscoe coat aj dalal h lough f rees k singh exercisebased rehabilitation heart failure cochrane database syst rev 2014cd003331 339 schou gustafsson f videbaek l tuxen c keller n handberg j sejr knudsen espersen g markenvard j egstrup k ulriksen h hildebrandt pr downloaded guest 24 november 2024 northstar investigator member danish heart failure clinic network extended heart failure clinic followup lowrisk patient random ized clinical northstar eur heart j 201334432442 340 thorvaldsen benson l dahlstrom u edner lund lh use evidence based survival heart failure sweden 20032012 eur j heart fail 201618503511 341 lund lh braunschweig f benson l stahlberg dahlstrom u linde c association demographic organizational clinical socioeconomic characteristic underutilization cardiac resynchronization result swedish heart failure registry eur j heart fail 20171912701279 342 savarese g carrero jj pitt b anker sd rosano gmc dahlstrom u lund lh factor associated underuse mineralocorticoid receptor antagonist heart failure reduced ejection fraction analysis 11 215 patient swedish heart failure registry eur j heart fail 20182013261334 343 lund lh carrero jj farahmand b henriksson km jonsson jernberg dahlstrom u association enrolment heart failure quality registry subsequent mortality–a nationwide cohort eur j heart fail 20171911071116 344 clark al goode k cleland jg prevalence incidence left bundle branch block ambulant patient chronic heart failure eur j heart fail 200810696702 345 troughton rw frampton cm yandle tg espiner ea nicholls richards heart failure guided plasma aminoterminal brain natriu retic peptide nbnp concentration lancet 200035511261130 346 berger r moertl peter ahmadi r huelsmann yamuti wagner b pacher r nterminal probtype natriuretic peptideguided intensive patient management addition multidisciplinary care chronic heart failure 3 arm prospective randomized pilot j coll cardiol 201055645653 347 jourdain p jondeau g funck f gueffet p le helloco donal e aupetit jf aumont mc galinier eicher jc cohensolal juilliere plasma brain natriuretic peptideguided improve outcome heart failure starsbnp multicenter j coll cardiol 20074917331739 348 lainchbury jg troughton rw strangman km frampton cm pilbrow yandle tg hamid ak nicholls richards nterminal probtype natriuretic peptideguided chronic heart failure result battlescarred ntprobnpassisted lessen serial cardiac readmission death j coll cardiol 2009555360 349 pfisterer buser p rickli h gutmann erne p rickenbacher p vuillomenet jeker u dubach p beer h yoon si suter osterhues hh schieber mm hilti p schindler r brunnerla rocca hp timechf investigator bnpguided v symptomguided heart failure intensified v standard medical elderly patient congestive heart failure timechf randomized jama 2009301383392 350 felker gm anstrom kj adam kf ezekowitz ja fiuzat houstonmiller n januzzi jl jr mark db pina il passmore g whellan dj yang h cooper l leifer e desvignenickens p o’connor cm effect natriuretic peptide guided hospitalization cardiovascular mortality highrisk patient heart failure reduced ejection fraction randomized clinical jama 2017318713720 351 porapakkham p porapakkham p zimmet h billah b krum h btype natriu retic peptideguided heart failure metaanalysis arch intern med 2010170507514 352 troughton rw frampton cm brunnerla rocca hp pfisterer eurlings lw erntell h persson h o’connor cm moertl karlstrom p dahlstrom u gaggin hk januzzi jl berger r richards pinto ym nicholls effect btype natriuretic peptideguided chronic heart failure total mortality hospitalization individual patient metaanalysis eur heart j 20143515591567 353 anand fisher ld chiang yt latini r masson maggioni ap glazer rd tognoni g cohn jn valheft investigator change brain natriuretic pep tide norepinephrine time mortality morbidity valsartan heart failure valheft circulation 200310712781283 354 zile mr claggett bl prescott mf mcmurray jj packer rouleau jl swedberg k desai gong j shi vc solomon sd prognostic implication change nterminal probtype natriuretic peptide patient heart fail ure j coll cardiol 20166824252436 355 brahmbhatt dh cowie mr remote management heart failure overview telemonitoring technology card fail rev 201958692 356 cleland jg clark ra pellicori p inglis sc caring people heart failure many medical problem beyond covid19 pan demic advantage universal access home telemonitoring eur j heart fail 202022995998 357 inglis sc clark ra dierckx r prietomerino cleland jg structured tele phone support noninvasive telemonitoring patient heart failure heart 2017103255257 358 frederix caiani eg dendale p anker bax j bohm cowie crawford j de groot n dilaveris p hansen koehler f krstacic g lambrinou e lancellotti p meier p neubeck l parati g piotrowicz e tubaro van der velde e esc ecardiology working group position paper overcoming chal lenges digital health implementation cardiovascular medicine eur j prev cardiol 20192611661177 359 lin mh yuan wl huang tc zhang hf mai jt wang jf clinical effectiveness telemedicine chronic heart failure systematic review metaanalysis j investig med 201765899911 360 adamson pb ginn g anker sd bourge rc abraham wt remote haemodynamicguided care patient chronic heart failure meta analysis completed eur j heart fail 201719426433 361 chaudhry si mattera ja curtis jp spertus ja herrin j lin z phillips co hodshon bv cooper l krumholz hm telemonitoring patient heart failure n engl j med 201036323012309 362 koehler f winkler schieber sechtem u stangl k bohm boll h baumann g honold koehler k gelbrich g kirwan ba anker sd telemedical interventional monitoring heart failure investigator impact remote telemedical management mortality hospitalization ambula tory patient chronic heart failure telemedical interventional monitor ing heart failure circulation 201112318731880 363 koehler f koehler k deckwart prescher wegscheider k winkler vettorazzi e polze stangl k hartmann marx neuhaus p scherf kirwan ba anker sd telemedical interventional management heart failure ii timhf2 randomised controlled investigating impact telemedi cine unplanned cardiovascular hospitalisation mortality heart failure patient design description intervention eur j heart fail 20182014851493 364 koehler f koehler k deckwart prescher wegscheider k kirwan ba winkler vettorazzi e bruch l oeff zugck c doerr g naegele h stork butter c sechtem u angermann c gola g prondzinsky r edelmann f spethmann schellong sm schulze pc bauersachs j wellge b schoebel c tajsic dreger h anker sd stangl k efficacy telemedical interventional management patient heart failure timhf2 randomised controlled parallelgroup unmasked lancet 201839210471057 365 kalterleibovici freimark freedman l kaufman g ziv murad h benderly silverman bg friedman n cukiermanyaffe asher e grupper goldman amitai matetzky shani silber h israel heart failure disease management investigator disease management patient chronic heart failure universal access health care randomized controlled bmc med 20171590 366 jayaram nm khariton krumholz hm chaudhry si mattera j tang f herrin j hodshon b spertus ja impact telemonitoring health status circ cardiovasc qual outcome 201710e004148 367 shochat mk shotan blondheim kazatsker dahan asif rozenman kleiner weinstein jm frimerman vasilenko l meisel sr noninvasive lung impedanceguided preemptive chronic heart failure patient randomized controlled impedancehf j card fail 201622713722 368 van veldhuisen dj braunschweig f conraads v ford cowie mr jondeau g kautzner j aguilera rm lunati yu cm gerritse b borggrefe dothf investigator intrathoracic impedance monitoring audible patient alert outcome patient heart failure circulation 201112417191726 369 hindricks g taborsky glikson heinrich u schumacher b katz brachmann j lewalter goette block kautzner j sack husser piorkowski c sogaard p intime group implantbased multiparameter telemonitoring patient heart failure intime randomised con trolled lancet 2014384583590 370 morgan jm kitt gill j mccomb jm ng ga raftery j roderick p seed williams sg witte kk wright dj harris cowie mr remote management heart failure using implantable electronic device eur heart j 20173823522360 371 bohm drexler h oswald h rybak k bosch r butter c klein g gerritse b monteiro j israel c bimmel kaab huegl b brachmann j optilink hf investigator fluid status telemedicine alert heart failure random ized controlled eur heart j 20163731543163 372 abraham wt stevenson lw bourge rc lindenfeld ja bauman jg adamson pb champion group sustained efficacy pulmonary artery pressure guide adjustment chronic heart failure complete followup result champion randomised lancet 2016387453461 373 lindenfeld j abraham wt maisel zile smart f costanzo mr mehra mr ducharme sears sf desai paul sood p johnson n ginn g adamson pb hemodynamicguided management heart failure guide hf heart j 20192141827 downloaded guest 24 november 2024 374 dierckx r inglis sc clark ra prietomerino cleland jg telemedicine heart failure new insight cochrane metaanalyses eur j heart fail 201719304306 375 fang jc ewald ga allen la butler j westlake canary ca colvinadams dickinson levy p stough wg sweitzer nk teerlink jr whellan dj albert nm krishnamani r rich mw walsh mn bonnell mr carson pe chan mc dry dl hernandez af hershberger katz sd moore rodgers je rogers jg vest ar givertz mm heart failure society america guideline committee advanced stage heart failure statement heart failure society america guideline committee j card fail 201521519534 376 crespoleiro metra lund lh milicic costanzo mr filippatos g gustafsson f tsui bargecaballero e de jonge n frigerio hamdan r hasin hulsmann nalbantgil potena l bauersachs j gkouziouta ruhparwar ristic ad straburzynskamigaj e mcdonagh seferovic p ruschitzka f advanced heart failure position statement heart failure association european society cardiology eur j heart fail 20182015051535 377 truby lk rogers jg advanced heart failure epidemiology diagnosis ther apeutic approach jacc heart fail 20208523536 378 rose ea gelijns ac moskowitz aj heitjan df stevenson lw dembitsky w long jw ascheim dd tierney ar levitan rg watson jt meier p ronan n shapiro pa lazar rm miller lw gupta l frazier oh desvignenickens p oz mc poirier vl randomized evaluation mechanical assistance congestive heart failure rematch group longterm use left ventricular assist device endstage heart failure n engl j med 200134514351443 379 ammar ka jacobsen sj mahoney dw kor ja redfield mm burnett jc jr rodeheffer rj prevalence prognostic significance heart failure stage application american college cardiologyamerican heart association heart failure staging criterion community circulation 200711515631570 380 xanthakis v enserro dm larson wollert kc januzzi jl levy aragam j benjamin ej cheng wang tj mitchell gf vasan r prevalence neurohor monal correlate prognosis heart failure stage community jacc heart fail 20164808815 381 stevenson lw pagani fd young jb jessup miller l kormos rl naftel dc ulisney k desvignenickens p kirklin jk intermacs profile advanced heart failure current picture j heart lung transplant 200928535541 382 bargecaballero e segoviacubero j almenarbonet l gonzalezvilchez f villaarranz delgadojimenez j lagegalle e perezvilla f lambert rodriguez jl manitolorite n arizondel prado jm brossaloidi v pascual figal fuentegalan lde l sanzjulve munizgarcia j crespoleiro preoperative intermacs profile determine postoperative outcome crit ically ill patient undergoing emergency heart transplantation analysis spanish national heart transplant registry circ heart fail 20136763772 383 goldstein dj meyns b xie r cowger j pettit nakatani netuka shaw yanase kirklin jk third annual report ishlt mechanically assisted circulatory support registry comparison centrifugal axial continuousflow left ventricular assist device j heart lung transplant 201938352363 384 kittleson mm shah p lala mclean rc pamboukian horstmanshof da thibodeau j shah k teuteberg j gilotra na taddeipeters wc cascino tm richards b khalatbari jeffries n stevenson lw mann aaronson kd stewart gc revival investigator intermacs profile outcome ambulatory advanced heart failure patient report revival registry j heart lung transplant 2020391626 385 mehra mr canter ce hannan mm semigran mj uber pa baran da danzigerisakov l kirklin jk kirk r kushwaha lund lh potena l ross hj taylor verschuuren eam zuckermann international society heart lung transplantation ishlt infectious disease pediatric heart failure transplantation council 2016 international society heart lung transplantation listing criterion heart transplantation 10year update j heart lung transplant 201635123 386 baumwol j need help–a mnemonic aid timely referral advanced heart failure j heart lung transplant 201736593594 387 maack c eschenhagen hamdani n heinzel fr lyon ar manstein dj metzger j papp z tocchetti cg yilmaz mb anker sd balligand jl bauersachs j brutsaert carrier l chlopicki cleland jg de boer ra dietl fischmeister r harjola vp heymans hilfikerkleiner holzmeister j de keulenaer g limongelli g linke wa lund lh masip j metra mueller c pieske b ponikowski p ristic ruschitzka f seferovic pm skouri h zimmermann wh mebazaa targeting inotropy eur heart j 20194036263644 388 ahmad miller pe mccullough desai nr riello r psotka bohm allen la teerlink jr rosano gmc lindenfeld j ha positive inotropy failed chronic heart failure lesson prior inotrope eur j heart fail 20192110641078 389 comincolet j manito n segoviacubero j delgado j garcia pinilla jm almenar l crespoleiro sionis blasco pascualfigal gonzalez vilchez f lambertrodriguez jl grau bruguera j lionheart investigator efficacy safety intermittent intravenous outpatient administration levosimendan patient advanced heart failure lionheart multicentre randomised eur j heart fail 20182011281136 390 nizamic murad mh allen la mcilvennan ck wordingham se matlock dd dunlay sm ambulatory inotrope infusion advanced heart failure sys tematic review metaanalysis jacc heart fail 20186757767 391 bart ba goldsmith sr lee kl givertz mm o’connor cm bull da redfield mm deswal rouleau jl lewinter mm ofili eo stevenson lw semigran mj felker gm chen hh hernandez af anstrom kj mcnulty se velazquez ej ibarra jc mascette braunwald e heart failure clinical research network ultrafiltration decompensated heart failure cardiorenal syn drome n engl j med 201236722962304 392 costanzo mr guglin saltzberg mt jessup bart ba teerlink jr jaski fang jc feller ed haas gj anderson schollmeyer mp sobotka pa unload investigator ultrafiltration intravenous diuretic patient hospitalized acute decompensated heart failure j coll cardiol 200749675683 393 gustafsson f rogers jg left ventricular assist device advanced heart failure patient selection outcome eur j heart fail 201719595602 394 bargecaballero e almenarbonet l gonzalezvilchez f lambertrodriguez jl gonzalezcostello j segoviacubero j castellavilla delgadojimenez j garridobravo ip rangelsousa martinezselles de la fuentegalan l rabagoaraciljuan g sanzjulve hervassotomayor mirabetperez muniz j crespoleiro clinical outcome temporary mechanical circula tory support direct bridge heart transplantation nationwide spanish registry eur j heart fail 201820178186 395 potapov ev antonides c crespoleiro combes farber g hannan mm kukucka de jonge n loforte lund lh mohacsi p morshuis netuka ozbaran pappalardo f scandroglio schweiger tsui zimpfer gustafsson f 2019 eacts expert consensus longterm mechanical circulatory support eur j cardiothorac surg 201956230270 396 rogers jg butler j lansman sl gas portner pm pasque mk pierson rn 3rd intrepid investigator chronic mechanical circulatory support inotropedependent heart failure patient transplant candidate result intrepid j coll cardiol 200750741747 397 slaughter rogers jg milano ca russell sd conte jv feldman sun b tatooles aj delgado rm 3rd long jw wozniak tc ghumman w farrar dj frazier oh heartmate ii investigator advanced heart failure treated continuousflow left ventricular assist device n engl j med 200936122412251 398 starling rc naka boyle aj gonzalezstawinski g john r jorde u russell sd conte jv aaronson kd mcgee ec jr cotts wg denofrio pham dt farrar dj pagani fd result postus food drug administrationapproval continuous flow left ventricular assist device bridge heart transplantation prospective using intermacs interagency registry mechanically assisted circulatory support j coll cardiol 20115718901898 399 rogers jg pagani fd tatooles aj bhat g slaughter birks ej boyce sw najjar jeevanandam v anderson gregoric id mallidi h leadley k aaronson kd frazier oh milano ca intrapericardial left ventricular assist device advanced heart failure n engl j med 2017376451460 400 truby lk farr garan ar given r restaino sw latif f takayama h naka takeda k topkara vk impact bridge transplantation continuousflow left ventricular assist device posttransplantation mortality circulation 2019140459469 401 goldstein dj naka horstmanshof ravichandran ak schroder j ransom j itoh uriel n cleveland jc jr raval ny cogswell r suarez ee lowes bd kim g bonde p sheikh fh sood p farrar dj mehra mr association clinical outcome left ventricular assist device use bridge transplant destination intent multicenter maglev technology patient undergoing mechanical circulatory support heartmate 3 momentum 3 randomized clinical jama cardiol 20205411419 402 mehra mr uriel n naka cleveland jc jr yuzefpolskaya salerno ct walsh mn milano ca patel cb hutchins sw ransom j ewald ga itoh raval ny silvestry sc cogswell r john r bhimaraj bruckner ba lowes bd um jy jeevanandam v sayer g mangi aa molina ej sheikh f aaronson k pagani fd cotts wg tatooles aj babu chomsky katz jn tessmann pb dean krishnamoorthy chuang j topuria sood p goldstein dj downloaded guest 24 november 2024 momentum 3 investigator fully magnetically levitated left ventricular assist device – final report n engl j med 201938016181627 403 kirklin jk naftel dc pagani fd kormos rl stevenson lw blume ed myers sl miller baldwin jt young jb seventh intermacs annual report 15000 patient counting j heart lung transplant 20153414951504 404 theochari ca michalopoulos g oikonomou ek giannopoulos doulamis ip villela kokkinidis dg heart transplantation left ventricular assist device destination bridge transplantation 1year mortality systematic review metaanalysis ann cardiothorac surg 20187311 405 mehra mr goldstein dj uriel n cleveland jc jr yuzefpolskaya salerno c walsh mn milano ca patel cb ewald ga itoh dean krishnamoorthy cotts wg tatooles aj jorde bruckner ba estep jd jeevanandam v sayer g horstmanshof long jw gulati skipper er o’connell jb heatley g sood p naka momentum 3 investigator twoyear outcome magnetically levitated cardiac pump heart failure n engl j med 201837813861395 406 zimpfer gustafsson f potapov e pya schmitto j berchtoldherz morshuis shaw sm saeed lavee j heatley g gazzola c garbade j twoyear outcome implantation full magnetically levitated left ventricular assist device result elevate registry eur heart j 20204138013809 407 estep jd starling rc horstmanshof da milano ca selzman ch shah kb loebe moazami n long jw stehlik j kasirajan v haas dc o’connell jb boyle aj farrar dj rogers jg roadmap investigator risk assessment comparative effectiveness left ventricular assist device medical man agement ambulatory heart failure patient result roadmap j coll cardiol 20156617471761 408 starling rc estep jd horstmanshof da milano ca stehlik j shah kb bruckner ba lee long jw selzman ch kasirajan v haas dc boyle aj chuang j farrar dj rogers jg roadmap investigator risk assessment comparative effectiveness left ventricular assist device medical man agement ambulatory heart failure patient roadmap 2year result jacc heart fail 20175518527 409 slaughter pagani fd mcgee ec birks ej cotts wg gregoric howard frazier icenogle najjar boyce sw acker john r hathaway dr najarian kb aaronson kd heartware bridge transplant advance investigator heartware ventricular assist system bridge transplant combined result bridge transplant continued access protocol j heart lung transplant 201332675683 410 karason k lund lh dalen bjorklund e grinnemo k braun nilsson j van der wal h holm j hubbert l lindmark k szabo b holmberg e dellgren g swevad investigator randomized left ventricular assist device destination guidelinedirected medical patient advanced heart failure rationale design swedish evaluation left ventricular assist device swevad eur j heart fail 202022739750 411 khush kk cherikh w chamber dc harhay mo hayes jr hsich e meiser b potena l robinson rossano jw sadavarte singh tp zuckermann stehlik j international society heart lung transplantation international thoracic organ transplant registry international society heart lung transplantation thirtysixth adult heart transplantation report–2019 focus theme donor recipient size match j heart lung transplant 20193810561066 412 lund lh edward lb kucheryavaya ay dipchand ai benden c christie jd dobbels f kirk r rahmel ao yusen rd stehlik j international society h heart lung transplantation registry international society heart lung transplantation thirtieth official adult heart transplant report– 2013 focus theme age j heart lung transplant 201332951964 413 guglin zucker mj borlaug ba breen e cleveland j johnson mr panjrath g patel jk starling rc bozkurt b acc heart failure transplant member section leadership council evaluation heart transplantation lvad implantation jacc council perspective j coll cardiol 20207514711487 414 bernhardt schloglhofer lauenroth v mueller f mueller schoede klopsch c driveline expert staging care destine group ventricular assist device driveline infection group prevention early driveline infection ventricular assist device patient – destine staging proposal first standard care protocol j crit care 202056106112 415 defilippis em breathett k donald em nakagawa takeda k takayama h truby lk sayer g colombo pc yuzefpolskaya uriel n farr topkara vk psychosocial risk association outcome continuousflow left ventricular assist device patient circ heart fail 202013e006910 416 jaarsma hill l bayesgenis la rocca hb castiello celutkiene j marque sule e plymen cm piper se riegel b rutten fh ben gal bauersachs j coat ajs chioncel lopatin lund lh lainscak moura b mullens w piepoli mf rosano g seferovic p stromberg selfcare heart failure patient practical management recommendation heart failure association european society cardiology eur j heart fail 202123157174 417 jorde kushwaha tatooles aj naka bhat g long jw horstmanshof da kormos rl teuteberg jj slaughter birks ej farrar dj park sj heartmate ii clinical investigator result destination postfood drug administration approval continuous flow left ventricular assist device prospective using intermacs registry interagency registry mechanically assisted circulatory support j coll cardiol 20146317511757 418 sahlollbey n lee cks shirin joseph p impact palliative care clini cal patientcentred outcome patient advanced heart failure sys tematic review randomized controlled eur j heart fail 20202223402346 419 fendler tj swetz km allen la teambased palliative endoflife care heart failure heart fail clin 201511479498 420 brannstrom boman k effect personcentred integrated chronic heart failure palliative home care prefer randomized controlled eur j heart fail 20141611421151 421 o’donnell ae schaefer kg stevenson lw devoe k walsh k mehra mr desai social workeraided palliative care intervention highrisk patient heart failure swaphf pilot randomized clinical jama cardiol 20183516519 422 johnson mj mcdonagh ta harkness mckay se dargie hj morphine relief breathlessness patient chronic heart failure–a pilot eur j heart fail 20024753756 423 oxberry sg bland jm clark al cleland jg johnson mj repeat opioids may effective breathlessness chronic heart failure given long enough j palliat med 201316250255 424 blinderman cd billing ja comfort care patient dying hospital n engl j med 201537325492561 425 nieminen brutsaert dickstein k drexler h follath f harjola vp hochadel komajda lassus j lopezsendon jl ponikowski p tavazzi l euroheart survey investigator heart failure association european society cardiology euroheart failure survey ii ehf ii survey hospi talized acute heart failure patient description population eur heart j 20062727252736 426 chioncel mebazaa harjola vp coat aj piepoli mf crespoleiro laroche c seferovic pm anker sd ferrari r ruschitzka f lopezfernandez miani filippatos g maggioni ap esc heart failure longterm registry investigator clinical phenotype outcome patient hospitalized acute heart failure esc heart failure longterm registry eur j heart fail 20171912421254 427 chioncel mebazaa maggioni ap harjola vp rosano g laroche c piepoli mf crespoleiro lainscak ponikowski p filippatos g ruschitzka f seferovic p coat ajs lund lh esceorphfa heart failure longterm registry investigator acute heart failure congestion perfusion status – impact clinical classification inhospital longterm come insight esceorphfa heart failure longterm registry eur j heart fail 20192113381352 428 miro garcia sarasola fuenzalida c calderon jacob j aguirre wu dm rizzi malchair p haro herrera gil v martinsanchez fj llorens p herrero puente p bueno h dominguez rodriguez muller ce mebazaa chioncel alquezararbe icasemes research group department involved first episode acute heart failure subsequent emer gency department revisits rehospitalisations outlook novica cohort eur j heart fail 20192112311244 429 solomon sd dobson j pocock skali h mcmurray jj granger cb yusuf swedberg k young jb michelson el pfeffer candesartan heart failure assessment reduction mortality morbidity charm investigator influence nonfatal hospitalization heart failure subsequent mortality patient chronic heart failure circulation 200711614821487 430 tomasoni lombardi cm sbolli cotter g metra acute heart failure question answer prog cardiovasc dis 202063599606 431 butt jh fosbol el gerds ta andersson c mcmurray jjv petrie mc gustafsson f madelaire c kristensen sl gislason gh torppedersen c kober l schou readmission death patient admitted newonset worsening chronic heart failure insight nationwide cohort eur j heart fail 20202217771785 432 javaloyes p miro gil v martinsanchez fj jacob j herrero p takagi k alquezararbe lopez diez mp martin e bibiano c escoda r gil c fuentes llopis garcia g alvarez perez jm jerez tost j llauger l romero r garrido jm rodriguezadrada e sanchez c rossello x parissis j mebazaa chioncel llorens p icasemes research group clinical phenotype acute heart failure based sign symptom perfusion congestion emergency department presentation relationship downloaded guest 24 november 2024 patient management outcome eur j heart fail 20192113531365 433 januzzi jl van kimmenade r lainchbury j bayesgenis ordonezllanos j santalobel pinto ym richards ntprobnp testing diagnosis shortterm prognosis acute destabilized heart failure international pooled analysis 1256 patient international collaborative ntprobnp eur heart j 200627330337 434 januzzi jl jr chentournoux aa christenson rh doros g hollander je levy pd nagurney jt nowak rm pang p patel peacock wf river ej walter el gaggin hk iconreloaded investigator nterminal probtype natriu retic peptide emergency department iconreloaded j coll cardiol 20187111911200 435 maisel mueller c nowak r peacock wf landsberg jw ponikowski p mockel hogan c wu ah richards clopton p filippatos g di somma anand ng l daniel lb neath sx christenson r potocki mccord j terracciano g kremastinos hartmann von haehling bergmann morgenthaler ng anker sd midregion prohormone marker diagnosis prognosis acute dyspnea result bach biomarkers acute heart failure j coll cardiol 20105520622076 436 harjola vp parissis j bauersachs j brunnerla rocca hp bueno h celutkiene j chioncel coat ajs collins sp de boer ra filippatos g gayat e hill l laine lassus j lommi j masip j mebazaa metra miro mortara mueller c mullens w peacock wf pentikainen piepoli mf polyzogopoulou e rudiger ruschitzka f seferovic p sionis teerlink jr thum varpula weinstein jm yilmaz mb acute coronary syndrome acute heart failure diagnostic dilemma highrisk combination statement acute heart failure committee heart failure association european society cardiology eur j heart fail 20202212981314 437 harjola vp mullens w banaszewski bauersachs j brunnerla rocca hp chioncel collins sp doehner w filippatos g flammer aj fuhrmann v lainscak lassus j legrand masip j mueller c papp z parissis j platz e rudiger ruschitzka f schafer seferovic pm skouri h yilmaz mb mebazaa organ dysfunction injury failure acute heart failure pathophysiology diagnosis management review behalf acute heart failure committee heart failure association hfa european society cardiology esc eur j heart fail 201719821836 438 harjola vp parissis j brunnerla rocca hp celutkiene j chioncel collins sp de backer filippatos g gayat e hill l lainscak lassus j masip j mebazaa miro mortara mueller c mullens w nieminen rudiger ruschitzka f seferovic pm sionis vieillardbaron weinstein jm de boer ra crespoleiro piepoli riley jp comprehensive inhospital monitoring acute heart failure application clinical practice future direction research statement acute heart failure committee heart failure association hfa european society cardiology esc eur j heart fail 20182010811099 439 ter maaten jm damman k hanberg j givertz mm metra o’connor cm teerlink jr ponikowski p cotter g davison b cleland jg bloomfield dm hillege hl van veldhuisen dj voors aa testani jm hypochloremia diuretic resistance outcome patient acute heart failure circ heart fail 20169 440 nunez j llacer p garciablas bonanad c ventura nunez jm sanchez r facila l de la espriella r vaquer jm cordero roque chamorro c bodi v valero e santa e moreno mdc minana g carratala rodriguez e mollar palau p bosch mj bertomeugonzalez v lupon j navarro j chorro fj gorriz jl sanchis j voors aa bayesgenis ca125guided diuretic treat ment usual care patient acute heart failure renal dysfunc tion j med 2020133370380 e374 441 nikolaou parissis j yilmaz mb seronde mf kivikko laribi paugam burtz c cai pohjanjousi p laterre pf deye n poder p cohensolal mebazaa liver function abnormality clinical profile outcome acute decompensated heart failure eur heart j 201334742749 442 mockel de boer ra slagman ac von haehling schou vollert jo wiemer jc ebmeyer martınsanchez fj maisel giannitsis e improve management acute heart failure procalcitonin europe result randomized clinical impact eu biomarkers cardiology bic 18 eur j heart fail 202022267275 443 masip j de mendoza planas k paez j sanchez b cancio b peripheral venous blood gas pulseoximetry acute cardiogenic pulmonary oedema eur heart j acute cardiovasc care 20121275280 444 masip j gaya paez j betbese vecilla f manresa r ruiz p pulse oximetry diagnosis acute heart failure rev esp cardiol engl ed 201265879884 445 nieminen bohm cowie mr drexler h filippatos g jondeau g hasin lopezsendon j mebazaa metra rhodes swedberg k priori sg garcia blanc jj budaj cowie mr dean v decker j burgos ef lekakis j lindahl b mazzotta g morais j oto smiseth oa garcia dickstein k albuquerque conthe p crespoleiro ferrari r follath f gavazzi janssens u komajda morais j moreno r singer singh tendera thygesen k esc committe practice guideline cpg executive summary guideline diagnosis acute heart failure task force acute heart failure european society cardiology eur heart j 200526384416 446 nohria tsang sw fang jc lewis ef jarcho ja mudge gh stevenson lw clinical assessment identifies hemodynamic profile predict outcome patient admitted heart failure j coll cardiol 20034117971804 447 gheorghiade follath f ponikowski p barsuk jh blair je cleland jg dickstein k drazner mh fonarow gc jaarsma jondeau g sendon jl mebazaa metra nieminen pang p seferovic p stevenson lw van veldhuisen dj zannad f anker sd rhodes mcmurray jj filippatos g european society cardiology european society intensive care medicine assessing grading congestion acute heart failure scientific statement acute heart failure committee heart failure association european society cardiology endorsed european society intensive care medicine eur j heart fail 201012423433 448 masip j peacock wf price cullen l martinsanchez fj seferovic p maisel miro filippatos g vrints c christ cowie platz e mcmurray j disomma zeymer u bueno h gale cp lettino tavares ruschitzka f mebazaa harjola vp mueller c acute heart failure group acute cardiovascular care association committee acute heart failure heart failure association european society cardiology indication practical approach noninvasive ventilation acute heart fail ure eur heart j 2018391725 449 harjola vp mebazaa celutkiene j bettex bueno h chioncel crespo leiro falk v filippatos g gibbs leitemoreira lassus j masip j mueller c mullens w naeije r nordegraaf av parissis j riley jp ristic rosano g rudiger ruschitzka f seferovic p sztrymf b vieillardbaron yilmaz mb konstantinides contemporary management acute right ventric ular failure statement heart failure association working group pulmonary circulation right ventricular function european society cardiology eur j heart fail 201618226241 450 chioncel parissis j mebazaa thiele h desch bauersachs j harjola vp antohi el arrigo gal tb celutkiene j collins sp debacker iliescu va jankowska e jaarsma keramida k lainscak lund lh lyon ar masip j metra miro mortara mueller c mullens w nikolaou piepoli price rosano g vieillardbaron weinstein jm anker sd filippatos g ruschitzka f coat ajs seferovic p epidemiology pathophysiology con temporary management cardiogenic shock – position statement heart failure association european society cardiology eur j heart fail 20202213151341 451 thiele h ohman em de wahathiele zeymer u desch management cardiogenic shock complicating myocardial infarction update 2019 eur heart j 20194026712683 452 mebazaa combes van diepen hollinger katz jn landoni g hajjar la lassus j lebreton g montalescot g park jj price sionis yannopolos harjola vp levy b thiele h management cardiogenic shock complicating myocardial infarction intensive care med 201844760773 453 zymlinski r biegus j sokolski siwolowski p nawrockamillward todd j jankowska ea banasiak w cotter g cleland jg ponikowski p increased blood lactate prevalent identifies poor prognosis patient acute heart failure without overt peripheral hypoperfusion eur j heart fail 20182010111018 454 menon v slater jn white hd sleeper la cocke hochman j acute myo cardial infarction complicated systemic hypoperfusion without hypotension report shock registry j med 2000108374380 455 harjola p miro martinsanchez fj escalada x freund penaloza christ cone dc laribi kuisma tarvasmaki harjola vp emsahf group prehospital management protocol perceived difficulty diagnos ing acute heart failure esc heart fail 20207289296 456 takahashi kohsaka miyata h yoshikawa takagi harada k miyamoto sakai nagao k sato n takayama tokyo ccu network council association prehospital time interval shortterm outcome acute heart failure patient j card fail 201117742747 457 park jh balmain berry c morton jj mcmurray jj potentially detrimental car diovascular effect oxygen patient chronic left ventricular systolic dysfunction heart 201096533538 458 gray goodacre newby de masson sampson f nicholl j 3cpo trialists noninvasive ventilation acute cardiogenic pulmonary edema n engl j med 2008359142151 459 weng cl zhao yt liu qh fu cj sun f yl chen yw qy meta analysis noninvasive ventilation acute cardiogenic pulmonary edema ann intern med 2010152590600 460 felker gm lee kl bull da redfield mm stevenson lw goldsmith sr lewinter mm deswal rouleau jl ofili eo anstrom kj hernandez af mcnulty se velazquez ej kfoury ag chen hh givertz mm semigran mj downloaded guest 24 november 2024 bart ba mascette braunwald e o’connor cm network nhfcr diuretic strategy patient acute decompensated heart failure n engl j med 2011364797805 461 felker gm ellison dh mullens w cox zl testani jm diuretic patient heart failure jacc stateoftheart review j coll cardiol 20207511781195 462 brisco zile mr hanberg j wilson fp parikh cr coca sg tang wh testani jm relevance change serum creatinine heart failure decongestive strategy insight j card fail 201622753760 463 damman k kjekshus j wikstrand j cleland jg komajda wedel h waagstein f mcmurray jj loop diuretic renal function clinical outcome patient heart failure reduced ejection fraction eur j heart fail 201618328336 464 ter maaten jm marten p damman k dickstein k ponikowski p lang cc ng anker sd samani nj filippatos g cleland jg zannad f hillege hl van veldhuisen dj metra voors aa mullens w higher dos loop diuretic limit uptitration angiotensinconverting enzyme inhibitor patient heart failure reduced ejection fraction clin cardiol 202010910481059 465 cubbon rm woolston adam b gale cp gilthorpe baxter pd kearney lc mercer b rajwani batin pd kahn sapsford rj witte kk kearney mt prospective development validation model predict heart failure hospitalisation heart 2014100923929 466 kapelios cj laroche c crespoleiro anker sd coat ajs diazmolina b filippatos g lainscak maggioni ap mcdonagh mebazaa metra moura b mullens w piepoli mf rosano gmc ruschitzka f seferovic pm lund lh heart failure longterm registry investigator group association loop diuretic change outcome chronic heart failure observation esceorp heart failure longterm registry eur j heart fail 20202214241437 467 mebazaa yilmaz mb levy p ponikowski p peacock wf laribi ristic ad lambrinou e masip j riley jp mcdonagh mueller c defilippi c harjola vp thiele h piepoli mf metra maggioni mcmurray j dickstein k damman k seferovic pm ruschitzka f leitemoreira af bellou anker sd filippatos g recommendation prehospital early hospital management acute heart failure consensus paper heart failure association european society cardiology european society emergency medicine society academic emergency medicine eur j heart fail 201517544558 468 damman k ter maaten jm coster je krikken ja van deursen vm krijnen hk hofman nieuwland w van veldhuisen dj voors aa van der meer p clinical importance urinary sodium excretion acute heart failure eur j heart fail 20202214381447 469 mullens w verbrugge fh nijst p marten p tartaglia k theunissen e bruckers l droogne w troisfontaines p damman k lassus j mebazaa filippatos g ruschitzka f dupont rationale design advor acetazolamide decompensated heart failure volume overload eur j heart fail 20182015911600 470 cox zl hung r lenihan dj testani jm diuretic strategy loop diuretic resistance acute heart failure 3t jacc heart fail 20208157168 471 damman k testani jm kidney heart failure update eur heart j 20153614371444 472 ambrosy ap pang p khan konstam fonarow gc traver b maggioni ap cook swedberg k burnett jc jr grinfeld l udelson je zannad f gheorghiade everest investigator clinical course predictive value congestion hospitalization patient admitted worsening sign symptom heart failure reduced ejection fraction finding everest eur heart j 201334835843 473 faselis c arundel c patel lam ph gottlieb zile mr deedwania p filippatos g sheriff hm zeng q morgan cj wopperer nguyen allman rm fonarow gc ahmed loop diuretic prescription 30day outcome older patient heart failure j coll cardiol 202076669679 474 sharon shpirer kaluski e moshkovitz milovanov polak r blatt simovitz shaham faigenberg z metzger stav yogev r golik krakover r vered z cotter g highdose intravenous isosorbidedinitrate safer better bipap ventilation combined conventional severe pulmonary edema j coll cardiol 200036832837 475 publication committee vmac investigator vasodilatation management acute chf intravenous nesiritide v nitroglycerin treat ment decompensated congestive heart failure randomized controlled jama 200228715311540 476 cotter g metzkor e kaluski e faigenberg z miller r simovitz shaham marghitay koren blatt moshkovitz zaidenstein r golik randomised highdose isosorbide dinitrate plus lowdose furosemide highdose furosemide plus lowdose isosorbide dinitrate severe pul monary oedema lancet 1998351389393 477 levy p compton welch r delgado g jennett penugonda n dunne r zalenski r severe decompensated heart failure highdose intravenous nitroglycerin feasibility outcome analysis ann emerg med 200750144152 478 mebazaa motiejunaite j gayat e crespoleiro lund lh maggioni ap chioncel akiyama e harjola vp seferovic p laroche c julve roig e ruschitzka f filippatos g esc heart failure longterm registry investigator longterm safety intravenous cardiovascular agent acute heart failure result european society cardiology heart failure longterm regis try eur j heart fail 201820332341 479 kozhuharov n goudev flores maeder mt walter j shrestha gualandro dm de oliveira junior mt sabti z muller b noveanu socrates ziller r bayesgenis sionis simon p michou e gujer gori wenzel p pfister conen kapos kobza r rickli h breidthardt munzel erne p mueller c investigator g mueller c erne p muller b rickli h maeder tavares de oliveira jr munzel bayesgenis sionis goudev dimov b hartwiger arenja n glatz b herr n isenrich r mosimann twerenbold r boeddinghaus j nestelberger puelacher c freese vogele j meissner k martin j strebel wussler schumacher c osswald vogt f hilti j barata schneider schwarz j fitze b hartwiger arenja n glatz b herr n isenrich r mosimann twerenbold r boeddinghaus j nestelberger puelacher c freese vogele j meissner k martin j strebel wussler schumacher c osswald vogt f hilti j barata schneider schwarz j fitze b arenja n rentsch k bossa jallad soeiro georgiev jansen gebel g bossard christ effect strat egy comprehensive vasodilation v usual care mortality heart failure rehospitalization among patient acute heart failure galactic randomized clinical jama 201932222922302 480 freund cachanado delannoy q laribi yordanov gorlicki j chouihed feralpierssens al truchot j desmettre occelli c bobbia x khellaf ganansia bokobza j balen f beaune bloom b simon mebazaa effect emergency department care bundle 30day hospital discharge survival among elderly patient acute heart failure elisabeth randomized clinical jama 202032419481956 481 khot un novaro gm popovic zb mill rm thomas jd tuzcu em hammer nissen se francis g nitroprusside critically ill patient left ventricular dysfunction aortic stenosis n engl j med 200334817561763 482 mebazaa nieminen filippatos g cleland jg salon je thakkar r padley rj huang b cohensolal levosimendan v dobutamine outcome acute heart failure patient betablockers survive eur j heart fail 200911304311 483 metra nodari d’aloia muneretto c robertson ad bristow mr dei ca l betablocker influence hemodynamic response inotropic agent patient heart failure randomized comparison dobutamine enoximone chronic metoprolol carvedi lol j coll cardiol 20024012481258 484 packer colucci w fisher l massie bm teerlink jr young j padley rj thakkar r delgadoherrera l salon j garratt c huang b sarapohja revive heart failure group effect levosimendan shortterm clinical course patient acutely decompensated heart failure jacc heart fail 20131103111 485 de backer biston p devriendt j madl c chochrad aldecoa c brasseur defrance p gottignies p vincent jl soap ii investigator comparison dopamine norepinephrine shock n engl j med 2010362779789 486 levy b clerejehl r legras morichaubeauchant leone frederique g quenot jp kimmoun cariou lassus j harjola vp meziani f louis g rossignol p duarte k girerd n mebazaa vignon p collaborator epinephrine norepinephrine cardiogenic shock acute myocardial infarction j coll cardiol 201872173182 487 leopold v gayat e pirracchio r spinar j parenica j tarvasmaki lassus j harjola vp champion zannad f valente urban p chua hr bellomo r popovic b ouweneel dm henriques jps simonis g levy b kimmoun gaudard p basir mb markota adler c reuter h mebazaa chouihed epinephrine shortterm survival cardiogenic shock individual data metaanalysis 2583 patient intensive care med 201844847856 488 peacock wf hollander je diercks db lopatin fonarow g emerman cl morphine outcome acute decompensated heart failure adhere analysis emerg med j 200825205209 489 gil v dominguezrodriguez masip j peacock wf miro morphine use acute cardiogenic pulmonary edema effect patient outcome systematic review curr heart fail rep 2019168188 downloaded guest 24 november 2024 490 miro gil v martinsanchez fj herreropuente p jacob j mebazaa harjola vp rio j hollander je peacock wf llorens p icasemes research group morphine use ed outcome patient acute heart fail ure propensity scorematching analysis based eahfe registry chest 2017152821832 491 caspi naami r halfin e aronson adverse dosedependent effect morphine acute heart failure int j cardiol 2019293131136 492 sethi nj nielsen ee safi feinberg j gluud c jakobsen jc digoxin atrial fibrillation atrial flutter systematic review metaanalysis sequential analysis randomised clinical plo one 201813e0193924 493 khand au rankin ac martin w taylor j gemmell cleland jg carvedilol alone combination digoxin management atrial fibrillation patient heart failure j coll cardiol 20034219441951 494 tebbe u schellong sm haas gerlach abletshauser c sieder c bramlage p riess h certoparin unfractionated heparin prevent venous thromboembolic event patient hospitalized heart failure subgroup analysis randomized controlled certify heart j 2011161322328 495 dentali f douketis jd gianni lim w crowther metaanalysis anticoa gulant prophylaxis prevent symptomatic venous thromboembolism hospi talized medical patient ann intern med 2007146278288 496 seferovic pm piepoli mf lopatin jankowska e polovina anguitasanchez stork lainscak milicic milinkovic filippatos g coat ajs heart failure association board european society cardiology heart failure association european society cardiology quality care centre pro gramme design accreditation document eur j heart fail 202022763774 497 tehrani bn truesdell ag sherwood mw desai tran ha epps kc singh r psotka shah p cooper lb rosner c raja barnett sd saulino p defilippi cr gurbel pa murphy ce o’connor cm standardized teambased care cardiogenic shock j coll cardiol 20197316591669 498 basir mb kapur nk patel k salam schreiber kaki hanson almany timmis dixon kolski b todd j senter marso lasorda wilkins c lalonde attallah larkin dupont marshall j patel n overly green tehrani b truesdell ag sharma r akhtar mcrae 3rd o’neill b finley j rahman foster askari r goldsweig martin bharadwaj khuddus caputo c korpas cawich mcallister blank n alraies mc fisher r khandelwal alaswad k lemor johnson hacala o’neill ww national cardiogenic shock initiative investigator improved outcome associated use shock protocol update national cardiogenic shock initiative catheter cardiovasc interv 20199311731183 499 tehrani bn truesdell ag psotka rosner c singh r sinha damluji aa batchelor wb standardized comprehensive approach man agement cardiogenic shock jacc heart fail 20208879891 500 thiele h zeymer u neumann fj ferenc olbrich hg hausleiter j richardt g hennersdorf empen k fuernau g desch eitel hambrecht r fuhrmann j bohm ebelt h schneider schuler g werdan k iabpshock ii investigator intraaortic balloon support myocardial infarction cardiogenic shock n engl j med 201236712871296 501 thiele h zeymer u neumann fj ferenc olbrich hg hausleiter j de waha richardt g hennersdorf empen k fuernau g desch eitel hambrecht r lauer b bohm ebelt h schneider werdan k schuler g intraaortic balloon pump cardiogenic shock ii iabpshock ii investi gator intraaortic balloon counterpulsation acute myocardial infarction complicated cardiogenic shock iabpshock ii final 12 month result randomised openlabel lancet 201338216381645 502 thiele h zeymer u thelemann n neumann fj hausleiter j abdelwahab meyersaraei r fuernau g eitel hambrecht r bohm werdan k felix sb hennersdorf schneider ouarrak desch de wahathiele iabp shock ii investigator intraaortic balloon pump cardiogenic shock complicating acute myocardial infarction longterm 6year outcome randomized iabpshock ii circulation 2019139395403 503 seyfarth sibbing bauer frohlich g bottflugel l byrne r dirschinger j kastrati schomig randomized clinical evaluate safety effi cacy percutaneous left ventricular assist device intraaortic balloon pumping cardiogenic shock caused myocardial infarction j coll cardiol 20085215841588 504 ouweneel dm eriksen e sjauw kd van dongen im hirsch packer ej vi mm wykrzykowska jj koch kt baan j de winter rj piek jj lagrand wk de mol ba tijssen jg henriques jp percutaneous mechanical circulatory support intraaortic balloon pump cardiogenic shock acute myocardial infarction j coll cardiol 201769278287 505 schrage b ibrahim k loehn werner n sinning jm pappalardo f pieri skurk c lauten landmesser u westenfeld r horn p pauschinger eckner twerenbold r nordbeck p salinger abel p empen k busch mc felix sb sieweke jt moller je pareek n hill j maccarthy p bergmann mw henriques jps mobiuswinkler schulze pc ouarrak zeymer u schneider blankenberg thiele h schafer westermann impella sup port acute myocardial infarction complicated cardiogenic shock circulation 201913912491258 506 dhruva ross j mortazavi bj hurley nc krumholz hm curtis jp berkowitz masoudi fa messenger jc parzynski c ngufor c girotra amin ap shah nd desai nr association use intravascular microaxial left ventricular assist device v intraaortic balloon pump inhospital mor tality major bleeding among patient acute myocardial infarction com plicated cardiogenic shock jama 2020323734745 507 kar b gregoric id basra idelchik gm loyalka p percutaneous ventric ular assist device severe refractory cardiogenic shock j coll cardiol 201157688696 508 ouweneel dm schotborgh jv limpens j sjauw kd engstrom ae lagrand wk cherpanath tgv driessen ahg de mol b henriques jps extracorporeal life support cardiac arrest cardiogenic shock sys tematic review metaanalysis intensive care med 20164219221934 509 combes price slutsky brodie temporary circulatory support cardiogenic shock lancet 2020396199212 510 pappalardo f schulte c pieri schrage b contri r soeffker g greco lembo r mullerleile k colombo sydow k de bonis wagner f reichenspurner h blankenberg zangrillo westermann concomitant implantation impellar top venoarterial extracorporeal membrane oxygenation may improve survival patient cardiogenic shock eur j heart fail 201719404412 511 anderson mb goldstein j milano c morris ld kormos rl bhama j kapur nk bansal garcia j baker jn silvestry holman wl douglas p o’neill w benefit novel percutaneous ventricular assist device right heart fail ure prospective recover right impella rp device j heart lung transplant 20153415491560 512 ponikowski p kirwan ba anker sd mcdonagh dorobantu drozdz j fabien v filippatos g gohring um keren khintibidze kragten h martinez fa metra milicic nicolau jc ohlsson parkhomenko pascualfigal da ruschitzka f sim skouri h van der meer p lewis b comincolet j von haehling cohensolal danchin n doehner w dargie hj motro butler j friede jensen kh pocock jankowska ea affirm ahf investigator ferric carboxymaltose iron deficiency discharge acute heart failure multicentre doubleblind randomised controlled lancet 202039618951904 513 bhagat aa greene sj vaduganathan fonarow gc butler j initiation con tinuation switching withdrawal heart failure medical hospitalization jacc heart fail 20197112 514 prins kw neill jm tyler jo eckman pm duval effect betablocker drawal acute decompensated heart failure systematic review meta analysis jacc heart fail 20153647653 515 metra gheorghiade bonow ro dei ca l postdischarge assessment heart failure hospitalization next step forward circulation 201012217821785 516 greene sj fonarow gc vaduganathan khan butler j gheorghiade vulnerable phase hospitalization heart failure nat rev cardiol 201512220229 517 lee kk yang j hernandez af steimle ae go postdischarge followup characteristic associated 30day readmission heart failure hospitaliza tion med care 201654365372 518 edmonston dl wu j matsouaka ra yancy c heidenreich p pina il hernandez fonarow gc devore ad association postdischarge spe cialty outpatient visit readmission mortality highrisk heart failure patient heart j 2019212101112 519 ling lh kistler pm kalman jm schilling rj hunter rj comorbidity atrial fibrillation heart failure nat rev cardiol 201613131147 520 carlisle fudim devore ad piccini jp heart failure atrial fibrillation like fire fury jacc heart fail 20197447456 521 gorenek b halvorsen kudaiberdieva g bueno h van gelder ic lettino marin f masip j mueller c okutucu poess j potpara price lip gyh atrial fibrillation acute heart failure position statement acute cardiovascular care association european heart rhythm association european society cardiology eur heart j acute cardiovasc care 20209348357 522 slawik j adrian l hohl lothschutz laufs u bohm irregular pacing ventricular cardiomyocytes induces profibrotic signalling involving paracrine effect transforming growth factor beta connective tissue growth factor eur j heart fail 201921482491 523 kotecha lam c van veldhuisen dj van gelder ic voors aa rienstra heart failure preserved ejection fraction atrial fibrillation vicious twin j coll cardiol 20166822172228 downloaded guest 24 november 2024 524 smit md moes maass ah achekar id van geel pp hillege hl van veldhuisen dj van gelder ic importance whether atrial fibrillation heart failure develops first eur j heart fail 20121410301040 525 swedberg k olsson lg charlesworth cleland j hanrath p komajda metra torppedersen c poolewilson p prognostic relevance atrial fibrillation patient chronic heart failure longterm betablockers result comet eur heart j 20052613031308 526 mogensen um jhund p abraham wt desai dickstein k packer rouleau jl solomon sd swedberg k zile mr køber l mcmurray jjv paradigmhf atmosphere investigator committee type atrial fibrillation outcome patient heart failure reduced ejec tion fraction j coll cardiol 20177024902500 527 hoppe uc casares jm eiskjaer h hagemann cleland jg freemantle n erdmann e effect cardiac resynchronization incidence atrial fibrilla tion patient severe heart failure circulation 20061141825 528 ruff ct giugliano rp braunwald e hoffman eb deenadayalu n ezekowitz md camm aj weitz ji lewis b parkhomenko yamashita antman em comparison efficacy safety new oral anticoagulant warfarin patient atrial fibrillation metaanalysis randomised lancet 2014383955962 529 reddy vy doshi sk sievert h buchbinder neuzil p huber k halperin jl holmes protect atrial fibrillation investigator percutaneous left atrial appendage clo sure stroke prophylaxis patient atrial fibrillation 2.3year followup protect atrial fibrillation watchman left atrial appendage system embolic protection patient atrial fibrillation circulation 2013127720729 530 holmes dr jr kar price mj whisenant b sievert h doshi sk huber k reddy vy prospective randomized evaluation watchman left atrial appendage closure device patient atrial fibrillation longterm warfarin prevail j coll cardiol 201464112 531 van gelder ic wyse dg chandler cooper ha olshansky b hagens crijns hj race affirm investigator doe intensity ratecontrol influ ence outcome atrial fibrillation analysis pooled data race affirm europace 20068935942 532 hess pl sheng matsouaka r devore ad heidenreich pa yancy cw bhatt dl allen la peterson pn ho pm lewis wr hernandez af fonarow gc piccini jp strict lenient poor rate control among patient atrial fibrillation heart failure get guideline – heart failure program j cardiol 2020125894900 533 sartipy u savarese g dahlstrom u fu lund lh association heart rate mortality sinus rhythm atrial fibrillation heart failure pre served ejection fraction eur j heart fail 201921471479 534 van gelder ic rienstra crijns hj olshansky b rate control atrial fibrilla tion lancet 2016388818828 535 kotecha flather md altman dg holmes j rosano g wikstrand j packer coat ajs manzano l bohm van veldhuisen dj andersson b wedel h von lueder tg rigby hjalmarson kjekshus j cleland jgf betablockers heart failure collaborative group heart rate rhythm benefit betablockers patient heart failure j coll cardiol 20176928852896 536 kotecha bunting kv gill sk mehta stanbury jones jc haynes calvert mj deeks jj steed rp strauss vy rahimi k camm aj griffith lip gyh townend jn kirchhof p rate control evaluation permanent atrial fibrillation rateaf team effect digoxin v bisoprolol heart rate control atrial fibrillation patientreported quality life rateaf randomized clinical jama 202032424972508 537 hofmann r steinwender c kammler j kypta leisch f effect high intravenous bolus amiodarone patient atrial fibrillation rapid ven tricular rate int j cardiol 20061102732 538 wood brownmahoney c kay gn ellenbogen ka clinical outcome ablation pacing atrial fibrillation metaanalysis circulation 200010111381144 539 lim kt davis mj powell arnolda l moulden k bulsara weerasooriya r ablate pace strategy atrial fibrillation longterm outcome aircraft europace 20079498505 540 gasparini kloppe lunati anselme f landolina martinezferrer jb proclemer morani g biffi ricci r rordorf r mangoni l manotta l grammatico leyva f boriani g atrioventricular junction ablation patient atrial fibrillation treated cardiac resynchronization positive impact ventricular arrhythmia implantable cardioverterdefibrillator thera pie hospitalization eur j heart fail 20182014721481 541 deedwania pc singh bn ellenbogen k fisher fletcher r singh sn spontaneous conversion maintenance sinus rhythm amiodarone patient heart failure atrial fibrillation observation veteran affair congestive heart failure survival antiarrhythmic chfstat department veteran affair chfstat investigator circulation 19989825742579 542 antiarrhythmic drug evaluation group adeg multicentre randomized benefitrisk profile amiodarone flecainide propafenone patient cardiac disease complex ventricular arrhythmia eur heart j 19921312511258 543 connolly sj camm aj halperin jl joyner c alings amerena j atar avezum blomstrom p borggrefe budaj chen sa ching ck commerford p dans davy jm delacretaz e di pasquale g diaz r dorian p flaker g golitsyn gonzalezhermosillo granger cb heidbuchel h kautzner j kim j lanas f lewis b merino jl morillo c murin j narasimhan c paolasso e parkhomenko peter n sim kh stile mk tanomsup toivonen l tomcsanyi j torppedersen c tse hf vardas p vinereanu xavier zhu j zhu jr baretcormel l weinling e staiger c yusuf chrolavicius afzal r hohnloser sh pallas investigator dronedarone highrisk permanent atrial fibrillation n engl j med 201136522682276 544 chatterjee ghosh j lichstein e aikat mukherjee metaanalysis cardi ovascular outcome dronedarone patient atrial fibrillation heart failure j cardiol 2012110607613 545 shelton rj clark al goode k rigby houghton kaye gc cleland jg randomised controlled rate rhythm control patient chronic atrial fibrillation heart failure cafeii heart 200995924930 546 capucci villani gq aschieri rosi piepoli mf oral amiodarone increase efficacy directcurrent cardioversion restoration sinus rhythm patient chronic atrial fibrillation eur heart j 2000216673 547 van gelder ic hagens bosker ha kingma jh kamp kingma said sa darmanata ji timmermans aj tijssen jg crijns hj rate control electrical cardioversion persistent atrial fibrillation group com parison rate control rhythm control patient recurrent persistent atrial fibrillation n engl j med 200234718341840 548 wyse dg waldo al dimarco jp domanski mj rosenberg schron eb kellen jc greene hl mickel mc dalquist je corley sd atrial fibrillation followup investigation rhythm management affirm investigator com parison rate control rhythm control patient atrial fibrillation n engl j med 200234718251833 549 carlsson j miketic windeler j cuneo haun micus walter tebbe u staf investigator randomized ratecontrol rhythmcontrol persistent atrial fibrillation strategy atrial fibrillation staf j coll cardiol 20034116901696 550 roy talajic nattel wyse dg dorian p lee kl bourassa arnold jm buxton ae camm aj connolly sj dubuc ducharme guerra pg hohnloser sh lambert j le heuzey jy o’hara g pedersen od rouleau jl singh bn stevenson lw stevenson wg thibault b waldo al atrial fibrillation congestive heart failure investigator rhythm control rate control atrial fibrillation heart failure n engl j med 200835826672677 551 kirchhof p camm aj goette brandes eckardt l elvan fetsch van gelder ic haase haegeli lm hamann f heidbuchel h hindricks g kautzner j kuck kh mont l ng ga rekosz j schoen n schotten u suling taggeselle j themistoclakis vettorazzi e vardas p wegscheider k willems crijns h breithardt g eastafnet 4 investigator early rhythmcontrol patient atrial fibrillation n engl j med 202038313051316 552 marrouche nf brachmann j andresen siebels j boersma l jordaens l merkely b pokushalov e sander p proff j schunkert h christ h vogt j bansch castleaf investigator catheter ablation atrial fibrillation heart failure n engl j med 2018378417427 553 packer dl mark db robb ra monahan kh bahnson td poole je noseworthy pa rosenberg yd jeffries n mitchell lb flaker gc pokushalov e romanov bunch tj noelker g ardashev revishvili wilber dj cappato r kuck kh hindricks g davy dw kowey pr naccarelli gv reiffel ja piccini jp silverstein ap alkhalidi hr lee kl cabana investigator effect catheter ablation v antiarrhythmic drug mor tality stroke bleeding cardiac arrest among patient atrial fibrillation cabana randomized clinical jama 201932112611274 554 packer dl piccini jp monahan kh alkhalidi hr silverstein ap noseworthy pa poole je bahnson td lee kl mark db cabana investigator ablation drug atrial fibrillation heart failure result cabana circulation 202114313771390 555 kuck kh merkely b zahn r arentz seidl k schluter tilz rr piorkowski c geller l kleemann hindricks g catheter ablation best medical patient persistent atrial fibrillation congestive heart failure randomized amica circ arrhythm electrophysiol 201912e007731 556 di biase l mohanty p mohanty santangeli p trivedi c lakkireddy reddy jais p themistoclakis dello russo casella pelargonio g narducci downloaded guest 24 november 2024 schweikert r neuzil p sanchez j horton r beheiry hongo r hao rossillo forleo g tondo c burkhardt jd haissaguerre natale ablation amiodarone persistent atrial fibrillation patient congestive heart failure implanted device result aatac multicenter randomized circulation 201613316371644 557 mark db anstrom kj sheng piccini jp baloch kn monahan kh daniel mr bahnson td poole je rosenberg lee kl packer dl cabana investigator effect catheter ablation v medical quality life among patient atrial fibrillation cabana randomized clinical jama 201932112751285 558 xiong q lau yc senoo k lane da hong k lip gy nonvitamin k antago nist oral anticoagulant noacs patient concomitant atrial fibrillation heart failure systemic review metaanalysis randomized eur j heart fail 20151711921200 559 nielsen pb larsen tb skjoth f overvad tf lip gy stroke thromboem bolic event rate atrial fibrillation according different guideline threshold nationwide cohort sci rep 2016627410 560 latchamsetty r bogun f premature ventricular complexinduced cardiomyop athy jacc clin electrophysiol 20195537550 561 mondesert b khairy p schram g shohoudi talajic andrade jg dubuc guerra pg macle l roy dyrda k thibault b barrero diaz kouz mcnicoll nowakowska rivard l impact revascularization patient sustained ventricular arrhythmia prior myocardial infarction pre served left ventricular ejection fraction heart rhythm 20161312211227 562 yarlagadda rk iwai stein km markowitz sm shah bk cheung jw tan v lerman bb mittal reversal cardiomyopathy patient repetitive monomorphic ventricular ectopy originating right ventricular outflow tract circulation 200511210921097 563 berruezo penela jauregui b sotoiglesias aguinaga l ordonez fernandezarmenta j martinez tercedor l bisbal f acosta j martialmor j acena anguera rossi l linhart borras r doltra sanchez p ortizperez jt perea rj pratgonzalez teres c bosch x mortality morbidity reduction frequent premature ventricular complex ablation patient left ventricular systolic dysfunction europace 2019211079 1087 564 cronin em bogun fm maury p peichl p chen namboodiri n aguinaga l leite lr alkhatib sm anter e berruezo callans dj chung mk cuculich p d’avila deal bj della bella p deneke dickfeld tm hadid c haqqani hm kay gn latchamsetty r marchlinski f miller jm nogami patel ar pathak rk saenz morale lc santangeli p sapp jl sarkozy soejima k stevenson wg tedrow ub tzou w varma n zeppenfeld k esc scientific document group 2019 hrsehraaphrslahrs expert consensus state ment catheter ablation ventricular arrhythmia europace 20192111431144 565 cho sw gwag hb hwang jk chun kj park km yk kim j park sj clinical feature predictor longterm prognosis pacinginduced cardio myopathy eur j heart fail 201921643651 566 vijayaraman p herweg b ellenbogen ka gajek j hisoptimized cardiac resynchronization maximize electrical resynchronization feasibility circ arrhythm electrophysiol 201912e006934 567 abdelrahman subzposh fa beer durr b naperkowski sun h oren jw dandamudi g vijayaraman p clinical outcome bundle pacing com pared right ventricular pacing j coll cardiol 20187123192330 568 ziff oj samra howard jp bromage di ruschitzka f francis dp kotecha betablocker efficacy across different cardiovascular indication umbrella review metaanalytic assessment bmc med 202018103 569 fox k ford steg pg tendera robertson ferrari r beautiful investigator relationship ivabradine cardiovascular outcome patient stable coronary artery disease left ventricular systolic dysfunction limiting angina subgroup analysis randomized controlled beautiful eur heart j 20093023372345 570 packer o’connor cm ghali jk pressler carson pe belkin rn miller ab neuberg gw frid wertheimer jh cropp ab demets dl effect amlodipine morbidity mortality severe chronic heart failure prospective randomized amlodipine survival evaluation group n engl j med 199633511071114 571 cohn jn ziesche smith r anand dunkman wb loeb h cintron g boden w baruch l rochin p loss l effect calcium antagonist felodipine supplementary vasodilator patient chronic heart failure treated enalapril vheft iii vasodilatorheart failure vheft group circulation 199796856863 572 iona group effect nicorandil coronary event patient stable angina impact nicorandil angina iona randomised lancet 200235912691275 573 kanamasa k hayashi kimura ikeda ishikawa k longterm continuous oral transdermal nitrate increase cardiac event healed myocardial infarction patient angiology 200253399408 574 wilson sr scirica bm braunwald e murphy sa karwatowskaprokopczuk e buros jl chaitman br morrow da efficacy ranolazine patient chronic angina observation randomized doubleblind placebocon trolled merlintimi metabolic efficiency ranolazine less ischemia nonstsegment elevation acute coronary syndrome 36 j coll cardiol 20095315101516 575 gao ning n niu x hao g meng z trimetazidine metaanalysis rand omised controlled heart failure heart 201197278286 576 vitale c wajngaten sposato b gebara rossini p fini volterrani rosano gm trimetazidine improves left ventricular function quality life elderly patient coronary artery disease eur heart j 20042518141821 577 zhang l lu jiang h zhang l sun zou ge j additional use trimetazi dine patient chronic heart failure metaanalysis j coll cardiol 201259913922 578 goldstein boccuzzi sj cruess nattel diltiazem increase lateonset congestive heart failure postinfarction patient early reduction ejection fraction adverse experience committee multicenter diltiazem postinfarction research group circulation 1991835260 579 zannad f anker sd byra wm cleland jgf fu gheorghiade lam csp mehra mr neaton jd nessel cc spiro te van veldhuisen dj greenberg b commander heart failure investigator rivaroxaban patient heart failure sinus rhythm coronary disease n engl j med 2018379 13321342 580 branch kr probstfield jl eikelboom jw bosch j maggioni ap cheng rk bhatt dl avezum fox kaa connolly sj shestakovska yusuf rivaroxaban without aspirin patient heart failure chronic coronary peripheral artery disease circulation 2019140529537 581 velazquez ej lee kl jones rh alkhalidi hr hill ja panza ja michler bonow ro doenst petrie mc oh jk l moore vl desvigne nickens p sopko g rouleau jl stiches investigator coronaryartery bypass surgery patient ischemic cardiomyopathy n engl j med 201637415111520 582 panza ja holly ta asch fm l pellikka pa velazquez ej lee kl borges neto farsky p jones rh berman bonow ro inducible myocardial ischemia outcome patient coronary artery disease left ventric ular dysfunction j coll cardiol 20136118601870 583 cleland jg calvert freemantle n arrow ball sg bonser r chattopadhyay norell pennell dj senior r heart failure revascularisation heart eur j heart fail 201113227233 584 perera clayton petrie mc greenwood jp o’kane pd evans r sculpher mcdonagh gershlick de belder redwood carrwhite g marber revived investigator percutaneous revascularization ischemic ventric ular dysfunction rationale design revivedbcis2 percutaneous coronary intervention ischemic cardiomyopathy jacc heart fail 20186517526 585 bangalore guo samadashvili z blecker hannan el revascularization patient multivessel coronary artery disease severe left ventricular sys tolic dysfunction everolimuseluting stent coronary artery bypass graft surgery circulation 201613321322140 586 nagendran j bozso sj norris cm mcalister fa appoo jj moon mc freed dh nagendran j coronary artery bypass surgery improves outcome patient diabetes left ventricular dysfunction j coll cardiol 201871819827 587 park ahn jm kim park h kang dy lee ph jeong yj hyun j lee j kim jh yang choe k park sj park dw irismain registry investigator revascularization patient left main coronary artery disease left ven tricular dysfunction j coll cardiol 20207613951406 588 marui kimura nishiwaki n mitsudo k komiya hanyu shiomi h tanaka sakata r credokyoto pcicabg registry cohort2 investigator comparison fiveyear outcome coronary artery bypass grafting percutaneous coronary intervention patient left ventricular ejection fraction 50 50m cre50kyoto pcicabg registry cohort2 j cardiol 2014114988996 589 wolff g dimitroulis andreotti f kolodziejczak jung c scicchitano p devito f zito occhipinti castiglioni b calveri g maisano f ciccone mm de servi navarese ep survival benefit invasive conservative strategy heart failure patient reduced ejection fraction coro nary artery disease metaanalysis circ heart fail 201710e003255 590 gaudino hameed khan fm tam dy rahouma yongle r naik di franco demetres petrie mc jolicoeur em girardi ln fremes se downloaded guest 24 november 2024 strategy ischaemic left ventricular dysfunction network meta analysis eur j cardiothorac surg 202159293301 591 genereux p pibarot p redfors b mack mj makkar rr jaber wa svensson lg kapadia tuzcu em thourani vh babaliaros v herrmann hc szeto wy cohen dj lindman br mcandrew alu mc douglas p hahn rt kodali sk smith cr miller dc webb jg leon mb staging classification aortic stenosis based extent cardiac damage eur heart j 20173833513358 592 vahanian beyersdorf f praz f milojevic baldus johann b capodanno conradi l de bonis de pauli r delgado v freemantle n gilard haugaa kh jeppsson ju¨ni p pierard l prendergast pd rafael sadaba j tribouilloy c wojakowski w esceacts scientific document group esceacts guideline management valvular heart disease eur heart j 2021 doi10.1093eurheartjehab395 593 leon mb smith cr mack miller dc moses jw svensson lg tuzcu em webb jg fontana gp makkar rr brown dl block pc guyton ra pichard ad bavaria je herrmann hc douglas p petersen jl akin jj anderson wn wang pocock partner investigator transcatheter aorticvalve implantation aortic stenosis patient cannot undergo surgery n engl j med 201036315971607 594 smith cr leon mb mack mj miller dc moses jw svensson lg tuzcu em webb jg fontana gp makkar rr williams dewey kapadia babaliaros v thourani vh corso p pichard ad bavaria je herrmann hc akin jj anderson wn wang pocock sj partner investigator transcatheter surgical aorticvalve replacement highrisk patient n engl j med 201136421872198 595 adam dh popma jj reardon mj yakubov sj coselli j deeb gm gleason tg buchbinder hermiller j jr kleiman n chetcuti heiser j merhi w zorn g tadros p robinson n petrossian g hughes gc harrison jk conte j maini b mumtaz chenoweth oh jk u corevalve clinical investigator transcatheter aorticvalve replacement selfexpanding prosthesis n engl j med 201437017901798 596 popma jj adam dh reardon mj yakubov sj kleiman n heimansohn hermiller j jr hughes gc harrison jk coselli j diez j kafi schreiber gleason tg conte j buchbinder deeb gm carabello b serruys pw chenoweth oh jk corevalve united state clinical investigator transcatheter aortic valve replacement using selfexpanding bioprosthesis patient severe aortic stenosis extreme risk surgery j coll cardiol 20146319721981 597 leon mb smith cr mack mj makkar rr svensson lg kodali sk thourani vh tuzcu em miller dc herrmann hc doshi cohen dj pichard ad kapadia dewey babaliaros v szeto wy williams mr kereiakes zajarias greason kl whisenant bk hodson rw moses jw trento brown dl fearon wf pibarot p hahn rt jaber wa anderson wn alu mc webb jg partner 2 investigator transcatheter surgical aorticvalve replacement intermediaterisk patient n engl j med 201637416091620 598 reardon mj van mieghem nm popma jj kleiman n sondergaard l mumtaz adam dh deeb gm maini b gada h chetcuti gleason heiser j lange r merhi w oh jk olsen p piazza n williams windecker yakubov sj grube e makkar r lee j conte j vang e nguyen h chang mugglin serruys pw kappetein ap surtavi investigator surgical transcatheter aorticvalve replacement intermediaterisk patient n engl j med 201737613211331 599 popma jj deeb gm yakubov sj mumtaz gada h o’hair bajwa heiser jc merhi w kleiman n askew j sorajja p rovin j chetcuti sj adam dh teirstein p zorn gl 3rd forrest jk tchetche resar j walton piazza n ramlawi b robinson n petrossian g gleason tg oh jk boulware mj qiao h mugglin reardon mj evolut low risk investigator transcatheter aorticvalve replacement selfexpanding valve lowrisk patient n engl j med 201938017061715 600 mack mj leon mb thourani vh makkar r kodali sk russo kapadia sr malaisrie sc cohen dj pibarot p leipsic j hahn rt blanke p williams mr mccabe jm brown dl babaliaros v goldman szeto wy genereux p pershad pocock sj alu mc webb jg smith cr partner 3 investigator transcatheter aorticvalve replacement balloonexpandable valve low risk patient n engl j med 201938016951705 601 elder dh wei l szwejkowski br libianto r nadir pauriah rekhraj lim tk george j doney pringle sd choy struthers ad lang cc impact reninangiotensinaldosterone system blockade heart failure outcome mortality patient identified aortic regurgitation large population cohort j coll cardiol 20115820842091 602 chaliki hp mohty avierinos jf scott cg schaff hv tajik aj enriquez sarano outcome aortic valve replacement patient severe aortic regurgitation markedly reduced left ventricular function circulation 200210626872693 603 tornos p sambola permanyermiralda g evangelista gomez z soler soler j longterm outcome surgically treated aortic regurgitation influence guideline adherence toward early surgery j coll cardiol 20064710121017 604 yoon sh schmidt bleiziffer schofer n fiorina c munozgarcia aj yzeiraj e amatsantos ij tchetche jung c fujita b mangieri deutsch ubben deuschl f kuwata de biase c williams dhoble kim wk ferrari e barbanti vollema em miceli giannini c attizzani gf kong wkf gutierrezibanes e jimenez diaz va wijeysundera hc kaneko h chakravarty makar sievert h hengstenberg c prendergast bd vincent f abdelwahab nombelafranco l silaschi tarantini g butter c ensminger sm hildicksmith petronio yin wh de marco f testa l van mieghem nm whisenant bk kuck kh colombo kar moris c delgado v maisano f nietlispach f mack mj schofer j schaefer u bax jj frerker c latib makkar rr transcatheter aortic valve replacement pure native aortic valve regurgitation j coll cardiol 20177027522763 605 feldman foster e glower dd kar rinaldi mj fail p smalling rw siegel r rose ga engeron e loghin c trento skipper er fudge letsou gv massaro jm mauri l everest ii investigator percutaneous repair surgery mitral regurgitation n engl j med 201136413951406 606 tamargo obokata reddy ynv pislaru sv lin g egbe ac nishimura ra borlaug ba functional mitral regurgitation left atrial myopathy heart failure preserved ejection fraction eur j heart fail 202022489498 607 dziadzko v clavel dziadzko medinainojosa jr michelena h maalouf j nkomo v thapa p enriquezsarano outcome undertreatment mitral regurgitation community cohort lancet 2018391960969 608 goliasch g bartko pe pavo n neuhold wurm r mascherbauer j lang im strunk g hulsmann refining prognostic impact functional mitral regurgitation chronic heart failure eur heart j 2018393946 609 bertrand pb schwammenthal e levine ra vandervoort pm exercise dynam ic secondary mitral regurgitation pathophysiology therapeutic implica tions circulation 2017135297314 610 obadia jf messikazeitoun leurent g iung b bonnet g piriou n lefevre piot c rouleau f carrie nejjari ohlmann p leclercq f saint etienne c teiger e leroux l karam n michel n gilard donal e trochu jn cormier b armoiry x boutitie f maucortboulch barnel c samson g guerin p vahanian mewton n mitrafr investigator percutaneous repair medical secondary mitral regurgitation n engl j med 201837922972306 611 iung b armoiry x vahanian boutitie f mewton n trochu jn lefevre messikazeitoun guerin p cormier b brochet e thibault h himbert thivolet leurent g bonnet g donal e piriou n piot c habib g rouleau f carrie nejjari ohlmann p saint etienne c leroux l gilard samson g rioufol g maucortboulch obadia jf mitrafr investigator percutaneous repair medical secondary mitral regurgitation outcome 2 year eur j heart fail 20192116191627 612 stone gw lindenfeld j abraham wt kar lim mishell jm whisenant b grayburn pa rinaldi kapadia sr rajagopal v sarembock ij brieke marx cohen dj weissman nj mack mj coapt investigator transcatheter mitralvalve repair patient heart failure n engl j med 201837923072318 613 senni adamo metra alfieri vahanian functional mitral regurgitation chronic heart failure get ‘proof concept’ mitrafr coapt eur j heart fail 201921852861 614 grayburn pa sannino packer proportionate disproportionate func tional mitral regurgitation new conceptual framework reconciles result mitrafr coapt jacc cardiovasc imaging 201912353362 615 coat ajs anker sd baumbach alfieri von bardeleben r bauersachs j bax jj boveda celutkiene j cleland jg dagres n deneke farmakis filippatos g hausleiter j hindricks g jankowska ea lainscak leclercq c lund lh mcdonagh mehra mr metra mewton n mueller c mullens w muneretto c obadia jf ponikowski p praz f rudolph v ruschitzka f vahanian windecker zamorano jl edvardsen heidbuchel h seferovic pm prendergast b management secondary mitral regurgitation patient heart failure joint position statement heart failure association hfa european association cardiovascular imaging eacvi european heart rhythm association ehra european association percutaneous cardiovascular intervention eapci esc eur heart j 20214212541269 616 adamo fiorelli f melica b d’ortona r lupi l giannini c silva g fiorina c branca l chiari e chizzola g spontoni p espada guerreiro c curello petronio metra coaptlike profile predicts longterm outcome patient secondary mitral regurgitation undergoing mitraclip implantation jacc cardiovasc interv 2021141525 downloaded guest 24 november 2024 617 godino c munafo scotti estevezloureiro r portoles hernandez arzamendi fernandez peregrina e taramasso fam np ho ec asgar vitrella g raineri c adamo fiorina c montalto c fraccaro c giannini c fiorelli f popolo rubbio ooms jf compagnone maffeo bettari l furholz tamburino c petronio grasso c agricola e van mieghem nm tarantini g curello praz f pascual potena l colombo maisano f metra margonato crimi g saia f mitraclip secondary mitral regurgitation bridge heart transplantation 1year outcome international mitrabridge registry j heart lung transplant 20203913531362 618 witte kk lipiecki j siminiak meredith malkin cj goldberg sl stark von bardeleben r cremer pc jaber wa celermajer kaye dm sievert h reduce fmr randomized shamcontrolled percutane ous mitral annuloplasty functional mitral regurgitation jacc heart fail 20197945955 619 geyer keller k sotiriou e tamm ar ruf tf kreidel f beirasfernandez gori schulz e munzel von bardeleben r association transcatheter direct mitral annuloplasty acute anatomic haemodynamic clinical come severe mitral valve regurgitation esc heart fail 2020733363344 620 giallauria f di lorenzo parlato testa c bobbio e vigorito c coat ajs individual patient data metaanalysis effect carillon v r mitral contour system esc heart fail 2020733833391 621 lipiecki j fahrat h monzy caillot n siminiak johnson vogt stark goldberg sl longterm prognosis patient treated coronary sinus based percutaneous annuloplasty single centre experience esc heart fail 2020733293335 622 ruf tf kreidel f tamm ar geyer hahad zirbs jc schwidtal bl beirasfernandez witte kk munzel von bardeleben r transcatheter indirect mitral annuloplasty induces annular left atrial remodelling secon dary mitral regurgitation esc heart fail 2020714001408 623 sorajja p moat n badhwar v walter paone g bethea b bae r dahle g mumtaz grayburn p kapadia babaliaros v guerrero satler l thourani v bedogni f rizik denti p dumonteil n modine sinhal chuang popma jj blanke p leipsic j muller initial feasibility new transcatheter mitral prosthesis first 100 patient j coll cardiol 20197312501260 624 zack cj fender ea chandrashekar p reddy ynv bennett ce stulak jm miller vm nishimura ra national trend outcome isolated tricuspid valve surgery j coll cardiol 20177029532960 625 taramasso benfari g van der bijl p alessandrini h attingertoller biasco l lurz p braun brochet e connelly ka de bruijn denti p deuschl f estevezloureiro r fam n frerker c gavazzoni hausleiter j ho e juliard jm kaple r besler c kodali kreidel f kuck kh latib lauten monivas v mehr muntanecarol g nazif nickening g pedrazzini g philippon f pozzoli praz f puri r rodescabau j schafer u schofer j sievert h tang ghl thiele h topilsky rommel kp delgado v vahanian von bardeleben r webb jg weber windecker winkel zuber leon mb hahn rt bax jj enriquezsarano maisano f transcatheter medical patient symptomatic severe tricuspid regurgitation j coll cardiol 20197429983008 626 rapsomaniki e timmis george j pujadesrodriguez shah ad denaxas white ir caulfield mj deanfield je smeeth l williams b hingorani hemingway h blood pressure incidence twelve cardiovascular disease lifetime risk healthy lifeyears lost agespecific association 1.25 million people lancet 201438318991911 627 cohn jn pfeffer rouleau j sharpe n swedberg k straub wiltse c wright tj moxcon investigator adverse mortality effect central sympa thetic inhibition sustainedrelease moxonidine patient heart failure moxcon eur j heart fail 20035659667 628 kato onishi k yamanaka takamura dohi k yamada n wada h nobori ito exaggerated hypertensive response exercise patient diastolic heart failure hypertens 200831679684 629 uijl savarese g vaartjes dahlstrom u brugts jj linssen gcm van empel v brunnerla rocca hp asselbergs fw lund lh hoe aw koudstaal identification distinct phenotypic cluster heart failure preserved ejec tion fraction eur j heart fail 202123973982 630 thomopoulos c parati g zanchetti effect blood pressurelowering cardiovascular outcome mortality 14 effect different class antihypertensive drug older younger patient overview metaanalysis j hypertens 20183616371647 631 vaduganathan pareek kristensen amd bieringsorensen byrne c almarzooq z olesen tb olsen mh bhatt dl prevention heart failure event intensive standard blood pressure lowering across spec trum kidney function albuminuria sprint substudy eur j heart fail 202123384392 632 fagard rh celis h thijs l wouters regression left ventricular mass antihypertensive metaanalysis randomized comparative hypertension 20095410841091 633 cautela j tartiere jm cohensolal bellemainappaix theron tibi januzzi jl jr roubille f girerd n management low blood pressure ambulatory heart failure reduced ejection fraction patient eur j heart fail 20202213571365 634 kang sh kim j park jj oh iy yoon ch kim hj kim k choi dj risk stroke congestive heart failure without atrial fibrillation int j cardiol 2017248182187 635 abdulrahim ah perez ac fulton rl jhund p latini r tognoni g wikstrand j kjekshus j lip gy maggioni ap tavazzi l lee kr mcmurray jj investigator controlled rosuvastatin multinational heart failure corona gissiheart failure gissihf committee investigator risk stroke chronic heart failure patient without atrial fibril lation analysis controlled rosuvastatin multinational heart failure corona gruppo italiano per lo studio della sopravvivenza nell’insufficienza cardiacaheart failure gissihf circulation 201513114861494 discussion 1494 636 abdulrahim ah perez ac macisaac rl jhund p claggett bl carson pe komajda mckelvie r zile mr swedberg k yusuf pfeffer solomon sd lip gyh lee kr mcmurray jjv candesartan heart failure assessment reduction mortality morbiditypreserved charmpreserved irbesartan heart failure preserved systolic function ipreserve steering committee risk stroke chronic heart failure patient pre served ejection fraction without atrial fibrillation analysis charm preserved ipreserve eur heart j 201738742750 637 mehra mr vaduganathan fu ferreira jp anker sd cleland jgf lam csp van veldhuisen dj byra wm spiro te deng h zannad f greenberg b comprehensive analysis effect rivaroxaban stroke transient ischaemic attack patient heart failure coronary artery disease sinus rhythm commander heart failure eur heart j 20194035933602 638 kotecha chudasama r lane da kirchhof p lip gy atrial fibrillation heart failure due reduced preserved ejection fraction systematic review metaanalysis death adverse outcome int j cardiol 2016203660666 639 adelborg k szepligeti sundboll j horvathpuho e henderson vw ording pedersen l sorensen ht risk stroke patient heart failure populationbased 30year cohort stroke 20174811611168 640 witt bj brown rd jr jacobsen sj weston sa ballman kv meverden ra roger vl ischemic stroke heart failure communitybased heart j 2006152102109 641 homma thompson jl pullicino pm levin b freudenberger r teerlink jr ammon se graham sacco rl mann dl mohr jp massie bm labovitz aj anker sd lok dj ponikowski p estol cj lip gy di tullio mr sanford ar mejia v gabriel ap del valle buchsbaum r warcef investigator warfarin aspirin patient heart failure sinus rhythm n engl j med 201236618591869 642 hopper skiba krum h updated metaanalysis antithrombotic patient heart failure sinus rhythm eur j heart fail 2013156978 643 bauersachs j konig van der meer p petrie mc hilfikerkleiner mbakwem hamdan r jackson forsyth p de boer ra mueller c lyon ar lund lh piepoli mf heymans chioncel anker sd ponikowski p seferovic pm johnson mr mebazaa sliwa k pathophysiology diagnosis manage ment peripartum cardiomyopathy position statement heart failure association european society cardiology group peripartum cardiomyopathy eur j heart fail 201921827843 644 singh dp patel h left ventricular noncompaction cardiomyopathy statpearls internet treasure island fl statpearls publishing 2021 pmid 30725710 645 subahi hassan aai abubakar h ibrahim w isolated left ventricular non compaction lvnc recurrent stroke anticoagulate anticoa gulate question bmj case rep 20172017bcr2017220954 646 seferovic pm petrie mc filippatos g anker sd rosano g bauersachs j paulus wj komajda cosentino f de boer ra farmakis doehner w lambrinou e lopatin piepoli mf theodorakis mj wiggers h lekakis j mebazaa mama tschope c hoe aw seferovic jp logue j mcdonagh riley jp milinkovic polovina van veldhuisen dj lainscak maggioni ap ruschitzka f mcmurray jjv Type 2 diabetes mellitus heart failure position statement heart failure association european society cardiology eur j heart fail 201820853872 647 seferovic pm coat ajs ponikowski p filippatos g huelsmann jhund p polovina mm komajda seferovic j sari cosentino f ambrosio g metra piepoli chioncel lund lh thum de boer ra mullens w lopatin volterrani hill l bauersachs j lyon petrie mc anker rosano downloaded guest 24 november 2024 gmc european society cardiologyheart failure association position paper role safety new glucoselowering drug patient heart fail ure eur j heart fail 202022196213 648 cosentino f cannon cp cherney dzi masiukiewicz u pratley r dagogo jack frederich r charbonnel b mancuso j shih wj terra sg cater nb gantz mcguire dk vertis cardiovascular investigator efficacy ertugliflozin heart failurerelated event patient type 2 diabetes mellitus established atherosclerotic cardiovascular disease result vertis cardiovascular circulation 202014222052215 649 mcguire dk shih wj cosentino f charbonnel b cherney dzi dagogojack pratley r greenberg wang huyck gantz terra sg masiukiewicz u cannon cp association sglt2 inhibitor cardiovascular kidney outcome patient type 2 diabetes metaanalysis jama cardiol 20216148158 650 seferovic pm ponikowski p anker sd bauersachs j chioncel cleland jgf de boer ra drexel h ben gal hill l jaarsma jankowska ea anker lainscak lewis b mcdonagh metra milicic mullens w piepoli mf rosano g ruschitzka f volterrani voors aa filippatos g coat ajs clinical practice update heart failure 2019 pharmacotherapy procedure device patient management expert consensus meeting report heart failure association european society cardiology eur j heart fail 20192111691186 651 eurich dt weir dl majumdar sr tsuyuki rt johnson ja tjosvold l vanderloo se mcalister fa comparative safety effectiveness metformin patient diabetes mellitus heart failure systematic review obser vational involving 34000 patient circ heart fail 20136395402 652 andersson c olesen jb hansen pr weeke p norgaard jorgensen ch lange abildstrom sz schramm tk vaag kober l torppedersen c gislason gh metformin associated low risk mortality diabetic patient heart failure retrospective nationwide cohort diabetologia 20105325462553 653 scirica bm bhatt dl braunwald e steg pg davidson j hirshberg b ohman p frederich r wiviott sd hoffman eb cavender udell ja desai nr mosenzon mcguire dk ray kk leiter la raz savortimi 53 steering committee investigator saxagliptin cardiovascular outcome patient type diabetes mellitus n engl j med 201336913171326 654 zannad f cannon cp cushman wc bakris gl menon v perez fleck pr mehta cr kupfer wilson c lam h white wb examine investigator heart failure mortality outcome patient type 2 diabetes taking alogliptin placebo examine multicentre randomised doubleblind lancet 201538520672076 655 green jb bethel armstrong pw buse jb engel garg j josse r kaufman kd koglin j korn lachin jm mcguire dk pencina mj standl e stein pp suryawanshi van de werf f peterson ed holman rr tecos group effect sitagliptin cardiovascular outcome type 2 diabetes n engl j med 2015373232242 656 rosenstock j perkovic v johansen oe cooper kahn se marx n alexander jh pencina toto rd wanner c zinman b woerle hj baanstra pfarr e schnaidt meinicke george jt von eynatten mcguire dk carmelina investigator effect linagliptin v placebo major cardiovas cular event adult type 2 diabetes high cardiovascular renal risk carmelina randomized clinical jama 20193216979 657 mcmurray jjv ponikowski p bolli gb lukashevich v kozlovski p kothny w lewsey jd krum h vividd committee investigator effect vil dagliptin ventricular function patient type 2 diabetes mellitus heart failure randomized placebocontrolled jacc heart fail 20186817 658 sinha b ghosal metaanalyses effect dpp4 inhibitor sglt2 inhibitor glp1 receptor analogue cardiovascular death myocardial infarction stroke hospitalization heart failure diabetes clin pract 2019150816 659 savarese g d’amore c federici de martino f dellegrottaglie marciano c ferrazzano f losco lund lh trimarco b rosano gm perronefilardi p effect dipeptidyl peptidase inhibitor sodiumglucose linked cotransporter2 inhibitor cardiovascular event patient type 2 dia betes mellitus metaanalysis int j cardiol 2016220595601 660 kristensen sl rorth r jhund p docherty kf sattar n preiss kober l petrie mc mcmurray jjv cardiovascular mortality kidney outcome glp1 receptor agonist patient type 2 diabetes systematic review metaanalysis cardiovascular outcome lancet diabetes endocrinol 20197776785 661 jorsal kistorp c holmager p tougaard r nielsen r hanselmann nilsson b moller je hjort j rasmussen j boesgaard tw schou videbaek l gustafsson flyvbjerg wiggers h tarnow l effect liraglutide glucagonlike peptide1 analogue left ventricular function stable chronic heart failure patient without diabetes livea multicentre double blind randomised placebocontrolled eur j heart fail 2017196977 662 margulies kb hernandez af redfield mm givertz mm oliveira gh cole r mann dl whellan dj kiernan felker gm mcnulty se anstrom kj shah mr braunwald e cappola tp nhlbi heart failure clinical research network effect liraglutide clinical stability among patient advanced heart failure reduced ejection fraction randomized clinical jama 2016316500508 663 gerstein hc jung h ryden l diaz r gilbert yusuf origin investigator effect basal insulin glargine first recurrent episode heart failure hospitalization origin outcome reduction initial glargine intervention circulation 20181378890 664 cosmi f shen l magnoli abraham wt anand cleland jg cohn jn cosmi de berardis g dickstein k franzosi gullestad l jhund p kjekshus j kober l lepore v lucisano g maggioni ap masson mcmurray jjv nicolucci petrarolo v robusto f staszewsky l tavazzi l teli r tognoni g wikstrand j latini r insulin associated worse outcome patient chronic heart failure diabetes eur j heart fail 201820888895 665 shen l rorth r cosmi kristensen sl petrie mc cosmi f latini r kober l anand carson pe granger cb komajda mckelvie r solomon sd staszewsky l swedberg k huynh zile mr jhund p mcmurray jjv insulin clinical outcome patient diabetes heart failure preserved ejection fraction eur j heart fail 201921974984 666 tzoulaki molokhia curcin v little mp millett cj ng hughes ri khunti k wilkins mr majeed elliott p risk cardiovascular disease cause mortality among patient type 2 diabetes prescribed oral antidiabetes drug retrospective cohort using uk general practice research database bmj 2009339b4731 667 roumie cl min jy d’agostino mcgowan l presley c grijalva cg hackstadt aj hung greevy ra elasy griffin mr comparative safety sulfony lurea metformin monotherapy risk heart failure cohort j heart assoc 20176 668 lago rm singh pp nesto rw congestive heart failure cardiovascular death patient prediabetes type 2 diabetes given thiazolidinediones metaanalysis randomised clinical lancet 200737011291136 669 vargasuricoechea h boneloperdomo thyroid dysfunction heart fail ure mechanism association curr heart fail rep 2017144858 670 kannan l shaw pa morley mp brandimarto j fang jc sweitzer nk cappola tp cappola ar thyroid dysfunction heart failure cardiovascular come circ heart fail 201811e005266 671 sato yoshihisa kimishima kiko kanno yokokawa abe misaka sato oikawa kobayashi yamaki kunii h nakazato k takeishi low t3 syndrome associated high mortality hospitalized patient heart failure j card fail 201925195203 672 stott dj rodondi n kearney pm ford westendorp rgj mooijaart sp sattar n aubert ce aujesky bauer dc baumgartner c blum mr browne jp byrne collet th dekker om den elzen wpj du puy r elli g feller floriani c hendry k hurley c jukema jw kean kelly krebs langhorne p mccarthy g mccarthy v mcconnachie mcdade messow o’flynn o’riordan poortvliet rke quinn tj russell sinnott c smit jwa van dorland ha walsh ka walsh ek watt wilson r gussekloo j trust group thyroid hormone older adult subclinical hypothyroidism n engl j med 201737625342544 673 feller snel moutzouri e bauer dc de montmollin aujesky ford gussekloo j kearney pm mooijaart quinn stott westendorp r rodondi n dekker om association thyroid hormone quality life thyroidrelated symptom patient subclinical hypothyroidism systematic review metaanalysis jama 201832013491359 674 peeters rp subclinical hypothyroidism n engl j med 201737625562565 675 packer lam csp lund lh maurer borlaug ba characterization inflammatorymetabolic phenotype heart failure preserved ejection fraction hypothesis explain influence sex evolution potential disease eur j heart fail 20202215511567 676 obokata reddy ynv pislaru sv melenovsky v borlaug ba evidence sup porting existence distinct obese phenotype heart failure pre served ejection fraction circulation 2017136619 677 rao vn fudim mentz rj michos ed felker gm regional adiposity heart failure preserved ejection fraction eur j heart fail 20202215401550 678 carbone lavie cj arena r obesity heart failure focus obesity paradox mayo clin proc 201792266279 679 horwich tb fonarow gc clark al obesity obesity paradox heart failure prog cardiovasc dis 201861151156 680 adamopoulos c meyer p desai rv karatzidou k ovalle f white aban love te deedwania p anker sd ahmed absence obesity paradox downloaded guest 24 november 2024 patient chronic heart failure diabetes mellitus propensitymatched eur j heart fail 201113200206 681 zamora e lupon j enjuanes c pascualfigal de antonio domingo comincolet j vila j penafiel j farre n alonso n santesmases j troya bayesgenis benefit obesity paradox diabetic patient heart failure eur j heart fail 201618851858 682 piepoli mf corra u veglia f bonomi salvioni e cattadori g metra lombardi c sinagra g limongelli g raimondo r f magri belardinelli r parati g mina c scardovi ab guazzi cicoira scrutinio di lenarda bussotti frigerio correale villani gq paolillo passino c agostoni p mecki score research group exercise tolerance explain obesity paradox patient systolic heart failure data mecki score research group eur j heart fail 201618545553 683 streng kw voors aa hillege hl anker sd cleland jg dickstein k filippatos g metra ng ponikowski p samani nj van veldhuisen dj zwinderman ah zannad f damman k van der meer p lang cc waistto hip ratio mortality heart failure eur j heart fail 20182012691277 684 carbone elagizi lavie cj obesity mortality risk heart failure adipose tissue distribution matter eur j heart fail 20182012781280 685 packer patient obesity type 2 diabetes atrial fibrilla tion also undiagnosed heart failure critical conceptual framework understanding mechanism improving diagnosis eur j heart fail 202022214227 686 vitale c jankowska e hill l piepoli doehner w anker sd lainscak jaarsma ponikowski p rosano gmc seferovic p coat aj heart failure associationeuropean society cardiology position paper frailty patient heart failure eur j heart fail 20192112991305 687 denfeld qe wintersstone k mudd jo gelow jm kurdi lee c prev alence frailty heart failure systematic review metaanalysis int j cardiol 2017236283289 688 bieleckadabrowa ebner n santos mr ishida j hasenfuss g von haehling cachexia muscle wasting frailty cardiovascular disease eur j heart fail 20202223142326 689 khan h kalogeropoulos ap georgiopoulou vv newman ab harris tb rodondi n bauer dc kritchevsky sb butler j frailty risk heart failure older adult health aging body composition heart j 2013166887894 690 wood nf lacroix az gray sl aragaki cochrane bb brunner rl masaki k murray newman ab women’s health initiative frailty emergence consequence woman aged 65 older women’s health initiative observational j geriatr soc 20055313211330 691 vidan mt blayanovakova v sanchez e ortiz j serrarexach ja bueno h prevalence prognostic impact frailty component non dependent elderly patient heart failure eur j heart fail 201618869875 692 dewan p jackson jhund p shen l ferreira jp petrie mc abraham wt desai dickstein k kober l packer rouleau jl solomon sd swedberg k zile mr mcmurray jjv prevalence importance frailty heart fail ure reduced ejection fraction – analysis paradigmhf atmosphere eur j heart fail 20202221232133 693 sander na supiano lewis ef liu j claggett b pfeffer desai sweitzer nk solomon sd fang jc frailty syndrome outcome topcat eur j heart fail 20182015701577 694 evans wj morley je argiles j bale c baracos v guttridge jatoi kalantarzadeh k loch h mantovani g mark mitch muscaritoli najand ponikowski p rossi fanelli f schambelan schols schuster thomas wolfe r anker sd cachexia new definition clin nutr 200827793799 695 loncar g springer j anker doehner w lainscak cardiac cachexia hic et nunc j cachexia sarcopenia muscle 20167246260 696 von haehling lainscak springer j anker sd cardiac cachexia systematic overview pharmacol ther 2009121227252 697 anker holcomb r muscaritoli von haehling haverkamp w jatoi morley je strasser f landmesser u coat ajs anker sd orphan disease sta tus cancer cachexia usa european union systematic review j cachexia sarcopenia muscle 2019102234 698 bauer j morley je schols ferrucci l cruzjentoft aj dent e baracos crawford ja doehner w heymsfield sb jatoi kalantarzadeh k lainscak landi f laviano mancuso muscaritoli prado cm strasser f von haehling coat ajs anker sd sarcopenia time action scwd position paper j cachexia sarcopenia muscle 201910956961 699 ameri p canepa anker belenkov berglerklein j cohensolal farmakis lopezfernandez lainscak pudil r ruschitska f seferovic p filippatos g coat suter von haehling ciardiello f de boer ra lyon ar tocchetti cg heart failure association cardiooncology group european society cardiology cancer diagnosis patient heart failure epidemiology clinical implication gap knowledge eur j heart fail 201820879887 700 fonseca g santos mr de souza fr takayama l rodrigues pereira rm negrao ce alves mnn discriminating sarcopenia overweightobese male patient heart failure influence body mass index esc heart fail 202078491 701 emami saitoh valentova sandek evertz r ebner n loncar g springer j doehner w lainscak hasenfuss g anker sd von haehling comparison sarcopenia cachexia men chronic heart failure result investigating comorbidities aggravating heart failure sicahf eur j heart fail 20182015801587 702 fulster tacke sandek ebner n tschope c doehner w anker sd von haehling muscle wasting patient chronic heart failure result investigating comorbidities aggravating heart failure sica hf eur heart j 201334512519 703 springer j springer ji anker sd muscle wasting sarcopenia heart failure beyond update 2017 esc heart fail 20174492498 704 von haehling ebner n santos mr springer j anker sd muscle wasting cachexia heart failure mechanism nat rev cardiol 201714323341 705 caminiti g volterrani iellamo f marazzi g massaro r miceli mammi c piepoli fini rosano gm effect longacting testosterone functional exercise capacity skeletal muscle performance insulin resistance baroreflex sensitivity elderly patient chronic heart failure double blind placebocontrolled randomized j coll cardiol 200954919927 706 anand gupta p anemia iron deficiency heart failure current concept emerging circulation 20181388098 707 iorio senni barbati g greene sj poli zambon e di nora c cioffi g tarantini l gavazzi sinagra g di lenarda prevalence prognostic impact noncardiac comorbidities heart failure outpatient preserved reduced ejection fraction communitybased eur j heart fail 20182012571266 708 okonko mandal ak missouri cg poolewilson pa disordered iron homeostasis chronic heart failure prevalence predictor relation ane mia exercise capacity survival j coll cardiol 20115812411251 709 mcdonagh damy doehner w lam csp sindone van der meer p cohensolal kindermann manito n pfister pohjantahtimaaroos h taylor j comincolet j screening diagnosis iron deficiency chronic heart failure putting 2016 european society cardiology heart failure guideline clinical practice eur j heart fail 20182016641672 710 cappellini md comincolet j de francisco dignass doehner w lam c macdougall ic rogler g camaschella c kadir r kassebaum nj spahn dr taher musallam km iron core group iron deficiency across chronic inflammatory condition international expert opinion definition diagnosis management j hematol 20179210681078 711 lopez cacoub p macdougall ic peyrinbiroulet l iron deficiency anaemia lancet 2016387907916 712 sierpinski r josiak k suchocki wojtaspolc k mazur g butrym rozentryt p van der meer p comincolet j von haehling kosmala w przewlockakosmala banasiak w nowak j voors aa anker sd cleland jgf ponikowski p jankowska ea high soluble transferrin receptor patient heart failure measure iron deficiency strong predictor mor tality eur j heart fail 2020 oct 27 doi 10.1002ejhf2036 epub ahead print 713 rocha bml cunha gjl falcao menezes lf burden iron deficiency heart failure therapeutic approach j coll cardiol 201871782793 714 klip comincolet j voors aa ponikowski p enjuanes c banasiak w lok dj rosentryt p torrens polonski l van veldhuisen dj van der meer p jankowska ea iron deficiency chronic heart failure international pooled analysis heart j 2013165575582e3 715 jankowska ea rozentryt p witkowska nowak j hartmann ponikowska b borodulinnadzieja l banasiak w polonski l filippatos g mcmurray jj anker sd ponikowski p iron deficiency ominous sign patient sys tolic chronic heart failure eur heart j 20103118721880 716 von haehling jankowska ea van veldhuisen dj ponikowski p anker sd iron deficiency cardiovascular disease nat rev cardiol 201512659669 717 stugiewicz tkaczyszyn kasztura banasiak w ponikowski p jankowska ea influence iron deficiency functioning skeletal muscle experimental evidence clinical implication eur j heart fail 201618762773 718 jankowska ea malyszko j ardehali h koczorawska e banasiak w von haehling macdougall ic weiss g mcmurray jj anker sd gheorghiade ponikowski p iron status patient chronic heart failure eur heart j 201334827834 719 swedberg k young jb anand cheng desai diaz r maggioni ap mcmurray jj o’connor c pfeffer solomon sd sun tendera van downloaded guest 24 november 2024 veldhuisen dj redhf committee redhf investigator ane mia darbepoetin alfa systolic heart failure n engl j med 201336812101219 720 anker sd comin colet j filippatos g willenheimer r dickstein k drexler h luscher tf bart b banasiak w niegowska j kirwan ba mori c von eisenhart rothe b pocock sj poolewilson pa ponikowski p fairhf investigator ferric carboxymaltose patient heart failure iron defi ciency n engl j med 200936124362448 721 comincolet j lainscak dickstein k filippatos g johnson p luscher tf mori c willenheimer r ponikowski p anker sd effect intravenous ferric carboxymaltose healthrelated quality life patient chronic heart failure iron deficiency subanalysis fairhf eur heart j 2013343038 722 ponikowski p van veldhuisen dj comincolet j ertl g komajda mareev v mcdonagh parkhomenko tavazzi l levesque v mori c roubert b filippatos g ruschitzka f anker sd confirmhf investigator beneficial effect longterm intravenous iron ferric carboxymaltose patient symptomatic heart failure iron deficiency eur heart j 201536657668 723 van veldhuisen dj ponikowski p van der meer p metra bohm doletsky voors aa macdougall ic anker sd roubert b zakin l cohensolal effecthf investigator effect ferric carboxymaltose exercise capacity patient chronic heart failure iron deficiency circulation 201713613741383 724 jankowska ea tkaczyszyn suchocki drozd von haehling doehner w banasiak w filippatos g anker sd ponikowski p effect intravenous iron irondeficient patient systolic heart failure metaanalysis randomized controlled eur j heart fail 201618786795 725 anker sd kirwan ba van veldhuisen dj filippatos g comincolet j ruschitzka f luscher tf arutyunov gp motro mori c roubert b pocock sj ponikowski p effect ferric carboxymaltose hospitalisation mor tality rate irondeficient heart failure patient individual patient data metaanalysis eur j heart fail 201820125133 726 filippatos g farmakis colet jc dickstein k luscher tf willenheimer r parissis j gaudesius g mori c von eisenhart rothe b greenlaw n ford ponikowski p anker sd intravenous ferric carboxymaltose irondeficient chronic heart failure patient without anaemia subanalysis fairhf eur j heart fail 20131512671276 727 von haehling ebner n evertz r ponikowski p anker sd iron deficiency heart failure overview jacc heart fail 201973646 728 lewis gd malhotra r hernandez af mcnulty se smith felker gm tang whw larue sj redfield mm semigran mj givertz mm van buren p whellan anstrom kj shah mr desvignenickens p butler j braunwald e nhlbi heart failure clinical research network effect oral iron repletion exercise capacity patient heart failure reduced ejection fraction iron deficiency ironout heart failure randomized clinical jama 201731719581966 729 mullens w damman k testani jm marten p mueller c lassus j tang whw skouri h verbrugge fh orso f hill l ural lainscak rossignol p metra mebazaa seferovic p ruschitzka f coat evaluation kidney function throughout heart failure trajectory – position statement heart failure association european society cardiology eur j heart fail 202022584603 730 ter maaten jm damman k verhaar mc paulus wj duncker dj cheng c van heerebeek l hillege hl lam c navis g voors aa connecting heart failure preserved ejection fraction renal dysfunction role endothelial dysfunction inflammation eur j heart fail 201618588598 731 van der pol van gilst wh voors aa van der meer p treating oxidative stress heart failure past present future eur j heart fail 201921425435 732 lofman szummer k dahlstrom u jernberg lund lh association prognostic impact chronic kidney disease heart failure preserved midrange reduced ejection fraction eur j heart fail 20171916061614 733 lofman szummer k evans carrero jj lund lh jernberg incidence association prognostic impact worsening renal function heart failure different ejection fraction category j cardiol 201912415751583 734 schefold jc filippatos g hasenfuss g anker sd von haehling heart failure kidney dysfunction epidemiology mechanism management nat rev nephrol 201612610623 735 damman k valente voors aa o’connor cm van veldhuisen dj hillege hl renal impairment worsening renal function outcome patient heart failure updated metaanalysis eur heart j 201435455469 736 braunwald e diabetes heart failure renal dysfunction vicious circle prog cardiovasc dis 201962298302 737 zannad f ferreira jp pocock sj zeller c anker sd butler j filippatos g hauske sj brueckmann pfarr e schnee j wanner c packer cardiac kidney benefit empagliflozin heart failure across spectrum kidney function insight emperorreduced circulation 2021143310321 738 heerspink hjl stefansson bv correarotter r chertow gm greene hou ff mann jfe mcmurray jjv lindberg rossing p sjostrom cd toto rd langkilde wheeler dc dapackd committee investigator dapagliflozin patient chronic kidney disease n engl j med 202038314361446 739 metra davison b bettari l sun h edward c lazzarini v piovanelli b carubelli v bugatti lombardi c cotter g dei ca l worsening renal function ominous prognostic sign patient acute heart failure role congestion interaction renal function circ heart fail 201255462 740 testani jm kimmel se dry dl coca sg prognostic importance early worsening renal function initiation angiotensinconverting enzyme inhib itor patient cardiac dysfunction circ heart fail 20114685691 741 damman k tang wh felker gm lassus j zannad f krum h mcmurray jj current evidence patient chronic systolic heart failure renal insufficiency practical consideration published data j coll cardiol 201463853871 742 house aa management heart failure advancing ckd core curriculum 2018 j kidney dis 201872284295 743 kotecha gill sk flather md holmes j packer rosano g bohm mcmurray jjv wikstrand j anker sd van veldhuisen dj manzano l von lueder tg rigby andersson b kjekshus j wedel h ruschitzka f cleland jgf damman k redon j coat ajs betablockers heart failure collaborative group impact renal impairment betablocker efficacy patient heart failure j coll cardiol 20197428932904 744 jhund p solomon sd docherty kf heerspink hjl anand bohm chopra v de boer ra desai ge j kitakaze merkley b o’meara e shou tereshchenko verma vinh pn inzucchi se kober l kosiborod mn martinez fa ponikowski p sabatine bengtsson langkilde sjostrand mcmurray jjv efficacy dapagliflozin renal function come patient heart failure reduced ejection fraction result dapahf circulation 2021143298309 745 boerrigter g costelloboerrigter lc abraham wt sutton heublein dm kruger km hill mr mccullough pa burnett jc jr cardiac resynchronization improves renal function human heart failure reduced glomerular filtration rate j card fail 200814539546 746 roehm b vest ar weiner de left ventricular assist device kidney disease dialysis j kidney dis 201871257266 747 goldenberg moss aj mcnitt zareba w andrew hall wj greenberg h case rb multicenter automatic defibrillator implantation trialii investigator relation among renal function risk sudden cardiac death benefit implanted cardiac defibrillator patient ischemic left ven tricular dysfunction j cardiol 200698485490 748 goldenberg younis aktas mk mcnitt zareba w kutyifa v competing risk analysis ventricular arrhythmia event heart failure patient mod erately compromised renal dysfunction europace 20202213841390 749 coiro girerd n sharma rossignol p tritto pitt b pfeffer mcmurray jjv ambrosio g dickstein k moss zannad f association dia betes kidney function according age systolic function inci dence sudden cardiac death nonsudden cardiac death myocardial infarction survivor heart failure eur j heart fail 20192112481258 750 teerlink jr diaz r felker gm mcmurray jjv metra solomon sd adam kf anand ariasmendoza bieringsorensen bohm bonderman cleland jgf corbalan r crespoleiro dahlstrom u echeverria correa le fang jc filippatos g fonseca c goncalvesova e goudev ar howlett jg lanfear de lund macdonald p mareev v momomura si o’meara e parkhomenko ponikowski p ramires fja serpytis p sliwa k spinar j suter tm tomcsanyi j vandekerckhove h vinereanu voors aa yilmaz mb zannad f sharpsten l legg jc abbasi sa varin c malik fi kurtz ce galactichf investigator omecamtiv mecarbil chronic heart failure reduced ejection fraction galactichf baseline characteristic compari son contemporary clinical eur j heart fail 20202221602171 751 urso c brucculeri caimi g acidbase electrolyte abnormality heart failure pathophysiology implication heart fail rev 201520493503 752 butler j vijayakumar pitt b need revisit heart failure guideline hyperkalaemia management use mineralocorticoid receptor antagonist eur j heart fail 20182012471251 753 vardeny claggett b anand rossignol p desai zannad f pitt b solomon sd randomized aldactone evaluation rale investigator incidence predictor outcome related hypo hyperkalemia downloaded guest 24 november 2024 patient severe heart failure treated mineralocorticoid receptor antagonist circ heart fail 20147573579 754 rossignol p dobre mcmurray jj swedberg k krum h van veldhuisen dj shi h messig vincent j girerd n bakris g pitt b zannad f incidence determinant prognostic significance hyperkalemia worsening renal function patient heart failure receiving mineralocorticoid receptor antagonist eplerenone placebo addition optimal medical result eplerenone mild patient hospitalization survival heart failure emphasishf circ heart fail 201475158 755 nunez j bayesgenis zannad f rossignol p nunez e bodi v minana g santa e chorro fj mollar carratala navarro j gorriz jl lupon j husser metra sanchis j longterm potassium monitoring dynamic heart failure risk mortality circulation 201813713201330 756 linde c qin l bakhai furuland h evans ayoubkhani palaka e bennett h mcewan p serum potassium clinical outcome heart failure patient result risk calculation 21 334 patient uk esc heart fail 20196280290 757 cooper lb benson l mentz rj savarese g devore ad carrero jj dahlstrom u anker sd lainscak hernandez af pitt b lund lh association potassium level outcome heart failure reduced ejection fraction cohort swedish heart failure registry eur j heart fail 20202213901398 758 rossignol p lainscak crespoleiro laroche c piepoli mf filippatos g rosano gmc savarese g anker sd seferovic pm ruschitzka f coat ajs mebazaa mcdonagh sahuquillo penco maggioni ap lund lh heart failure longterm registry investigator group unravelling interplay hyperkalaemia reninangiotensinaldosterone inhibitor use clinical outcome data 9222 chronic heart failure patient esc hfaeorp heart failure longterm registry eur j heart fail 20202213781389 759 ahmed zannad f love te tallaj j gheorghiade ekundayo oj pitt b propensitymatched association low serum potassium level mortality chronic heart failure eur heart j 20072813341343 760 rosano gmc tamargo j kjeldsen kp lainscak agewall anker sd ceconi c coat ajs drexel h filippatos g kaski jc lund l niessner ponikowski p savarese g schmidt ta seferovic p wassmann walther lewis b expert consensus document management hyperkalaemia patient cardiovascular disease treated renin angiotensin aldosterone system inhibitor coordinated working group cardiovascular pharmacotherapy european society cardiology eur heart j cardiovasc pharmacother 20184180188 761 ferreira jp mogensen um jhund p desai rouleau jl zile mr rossignol p zannad f packer solomon sd mcmurray jjv serum potassium paradigmhf eur j heart fail 20202220562064 762 rossignol p duarte k girerd n karoui mcmurray jjv swedberg k van veldhuisen dj pocock dickstein k zannad f pitt b cardiovascular risk associated serum potassium context mineralocorticoid receptor antagonist use patient heart failure left ventricular dysfunction eur j heart fail 20202214021411 763 desai liu j pfeffer claggett b fleg j lewis ef mckinlay o’meara e shah sj sweitzer nk solomon pitt b incident hyperkalemia hypokalemia clinical outcome spironolactone heart failure pre served ejection fraction analysis topcat j card fail 201824313320 764 desai hyperkalemia patient heart failure incidence prevalence management curr heart fail rep 20096272280 765 savarese g xu h trevisan dahlstrom u rossignol p pitt b lund lh carrero jj incidence predictor outcome association dyskalemia heart failure preserved midrange reduced ejection fraction jacc heart fail 201976576 766 rosano gmc spoletini agewall pharmacology new hyperkalaemia patiromer sodium zirconium cyclosilicate eur heart j suppl 201921a28a33 767 anker sd kosiborod zannad f pina il mccullough pa filippatos g van der meer p ponikowski p rasmussen h lavin pt singh b yang deedwania p maintenance serum potassium sodium zirconium cyclosili cate zs9 heart failure patient result phase 3 randomized double blind placebocontrolled eur j heart fail 20151710501056 768 pitt b bakris gl bushinsky da garza mayo mr stasiv christschmidt h berman l weir mr effect patiromer reducing serum potassium preventing recurrent hyperkalaemia patient heart failure chronic kidney disease raas inhibitor eur j heart fail 20151710571065 769 trevisan de deco p xu h evans lindholm b bellocco r barany p jernberg lund lh carrero jj incidence predictor clinical management hyperkalaemia new user mineralocorticoid receptor antagonist eur j heart fail 20182012171226 770 ferreira jp rossello x pocock sj rossignol p claggett bl rouleau jl solomon sd pitt b pfeffer zannad f spironolactone heart failure preserved ejection fraction finding topcat eur j heart fail 20202216151624 771 volterrani perrone v sangiorgi giacomini e iellamo f degli esposti l lhus group effect hyperkalaemia nonadherence renin angiotensinaldosterone system inhibitor patient heart failure italy propensitymatched eur j heart fail 20202220492055 772 pitt b anker sd bushinsky da kitzman dw zannad f huang iz investigator pearlhf evaluation efficacy safety rly5016 pol ymeric potassium binder doubleblind placebocontrolled patient chronic heart failure pearlhf eur heart j 201132820828 773 pitt b bakris gl weir mr freeman mw lainscak mayo mr garza zawadzki r berman l bushinsky da longterm effect patiromer hyperkalaemia patient mild heart failure diabetic nephr opathy angiotensinconverting enzymesangiotensin receptor blocker result amethystdn esc heart fail 20185592602 774 agarwal r rossignol p romero garza mayo mr warren j white wb williams b patiromer placebo enable spironolactone use patient resistant hypertension chronic kidney disease amber phase 2 randomised doubleblind placebocontrolled lancet 201939415401550 775 rossignol p williams b mayo mr warren arthur ackourey g white wb agarwal r patiromer placebo enable spironolactone use patient resistant hypertension chronic kidney disease amber result prespecified subgroup heart failure eur j heart fail 20202214621471 776 pitt b bushinsky da kitzman dw ruschitzka f metra filippatos g rossignol p du mond c garza berman l lainscak patiromer investigator evaluation individualized titration regimen patiromer prevent hyperkalaemia patient heart failure chronic kidney dis ease esc heart fail 20185257266 777 ali w bakris g evolution patiromer use review curr cardiol rep 20202294 778 farmakis filippatos g parissis j kremastinos dt gheorghiade hyponatremia heart failure heart fail rev 2009145963 779 rodriguez hernandez cheungpasitporn w kashani kb riaz rangaswami j herzog e guglin krittanawong c hyponatremia heart fail ure pathogenesis management curr cardiol rev 201915252261 780 albert nm nutter b forney j slifcak e tang wh randomized controlled pilot outcome strict allowance fluid hyponatremic heart failure salthf j card fail 20131919 781 dunlap hauptman pj amin chase sl chiodo ja 3rd chiong jr dasta jf current management hyponatremia acute heart failure report hyponatremia registry patient euvolemic hypervolemic hyponatremia hn registry j heart assoc 20176e005261 782 konstam gheorghiade burnett jc jr grinfeld l maggioni ap swedberg k udelson je zannad f cook ouyang j zimmer c orlandi c efficacy vasopressin antagonism heart failure outcome tolvaptan everest investigator effect oral tolvaptan patient hospitalized worsening heart failure everest outcome jama 200729713191331 783 felker gm mentz rj cole rt adam kf egnaczyk gf fiuzat patel cb echols khouri tauras jm gupta monds p robert r o’connor cm efficacy safety tolvaptan patient hospitalized acute heart failure j coll cardiol 20176913991406 784 matsue ter maaten jm suzuki torii yamaguchi fukamizu ono fujii h kitai nishioka sugi k onishi noda kagiyama n satoh yoshida k van der meer p damman k voors aa goldsmith sr early treat ment tolvaptan improves diuretic response acute heart failure renal dysfunction clin cardiol 2017106802812 785 konstam kiernan chandler dhingra r mody fv eisen h haught wh wagoner l gupta patten r gordon p korr k fileccia r pressler sj gregory wedge p dowling romeling konstam jm massaro jm udelson je secret chf investigator coordinator committee member shortterm effect tolvaptan patient acute heart failure volume overload j coll cardiol 20176914091419 786 licata g di pasquale p parrinello g cardinale scandurra follone g argano c tuttolomondo paterna effect highdose furosemide smallvolume hypertonic saline solution infusion comparison high furosemide bolus refractory congestive heart failure longterm effect heart j 2003145459466 787 paterna di pasquale p parrinello g amato p cardinale follone g giubilato licata g effect highdose furosemide smallvolume hyper tonic saline solution infusion comparison high furosemide bolus refractory congestive heart failure eur j heart fail 20002305313 downloaded guest 24 november 2024 788 griffin soufer goljo e colna rao v jeon raghavendra p d’ambrosi j riello r coca sg mahoney jacoby ahmad chen tang whw turner j mullens w wilson fp testani jm real world use hypertonic saline refractory acute decompensated heart failure u cen ter’s experience jacc heart fail 20208199208 789 cuthbert jj pellicori p rigby pan kazmi shah p clark al low serum chloride patient chronic heart failure clinical association prognos tic significance eur j heart fail 20182014261435 790 testani jm hanberg j arroyo jp brisco ter maaten jm wilson fp bellumkonda l jacoby tang wh parikh cr hypochloraemia strongly independently associated mortality patient chronic heart fail ure eur j heart fail 201618660668 791 marchenko r sigal wasser te reyer j green j mercogliano c khan donato aa hypochloraemia 30 day readmission rate patient acute decompensated heart failure esc heart fail 20207903907 792 grodin jl simon j hachamovitch r wu jackson g halkar starling rc testani jm tang wh prognostic role serum chloride level acute decom pensated heart failure j coll cardiol 201566659666 793 hanberg j rao v ter maaten jm laur brisco perry wilson f grodin jl assefa samuel broughton j planavsky nj ahmad bellumkonda l tang wh parikh cr testani jm hypochloremia diuretic resistance heart fail ure mechanistic insight circ heart fail 20169 794 verbrugge fh marten p ameloot k haemels v penders j dupont tang whw droogne w mullens w acetazolamide increase natriuresis con gestive heart failure high risk diuretic resistance eur j heart fail 20192114151422 795 axson el ragutheeswaran k sundaram v bloom ci bottle cowie mr quint jk hospitalisation mortality patient comorbid copd heart failure systematic review metaanalysis respir 20202154 796 canepa straburzynskamigaj e drozdz j fernandezvivancos c pinilla jmg nyolczas n temporelli pl mebazaa lainscak laroche c maggioni ap piepoli mf coat ajs ferrari r tavazzi l eschfa heart failure longterm registry investigator characteristic 1year prognosis ho pitalized ambulatory heart failure patient chronic obstructive pulmo nary disease european society cardiology heart failure longterm registry eur j heart fail 201820100110 797 uijl koudstaal direk k denaxas groenwold rhh banerjee hoe aw hemingway h asselbergs fw risk factor incident heart failure age sexspecific stratum populationbased cohort using linked electronic health record eur j heart fail 20192111971206 798 caravita vachiery jl obstructive ventilatory disorder heart failure–caused heart lung curr heart fail rep 201613310318 799 magnussen h canepa zambito pe brusasco v meinertz rosenkranz learn pulmonary function testing heart failure eur j heart fail 20171912221229 800 canepa franssen fme olschewski h lainscak bohm tavazzi l rosenkranz diagnostic therapeutic gap patient heart failure chronic obstructive pulmonary disease jacc heart fail 20197823833 801 global initiative chronic obstructive lung disease global strategy diagnosis management prevention chronic obstructive pulmonary dis ease 2020 report 2020finalver1.203dec19wmvpdf 31 may 2020 802 global initiative asthma global strategy asthma management prevention 2019 28 may 2021 803 brook rd anderson ja calverley pm celli br crim c denvir magder martinez fj rajagopalan vestbo j yates j newby de summit investigator cardiovascular outcome inhaled beta2agonistcorticosteroid patient copd high cardiovascular risk heart 201710315361542 804 vestbo j anderson ja brook rd calverley pm celli br crim c martinez f yates j newby de summit investigator fluticasone furoate vilanterol survival chronic obstructive pulmonary disease heightened cardio vascular risk summit doubleblind randomised controlled lancet 201638718171826 805 hohlfeld jm vogelclaussen j biller h berliner berschneider k tillmann hc hiltl bauersachs j welte effect lung deflation indacaterol plus glycopyrronium ventricular filling patient hyperinflation copd claim doubleblind randomised crossover placebocontrolled single centre lancet respir med 20186368378 806 pearse sg cowie mr sleepdisordered breathing heart failure eur j heart fail 201618353361 807 cowie mr gallagher sleep disordered breathing heart failure doe future hold jacc heart fail 20175715723 808 cowie mr woehrle h wegscheider k angermann c d’ortho mp erdmann e levy p simonds ak somers vk zannad f teschler h adaptive servo ventilation central sleep apnea systolic heart failure n engl j med 201537310951105 809 costanzo mr ponikowski p javaheri augostini r goldberg l holcomb r kao khayat rn oldenburg stellbrink c abraham wt remede´ system pivotal group transvenous neurostimulation central sleep apnoea randomised controlled lancet 2016388974982 810 costanzo mr ponikowski p coat javaheri augostini r goldberg lr holcomb r kao khayat rn oldenburg stellbrink c mckane abraham wt remede´ system pivotal group phrenic nerve stimu lation treat patient central sleep apnoea heart failure eur j heart fail 20182017461754 811 kjekshus j apetrei e barrio v bo¨hm cleland jg cornel jh dunselman p fonseca c goudev grande p gullestad l hjalmarson hradec j janosi kamensky g komajda korewicki j kuusi mach f mareev v mcmurray jj ranjith n schaufelberger vanhaecke j van veldhuisen dj waagstein f wedel h wikstrand j corona group rosuvastatin older patient systolic heart failure n engl j med 200735722482261 812 tavazzi l maggioni ap marchioli r barlera franzosi latini r lucci nicolosi gl porcu tognoni g gissihf investigator effect rosuvastatin patient chronic heart failure gissihf randomised double blind placebocontrolled lancet 200837212311239 813 algobari le hh fall gueyffier f burnand b benefit statin sudden cardiac death prevention patient heart failure reduced ejec tion fraction metaanalysis randomized controlled plo one 201712e0171168 814 rogers jk jhund p perez ac bohm cleland jg gullestad l kjekshus j van veldhuisen dj wikstrand j wedel h mcmurray jj pocock sj effect rosuvastatin repeat heart failure hospitalization corona controlled rosuvastatin multinational heart failure jacc heart fail 20142289297 815 feinstein mj jhund p kang j ning h maggioni wikstrand j kjekshus j tavazzi l mcmurray j lloydjones dm statin reduce risk myocar dial infarction patient heart failure pooled individuallevel reanalysis corona gissihf eur j heart fail 201517434441 816 thanassoulis g brophy jm richard h pilote l gout allopurinol use heart failure outcome arch intern med 201017013581364 817 borghi c palazzuoli landolfo cosentino e hyperuricemia novel old disorderrelationship potential mechanism heart failure heart fail rev 2020254351 818 doehner w springer j landmesser u struthers ad anker sd uric acid chronic heart failure–current pathophysiological concept eur j heart fail 20081012691270 819 huang h huang b li huang li j yao h jing x chen j wang j uric acid risk heart failure systematic review metaanalysis eur j heart fail 2014161524 820 white wb saag kg becker borer j gorelick pb whelton hunt b castillo gunawardhana l care investigator cardiovascular safety febuxostat allopurinol patient gout n engl j med 201837812001210 821 hare jm mangal b brown j fisher c jr freudenberger r colucci w mann dl liu p givertz mm schwarz rp optchf investigator impact oxypuri nol patient symptomatic heart failure result optchf j coll cardiol 20085123012309 822 ogino k kato furuse kinugasa ishida k osaki kinugawa igawa hisatome shigemasa c anker sd doehner w uric acidlowering benzbromarone patient heart failure doubleblind placebocon trolled crossover preliminary circ heart fail 201037381 823 givertz mm anstrom kj redfield mm deswal haddad h butler j tang wh dunlap lewinter mm mann dl felker gm o’connor cm goldsmith sr ofili eo saltzberg mt margulies kb cappola tp konstam semigran mj mcnulty se lee kl shah mr hernandez af nhlbi heart failure clinical research network effect xanthine oxidase inhibition hyperuricemic heart failure patient xanthine oxidase inhibition hyperuricemic heart failure patient exacthf circulation 201513117631771 824 verma eikelboom jw nidorf sm alomran gupta n teoh h friedrich jo colchicine cardiac disease systematic review metaanalysis randomized controlled bmc cardiovasc disord 20151596 825 frommeyer g krawczyk j dechering dg kochhauser leitz p fehr eckardt l colchicine increase ventricular vulnerability experimental wholeheart model basic clin pharmacol toxicol 2017120505508 826 arfe scotti l varaslorenzo c nicotra f zambon kollhorst b schink garbe e herings r straatman h schade r villa lucchi valkhoff v romio thiessard f schuemie pariente sturkenboom corrao g safety nonsteroidal antiinflammatory drug project consortium non downloaded guest 24 november 2024 steroidal antiinflammatory drug risk heart failure four european country nested casecontrol bmj 2016354i4857 827 khalid dasu n shah brown k kaell levine dasu k raminfard incidence congestive heart failure rheumatoid arthritis review litera ture metaregression analysis esc heart fail 2020737453753 828 mantel holmqvist andersson dc lund lh askling j association rheumatoid arthritis risk ischemic nonischemic heart fail ure j coll cardiol 20176912751285 829 chung e packer lo kh fasanmade aa willerson jt antitnf congestive heart failure investigator randomized doubleblind pla cebocontrolled pilot infliximab chimeric monoclonal antibody tumor necrosis factoralpha patient moderatetosevere heart failure result antitnf congestive heart failure attach circulation 200310731333140 830 mann dl mcmurray jj packer swedberg k borer j colucci w djian j drexler h feldman kober l krum h liu p nieminen tavazzi l van veldhuisen dj waldenstrom warren westheim zannad f fleming targeted anticytokine patient chronic heart failure result randomized etanercept worldwide evaluation renewal circulation 200410915941602 831 kotyla pj bimodal function antitnf shall concerned antitnf patient rheumatoid arthritis heart failure int j mol sci 2018191739 832 baumhakel schlimmer n kratz hackett g jackson g bohm cardiovascular risk drug erectile function–a systematic analysis int j clin pract 201165289298 833 jaarsma sexual function patient heart failure fact number esc heart fail 2017437 834 levine ab punihaole levine tb characterization role nitric oxide clinical application cardiology 20121225568 835 giannetta e feola gianfrilli pofi r dall’armi v badagliacca r barbagallo f lenzi isidori chronic inhibition phosphodiesterase type 5 cardio protective safe metaanalysis randomized controlled bmc med 201412185 836 angermann ce ertl g depression anxiety cognitive impairment comor bid mental health disorder heart failure curr heart fail rep 201815398410 837 sbolli fiuzat cani o’connor cm depression heart failure lonely comorbidity eur j heart fail 20202220072017 838 jha mk qamar vaduganathan charney murrough jw screening management depression patient cardiovascular disease jacc state oftheart review j coll cardiol 20197318271845 839 berkman lf blumenthal j burg carney rm catellier cowan mj czajkowski sm debusk r hosking j jaffe kaufmann pg mitchell p norman j powell lh raczynski jm schneiderman n enhancing recovery coronary heart disease patient investigator effect treating depression low per ceived social support clinical event myocardial infarction enhancing recovery coronary heart disease patient enrichd random ized jama 200328931063116 840 o’connor cm jiang w kuchibhatla silva sg cuffe callwood dd zakhary b stough wg aria rm rivelli sk krishnan r sadhartchf investigator safety efficacy sertraline depression patient heart failure result sadhartchf sertraline depression heart disease chronic heart failure j coll cardiol 201056692699 841 angermann ce gelbrich g stork gunold h edelmann f wachter r schunkert h graf kindermann haass blankenberg pankuweit prettin c gottwik bohm faller h deckert j ertl g moodhf investigator committee member effect escitalopram allcause mor tality hospitalization patient heart failure depression moodhf randomized clinical jama 201631526832693 842 de boer ra meijers wc van der meer p van veldhuisen dj cancer heart disease association relation eur j heart fail 20192115151525 843 farmakis mantzourani filippatos g anthracyclineinduced cardiomyop athy secret lie eur j heart fail 201820907909 844 zamorano jl lancellotti p rodriguez munoz aboyans v asteggiano r galderisi habib g lenihan dj lip gy lyon ar lopez fernandez mohty piepoli mf tamargo j torbicki suter tm zamorano jl aboyans v achenbach agewall badimon l baronesquivias g baumgartner h bax jj bueno h carerj dean v erol c fitzsimons gaemperli kirchhof p kolh p lancellotti p lip gy nihoyannopoulos p piepoli mf ponikowski p roffi torbicki vaz carneiro windecker authorstask force member esc committee practice guideline document reviewer esc position paper cancer cardiovascular toxicity developed auspex esc committee practice guideline task force cancer cardiovascular toxicity european society cardiology esc eur j heart fail 201719942 845 zamorano jl gottfridsson c asteggiano r atar badimon l bax jj cardinale cardone feijen eam ferdinandy p lopezfernandez gale cp maduro jh moslehi j omland plana gomez jc scott j suter tm minotti g cancer patient cardiology eur j heart fail 20202222902309 846 lyon ar dent stanway earl h brezdenmasley c cohensolal tocchetti cg moslehi jj groarke jd berglerklein j khoo v tan anker von haehling maack c pudil r barac thavendiranathan p ky b neilan tg belenkov rosen sd iakobishvili z sverdlov al hajjar la macedo av manisty c ciardiello f farmakis de boer ra skouri h suter tm cardinale witteles rm fradley herrmann j cornell rf wechelaker mauro mj milojkovic de lavallade h ruschitzka f coat ajs seferovic pm chioncel thum bauersachs j andres wright dj lopezfernandez plummer c lenihan baseline cardiovascular risk assess ment cancer patient scheduled receive cardiotoxic cancer position statement new risk assessment tool cardiooncology group heart failure association european society cardiology collaboration international cardiooncology society eur j heart fail 20202219451960 847 ganatra carver jr hayek ky b leja mj lenihan dj lenneman c mousavi n park jh perales ryan td scherrercrosbie steingart rm yang eh zaha v barac liu je chimeric antigen receptor tcell cancer heart jacc council perspective j coll cardiol 20197431533163 848 lenneman cg sawyer db cardiooncology update cardiotoxicity cancerrelated circ 201611810081020 849 lyon ar yousaf n battisti nml moslehi j larkin j immune checkpoint inhibi tor cardiovascular toxicity lancet oncol 201819e447e458 850 boekel nb duane fk jacobse jn hauptmann schaapveld sonke g gietema ja hooning mj seynaeve cm maas darby sc aleman bmp taylor cw van leeuwen fe heart failure breast cancer eur j heart fail 202022366374 851 farmakis parissis j filippatos g insight oncocardiology atrial fibrilla tion cancer j coll cardiol 201463945953 852 tromp j boerman lm sama ie maass maduro jh hummel ym berger de bock gh gietema ja berendsen aj van der meer p longterm survivor early breast cancer treated chemotherapy characterized pro inflammatory biomarker profile compared matched control eur j heart fail 20202212391246 853 hasin gerber weston sa jiang r killian jm manemann sm cerhan jr roger vl heart failure myocardial infarction associated increased risk cancer j coll cardiol 201668265271 854 banke schou videbaek l moller je torppedersen c gustafsson f dahl j kober l hildebrandt pr gislason gh incidence cancer patient chronic heart failure longterm followup eur j heart fail 201618260266 855 meijers wc de boer ra common risk factor heart failure cancer cardiovasc 2019115844853 856 de boer ra hulot j tocchetti cg aboumsallem jp ameri p anker sd bauersachs j bertero e coat ajs celutkiene j chioncel dodion p eschenhagen farmakis bayesgenis jager jankowska ea kitsis rn konety sh larkin j lehmann l lenihan dj maack c moslehi jj muller oj nowaksliwinska p piepoli mf ponikowski p pudil r rainer pp ruschitzka f sawyer seferovic pm suter thum van der meer p van laake lw von haehling heymans lyon ar back j common mechanistic pathway cancer heart failure scientific roadmap behalf translational research committee heart failure association hfa european society cardiology esc eur j heart fail 20202222722289 857 selvaraj bhatt dl claggett b djousse l shah sj chen j imran tf qazi sesso hd gaziano jm schrag lack association heart failure incident cancer j coll cardiol 20187115011510 858 meijers wc maglione bakker sjl oberhuber r kieneker lm de jong haubner bj nagengast wb lyon ar van der vegt b van veldhuisen dj westenbrink bd van der meer p sillje hhw de boer ra heart failure stimu lates tumor growth circulating factor circulation 2018138678691 859 lancellotti p suter tm lopezfernandez galderisi lyon ar van der meer p cohen solal zamorano jl jerusalem g moonen aboyans v bax jj asteggiano r cardiooncology service rationale organization imple mentation eur heart j 20194017561763 860 farmakis keramida k filippatos g build cardiooncology service eur j heart fail 20182017321734 861 cardinale colombo lamantia g colombo n civelli de giacomi g rubino veglia f fiorentini c cipolla cm anthracyclineinduced downloaded guest 24 november 2024 cardiomyopathy clinical relevance response pharmacologic j coll cardiol 201055213220 862 cardinale colombo bacchiani g tedeschi meroni ca veglia f civelli lamantia g colombo n curigliano g fiorentini c cipolla cm early detection anthracycline cardiotoxicity improvement heart failure circulation 201513119811988 863 gulati g heck sl ree ah hoffmann p schulzmenger j fagerland mw gravdehaug b von knobelsdorffbrenkenhoff f bratland storas th hagve ta rosjo h steine k geisler j omland prevention cardiac dysfunction adjuvant breast cancer prada 2 x 2 factorial randomized placebocontrolled doubleblind clinical candesartan metoprolol eur heart j 20163716711680 864 pituskin e mackey jr koshman jassal pitz haykowsky mj pagano jj chow k thompson rb vos lj ghosh oudit gy ezekowitz ja paterson di multidisciplinary approach novel cardiooncology research manticore 101breast randomized prevention trastuzumabassociated cardiotoxicity j clin oncol 201735870877 865 celutkiene j pudil r lopezfernandez grapsa j nihoyannopoulos p berglerklein j cohensolal farmakis tocchetti cg von haehling barberis v flachskampf fa ceponiene haeglerlaube e suter lapinskas prasad de boer ra wechalekar k anker iakobishvili z bucciarelli ducci c schulzmenger j cosyns b gaemperli belenkov hulot j galderisi lancellotti p bax j marwick th chioncel jaarsma mullens w piepoli thum heymans mueller c moura b ruschitzka f zamorano jl rosano g coat ajs asteggiano r seferovic p edvardsen lyon ar role cardiovascular imaging cancer patient receiving cardiotoxic position statement behalf heart failure association hfa european association cardiovascular imaging eacvi cardiooncology council european society cardiology esc eur j heart fail 20202215041524 866 keramida k farmakis bingcang j sulemane sutherland bingcang ra ramachandran k tzavara c charalampopoulos g filippiadis kouris n nihoyannopoulos p longitudinal change right ventricular deformation mechanic trastuzumab breast cancer patient eur j heart fail 201921529535 867 thavendiranathan p negishi somerset e negishi k penicka lemieux j aakhus miyazaki shirazi galderisi marwick th succour investigator strainguided management potentially cardiotoxic cancer ther apy j coll cardiol 202177392401 868 michel l mincu ri mahabadi aa settelmeier alrashid f rassaf totzeck troponins brain natriuretic peptide prediction cardiotoxicity cancer patient metaanalysis eur j heart fail 202022350361 869 pudil r mueller c celutkiene j henriksen pa lenihan dent barac stanway moslehi j suter tm ky b sterba cardinale cohensolal tocchetti cg farmakis berglerklein j anker von haehling belenkov iakobishvili z maack c ciardiello f ruschitzka f coat ajs seferovic p lainscak piepoli mf chioncel bax j hulot j skouri h haglerlaube e asteggiano r fernandez tl de boer ra lyon ar role serum biomarkers cancer patient receiving cardiotoxic cancer position statement cardiooncology group heart failure association cardiooncology council european society cardiology eur j heart fail 20202219661983 870 hu jr florido r lipson ej naidoo j ardehali r tocchetti cg lyon ar padera rf johnson db moslehi j cardiovascular toxicity associated immune checkpoint inhibitor cardiovasc 2019115854868 871 banke fosbol el moller je gislason gh andersen bernsdorf jensen mb schou ejlertsen b longterm effect epirubicin incidence heart failure woman breast cancer insight randomized clinical eur j heart fail 20182014471453 872 platz e jhund p claggett bl pfeffer swedberg k granger cb yusuf solomon sd mcmurray jj prevalence prognostic importance precipitat ing factor leading heart failure hospitalization recurrent hospitalization mortality eur j heart fail 201820295303 873 tomasoni italia l adamo inciardi rm lombardi cm solomon sd metra covid 19 heart failure infection inflammation angiotensin ii stimulation searching evidence new disease eur j heart fail 20202295796623512526 874 corralesmedina vf alvarez kn weissfeld la angus dc chirinos ja chang cc newman loehr l folsom ar elkind lyles mf kronmal ra yende association hospitalization pneumonia subsequent risk cardiovascular disease jama 2015313264274 875 violi f cangemi r falcone taliani g pieralli f vannucchi v nozzoli c venditti chirinos ja corralesmedina vf sixtus group cardiovascular complication shortterm mortality risk community acquired pneumonia clin infect dis 20176414861493 876 rey jr carocodon j rosillo iniesta castrejoncastrejon marco clement martinpolo l merinoargos c rodriguezsotelo l garciaveas jm martinezmarin la martinezcossiani buno gonzalezvalle l herrero lopezsendon jl merino jl cardcovid investigator heart failure covid19 patient prevalence incidence prognostic implication eur j heart fail 20202222052215 877 cannata bromage di rind ia gregorio c bannister c albarjas piper shah mcdonagh ta temporal trend decompensated heart failure outcome covid19 multisite report heart failure referral centre london eur j heart fail 20202222192224 878 konig hohenstein meierhellmann kuhlen r hindricks g bollmann helios hospital g inhospital care acute heart failure covid19 pandemic insight germanwide helios hospital network eur j heart fail 20202221902201 879 zhang coat ajs zheng z adamo ambrosio g anker sd butler j xu mao j khan bai l mebazaa ponikowski p tang q ruschitzka f seferovic p tschope c zhang gao c zhou senni zhang j metra management heart failure patient covid19 joint position paper chinese heart failure association national heart failure committee heart failure association european society cardiology eur j heart fail 202022941956 880 modin jorgensen gislason g jensen j kober l claggett b hegde sm solomon sd torppedersen c bieringsorensen influenza vaccine heart failure circulation 2019139575586 881 vardeny claggett b udell ja packer zile rouleau j swedberg k desai lefkowitz shi v mcmurray jjv solomon sd paradigmhf investigator influenza vaccination patient chronic heart failure paradigmhf jacc heart fail 20164152158 882 gotsman shuvy tahiroglu zwas dr keren influenza vaccination outcome heart failure j cardiol 2020128134139 883 bhatt jering k vaduganathan claggett bl cunningham jw rosenthal n signorovitch j thune jj vardeny solomon sd clinical outcome patient heart failure hospitalized covid19 jacc heart fail 202196573 884 regitzzagrosek v rooshesselink jw bauersachs j blomstro¨mlundqvist c cıfkova r de bonis iung b johnson mr kintscher u kranke p lang im morais j pieper pg presbitero p price rosano gmc seeland u simoncini swan l warnes ca esc scientific document group management cardiovascular disease pregnancy eur heart j 20183931653241 885 sliwa k van der meer p petrie mc frogoudaki johnson mr hilfikerkleiner hamdan r jackson ibrahim b mbakwem tschope c regitz zagrosek v omerovic e rooshesselink j gatzoulis tutarel price heymans coat ajs muller c chioncel thum de boer ra jankowska e ponikowski p lyon ar rosano g seferovic pm bauersachs j risk stratifica tion management woman cardiomyopathyheart failure planning pregnancy presenting duringafter pregnancy position statement heart failure association european society cardiology group peripartum cardiomyopathy eur j heart fail 202123527540 886 sliwa k petrie mc van der meer p mebazaa hilfikerkleiner jackson maggioni ap laroche c regitzzagrosek v schaufelberger tavazzi l roos hesselink jw seferovic p van spaendonckzwarts k mbakwem bohm mouquet f pieske b johnson mr hamdan r ponikowski p van veldhuisen dj mcmurray jjv bauersachs j clinical presentation management 6 month outcome woman peripartum cardiomyopathy esc eorp registry eur heart j 20204137873797 887 davis mb arany z mcnamara dm goland elkayam u peripartum cardio myopathy jacc stateoftheart review j coll cardiol 202075207221 888 moulig v pfeffer tj rickehoch schlothauer koenig schwab j berliner pfister r michels g haghikia falk c duncker veltmann c hilfiker kleiner bauersachs j longterm followup peripartum cardiomyopathy patient contemporary low mortality high cardiac recovery significant cardiovascular comorbidities eur j heart fail 20192115341542 889 stapel b kohlhaas rickehoch haghikia erschow knuuti j silvola jm roivainen saraste nickel ag saar ja sieve pietzsch muller bogeski kappl r jauhiainen thackeray jt scherr bengel fm hagl c tudorache bauersachs j maack c hilfikerkleiner low stat3 expression sensitizes toxic effect betaadrenergic receptor stimulation peripartum cardiomyopathy eur heart j 201738349361 890 hilfikerkleiner haghikia berliner vogelclaussen j schwab j franke schwarzkopf ehlermann p pfister r michels g westenfeld r stangl v kindermann kuhl u angermann ce schlitt fischer podewski e bohm sliwa k bauersachs j bromocriptine peripartum cardio myopathy multicentre randomized eur heart j 20173826712679 downloaded guest 24 november 2024 891 sliwa k blauwet l tibazarwa k libhaber e smedema jp becker mcmurray j yamac h labidi struman hilfikerkleiner evaluation bromocriptine acute severe peripartum cardiomyopathy proofof concept pilot circulation 201012114651473 892 arbustini e narula n dec gw reddy k greenberg b kushwaha marwick pinney bellazzi r favalli v kramer c robert r zoghbi wa bonow r tavazzi l fuster v narula j moges classification phenotype genotype nomenclature cardiomyopathy endorsed world heart federation j coll cardiol 20136220462072 893 hazebroek mr kemna mj schalla sandersvan wijk gerretsen sc dennert r merken j kuznetsova staessen ja brunnerla rocca hp van paassen p cohen tervaert jw heymans prevalence prognostic rele vance cardiac involvement ancaassociated vasculitis eosinophilic granu lomatosis polyangiitis granulomatosis polyangiitis int j cardiol 2015199170179 894 pinto ym elliott pm arbustini e adler anastasakis bohm duboc gimeno j de groote p imazio heymans klingel k komajda limongelli g linhart mogensen j moon j pieper pg seferovic pm schueler zamorano jl caforio al charron p proposal revised definition dilated cardiomyopathy hypokinetic nondilated cardiomyopathy impli cation clinical practice position statement esc working group myocardial pericardial disease eur heart j 20163718501858 895 seferovic pm polovina bauersachs j arad gal tb lund lh felix sb arbustini e caforio alp farmakis filippatos g gialafos e kanjuh v krljanac g limongelli g linhart lyon ar maksimovic r milicic milinkovic noutsias oto oto pavlovic su piepoli mf ristic ad rosano gmc seggewiss h asanin seferovic jp ruschitzka f celutkiene j jaarsma mueller c moura b hill l volterrani lopatin metra back j mullens w chioncel de boer ra anker rapezzi c coat ajs tschope c heart failure cardiomyopathy position paper heart failure association european society cardiology eur j heart fail 201921553576 896 member authorstask force elliott pm anastasakis borger borggrefe cecchi f charron p hagege aa lafont limongelli g mahrholdt h mckenna wj mogensen j nihoyannopoulos p nistri pieper pg pieske b rapezzi c rutten fh tillmanns c watkins h 2014 esc guideline diag nosis management hypertrophic cardiomyopathy task force diagnosis management hypertrophic cardiomyopathy european society cardiology esc eur heart j 20143527332779 897 bondue arbustini e bianco ciccarelli dawson de rosa hamdani n hilfikerkleiner meder b leitemoreira af thum tocchetti cg varricchi g van der velden j walsh r heymans complex road genotype phenotype dilated cardiomyopathy scientific update working group myocardial function european society cardiology cardiovasc 201811412871303 898 hershberger givertz mm ho cy judge dp kantor pf mcbride kl morale taylor mrg vatta ware sm genetic evaluation cardiomyop athy–a heart failure society america practice guideline j card fail 201824281302 899 merlo cannata gobbo stolfo elliott pm sinagra g evolving con cepts dilated cardiomyopathy eur j heart fail 201820228239 900 linschoten teske aj baa af vink dooijes baars hf asselbergs fw truncating titin ttn variant chemotherapyinduced cardiomyopathy j card fail 201723476479 901 wasielewski van spaendonckzwarts ky westerink nd jongbloed jd postma gietema ja van tintelen jp van den berg mp potential genetic pre disposition anthracyclineassociated cardiomyopathy family dilated cardiomyopathy open heart 20141e000116 902 ware j amorsalamanca tayal u govind r serrano salazarmendiguchia j garciapinilla jm pascualfigal da nunez j guzzomerello g gonzalez vioque e bardaji manito n lopezgarrido padronbarthe l edward e whiffin n walsh r buchan rj midwinter w wilk prasad pantazis baski j o’regan dp alonsopulpon l cook sa larapezzi e barton pj garciapavia p genetic etiology alcoholinduced cardiac toxicity j coll cardiol 20187122932302 903 ware j li j mazaika e yasso cm desouza cappola tp tsai ej hilfiker kleiner kamiya ca mazzarotto f cook sa halder prasad sk pisarcik j hanleyyanez k alharethi r damp j hsich e elkayam u sheppard r kealey alexis j ramani g safirstein j boehmer j pauly df wittstein thohan v zucker mj liu p gorcsan j 3rd mcnamara dm seidman ce seidman jg arany z ipac investigator imac shared genetic predisposition peripartum dilated cardiomyopathy n engl j med 2016374233241 904 van spaendonckzwarts ky posafalvi van den berg mp hilfikerkleiner bollen ia sliwa k alder almomani r van langen im van der meer p sinke rj van der velden j van veldhuisen dj van tintelen jp jongbloed jd titin gene mutation common family peripartum cardiomyop athy dilated cardiomyopathy eur heart j 20143521652173 905 choi sh weng lc roselli c lin h haggerty cm shoemaker mb barnard j arking de chasman di albert cm chaffin tucker nr smith jd gupta n gabriel margolin l shea shaffer cm yoneda zt boerwinkle e smith nl silverman ek redline vasan r burchard eg gogarten sm laurie c blackwell tw abecasis g carey dj fornwalt bk smelser dt baras dewey fe jaquish ce papanicolaou gj sotoodehnia n van wagoner dr psaty bm kathiresan darbar alonso heckbert sr chung mk roden dm benjamin ej murray mf lunetta kl lubitz sa ellinor pt discovehr nhlbi transomics precision medicine topmed consortium association titin lossoffunction variant earlyonset atrial fibrillation jama 201832023542364 906 hazebroek mr krapels verdonschot j van den wijngaard vanhoutte e hoos snijders l van montfort l witjens dennert r crijns h brunner la rocca hp brunner hg heymans prevalence pathogenic gene muta tions prognosis differ isolated left ventricular dysfunction com pared dilated cardiomyopathy circ heart fail 201811e004682 907 leone veinot jp angelini baandrup ut basso c berry g bruneval p burke butany j calabrese f d’amati g edward wd fallon jt fishbein mc gallagher pj halushka mk mcmanus b pucci rodriguez er saffitz je sheppard mn steenbergen c stone jr tan c thiene g van der wal ac winter gl 2011 consensus statement endomyocardial biopsy association european cardiovascular pathology society cardiovascular pathology cardiovasc pathol 201221245274 908 halliday bp owen r gregson j vassiliou v chen x wage r lota khalique z tayal u hammersley dj jones baksi aj cowie mr cleland jgf pennell dj prasad sk myocardial remodelling withdrawing heart failure patient recovered dilated cardiomyopathy insight tredhf eur j heart fail 202123293301 909 olivotto oreziak barrialesvilla r abraham tp masri garciapavia p saberi lakdawala nk wheeler mt owen kubanek wojakowski w jensen mk gimenoblanes j afshar k myers j hegde sm solomon sd sehnert aj zhang li w bhattacharya edelberg jm waldman cb lester sj wang ho cy jacoby explorerhcm investigator mavacamten symptomatic obstructive hypertrophic cardiomy opathy explorerhcm randomised doubleblind placebocontrolled phase 3 lancet 2020396759769 910 cadrintourigny j bosman lp nozza wang w tadros r bhonsale bourfiss fortier lie oh saguner svensson andorin tichnell c murray b zeppenfeld k van den berg mp asselbergs fw wilde aam krahn ad talajic rivard l chelko zimmerman sl kamel ir crosson je judge dp yap sc van der heijden jf tandri h jongbloed jdh guertin mc van tintelen jp platonov pg duru f haugaa kh khairy p hauer rnw calkin h te riele james ca new prediction model ventricular arrhythmia arrhythmogenic right ventricular cardiomyopathy eur heart j 20194018501858 911 leren saberniak j haland tf edvardsen haugaa kh combination ecg echocardiography identification arrhythmic event early arvc jacc cardiovasc imaging 201710503513 912 towbin ja mckenna wj abrams dj ackerman mj calkin h darrieux fcc daubert jp de chillou c depasquale ec desai estes nam 3rd hua w indik jh ingles j james ca john rm judge dp keegan r krahn ad link marcus fi mcleod cj mestroni l priori sg saffitz je sanatani shimizu w van tintelen jp wilde aam zareba w 2019 hr expert consensus statement evaluation risk stratification management arrhythmogenic cardiomy opathy heart rhythm 201916e301e372 913 kristensen sl levy wc shadman r nielsen jc haarbo j videbaek l bruun ne eiskjaer h wiggers h brandes thogersen hassager c svendsen jh hofsten de torppedersen c pehrson signorovitch j kober l thune jj risk model prediction implantable cardioverterdefibrillator benefit insight danish jacc heart fail 20197717724 914 corrado wichter link hauer r marchlinski f anastasakis bauce b basso c brunckhorst c tsatsopoulou tandri h paul schmied c pelliccia duru f protonotarios n estes na 3rd mckenna wj thiene g marcus fi calkin h arrhythmogenic right ventricular cardiomy opathydysplasia international task force consensus statement eur heart j 20153632273237 915 elliott pm anastasakis asimaki basso c bauce b brooke calkin h corrado duru f green kj judge dp kelsell lambiase pd mckenna wj pilichou k protonotarios saffitz je syrris p tandri h te riele thiene g tsatsopoulou tintelen jp definition arrhythmogenic cardi omyopathy updated expert panel report eur j heart fail 201921955964 916 mazzarotto f tayal u buchan rj midwinter w wilk whiffin n govind r mazaika e de marvao dawes tjw felkin le ahmad theotokis pi edward e ing ay thomson kl chan llh sim baksi aj pantazis robert watkins h funke b o’regan dp olivotto barton pjr prasad downloaded guest 24 november 2024 sk cook sa ware j walsh r reevaluating genetic contribution mon ogenic dilated cardiomyopathy circulation 2020141387398 917 caforio al pankuweit arbustini e basso c gimenoblanes j felix sb fu helio heymans jahns r klingel k linhart maisch b mckenna w mogensen j pinto ym ristic schultheiss hp seggewiss h tavazzi l thiene g yilmaz charron p elliott pm european society cardiology working group myocardial pericardial disease current state knowledge aetiology diagnosis management myocarditis position state ment european society cardiology working group myocardial pericardial disease eur heart j 20133426362648 2648a2648d 918 heymans eriksson u lehtonen j cooper lt jr quest new approach myocarditis inflammatory cardiomyopathy j coll cardiol 20166823482364 919 tschope c ammirati e bozkurt b caforio alp cooper lt felix sb hare jm heidecker b heymans hubner n kelle klingel k maatz h parwani spillmann f starling rc tsutsui h seferovic p van linthout myocarditis inflammatory cardiomyopathy current evidence future direction nat rev cardiol 202118169193 920 wahbi k ben yaou r gandjbakhch e anselme f gossios lakdawala nk stalens c sacher f babuty trochu jn moubarak g savvatis k porcher r laforet p fayssoil marijon e stojkovic behin leonardlouis sole g labombarda f richard p metay c quijanoroy dabaj klug vantyghem mc chevalier p ambrosi p salort e sadoul n waintraub x chikhaoui k mabo p combes n maury p sellal jm tedrow ub kalman jm vohra j androulakis afa zeppenfeld k thompson barnerias c becane hm bieth e boccara f bonnet bouhour f boule brehin ac chapon f cintas p cuisset jm davy jm de sandregiovannoli demurger f desguerre dieterich k durigneux j echanizlaguna eschalier r ferreiro ferrer x francannet c fradin gaborit b gay hagege isapof jeru junta morale r lagrue e lamblin n lascols laugel v lazarus leturcq f levy n magot manel v martin r mayer mercier meune c michaud minotmyhie mc muchir nadajpakleza pereon petiot p petit f praline j rollin sabouraud p sarret c schaeffer taithe f tard c tiffreau v toutain vatier c waltherlouvier u eymard b charron p vigouroux c bonne g kumar elliott p duboc development validation new risk prediction score lifethreatening ventricular tachyarrhythmias lamino pathies circulation 2019140293302 921 echeverria le marcus r novick g sosaestani ralston k zaidel ej forsyth c alp ri mendoza falconi mitelman j morillo ca pereiro ac pinazo mj salvatella r martinez f perel p liprandi pineiro dj molina gr whf iasc roadmap chaga disease glob heart 20201526 922 martinez f perna e perrone sv liprandi chaga disease heart failure expanding issue worldwide eur cardiol 2019148288 923 ommen sr mital burke day sm deswal elliott p evanovich hung j joglar ja kantor p kimmelstiel c kittleson link maron martinez mw miyake cy schaff hv semsarian c sorajja p 2020 ahaacc guideline diagnosis patient hypertrophic cardio myopathy executive summary report american college cardiologyamerican heart association joint committee clinical practice guideline circulation 2020142e533e557 924 walsh r mazzarotto f whiffin n buchan r midwinter w wilk li n felkin l ingold n govind r ahmad mazaika e allouba zhang x de marvao day sm ashley e colan sd michels pereira ac jacoby ho cy thomson kl watkins h barton pjr olivotto cook sa ware j quantitative approach variant classification increase yield precision genetic testing mendelian disease case hypertrophic cardiomyop athy genome med 2019115 925 ingles j goldstein j thaxton c caleshu c corty ew crowley sb dougherty k harrison sm mcglaughon j milko lv morale seifert ba strande n thomson k peter van tintelen j wallace k walsh r well q whiffin n witkowski l semsarian c ware j hershberger funke b evaluating clinical validity hypertrophic cardiomyopathy gene circ genom precis med 201912e002460 926 thomson kl ormondroyd e harper ar dent mcguire k baksi j blair e brennan p buchan r bueser campbell c carrwhite g cook daniel deevi svv goodship j hayesmoore jbg henderson lamb prasad raynermatthews p robert l sneddon l stark h walsh r ware j farrall watkins hc nihr bioresource rare disease consortium analysis 51 proposed hypertrophic cardiomyopathy gene genome sequencing data sarcomere negative case ha negligible diagnostic yield genet med 20192115761584 927 tuohy cv kaul song hk nazer b heitner sb hypertrophic cardiomyop athy future eur j heart fail 202022228240 928 o’mahony c akhtar mm anastasiou z guttmann op vriesendorp pa michels magri autore c fernandez ochoa jp leong kmw varnava monserrat l anastasakis garciapavia p rapezzi c biagini e gimeno jr limongelli g omar rz elliott pm effectiveness 2014 european society cardiology guideline sudden cardiac death hypertrophic cardio myopathy systematic review metaanalysis heart 2019105623631 929 o’mahony c jichi f ommen sr christiaans arbustini e garciapavia p cecchi f olivotto kitaoka h gotsman carrwhite g mogensen j antoniades l mohiddin sa maurer tang hc geske jb siontis kc mahmoud kd vermeer wilde favalli v guttmann op gallegodelgado dominguez f tanini kubo keren bueser water issa malcolmson j burn sekhri n hoeger cw omar rz elliott pm international external validation 2014 european society cardiology guideline sudden cardiac death prevention hypertrophic cardiomyopathy evidencehcm circulation 201813710151023 930 o’mahony c jichi f pavlou monserrat l anastasakis rapezzi c biagini e gimeno jr limongelli g mckenna wj omar rz elliott pm hypertrophic cardiomyopathy outcome investigator novel clinical risk prediction model sudden cardiac death hypertrophic cardiomyopathy hcm riskscd eur heart j 20143520102020 931 brignole moya de lange fj deharo jc elliott pm fanciulli fedorowski furlan r kenny ra martin probst v reed mj rice cp sutton r ungar van dijk jg esc scientific document group 2018 esc guideline diagnosis management syncope eur heart j 20183918831948 932 marcus fi mckenna wj sherrill basso c bauce b bluemke da calkin h corrado cox daubert jp fontaine g gear k hauer r nava picard mh protonotarios n saffitz je sanborn dm steinberg j tandri h thiene g towbin ja tsatsopoulou wichter zareba w diagnosis arrhythmo genic right ventricular cardiomyopathydysplasia proposed modification task force criterion circulation 201012115331541 933 corrado van tintelen pj mckenna wj hauer rnw anastastakis asimaki basso c bauce b brunckhorst c bucciarelliducci c duru f elliott p hamilton rm haugaa kh james ca judge link marchlinski fe mazzanti mestroni l pantazis pelliccia marra mp pilichou k platonov pga protonotarios rampazzo saffitz je saguner schmied c sharma tandri h te riele thiene g tsatsopoulou zareba w zorzi wichter marcus fi calkin h international expert arrhythmogenic right ventricular cardiomyopathy evaluation current diagnostic criterion dif ferential diagnosis eur heart j 20204114141429 934 reichl k kreykes se martin cm shenoy c desmoplakin variantassociated arrhythmogenic cardiomyopathy presenting acute myocarditis circ genom precis med 201811e002373 935 lopezayala jm pastorquirante f gonzalezcarrillo j lopezcuenca sanchezmunoz jj olivasandoval mj gimeno jr genetics myocarditis arrhythmogenic right ventricular dysplasia heart rhythm 201512766773 936 pelliccia solberg ee papadakis adami pe biffi caselli la gerche niebauer j pressler schmied cm serratosa l halle van buuren f borjesson carre f panhuyzengoedkoop nm heidbuchel h olivotto corrado sinagra g sharma recommendation participation com petitive leisure time sport athlete cardiomyopathy myocarditis pericarditis position statement sport cardiology section european association preventive cardiology eapc eur heart j 2019401933 937 sedaghathamedani f haas j zhu f geier c kayvanpour e liss lai frese k pribewolferts r amr li dt samani carstensen bordalo dm muller fischer c shao j wang j nie yuan l hassfeld schwartz c zhou zhou z shu wang huang k zeng q cheng l fehlmann ehlermann p keller dieterich c streckfussbomeke k liao gotthardt katus ha meder b clinical genetics outcome left ventricular non compaction cardiomyopathy eur heart j 20173834493460 938 towbin ja lorts jefferies jl left ventricular noncompaction cardiomyop athy lancet 2015386813825 939 towbin ja jefferies jl cardiomyopathy due left ventricular noncompac tion mitochondrial storage disease inborn error metabolism circ 2017121838854 940 shen mj arora r jalife j atrial myopathy jacc basic transl sci 20194640654 941 reddy ynv borlaug ba left atrial myopathy heart failure preserved ejection fraction eur j heart fail 202022486488 942 reddy ynv obokata gersh bj borlaug ba high prevalence occult heart failure preserved ejection fraction among patient atrial fibrillation dyspnea circulation 2018137534535 943 packer lam csp lund lh redfield mm interdependence atrial fibrilla tion heart failure preserved ejection fraction reflects common underlying atrial ventricular myopathy circulation 202014146 944 ac flamm sd marwick th klein al clinical utility multimodality la imaging assessment size function structure jacc cardiovasc imaging 20114788798 downloaded guest 24 november 2024 945 farmakis mueller c apple f highsensitivity cardiac troponin assay cardiovascular risk stratification general population eur heart j 20204140504056 946 westermann neumann jt sorensen na blankenberg highsensitivity assay troponin patient cardiac disease nat rev cardiol 201714472483 947 santema bt kloosterman van gelder ic mordi lang cc lam csp anker sd cleland jg dickstein k filippatos g van der harst p hillege hl ter maaten jm metra ng ponikowski p samani nj van veldhuisen dj zwinderman ah zannad f damman k van der meer p rienstra voors aa comparing biomarker profile patient heart failure atrial fibrilla tion v sinus rhythm reduced v preserved ejection fraction eur heart j 20183938673875 948 richards di somma mueller c nowak r peacock wf ponikowski p mockel hogan c wu ah clopton p filippatos g anand ng l daniel lb neath sx shah k christenson r hartmann anker sd maisel atrial fibrillation impairs diagnostic performance cardiac natriuretic peptide dyspneic patient result bach biomarkers acute heart failure jacc heart fail 20131192199 949 kamel h longstreth wt jr tirschwell dl kronmal ra broderick jp palesch yy meinzer c dillon c ewing spilker ja di tullio mr hod ea soliman ez chaturvedi moy c janis elkind atrial cardiopathy antithrombotic drug prevention cryptogenic stroke randomized rationale method int j stroke 201914207214 950 zelniker ta bonaca mp furtado rhm mosenzon kuder jf murphy sa bhatt dl leiter la mcguire dk wilding jph budaj kiss rg padilla f gausenilsson langkilde raz sabatine wiviott sd effect dapa gliflozin atrial fibrillation patient type 2 diabetes mellitus insight declaretimi 58 circulation 202014112271234 951 global burden disease collaborator global regional national incidence prevalence year lived disability 301 acute chronic disease injury 188 country 19902013 systematic analysis global burden disease 2013 lancet 2015386743800 952 cooper lt jr keren sliwa k matsumori mensah ga global burden myocarditis part 1 systematic literature review global burden disease injury risk factor 2010 glob heart 20149121129 953 merken j hazebroek van paassen p verdonschot j van empel v knackstedt c abdul hamid seiler kolb j hoermann p ensinger c brunnerla rocca hp poelzl g heymans immunosuppressive improves short longterm prognosis patient virusnegative nonfulminant inflammatory cardiomyopathy circ heart fail 201811e004228 954 ammirati e frigerio adler ed basso c birnie dh brambatti friedrich klingel k lehtonen j moslehi jj pedrotti p rimoldi oe schultheiss hp tschope c cooper lt jr camici pg management acute myocarditis chronic inflammatory cardiomyopathy expert consensus document circ heart fail 202013e007405 955 grigoratos c di bella g aquaro gd diagnostic prognostic role car diac magnetic resonance acute myocarditis heart fail rev 2019248190 956 ferreira vm schulzmenger j holmvang g kramer cm carbone sechtem u kindermann gutberlet cooper lt liu p friedrich cardiovascular magnetic resonance nonischemic myocardial inflammation expert recom mendations j coll cardiol 20187231583176 957 birnie dh nery pb ha ac beanlands r cardiac sarcoidosis j coll cardiol 201668411421 958 bang v ganatra shah sp dani neilan tg thavendiranathan p resnic f piemonte tc barac patel r sharma parikh r chaudhry gm vesely hayek leja venesy patten r lenihan nohria cooper lt management patient giant cell myocarditis jacc review topic week j coll cardiol 20217711221134 959 sinagra g porcari gentile p artico j fabris e bussani r merlo viral presenceguided immunomodulation lymphocytic myocarditis update eur j heart fail 202123211216 960 gannon mp schaub e grines cl saba sg state art evaluation prognostication myocarditis using cardiac mri j magn reson imaging 201949e122e131 961 maisch b hufnagel g kolsch funck r richter rupp h herzum pankuweit inflammatory dilated cardiomyopathy perimyocar ditis immunosuppression iv immunoglobulin herz 200429624636 962 kociol rd cooper lt fang jc moslehi jj pang p sabe shah rv sims db thiene g vardeny american heart association heart failure transplantation committee council clinical cardiology recognition initial management fulminant myocarditis scientific statement american heart association circulation 2020141e69e92 963 felix sb staudt dorffel wv stangl v merkel k pohl docke wd morgera neumayer hh wernecke kd wallukat g stangl k baumann g hemodynamic effect immunoadsorption subsequent immunoglobulin substitution dilated cardiomyopathy threemonth result randomized j coll cardiol 20003515901598 964 bajaj n gupta k gharpure n pate chopra l kalra r prabhu sd effect immunomodulation cardiac remodelling outcome heart failure quantitative synthesis literature esc heart fail 2020713191330 965 martineznaharro hawkins pn fontana cardiac amyloidosis clin med lond 201818s30s35 966 ruberg fl grogan hanna kelly jw maurer transthyretin amyloid cardiomyopathy jacc stateoftheart review j coll cardiol 20197328722891 967 gonzalezlopez e gallegodelgado guzzomerello g de harodel moral fj cobomarcos roble c bornstein b salas c larapezzi e alonso pulpon l garciapavia p wildtype transthyretin amyloidosis cause heart failure preserved ejection fraction eur heart j 20153625852594 968 helder mr schaff hv nishimura ra gersh bj dearani ja ommen sr mereuta om theis jd dogan edward wd impact incidental amyloido si prognosis patient hypertrophic cardiomyopathy undergoing septal myectomy left ventricular outflow tract obstruction j cardiol 201411413961399 969 treibel ta fontana gilbertson ja castelletti white sk scully pr robert n hutt df rowczenio dm whelan cj ashworth gillmore jd hawkins pn moon jc occult transthyretin cardiac amyloid severe calcific aortic stenosis prevalence prognosis patient undergoing surgical aortic valve replacement circ cardiovasc imaging 20169 970 cavalcante jl rijal abdelkarim althouse ad sharbaugh fridman soman p forman de schindler jt gleason tg lee j schelbert eb cardiac amyloidosis prevalent older patient aortic stenosis carry worse prognosis j cardiovasc magn reson 20171998 971 castano narotsky dl hamid n khalique ok morgenstern r deluca rubin j chiuzan c nazif vahl george kodali leon mb hahn r bokhari maurer unveiling transthyretin cardiac amyloidosis pre dictors among elderly patient severe aortic stenosis undergoing transcath eter aortic valve replacement eur heart j 20173828792887 972 nitsche c aschauer kammerlander aa schneider poschner duca f binder c koschutnik stiftinger j goliasch g sillermatula j winter mp anvaripirsch andreas geppert beitzke loewe c hacker agis h kain r lang bonderman hengstenberg c mascherbauer j lightchain transthyretin cardiac amyloidosis severe aortic stenosis prevalence screening possibility outcome eur j heart fail 20202218521862 973 garciapavia p rapezzi c adler arad basso c brucato burazor caforio alp damy eriksson u fontana gillmore jd gonzalezlopez e grogan heymans imazio kindermann kristen av maurer merlini g pantazis pankuweit rigopoulos ag linhart diagnosis cardiac amyloidosis position statement european society cardiology working group myocardial pericardial disease eur j heart fail 202123512526 974 boldrini cappelli f chacko l restrepocordoba lopezsainz giannoni aimo baggiano martineznaharro whelan c quarta c passino c castiglione v chubuchnyi v spini v taddei c vergaro g petrie ruizguerrero l monivas v mingosantos mirelis jg dominguez f gonzalezlopez e perlini pontone g gillmore j hawkins pn garciapavia p emdin fontana multiparametric echocardiography score diag nosis cardiac amyloidosis jacc cardiovasc imaging 202013909920 975 gillmore jd maurer falk rh merlini g damy dispenzieri wechalekar ad berk jl quarta cc grogan lachmann hj bokhari castano dorbala johnson gb glaudemans aw rezk fontana palladini g milani p guidalotti pl flatman k lane vonberg fw whelan cj moon jc ruberg fl miller ej hutt df hazenberg bp rapezzi c hawkins pn nonbiopsy diagnosis cardiac transthyretin amyloidosis circulation 201613324042412 976 zhao l tian z fang q diagnostic accuracy cardiovascular magnetic reso nance patient suspected cardiac amyloidosis systematic review metaanalysis bmc cardiovasc disord 201616129 977 bhuiyan helmke patel ar ruberg fl packman j cheung k grogan maurer pressurevolume relationship patient transthyretin attr cardiac amyloidosis secondary v122i mutation wildtype transthyretin transthyretin cardiac amyloid tracs circ heart fail 20114121128 978 cheung cc roston tm andrade jg bennett mt davis mk arrhythmia cardiac amyloidosis challenge risk stratification j cardiol 202036416423 979 maurer schwartz jh gundapaneni b elliott pm merlini g waddington cruz kristen av grogan witteles r damy drachman bm shah sj hanna judge dp barsdorf ai huber p patterson ta riley schumacher j stewart sultan mb rapezzi c attract investigator tafamidis patient transthyretin amyloid cardiomyopathy n engl j med 201837910071016 downloaded guest 24 november 2024 980 damy garciapavia p hanna judge dp merlini g gundapaneni b patterson ta riley schwartz jh sultan mb witteles r efficacy safety tafamidis dos tafamidis transthyretin cardiomyopathy clinical attract longterm extension eur j heart fail 202123277285 981 solomon sd adam kristen grogan gonzalezduarte maurer merlini g damy slama brannagan th 3rd dispenzieri berk jl shah garg p vaishnaw karsten v chen j gollob j vest j suhr effect patisiran rna interference therapeutic cardiac parameter patient hereditary transthyretinmediated amyloidosis circulation 2019139431443 982 suhr ob coelho buades j pouget j conceicao berk j schmidt h waddingtoncruz campistol jm bettencourt br vaishnaw gollob j adam efficacy safety patisiran familial amyloidotic polyneurop athy phase ii multidose orphanet j rare dis 201510109 983 rosenblum h castano alvarez j goldsmith j helmke maurer ttr transthyretin stabilizer associated improved survival patient ttr cardiac amyloidosis circ heart fail 201811e004769 984 kremastinos dt farmakis iron overload cardiomyopathy clinical practice circulation 201112422532263 985 farmakis triposkiadis f lekakis j parissis j heart failure haemoglobinopa thies pathophysiology clinical phenotype management eur j heart fail 201719479489 986 aessopos farmakis deftereos tsironi tassiopoulos moyssakis karagiorga thalassemia heart disease comparative evaluation thalasse mia major thalassemia intermedia chest 200512715231530 987 farmakis aessopos pulmonary hypertension associated hemoglobi nopathies prevalent overlooked circulation 201112312271232 988 baumgartner h de backer j babunarayan sv budts w chessa diller gp lung b kluin j lang im meijboom f moon p mulder bjm oechslin e roos hesselink jw schwerzmann sondergaard l zeppenfeld k esc scientific document group 2020 esc guideline management adult congeni tal heart disease eur heart j 202142563645 989 diller gp kempny alonsogonzalez r swan l uebing li w babu narayan wort sj dimopoulos k gatzoulis survival prospect cir cumstances death contemporary adult congenital heart disease patient followup large tertiary centre circulation 201513221182125 990 budts w rooshesselink j radlehurst eicken mcdonagh ta lambrinou e crespoleiro walker f frogoudaki aa heart failure adult congenital heart disease position paper working group grownup congenital heart disease heart failure association european society cardiology eur heart j 20163714191427 991 lluri g lin j reardon l miner p whalen k aboulhosn j early experience sacubitrilvalsartan adult patient congenital heart disease world j pediatr congenit heart surg 201910292295 992 appadurai v thoreau j malpas nicolae sacubitrilvalsartan adult con genital heart disease patient chronic heart failure – single centre case series call international registry heart lung circ 202029137141 993 maurer sj pujol salvador c schiele hager ewert p tutarel sacubitril valsartan heart failure adult complex congenital heart disease int j cardiol 2020300137140 994 van de bruaene meier l droogne w de meester p troost e gewillig budts w management acute heart failure adult patient congenital heart disease heart fail rev 201823114 995 minchin roland richardson j rowark guthrie b quality care united kingdom removal financial incentive n engl j med 2018379948957 996 song z ji safran dg chernew health care spending utilization quality 8 year global payment n engl j med 2019381252263 997 aktaa batra g wallentin l baigent c erlinge james ludman p maggioni ap price weston c casadei b gale cp european society cardiology methodology development quality indicator quantification cardiovascular care outcome eur heart j qual care clin outcome 2020 doi 10.1093ehjqccoqcaa069 998 arbelo e aktaa bollmann d’avila drossart dwight j hill mt hindricks g kusumoto fm lane da lau dh lettino lip gyh lobban pak hn potpara saenz lc van gelder ic varosy p gale cp dagres n reviewer boveda deneke defaye p conte g lenarczyk r providencia r guerra jm takahashi pisani c nava sarkozy glotzer tv martin oliveira quality indicator care outcome adult atrial fibrillation europace 202123494495 999 schiele f aktaa rossello x ahrens claeys mj collet jp fox kaa gale cp huber k iakobishvili z key lambrinou e leonardi lettino masoudi fa price quinn swahn e thiele h timmis tubaro vrints cjm walker bueno h scientific document group esc halvorsen jernberg jortveit j blondal ibanez b hassager c 2020 update quality indicator acute myocardial infarction position paper association acute cardiovascular care group quality indica tor acvc nsteacs guideline group eur heart j acute cardiovasc care 202110224233 1000 collet jp thiele h barbato e barthelemy bauersachs j bhatt dl dendale p dorobantu edvardsen folliguet gale cp gilard job juni p lambrinou e lewis b mehilli j meliga e merkely b mueller c roffi rutten fh sibbing siontis gcm esc scientific document group 2020 esc guideline management acute coronary syndrome patient present ing without persistent stsegment elevation eur heart j 20214212891367 1001 wallentin l gale cp maggioni bardinet casadei b euroheart european unified registry heart care evaluation randomized eur heart j 20194027452749 downloaded guest 24 november 2024